0001493152-24-015181.txt : 20240418 0001493152-24-015181.hdr.sgml : 20240418 20240418154729 ACCESSION NUMBER: 0001493152-24-015181 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240418 DATE AS OF CHANGE: 20240418 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Limitless X Holdings Inc. CENTRAL INDEX KEY: 0001803977 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISCELLANEOUS AMUSEMENT & RECREATION [7990] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 811034163 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-56453 FILM NUMBER: 24854209 BUSINESS ADDRESS: STREET 1: 9454 WILSHIRE BLVD. STREET 2: #300 CITY: BEVERLY HILLS STATE: CA ZIP: 90212 BUSINESS PHONE: 720-273-0433 MAIL ADDRESS: STREET 1: 9454 WILSHIRE BLVD. STREET 2: #300 CITY: BEVERLY HILLS STATE: CA ZIP: 90212 FORMER COMPANY: FORMER CONFORMED NAME: BIO LAB NATURALS, INC. DATE OF NAME CHANGE: 20200219 10-K 1 form10-k.htm
false FY 0001803977 0001803977 2023-01-01 2023-12-31 0001803977 2023-06-30 0001803977 2024-03-29 0001803977 2023-12-31 0001803977 2022-12-31 0001803977 us-gaap:NonrelatedPartyMember 2023-12-31 0001803977 us-gaap:NonrelatedPartyMember 2022-12-31 0001803977 us-gaap:RelatedPartyMember 2023-12-31 0001803977 us-gaap:RelatedPartyMember 2022-12-31 0001803977 us-gaap:PreferredClassAMember 2023-12-31 0001803977 us-gaap:PreferredClassAMember 2022-12-31 0001803977 us-gaap:PreferredClassBMember 2023-12-31 0001803977 us-gaap:PreferredClassBMember 2022-12-31 0001803977 2022-01-01 2022-12-31 0001803977 us-gaap:ProductMember 2023-01-01 2023-12-31 0001803977 us-gaap:ProductMember 2022-01-01 2022-12-31 0001803977 us-gaap:ServiceMember 2023-01-01 2023-12-31 0001803977 us-gaap:ServiceMember 2022-01-01 2022-12-31 0001803977 VYBE:RentalsMember 2023-01-01 2023-12-31 0001803977 VYBE:RentalsMember 2022-01-01 2022-12-31 0001803977 VYBE:CostOfRevenueMember 2023-01-01 2023-12-31 0001803977 VYBE:CostOfRevenueMember 2022-01-01 2022-12-31 0001803977 VYBE:CostOfRevenueOtherMember 2023-01-01 2023-12-31 0001803977 VYBE:CostOfRevenueOtherMember 2022-01-01 2022-12-31 0001803977 us-gaap:PreferredStockMember us-gaap:PreferredClassAMember 2021-12-31 0001803977 us-gaap:PreferredStockMember us-gaap:PreferredClassBMember 2021-12-31 0001803977 us-gaap:CommonStockMember 2021-12-31 0001803977 VYBE:CommonStockIssuableMember 2021-12-31 0001803977 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001803977 us-gaap:RetainedEarningsMember 2021-12-31 0001803977 2021-12-31 0001803977 us-gaap:PreferredStockMember us-gaap:PreferredClassAMember 2022-12-31 0001803977 us-gaap:PreferredStockMember us-gaap:PreferredClassBMember 2022-12-31 0001803977 us-gaap:CommonStockMember 2022-12-31 0001803977 VYBE:CommonStockIssuableMember 2022-12-31 0001803977 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001803977 us-gaap:RetainedEarningsMember 2022-12-31 0001803977 us-gaap:PreferredStockMember us-gaap:PreferredClassAMember 2022-01-01 2022-12-31 0001803977 us-gaap:PreferredStockMember us-gaap:PreferredClassBMember 2022-01-01 2022-12-31 0001803977 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001803977 VYBE:CommonStockIssuableMember 2022-01-01 2022-12-31 0001803977 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001803977 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001803977 us-gaap:PreferredStockMember us-gaap:PreferredClassAMember 2023-01-01 2023-12-31 0001803977 us-gaap:PreferredStockMember us-gaap:PreferredClassBMember 2023-01-01 2023-12-31 0001803977 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001803977 VYBE:CommonStockIssuableMember 2023-01-01 2023-12-31 0001803977 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001803977 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001803977 us-gaap:PreferredStockMember us-gaap:PreferredClassAMember 2023-12-31 0001803977 us-gaap:PreferredStockMember us-gaap:PreferredClassBMember 2023-12-31 0001803977 us-gaap:CommonStockMember 2023-12-31 0001803977 VYBE:CommonStockIssuableMember 2023-12-31 0001803977 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001803977 us-gaap:RetainedEarningsMember 2023-12-31 0001803977 us-gaap:CommonStockMember VYBE:BioLabNaturalsIncMember VYBE:LimitlessXShareholdersMember 2022-05-20 2022-05-20 0001803977 VYBE:ClassAConvertiblePreferredStockMember VYBE:HelionHoldingsLLCMember VYBE:JaspreetMathurMember 2022-05-20 0001803977 us-gaap:CommonStockMember VYBE:BioLabNaturalsIncMember 2022-05-20 2022-05-20 0001803977 srt:MinimumMember 2023-12-31 0001803977 srt:MaximumMember 2023-12-31 0001803977 VYBE:ThreeLargestSuppliersMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2023-01-01 2023-12-31 0001803977 VYBE:VybeSaleAgreementMember VYBE:EmblazeOneIncMember 2023-06-01 2023-06-01 0001803977 VYBE:VybeSaleAgreementMember VYBE:EmblazeOneIncMember 2023-06-01 0001803977 2023-06-01 0001803977 VYBE:EmblazeOneIncMember 2023-06-01 2023-06-01 0001803977 VYBE:EmblazeOneIncMember 2023-06-01 0001803977 VYBE:TwoLoanAuthorizationAndAgreementsMember 2022-04-01 0001803977 VYBE:TwoLoanAuthorizationAndAgreementsMember 2022-12-31 0001803977 VYBE:VybeLabsIncMember 2023-06-01 0001803977 2023-06-01 2023-06-01 0001803977 VYBE:LimitlessPerformanceIncMember 2021-12-01 2021-12-01 0001803977 us-gaap:IndividualMember VYBE:PrimeTimeLiveIncMember VYBE:UnsecuredConvertiblePromissoryNoteMember 2021-03-01 0001803977 us-gaap:IndividualMember VYBE:PrimeTimeLiveIncMember VYBE:UnsecuredConvertiblePromissoryNoteMember 2021-02-28 2021-03-01 0001803977 VYBE:PrimeTimeLiveIncMember 2023-12-31 0001803977 VYBE:PrimeTimeLiveIncMember 2023-01-01 2023-12-31 0001803977 VYBE:PrimeTimeLiveIncMember 2022-12-31 0001803977 VYBE:PrimeTimeLiveIncMember 2022-01-01 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableOneMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableOneMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableTwoMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableTwoMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableThreeMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableThreeMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableFourMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableFourMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableFiveMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableFiveMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableSixMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableSixMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableSevenMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableSevenMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableEightMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableEightMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableNineMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableNineMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableTenMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableTenMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableElevenMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableElevenMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableTwelveMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableTwelveMember 2022-12-31 0001803977 VYBE:ConvertibleNoteOfferingMember srt:MinimumMember 2022-11-28 0001803977 VYBE:ConvertibleNoteOfferingMember srt:MaximumMember 2022-11-28 0001803977 VYBE:ConvertibleNoteOfferingMember VYBE:TwelveAccreditedInvestorsMember 2022-12-31 0001803977 VYBE:ConvertibleNoteOfferingMember VYBE:TwelveAccreditedInvestorsMember 2023-12-31 0001803977 VYBE:ClassBPreferredStockMember 2023-10-23 2023-10-23 0001803977 us-gaap:CommonStockMember 2023-10-01 0001803977 VYBE:ClassBPreferredStockMember 2023-10-23 0001803977 VYBE:ShareholderMember 2023-01-01 2023-12-31 0001803977 VYBE:LoanPayableToShareholderOneMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderOneMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderTwoMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderTwoMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderThreeMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderThreeMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderFourMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderFourMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderFiveMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderFiveMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderSixMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderSixMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderSevenMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderSevenMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderEightMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderEightMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderNineMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderNineMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderTenMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderTenMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderElevenMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderElevenMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderTwelveMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderTwelveMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderThirteenMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderThirteenMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderFourteenMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderFourteenMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderFifteenMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderFifteenMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderSixteenMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderSixteenMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderOneMember 2021-12-06 0001803977 VYBE:LoanPayableToShareholderOneMember 2022-05-30 2022-06-01 0001803977 VYBE:LoanPayableToShareholderOneMember 2022-06-01 0001803977 VYBE:LoanPayableToShareholderOneMember 2021-12-05 2021-12-06 0001803977 VYBE:LoanPayableToShareholderTwoMember 2022-02-11 0001803977 VYBE:LoanPayableToShareholderTwoMember 2022-05-30 2022-06-01 0001803977 VYBE:LoanPayableToShareholderTwoMember 2022-06-01 0001803977 VYBE:LoanPayableToShareholderTwoMember 2022-02-10 2022-02-11 0001803977 VYBE:LoanPayableToShareholderThreeMember 2022-05-08 0001803977 VYBE:LoanPayableToShareholderThreeMember 2023-09-30 0001803977 VYBE:LoanPayableToShareholderThreeMember 2022-05-30 2022-06-01 0001803977 VYBE:LoanPayableToShareholderThreeMember 2022-06-01 0001803977 VYBE:LoanPayableToShareholderThreeMember 2022-05-07 2022-05-08 0001803977 VYBE:LoanPayableToShareholderFiveMember 2022-05-16 0001803977 VYBE:LoanPayableToShareholderFiveMember 2022-06-17 0001803977 VYBE:LoanPayableToShareholderFiveMember 2022-05-14 2022-05-16 0001803977 VYBE:LoanPayableToShareholderSeventeenMember 2022-05-18 0001803977 VYBE:LoanPayableToShareholderSeventeenMember 2022-06-19 0001803977 VYBE:LoanPayableToShareholderSeventeenMember 2022-05-18 2022-05-18 0001803977 VYBE:LoanPayableToShareholderSixMember 2022-06-01 0001803977 VYBE:LoanPayableToShareholderSixMember 2022-07-31 2022-08-01 0001803977 VYBE:LoanPayableToShareholderSixMember 2022-08-01 0001803977 VYBE:LoanPayableToShareholderSixMember 2022-05-30 2022-06-01 0001803977 VYBE:LoanPayableToShareholderSevenMember 2022-06-30 0001803977 VYBE:LoanPayableToShareholderSevenMember 2022-07-31 2022-08-01 0001803977 VYBE:LoanPayableToShareholderSevenMember 2022-08-01 0001803977 VYBE:LoanPayableToShareholderSevenMember 2022-06-30 2022-06-30 0001803977 VYBE:LoanPayableToShareholderEightMember 2022-08-25 0001803977 VYBE:LoanPayableToShareholderNineMember 2022-11-15 0001803977 VYBE:LoanPayableToShareholderTenMember 2023-05-16 0001803977 VYBE:LoanPayableToShareholderElevenMember 2023-05-18 0001803977 VYBE:LoanPayableToShareholderTwelveMember 2023-06-05 0001803977 VYBE:FundingCommitmentMember srt:ChiefExecutiveOfficerMember 2023-06-03 0001803977 VYBE:FundingCommitmentMember us-gaap:PreferredClassBMember srt:ChiefExecutiveOfficerMember 2023-06-03 0001803977 VYBE:FundingCommitmentMember 2023-12-31 0001803977 VYBE:NotesPayablesMember VYBE:ShareholderMember 2023-01-01 2023-12-31 0001803977 VYBE:NotesPayablesMember VYBE:ShareholderMember 2022-01-01 2022-12-31 0001803977 VYBE:FundingCommitmentMember VYBE:LoanPayableToShareholderThirteenMember 2023-12-31 0001803977 VYBE:FundingCommitmentMember VYBE:LoanPayableToShareholderFourteenMember 2023-12-31 0001803977 VYBE:FundingCommitmentMember VYBE:LoanPayableToShareholderFifteenMember 2023-12-31 0001803977 VYBE:FundingCommitmentMember VYBE:LoanPayableToShareholderSixteenMember 2023-12-31 0001803977 us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesOneMember 2023-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesOneMember 2022-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesTwoMember 2023-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesTwoMember 2022-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesThreeMember 2023-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesThreeMember 2022-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesFourMember 2023-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesFourMember 2022-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesFiveMember 2023-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesFiveMember 2022-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesSixMember 2023-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesSixMember 2022-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesSevenMember 2023-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesSevenMember 2022-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesOneMember 2022-05-10 0001803977 VYBE:NotePayablesToRelatedPartiesOneMember 2022-05-09 2022-05-10 0001803977 VYBE:NotePayablesToRelatedPartiesTwoMember 2022-05-10 0001803977 VYBE:NotePayablesToRelatedPartiesTwoMember 2022-05-09 2022-05-10 0001803977 VYBE:NotePayablesToRelatedPartiesThreeMember 2022-05-10 0001803977 VYBE:NotePayablesToRelatedPartiesThreeMember 2022-05-09 2022-05-10 0001803977 VYBE:NotePayablesToRelatedPartiesFourMember 2022-05-31 0001803977 VYBE:NotePayablesToRelatedPartiesFourMember 2022-05-31 2022-05-31 0001803977 VYBE:NotePayablesToRelatedPartiesFiveMember 2022-05-31 0001803977 VYBE:NotePayablesToRelatedPartiesFiveMember 2022-05-31 2022-05-31 0001803977 VYBE:NotePayablesToRelatedPartiesSixMember 2022-06-09 0001803977 VYBE:NotePayablesToRelatedPartiesSixMember 2022-06-08 2022-06-09 0001803977 VYBE:VybeLabsMember 2023-06-01 2023-06-01 0001803977 VYBE:NotePayablesToRelatedPartiesSevenMember 2023-06-01 0001803977 VYBE:NotesPayablesOneMember VYBE:ShareholderOneMember 2023-01-01 2023-12-31 0001803977 VYBE:NotesPayablesOneMember VYBE:ShareholderOneMember 2022-01-01 2022-12-31 0001803977 2023-05-31 2023-05-31 0001803977 2022-05-10 2022-05-10 0001803977 2022-06-10 2022-06-10 0001803977 VYBE:ClassAConvertiblePreferredStockMember 2023-12-31 0001803977 VYBE:ClassAConvertiblePreferredStockMember 2022-12-31 0001803977 VYBE:ClassAConvertiblePreferredStockMember 2023-01-01 2023-12-31 0001803977 VYBE:ClassBConvertiblePreferredStockMember 2023-10-23 2023-10-23 0001803977 VYBE:ClassBConvertiblePreferredStockMember 2023-10-23 0001803977 VYBE:IssuedMember 2021-01-01 2021-12-31 0001803977 VYBE:IssuableMember 2021-01-01 2021-12-31 0001803977 2021-01-01 2021-12-31 0001803977 VYBE:TwoThousandTwentyStockIncentivePlanMember 2020-01-15 0001803977 VYBE:TwoThousandTwentyStockIncentivePlanMember 2023-01-01 2023-12-31 0001803977 VYBE:TwoThousandTwentyStockIncentivePlanMember 2022-01-01 2022-12-31 0001803977 VYBE:TwoThousandTwentyTwoStockOptionPlanMember 2022-08-09 0001803977 VYBE:TwoThousandTwentyTwoStockOptionPlanMember 2023-01-01 2023-12-31 0001803977 VYBE:TwoThousandTwentyTwoStockOptionPlanMember 2022-01-01 2022-12-31 0001803977 VYBE:TwoThousandTwentyTwoRestrictedStockPlanMember 2022-08-09 0001803977 VYBE:TwoThousandTwentyTwoRestrictedStockPlanMember 2023-01-01 2023-12-31 0001803977 VYBE:TwoThousandTwentyTwoRestrictedStockPlanMember 2022-01-01 2022-12-31 0001803977 VYBE:NotesPayablesMember VYBE:ShareholderMember 2023-12-31 0001803977 VYBE:NotesPayablesMember VYBE:ShareholderMember 2022-12-31 0001803977 VYBE:NotesPayablesMember us-gaap:RelatedPartyMember 2023-12-31 0001803977 srt:OfficerMember 2023-01-01 2023-12-31 0001803977 srt:OfficerMember 2022-01-01 2022-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2023

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________to _____________

 

000-56453

Commission File Number

 

LIMITLESS X HOLDINGS, INC.
(Exact Name of Registrant as Specified in its Charter)

 

Delaware   81-1034163

State or Other Jurisdiction of Incorporation or Organization

 

(I.R.S. Employer Identification No.)

     
9454 Wilshire Blvd. #300, Beverly Hills, CA   90212
(Address of Principal Executive Offices)   (Zip Code)

 

(855) 413-7030

Registrant’s Telephone Number, Including Area Code

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
None   None   None

 

Securities registered pursuant to Section 12(g) of the Act:

 

Common Stock

Title of each class

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes ☒ No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ☐ Yes ☒ No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes No

 

The aggregate market value of voting stock held by non-affiliates of the Registrant on June 30, 2023 based on the closing bid price of $2.90 for shares of the registrant’s common stock as reported by the OTCQB, was approximately $3,899,529. Shares of common stock beneficially owned by each executive officer, director, and holder of more than 10% of our common stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

 

The registrant had outstanding 3,977,497 shares of common stock, par value $0.0001, as of March 29, 2024.

 

Documents Incorporated by Reference

 

None.

 

 

 

 
 

 

TABLE OF CONTENTS

 

  PAGE
PART I  
Item 1.Business 4
Item 1A.Risk Factors 8
Item 1B.Unresolved Staff Comments 26
Item 1C.Cybersecurity 26
Item 2.Properties 28
Item 3.Legal Proceedings 28
Item 4.Mine Safety Disclosures 28
   
PART II  
   
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 29
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 31
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 35
Item 8.Financial Statements and Supplementary Data 35
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 36
Item 9A.Controls and Procedures 36
Item 9B.Other Information 36
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 36
   
PART III  
   
Item 10.Directors, Executive Officers and Corporate Governance 37
Item 11.Executive Compensation. 41
Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 45
Item 13.Certain Relationships and Related Transactions, and Director Independence. 46
Item 14.Principal Accounting Fees and Services. 51
   
PART IV  
   
Item 15.Exhibits, Financial Statement Schedules. 52
   
Exhibit Index 51
Signatures 53
Index to Consolidated Financial Statements F-1

 

2
 

 

LIMITLESS X HOLDINGS, INC.

 

CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS

 

This Annual Report on Form 10-K (“Annual Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical fact included in this Annual Report are forward-looking statements. These forward-looking statements may include projections and estimates concerning the timing and success of specific projects and our future construction, revenues, income, cost of sales, expenses, and capital spending. Our forward-looking statements are generally accompanied by words such as “estimate,” “project,” “predict,” “believe,” “expect,” “intend,” “anticipate,” “potential,” “plan,” “goal,” “foresee,” “likely,” “target,” “may,” “should,” “could,” or other words that convey the uncertainty of future events or outcomes. The Company will continue to file annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission (the “SEC”). The forward-looking statements in this Annual Report speak only as of the date of this document, and we disclaim any obligation to update these statements unless required by law, and we caution you not to rely on them unduly. We have based these forward-looking statements on our current expectations and assumptions about future events. While our management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory, and other risks, contingencies, and uncertainties, most of which are difficult to predict and many of which are beyond our control.

 

These forward-looking statements reflect our management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Annual Report and are subject to risks and uncertainties. Moreover, we operate in a very highly competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on forward-looking statements contained herein.

 

You should read this Annual Report and the documents that we reference and have filed as exhibits with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

 

The forward-looking statements made in this Annual Report relate only to events as of the date on which such statements are made. We undertake no obligation to update any forward-looking statements after the date of this Annual Report or to conform such statements to actual results or revised expectations, except as required by law.

 

3
 

 

PART I

 

Throughout this Annual Report, references to the “Company,” “VYBE,” “we,” “us,” and “our” refer to Limitless X Holdings, Inc. and its subsidiaries, unless the context requires otherwise.

 

ITEM 1. BUSINESS.

 

Company Overview

 

Limitless X is a multinational consumer packaged goods company that specializes in developing and offering ‘Look Good, Feel Great’ products, specifically within the nutrition and beauty industry, through direct response advertising and our distinctive and highly successful celebrity-backed brand awareness strategies. We possess unique capabilities to greatly enhance the reputation and impact of brands, due to our extensive knowledge and expertise in digital marketing and our successful track record in launching new consumer products.

 

Leadership

 

Jas Mathur, our Chairman and Chief Executive Officer, is an entrepreneur with over 14 years of experience within the health, wellness, and dietary supplements industry and 25 years of experience as a webmaster and internet marketer. He is the owner of Emblaze One, a global interactive and web development agency with a staff of 100+. Mr. Mathur founded Limitless X in 2021, drawing upon his own personal battles with health and his transformative journey that resulted in a remarkable weight loss of over 250 lbs. His extraordinary achievements in the business world serve as a powerful source of motivation, inspiration, and empowerment for all those who cross paths with him, igniting their dreams, fostering belief, and empowering them to achieve greatness.

 

Our Services

 

Leveraging our top-notch business know-how, deep insights in the health and nutrition industry and a broad network in the industry to identify and boost unique investment opportunities, we help design, build, and grow successful e-commerce brands that have unique capabilities in each of their respective markets while enriching people’s lives. We empower founders by fostering connections with customers, strategic partners, and investors, using our unique direct-to-consumer model to maximize profits.

 

Product Development

 

We help create and grow strong, memorable brands. We help our partners at all stages of product development level, including with market research and product, label and packaging design. On the market research side, we examine the competitive landscape of industries by analyzing competitors’ products, conducting surveys, finding relevant partners, and researching resources. We then create an actionable plan to break into the relevant market. We also facilitate key introductions to strategic partners in the PR, IT, finance and legal industries and we help design and implement the product fulfillment process.

 

Product Manufacturing

 

We maintain complete control over the manufacturing process, from start to finish, including with the sourcing of high-quality ingredients, identifying reliable supply chain, distribution and manufacturers networks, and the designing of quality assurance and compliance processes.

 

Product Distribution and Fulfillment

 

Our streamlined omni-channel approach to product distribution prioritizes consumer interests to help deliver better conversion rates. It includes e-commerce websites, social media, shipping, distributed warehousing, payment processing and product returns. Reliable fulfillment and logistics process allows a fast delivery. Product orders are fulfilled via online, direct to consumer, retail, wholesale and big box retail channels.

 

4
 

 

Marketing, Advertising, and Consumer Outreach

 

In 2023, we shifted our business model from working with third-party affiliates and affiliate networks to now include an in-house, full service digital marketing team to decrease our customer acquisition costs, increase customer retention, satisfaction and build brand trust and loyalty. This shift allows us to control the content and marketing creatives, mitigate chargebacks, decrease refunds, lower customer acquisition costs, impact average order values, and create direct relationships with advertisement platforms.

 

Our marketing efforts are designed to increase consumer awareness of and demand for the brands we work with or own. Our marketing team helps design, form and generate the right content for each brand, and devises the best strategy for its distribution. We employ a broad mix of traditional marketing strategies, from: product sampling to exhibiting at consumer trade events and hosting celebrity-rich events where our company and brand(s) are prominently highlighted. Our primary driver is the use of social media platforms to communicate with consumers and build interest in the respective brand(s) and product(s). Our advertising and use of online resources are aimed at increasing consumer preference and usage of our products. Operating as an integrated marketing agency, we plan to offer global marketing services across all areas of the sales process in the near future.

 

Our Competitive Strengths

 

We constantly strive to find gaps in the relevant marketplace and help develop products that fill those gaps and meet or exceed the needs of the consumers. Because of our turnkey solution, we are able to launch products quickly and efficiently to meet consumer needs and cater to new advances in the health and wellness industry.

 

We believe that our experience has uniquely positioned us to scale and maintain an ecosystem of opinion leaders following wellness-focused brands. We believe we work with an “A-list” group of influencers who promote the products and services that are offered on our platform.

 

Our Clients

 

Currently, all of the brands in our portfolio are with affiliated companies that are owned 100% by our Chief Executive Officer, Jas Mathur.

 

Our Network of Influencers

 

We have brought together a network of high profile and influential individuals who have all have two things in common: Look Good and Feel Great. This includes: music artists, movie stars, professional athletes, popular social media influencers, fitness experts, and nutrition coaches. We utilize our network of influencers on an “as needed” basis and compensation terms vary depending on the influencer and product, as decided upon by our management. We do not have any formal long-term contracts with any one influencer. Our marketing team works with the brands to determine the appropriate audience for any given brand and reaches out to those persons in our network, who are then engaged to publicize on their media platforms a pre-approved post provided by our marketing team, and in turn, they receive commissions for sales of products they publicize. All of the products promoted are offered to consumers through our website.

 

Our Compliance Team

 

All of our compliance matters are managed in house by our Chief Operating Officer and our VP of Legal Affairs, including our data security, privacy rights, and ensuring that the products that we offer are in compliance with applicable government regulations. (See “Government Regulation” below.)

 

5
 

 

Our Strategy

 

We have manufacturing and distribution licensing agreements to market, manufacture, sell, and distribute the branded products on behalf of our licensors. The licensor retains the rights to continue its own use of these items under existing or new contracts in its discretion, and to develop new products. Our typical manufacturing and distribution licensing agreements allows us to:

 

  (a) Design or redesign the products;
  (b) Manufacture the products under such design specifications as may be mutually agreed upon by the licensor and us from time to time;
  (c) Promote, sell, and distribute the products in the United States and its territories;
  (d) Use the existing designs of the products and all intellectual property rights associated with or for such products, including all trademarks and patent rights, with the sale, promotion, and distribution of the products in the territory, including the display of any trademarks, and all other designs or marks which could be or that are actually later registered with the federal Patent and Trademark Office, on our vehicles and other merchandising equipment, and on stationery, packaging, and other advertising and promotional materials;
  (e) Use the existing domain names, web addresses, telephone lines, third-party vendors, and any other operational element currently in use by the licensor that can be transferred to us; and
  (f) Manufacture, promote, sell, and distribute new products designed or created by us that we deem preferable to sell under the licensor’s name; and in such case, we negotiate in good faith to agree on a royalty commission percentage or flat rate amount for the sale of new products using the licensor’s name.

 

Market Data and Research of Our Verticals

 

Health and Wellness

 

According to Zion Market Research, the global health and wellness market size is projected to reach $8,946 billion by the end of 2030, with a compound annual growth rate of approximately 6.9% between 2023 and 2030. In 2022, the market size was estimated to be $5,244 billion.

 

Intellectual Property

 

Currently, we do not own any registered trademarks, but we intend on acquiring some of the licenses we have worked with in the past and/or are working with today.

 

Seasonality

 

We do not experience seasonal variations in our quarterly operating results and capital requirements.

 

Human Capital

 

As of the date of this Annual Report, we have 12 full-time employees and no part-time employees. None of our employees are members of a labor union or covered by a collective bargaining agreement.

 

Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors, and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the granting of equity-based compensation awards in order to increase shareholder value and the success of our business by motivating such individuals to perform to the best of their abilities and achieve our objectives.

 

Legal Proceedings

 

There are no material proceedings to which any director or officer, or any associate of any such director or officer, is a party that is adverse to our Company or any of our subsidiaries or has a material interest adverse to our Company or any of our subsidiaries other than what is disclosed in the Company’s financial statements. No director or executive officer has been a director or executive officer of any business which has filed a bankruptcy petition or had a bankruptcy petition filed against it during the past ten years. No current director or executive officer has been convicted of a criminal offense or is the subject of a pending criminal proceeding during the past ten years. No current director or executive officer has been the subject of any order, judgment or decree of any court permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities during the past ten years. No current director or officer has been found by a court to have violated a federal or state securities or commodities law during the past ten years.

 

6
 

 

From time to time, the Company is involved in legal proceedings. The Company records a liability for those legal proceedings when it determines it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The Company also discloses when it is reasonably possible that a material loss may be incurred, however, the amount cannot be reasonably estimated. From time to time, the Company may enter into discussions regarding settlement of these matters, and may enter into settlement agreements, if it believes settlement is in the best interest of the Company and its shareholders.

 

The following is a summary of our current outstanding litigation:

 

Mentom Eyewear Inc. – A legal action was filed in the Los Angeles Superior Court against Limitless X Holdings Inc., four of its officers, and an unrelated company, alleging the breach of an Implied In-Fact Agreement and other causes of action related to that alleged agreement such as conversion, fraud and unjust enrichment, Mentom Eyewear Inc. v. Limitless X Holdings Inc., et al., Case Number 23STCV24681.  We believe that there was no such agreement, and that the plaintiff has no legal standing to bring such a matter against the Company or its officers.  The case is moving into the discovery phase where we believe the true facts will lead to a dismissal; however, if the case continues, we will vigorously defend against such claims as it is our position that the allegations are not supported by the facts.  No liability has been recorded for these litigations because the Company believes that any such liability is not probable and reasonably estimable at this time.

 

Harpo Inc. – A legal action was filed in the Central District of California against Limitless X Inc. and two of its officers along with Emblaze One, Inc., alleging trademark infringement and dilution, unfair competition, false advertising, and violation of the right of publicity, all based on allegations that one of our advertisements contained the unauthorized use of a celebrity’s name and intellectual property, Harpo Inc. and OW Licensing Company LLC v. Emblaze One, Inc., et al., Case Number 2:23-cv-04459 VAP (ASx).  Any exposure stemming from this action would be subject to indemnity from the advertising network responsible for the ads in question.  We have not yet filed a responsive pleading in this action as we are attempting a global settlement; however, if unable to settle we will defend the case vigorously and will attempt a contractual and equitable indemnity claim against the advertiser.  No liability has been recorded for this litigation because the Company believes that any such liability is not reasonably estimable at this time.

 

Properties

 

We own no property.

 

Corporate History and Background

 

The Company was formed in the State of Nevada on June 3, 1996, as Vyta Corp. On November 5, 2010, the Company changed its name to Bio Lab Naturals, Inc. On May 11, 2022, Bio Lab Naturals, Inc., a Delaware corporation (“Bio Lab”), entered into a Share Exchange Agreement (the “Share Exchange Agreement”) with Limitless X, Inc., a Nevada corporation (“LimitlessX”), and its 11 shareholders (the “LimitlessX Acquisition”). The parties completed and closed the LimitlessX Acquisition on May 20, 2022. Concurrently with the LimitlessX Acquisition, Jaspreet Mathur, the founder and principal shareholder of LimitlessX, also purchased from Helion Holdings LLC, shares of Bio Lab’s Class A Preferred Convertible Stock, which at all times have a number of votes equal to 60% of all of the issued and outstanding shares of common stock of Bio Lab. On June 10, 2022, the Company changed its name to Limitless X Holdings Inc.

 

Subsidiaries

 

We have 2 subsidiaries, Limitless X, Inc, a Nevada corporation and Prime Time Live, Inc., a Colorado corporation.

 

Corporate Information

 

We are a Delaware corporation. Our corporate headquarters are located at 9454 Wilshire Blvd., #300, Beverly Hills, CA 90212. Our telephone number is (833) 888-8923. We maintain a website at www. https://www.limitlessx.com/.

 

Reports to Security Holders

 

We provide an annual report that includes audited financial information to our shareholders. We will make our financial information equally available to any interested parties or investors through compliance with the disclosure rules for a small business issuer under the Exchange Act. We are subject to disclosure filing requirements including filing Form 10-K annually and Form 10-Q quarterly. In addition, we will file Form 8-K and other proxy and information statements from time to time as required. We do not intend to voluntarily file the above reports in the event that our obligation to file such reports is suspended under the Exchange Act. The public may read and copy any materials that we file with the SEC, at the SEC’s Public Reference Room at 100 F Street NE, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a website (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.

 

Our principal executive office located at 9454 Wilshire Blvd., #300, Beverly Hills, California 90212. Our main telephone number is 855-413-7030. Our website is https://limitlessx.com/. Our website or linked information included in our website are not incorporated into this Annual Report.

 

7
 

 

ITEM 1A. RISK FACTORS.

 

Our business, results of operations, and financial condition are subject to numerous risks and uncertainties. In connection with making any investment decision with respect to our securities, you should carefully consider the following risk factors, which address the material risks concerning our business and an investment in our securities, together with the other information contained in this filing. The risks described below are material risks currently known, expected, or reasonably foreseeable by us. However, the risks described below are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business, operating results, prospects, or financial condition. If any of the risks discussed in this filing occur, our business, prospects, liquidity, financial condition, and results of operations could be materially and adversely affected, in which case the trading price of our common stock could decline significantly. You should read these Risk Factors in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 and our consolidated financial statements and related notes in Item 8. Additionally, some statements herein constitute forward-looking statements. (See “Cautionary Note Concerning Forward-Looking Statements.”)

 

Summary of Risk Factors

 

  We have incurred significant losses, we expect to incur losses in the future, and we may not be able to generate sufficient revenue to achieve and maintain profitability.
     
  The report of the independent registered public accounting firm includes a going concern uncertainty explanatory paragraph.
     
  All of the current brands and products that we sell and promote are owned or controlled by our Chief Executive Officer and we may lose all of our business at any time.
     
  If we fail to cost-effectively acquire new consumers or retain our existing consumers, our business could be adversely affected.
     
  Use of social media and influencers may materially and adversely affect our reputation or subject us to fines or other penalties.
     
  If we fail to retain existing customers, or fail to maintain average order value levels, we may not be able to maintain our revenue base and margins, which would have a material adverse effect on our business and operating results.
     
  We rely on third parties for some essential business operations and services, and disruptions or failures in service or changes in terms may adversely affect our ability to deliver goods and services to our customers.
     
  Shipping is a critical part of our business and any changes in our shipping arrangements or any interruptions in shipping could adversely affect our operating results.
     
  Increases in labor costs, including wages, could adversely affect our business, financial condition, and results of operations.
     
  If we fail to maintain and enhance awareness of our brand, our business and financial results could be adversely affected.
     
  We could face liability for information displayed via our e-commerce webpages and our other websites.
     
  Advertising inaccuracies or product mislabeling may have an adverse effect on our business by exposing us to lawsuits, product recalls or regulatory enforcement actions, increasing our operating costs and reducing demand for our product offerings.
     
  We are subject to a number of other laws and regulations, which could impact our business.
     
  Our future financial performance and our ability to commercialize our products and services and to compete effectively will depend, in part, on our ability to manage any future growth effectively.
     
  We have authorized and designated Class A Preferred Convertible Stock, which have voting rights of 60% of our common stock at all times.
     
  Jaspreet Mathur, our Chief Executive Officer, owns greater than 50% of our voting securities which will cause us to be deemed a “controlled company” under the rules of NYSE American.

 

8
 

 

  Because insiders control our activities, that may cause us to act us in a manner that is most beneficial to them and not to outside shareholder which could cause us not to take actions that outside shareholders might view favorably.
     
  We are dependent upon our management, founders, key personnel, and consultants to execute our business plan, and many of them have concurrent responsibilities at other companies.
     
  There are limitations on the liability of our directors.
     
  We can issue future series of shares of preferred stock without shareholder approval which could adversely affect the rights of common shareholders.
     
  Our securities are considered a penny stock, and therefore are subject to the penny stock rules, as such, U.S. broker-dealers may be discouraged from effecting transactions in our securities.
     
  We have not paid dividends in the past and do not expect to pay dividends in the foreseeable future.

 

RISKS RELATED TO OUR BUSINESS

 

Our future profitability is uncertain.

 

We have incurred losses in recent quarters. Because we operate in a highly competitive industry, we have difficulty predicting our future operating results, and we cannot be certain that our revenue will grow at rates that will allow us to reach or maintain profitability on a quarterly or annual basis.

 

We have incurred recurring losses and may not be profitable in the future. Our plans to maintain and increase liquidity may not be successful. The report of the independent registered public accounting firm includes a going concern uncertainty explanatory paragraph.

 

We have a history of operating losses and negative cash flow in operating activities. We have incurred recurring net losses, including net losses from operations before income taxes of $16.1 million and $10.0 million for the years ended December 31, 2023 and 2022, respectively, and we had an accumulated deficit of $12.9 million at December 31, 2023. These factors raise substantial doubt as to our ability to continue as a going concern, and our independent registered public accounting firm has included a going concern uncertainty explanatory paragraph in their report for 2023. Our cash needs will depend on numerous factors, including our revenues, completion of our product development activities, customer and market acceptance of our product, and our ability to reduce and control costs. We expect to devote substantial capital resources to, among other things, fund operations and continue development plans. To support our existing and planned business model, the Company needs to raise additional capital to fund our future operations. The Company has not experienced any difficulty in raising funds through loans, and has not experienced any liquidity problems in settling payables in the normal course of business and repaying loans when they fall due. Successful renewal of our loans, however, is subject to numerous risks and uncertainties. In addition, the increasingly competitive industry conditions under which we operate may negatively impacted our results of operations and cash flows. Additional debt financing is anticipated to fund the Company’s operations in near future. However, there are no current agreements or understandings with regard to the form, time or amount of such financing and there is no assurance that any of this financing can be obtained or that the Company can continue as a going concern. 

 

We have incurred significant losses, we expect to incur losses in the future, and we may not be able to generate sufficient revenue to achieve and maintain profitability.

 

For the year ended December 31, 2023, we incurred net losses of $16.1 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we broaden our customer base, develop our retail and wholesale distribution platforms, and we make expenditures in an effort to enhance our existing online direct-to-consumer website. Historically, we have devoted most of our financial and other resources on sales and marketing; continued expansion of our business; and general administration expenses, including legal, accounting, and other expenses. We may not succeed in increasing our revenues, which historically have been reliant on our online direct-to-consumer website, in a manner that will be sufficient to offset these higher expenses. Any failure to increase our revenues as we implement initiatives to grow our business could prevent us from achieving profitability. We cannot be certain that we will be able to achieve profitability on a quarterly or annual basis, if at all. If we are unable to address these risks and difficulties as we encounter them, our business, financial condition, and results of operations may suffer.

 

All of the current brands and products that we sell and promote are owned or controlled by our Chief Executive Officer and we may lose all of our business at any time.

 

All of the current brands and products that we sell and promote are owned or controlled by Jas Mathur, our Chief Executive Officer. If Mr. Mathur chooses, on behalf of his companies and/or brands, to terminate all of the agreements he has with us, we will effectively lose all of our current business. All of our licensing agreements with our current marketed brands were entered into in 2021 and have five-year terms, whereby the licensors are not able to terminate the agreement with us except “for cause.” However, all such licensing agreements only grant us a non-exclusive license to manufacture, market, and distribute the brand’s products. Therefore, there is a possibility that the brands could work with other companies to manufacture, market, and distribute their products or replace us entirely. If this occurs, our revenues will significantly decline or stop completely. In addition, the trademarks for our name, “Limitless X,” and logo, are owned by entities that are owned or controlled by Mr. Mathur. In the event that he chooses to restrict our use of these trademarks, we will not be able to use our name and logo and would have to change our name.

 

9
 

 

We may not be able to successfully continue the business of Prime Time Live.

 

As a result of the LimitlessX Acquisition, we also acquired the business of Prime Time Live, Inc. (“PTL”), a digital marketer and service provider in the event industry. A major part of our business plan is to integrate the PTL platform with our offered services so that we can establish a more robust in-house digital marketing arm that we can utilize when promoting our customers’ brands and products. If we are not able to manage the integration of the PTL business successfully or cost effectively incorporate PTL’s platform, systems, and workflow with our brands’ existing marketing plans, our business, financial condition, results of operations, and prospects could be adversely affected.

 

If we fail to cost-effectively acquire new consumers or retain our existing consumers, our business could be adversely affected.

 

Our success depends on our ability to attract new customers and engage existing customers cost-effectively. To acquire and engage customers, we must, among other things, promote and sustain our platform, and provide high-quality products, user experiences, and customer service. If customers do not perceive our e-commerce service or products to be reliable and of high quality, if we fail to introduce new and improved products, or if we introduce new products that are not favorably received by the market, we may not be able to attract or retain customers.

 

We have historically acquired a significant number of our customers through digital advertising on social media. The advertisers we utilize may terminate their agreements with us at any time or introduce factors beyond our control, such as such as adjustments to algorithms that may decrease user engagement or negatively affect our ability to reach a broad audience; increases in pricing; and changes in policies that may delay or prevent our advertising through these channels, all of which could impact our ability to attract new customers.

 

We have marketing initiatives designed to acquire customers through increased search engine optimization and streaming digital video services. These new acquisition channels may not perform as well as our historical social media advertising channels. Our efforts to diversify customer acquisition channels may not be effective, which could negatively affect our results of operations.

 

Customer acquisition costs may fluctuate and rise on the channels that have been successful for us historically and on new channels that we are introducing. Rising costs may limit our ability to expand or maintain our customer acquisition efforts which could negatively affect our results of operations.

 

Other factors may reduce our ability to acquire, maintain, and further engage with customers, including the effectiveness of our marketing efforts and other expenditures we make to continue to acquire new customers and maintain and increase engagement with existing customers; system updates to advertising platforms; changes in search algorithms by search engines; the development of new search engines or social media sites that reduce traffic on existing search engines and social media sites; and consumer behavior changes as a result of the COVID-19 pandemic or otherwise.

 

Moreover, consumer preferences may change, and customers may not purchase through our marketplace as frequently or spend as much with us as historically has been the case. As a result of these potential changes, the revenue generated from customer transactions may not be as high as revenue generated from transactions historically.

 

We must expend resources to maintain consumer awareness of our brand, build brand loyalty and generate interest in our products. Our marketing strategies and channels will evolve, and our efforts may or may not be successful.

 

To remain competitive and expand and keep market share for our products across our various channels, we need to increase our marketing and advertising spending. Substantial advertising and promotional expenditures may be required to maintain or improve our brands’ market position or to introduce new products to the market. An increase in our marketing and advertising efforts may not maintain our current reputation, lead to increased brand awareness, or attract new customers. If we are unable to maintain and promote a favorable perception of our brand and products on a cost-effective basis, our business, financial condition, results of operations, and prospects could be adversely affected.

 

10
 

 

Use of social media and influencers may materially and adversely affect our reputation or subject us to fines or other penalties.

 

We use third-party social media platforms as, among other things, marketing tools. We also maintain relationships with many social media influencers and engage in sponsorship initiatives. As existing e-commerce and social media platforms continue to rapidly evolve and new platforms develop, we must continue to maintain a presence on these platforms and establish presences on new or emerging popular social media platforms. If we are unable to cost-effectively use social media platforms as marketing tools or if the social media platforms, we use change their policies or algorithms, we may not be able to fully optimize such platforms, and our ability to maintain and acquire customers and our financial condition may suffer.

 

Furthermore, as laws and regulations and public opinion rapidly evolve to govern the use of these platforms and devices, the failure by us, our employees, our network of social media influencers, our sponsors or third parties acting at our direction to abide by applicable laws and regulations in the use of these platforms and devices or otherwise could subject us to regulatory investigations, class action lawsuits, liability, fines or other penalties and have a material adverse effect on our business, financial condition and operating results.

 

In addition, an increase in the use of social media for product promotion and marketing may cause an increase in the burden on us to monitor compliance of such materials and increase the risk that such materials could contain problematic product or marketing claims in violation of applicable regulations. For example, in some cases, the FTC has sought enforcement action where an endorsement has failed to clearly and conspicuously disclose a financial relationship or material connection between an influencer and an advertiser.

 

We do not prescribe what our influencers post, and if we were held responsible for the content of their posts or their actions, we could be fined or forced to alter our practices, which could have an adverse impact on our business.

 

Negative commentary regarding us, our products or influencers and other third parties who are affiliated with us may be posted on social media platforms and may be adverse to our reputation or business. Influencers with whom we maintain relationships could engage in behavior or use their platforms to communicate directly with our customers in a manner that reflects poorly on our brand and may be attributed to us or otherwise adversely affect us. It is not possible to prevent such behavior, and the precautions we take to detect this activity may not be effective in all cases. Our target consumers often value readily available information and often act on such information without further investigation and without regard to its accuracy. The harm may be immediate without affording us an opportunity for redress or correction.

 

If we fail to retain existing customers, or fail to maintain average order value levels, we may not be able to maintain our revenue base and margins, which would have a material adverse effect on our business and operating results.

 

A significant portion of our net sales are generated from sales to existing customers. If existing customers no longer find our product offerings appealing, or if we are unable to timely update our product offerings to meet current trends and customer demands, our existing customers may make fewer or smaller purchases in the future. A decrease in the number of our customers who make repeat purchases or a decrease in their spending on the merchandise we offer could negatively impact our operating results. Further, we believe that our future success will depend in part on our ability to increase sales to our existing customers over time, and if we are unable to do so, our business may suffer. If we fail to generate repeat purchases or maintain high levels of customer engagement and average order value, our growth prospects, operating results, and financial condition could be materially adversely affected.

 

Traffic to our e-commerce webpages and conversion rates may decline.

 

In order to generate online customer traffic, we depend heavily on e-mailed catalogs, outbound emails, and an affiliate program. Our sales volume and e-commerce webpages traffic generally may be adversely affected by, among other things, a change in any of the above-mentioned dependencies as well as economic downturns, system failures, competition from other internet retailers, and non-internet retailers. A reduction in traffic to the e-commerce webpages as a result of these or any other factors could have a material adverse effect on our business, results of operations, and financial condition. In addition, e-commerce webpages sales conversion rates may decline due to, among other things, system failures and our ability to effectively predict and respond to changing trends and consumer demands, and to translate market trends into appropriate, saleable product offerings in a timely manner, all of which could also have a material adverse effect on our business, results of operations, and financial condition.

 

11
 

 

We must effectively manage our vendors to minimize inventory risk and maintain our margins.

 

We seek to avoid maintaining high inventory levels in an effort to limit the risk of outdated merchandise and inventory write-downs. If we underestimate quantities demanded by our customers and our vendors cannot restock, then we may disappoint customers who may then turn to our competitors. We require many of our vendors to meet minimum restocking requirements, but if our vendors cannot meet these requirements and we cannot find alternative vendors, we could be forced to carry more inventory than we have in the past. Our risk of inventory write-downs would increase if we were to hold large inventories of merchandise that prove to be unpopular.

 

We rely on third parties for some essential business operations and services, and disruptions or failures in service or changes in terms may adversely affect our ability to deliver goods and services to our customers.

 

We currently depend on third parties for important aspects of our business, such as printing, shipping, paper supplies, and operation of our e-commerce webpages and customer support. We have limited control over these third parties, and we are not their only client. In addition, we may not be able to maintain satisfactory relationships with any of these third parties on acceptable commercial terms. Further, we cannot be certain that the quality or cost of products and services that they provide will remain at currents levels or the levels needed to enable us to conduct our business efficiently and effectively.

 

Our business, including our costs and supply chain, is subject to risks associated with sourcing, manufacturing, warehousing, distribution, infrastructure, and logistics to third-party providers, and the loss of any of our key suppliers or logistical service providers could negatively impact our business.

 

All of the products we offer are supplied or manufactured by a limited number of third-party suppliers and manufacturers, and as a result we may be subject to price fluctuations or supply disruptions. Our operating results would be negatively impacted by increases in the costs of our products, and we have no guarantees that costs will not rise. In addition, as we expand into new categories and product types, we expect that we may not have strong purchasing power in these new areas, which could lead to higher costs than we have historically seen in our current categories. We may not be able to pass increased costs on to consumers, which could adversely affect our operating results. Moreover, in the event of a significant disruption in the supply of the materials used in the manufacture of the products we offer, we and the vendors that we work with might not be able to locate alternative suppliers of materials of comparable quality at an acceptable price.

 

In addition, products and merchandise we receive from manufacturers and suppliers may not be of sufficient quality or free from damage, or such products may be damaged during shipping, while stored in our warehouse fulfillment centers or with third-party ecommerce or retail customers or when returned by consumers. We may incur additional expenses and our reputation could be harmed if consumers and potential consumers believe that our products do not meet their expectations, are not properly labelled, or are damaged. Quality control problems could also result in regulatory action, such as FDA Warning Letters, restrictions on importation, product liability litigation, product seizures, products of inferior quality or product stock outages or shortages, harming our sales and creating inventory write-downs for unusable products.

 

We purchase significant amounts of product from a limited number of suppliers with limited supply capabilities. There can be no assurance that our current suppliers will be able to accommodate our anticipated growth or continue to supply current quantities at preferential prices. We generally do not maintain long-term supply contracts with any of our suppliers and any of our suppliers could discontinue selling to us at any time. An inability of our existing suppliers to provide materials in a timely or cost-effective manner could impair our growth and have an adverse effect on our business, financial condition, results of operations, and prospects.

 

We rely or may rely on software-as-a-service (“SaaS”) technologies from third parties in order to operate critical functions of our business, including financial management services, payment processing, customer relationship management services, website platform services, ecommerce services, email services, supply chain services, and data storage services. If these services become unavailable due to extended outages or interruptions or because they are no longer available on commercially reasonable terms or prices or for any other reason, or if we fail to migrate successfully to new services, our expenses could increase, our ability to manage our finances could be interrupted, our processes for managing sales of our offerings and supporting our consumers could be impaired, our ability to communicate with our suppliers could be weakened and our ability to access or save data stored to the cloud may be impaired until equivalent services, if available, are identified, obtained, and implemented, all of which could have an adverse effect on our business, financial condition, results of operations, and prospects.

 

12
 

 

We utilize cloud services from third-party data center facilities operated by AWS and Cloudflare. Any damage to, failure of, or interference with our cloud service that is hosted by us, AWS, Cloudfare, or by third-party providers we may utilize in the future, whether as a result of our actions, actions by the third-party data centers, actions by other third parties, or acts of nature, could result in interruptions in our cloud service and/or the loss of our or our customers’ data, including personal information. Impairment of, or interruptions in, our cloud services may subject us to claims and litigation and adversely affect our ability to attract new customers. Our business will also be harmed if our customers and potential customers believe our services are unreliable. Additionally, any limitation of the capacity of our data centers could impede our ability to scale, onboard new customers, or expand the usage of existing customers, which could adversely affect our business, financial condition, and results of operations. While we have disaster recovery arrangements in place, our preparations may not be adequate to account for disasters or similar events that may occur in the future and may not effectively permit us to continue operating in the event of any problems with respect to our systems or those of our third-party data centers or any other third-party facilities. Our disaster recovery and data redundancy measures may be inadequate, and our business interruption insurance may not be sufficient to compensate us for the losses that could occur.

 

If any of our key suppliers becomes insolvent, ceases or significantly reduces its operations, or experiences financial distress, or if any environmental, economic, or other outside factors impact their operations, our operations could be substantially disrupted. If we are unable to identify or enter into distribution relationships with new suppliers or to replace the loss of any of our existing suppliers, we may experience a competitive disadvantage, our business may be disrupted and our business, financial condition, results of operations, and prospects could be adversely affected.

 

If our third-party suppliers and manufacturers do not comply with ethical business practices or with applicable laws and regulations, our reputation, business, financial condition, results of operations, and prospects could be harmed.

 

We continually seek to expand our base of suppliers, especially as we identify new products that necessitate new or additional materials. We also require our new and existing suppliers to meet our ethical and business partner standards. Suppliers may also have to meet governmental and industry standards and any relevant standards required by our consumers, which may require additional investment and time on behalf of suppliers and us.

 

Our reputation and our consumers’ willingness to purchase our products depend in part on our suppliers’, manufacturers’, and retail partners’ compliance with ethical employment practices, such as with respect to child labor, wages and benefits, forced labor, discrimination, safe and healthy working conditions, and with all legal and regulatory requirements relating to the conduct of their businesses. We do not exercise control over our suppliers, manufacturers, and retail partners and cannot guarantee their compliance with ethical and lawful business practices. If our suppliers, manufacturers, or retail partners fail to comply with applicable laws, regulations, safety codes, employment practices, human rights standards, quality standards, environmental standards, production practices, or other obligations, norms, or ethical standards, our reputation and brand image could be harmed, and we could be exposed to litigation, investigations, enforcement actions, monetary liability, and additional costs that would harm our reputation, business, financial condition, results of operations, and prospects.

 

Shipping is a critical part of our business and any changes in our shipping arrangements or any interruptions in shipping could adversely affect our operating results.

 

We rely on several vendors for our shipping requirements. If we are not able to negotiate acceptable pricing or other terms with these vendors or if they experience performance problems or other difficulties, it could negatively impact our operating results and our consumer experience. Rising shipping costs and the imposition of surcharges from time to time could negatively impact our operating results. In addition, our ability to receive inbound inventory and ship products to consumers and retailers may be negatively affected by inclement weather, fire, flood, power loss, earthquakes, labor disputes, acts of war or terrorism, trade embargoes, customs and tax requirements, and similar factors. We are also subject to risks of damage or loss during delivery by our shipping vendors. If our products are not delivered in a timely fashion or are damaged or lost during delivery, our consumers could become dissatisfied and cease shopping on our site or retailer, which could have an adverse effect on our business, financial condition, operating results, and prospects.

 

13
 

 

We are subject to risks related to online payment methods, including third-party payment processing-related risks.

 

We currently accept payments using a variety of methods, including credit card, debit card, and gift cards. As we offer new payment options to consumers, we may be subject to additional regulations, compliance requirements, fraud, and other risks. We also rely on third parties to provide payment processing services, and for certain payment methods, we pay interchange and other fees, which may increase over time and raise our operating costs and affect our ability to achieve or maintain profitability. We are also subject to payment card association operating rules and certification requirements, including the Payment Card Industry Data Security Standard, or PCI-DSS, and rules governing electronic funds transfers, which could change or be reinterpreted to make it difficult or impossible for us to comply. If we (or a third party processing payment card transactions on our behalf) suffer a security breach affecting payment card information, we may have to pay onerous and significant fines, penalties and assessments arising out of the major card brands’ rules and regulations, contractual indemnifications, or liability contained in merchant agreements and similar contracts, and we may lose our ability to accept payment cards for payment for our goods and services, which could materially impact our operations and financial performance.

 

Furthermore, as our business changes, we may be subject to different rules under existing standards, which may require new assessments that involve costs above what we currently pay for compliance. As we offer new payment options to consumers, including by way of integrating emerging mobile and other payment methods, we may be subject to additional regulations, compliance requirements, and fraud. If we fail to comply with the rules or requirements of any provider of a payment method we accept, if the volume of fraud in our transactions limits or terminates our rights to use payment methods we currently accept, or if a data breach occurs relating to our payment systems, we may, among other things, be subject to fines or higher transaction fees and may lose, or face restrictions placed upon, our ability to accept credit card payments from consumers or facilitate other types of online payments. In addition, our customers could lose confidence in certain payment types, which may result in a shift to other payment types or potential changes to our payment systems that may result in higher costs.

 

We also occasionally receive orders placed with fraudulent data and we may ultimately be held liable for the unauthorized use of a cardholder’s card number in an illegal activity and be required by card issuers to pay charge-back fees. Charge-backs result not only in our loss of fees earned with respect to the payment, but also leave us liable for the underlying money transfer amount. If our charge-back rate becomes excessive, card associations also may require us to pay fines or refuse to process our transactions. In addition, we may be subject to additional fraud risk if third-party service providers or our employees fraudulently use consumer information for their own gain or facilitate the fraudulent use of such information. Overall, we may have little recourse if we process a criminally fraudulent transaction. If we fail to adequately control fraudulent credit card transactions, we may face civil liability, diminished public perception of our security measures, and significantly higher credit card-related costs, each of which could harm our business, results of operations and financial condition.

 

Merchandise returns could harm our business.

 

We allow our customers to return products, subject to our return policy. If the rate of merchandise returns increases significantly or if merchandise return economics become less efficient, our business, financial condition, and operating results could be harmed. Further, we modify our policies relating to returns from time to time, which may result in customer dissatisfaction or an increase in the number of product returns. From time to time our products are damaged in transit, which can increase return rates and harm our brands.

 

Our operations are currently dependent on a single warehouse and distribution center, and the loss of, or disruption in, the warehouse and distribution center and other factors affecting the distribution of merchandise could have a material adverse effect on our business and operations.

 

Our warehouse and fulfillment/distribution functions are currently primarily handled from a single facility. Our current fulfillment/distribution operations are dependent on the continued use of this facility. Any significant interruption in the operation of the warehouse and fulfillment/ distribution center due to COVID-19 restrictions, natural disasters, accidents, system issues or failures, or other unforeseen causes that materially impair our ability to access or use our facility, could delay or impair the ability to distribute merchandise and fulfill online orders, which could cause sales to decline.

 

14
 

 

We also depend upon third-party carriers for shipment of a significant amount of merchandise directly to our customers. An interruption in service by these third-party carriers for any reason could cause temporary disruptions in business, a loss of sales and profits, and other material adverse effects.

 

Our revenues and income could decline due to general economic trends and declines in consumer spending.

 

Our revenues are largely generated by discretionary consumer spending. Consumer spending tends to decline during recessionary periods and may also decline at other times. Accordingly, our revenues could decline during any general economic downturn.

 

We face risks related to recession, inflation, weak growth, and other economic conditions.

 

Customer demand for our products may be impacted by weak economic conditions, inflation, weak growth, recession, equity market volatility, or other negative economic factors in the United States or other nations. For example, under these conditions, potential customers may delay or cancel purchases of our products. Further, in the event of a recession, our manufacturing partners, suppliers, and other third-party partners may suffer their own financial and economic challenges and as a result they may demand pricing accommodations, delay payment, or become insolvent, which could harm our ability to meet our customer demands or otherwise could harm our business, financial condition, and results of operations. Similarly, disruptions in financial and credit markets may impact our ability to manage normal commercial relationships with our customers, suppliers, and lenders and might cause us to not be able to access sources of liquidity, and our borrowing costs could increase. If general macroeconomic conditions deteriorate, our business, financial condition, and results of operations could be materially and adversely affected.

 

In addition, we are also subject to risk from inflation and increasing market prices of certain supplies and raw materials, which are incorporated into our products or used by our suppliers to manufacture our products. These components, supplies, and commodities may from time to time become restricted, or general market factors and conditions may affect pricing of such components, supplies and commodities, such as inflation or supply chain constraints.

 

Changes in the economy could have a detrimental impact on our business.

 

Changes in the general economic climate could have a detrimental impact on our revenue. It is possible that recessionary pressures and other economic factors (such as declining incomes, future potential rising interest rates, higher unemployment, and tax increases) may adversely affect our business. Any of such events or occurrences could have a material adverse effect on our financial results.

 

Increases in labor costs, including wages, could adversely affect our business, financial condition, and results of operations.

 

Labor is a significant portion of our cost structure and is subject to many external factors, including unemployment levels, prevailing wage rates, minimum wage laws, potential collective bargaining arrangements, health insurance costs and other insurance costs, and changes in employment and labor legislation or other workplace regulation. From time to time, legislative proposals are made to increase the federal minimum wage in the United States, as well as the minimum wage in California and a number of other states and municipalities, and to reform entitlement programs, such as health insurance and paid leave programs. As minimum wage rates increase or related laws and regulations change, we may need to increase not only the wage rates of our minimum wage employees, but also the wages paid to our other hourly or salaried employees. Any increase in the cost of our labor could have an adverse effect on our business, financial condition, and results of operations or if we fail to pay such higher wages we could suffer increased employee turnover. Increases in labor costs could force us to increase prices, which could adversely impact our sales. If competitive pressures or other factors prevent us from offsetting increased labor costs by increases in prices, our profitability may decline and could have a material adverse effect on our business, financial condition, and results of operations.

 

15
 

 

We face competition in our market from various companies, most of which have greater financial, technical, and other resources than us.

 

We face significant competition from other marketing companies, and our operating results could suffer if we fail to compete effectively. The marketing industry is intensely competitive and subject to rapid and significant change. We have competitors both in the United States and internationally, including major marketing companies. Many of our competitors have substantially greater financial, technical, and other resources, such as larger staff and experienced marketing and manufacturing organizations. These companies may obtain market acceptance more rapidly than we can and may be more effective in selling and marketing their products and services as well. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Our ability to compete depends, in part, upon a number of factors outside our control, including the ability of our competitors to develop products and services that are superior. Competition may increase further as a result of greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring, or licensing similar products or services that we may develop. If we fail to successfully compete in our market, or if we incur significant expenses in order to compete, it could have a material adverse effect on our results of operations.

 

Our business model is evolving.

 

Our business model is unproven and is likely to continue to evolve. Accordingly, our initial business model may not be successful and may need to be changed. Our ability to generate significant revenues will depend, in large part, on our ability to successfully market our products to potential users who may not be convinced of the need for our products and services or who may be reluctant to rely upon third parties to develop and provide these products. We intend to continue to develop our business model as our market continues to evolve.

 

If we fail to maintain and enhance awareness of our brand, our business and financial results could be adversely affected.

 

We believe that maintaining and enhancing awareness of our brand is critical to achieving widespread acceptance and success of our business. We also believe that the importance of brand recognition will increase due to the relatively low barriers to entry in our market. Maintaining and enhancing our brand awareness may require us to spend increasing amounts of money on, and devote greater resources to, advertising, marketing, and other brand-building efforts and these investments may not be successful. Further, even if these efforts are successful, they may not be cost-effective. If we are unable to continuously maintain and enhance our media presence, our market may decrease and we may fail to attract advertisers and subscribers, which could in turn result in lost revenues and adversely affect our business and financial results.

 

An inability to maintain and enhance product image could harm our business.

 

It is important that we maintain and enhance a positive perception of any new products. The image and reputation of our products may be impacted for various reasons including, but not limited to, bad publicity, litigation, and complaints from regulatory bodies. Such problems, even when unsubstantiated, could be harmful to our image and the reputation of our products. These claims may not be covered by our insurance policies. Any resulting litigation could be costly for us, divert management attention, and could result in increased costs of doing business, or otherwise have a material adverse effect on our business, results of operations, and financial condition. Any negative publicity generated could damage our reputation and diminish the value of our brand, which could have a material adverse effect on our business, results of operations, and financial condition. Deterioration in our brand equity (brand image, reputation, and product quality) may have a material adverse effect on our financial results.

 

We could face liability for information displayed via our e-commerce webpages and our other websites.

 

We may be subjected to claims for defamation, negligence, copyright or trademark infringement, or based on other theories relating to the information we publish on our e-commerce webpages and on any of our websites. These types of claims have been brought, sometimes successfully, against similar companies in the past. Based on links we provide to third-party websites, we could also be subjected to claims based upon online content we do not control that is accessible from our e-commerce webpages.

16
 

 

The actual or perceived failure by us or our vendors to comply with applicable privacy and data protection laws, regulations, or industry standards could have an adverse effect on our business, financial condition, results of operations, and prospects.

 

We collect, store, share, use, retain, safeguard, transfer, analyze, and otherwise process, and our vendors process on our behalf, personal information, confidential information and other information necessary to provide and deliver our products through our e-commerce channel to operate our business, for legal and marketing purposes, and for other business-related purposes. Collection and use of this information might raise privacy and data protection concerns, which could negatively impact our business. Data privacy and information security has become a significant issue in the United States, Europe, and elsewhere. The legal and regulatory framework for privacy and security issues is rapidly evolving and is expected to increase our compliance costs and exposure to liability. There are numerous federal, state, local, and international laws, orders, codes, rules, regulations, and regulatory guidance regarding privacy, information security, and processing (collectively, “Data Protection Laws”), the number and scope of which is changing, subject to differing applications and interpretations, and which may be inconsistent among jurisdictions, or in conflict with other rules, laws, or obligations (collectively, “Data Protection Obligations”). Therefore, the regulatory framework for privacy and data protection worldwide is, and is likely to remain, uncertain and complex for the foreseeable future, and our actual or perceived failure to address or comply with applicable Data Protection Laws and Data Protection Obligations could have an adverse effect on our business, financial condition, results of operations, and prospects. We also expect that there will continue to be new Data Protection Laws and Data Protection Obligations, and we cannot yet determine the impact such future Data Protection Laws and Data Protection Obligations may have on our business. Any significant change to Data Protection Laws and Data Protection Obligations, including without limitation, regarding the manner in which the express or implied consent of consumers for processing is obtained, could increase our costs and require us to modify our operations, possibly in a material manner, which we may be unable to complete and may limit our ability to store and process consumer data and operate our business.

 

We are or may also be subject to the terms of our external and internal privacy and security policies, codes, representations, certifications, industry standards, publications, and frameworks (collectively, “Privacy Policies”) and contractual obligations to third parties related to privacy, information security and processing, including contractual obligations to indemnify and hold harmless third parties from the costs or consequences of non-compliance with Data Protection Laws or Data Protection Obligations.

 

We may not be successful in achieving compliance if our employees, partners, or vendors do not comply with applicable Data Protection Laws, Privacy Policies, and Data Protection Obligations. If we or our vendors fail (or are perceived to have failed) to comply with applicable Data Protection Laws, Privacy Policies, and Data Protection Obligations, or if our Privacy Policies are, in whole or part, found to be inaccurate, incomplete, deceptive, unfair, or misrepresentative of our actual practices, our business, financial condition, results of operations, and prospects could be adversely affected.

 

In the United States, our obligations include rules and regulations promulgated under the authority of the Federal Trade Commission (the “FTC”), the Electronic Communications Privacy Act, the Computer Fraud and Abuse Act, the California Consumer Privacy Act (the “CCPA”) and other state and federal laws relating to privacy and data security. The CCPA, which took effect on January 1, 2020, requires companies that process information of California residents to make new disclosures to consumers about their data collection, use and sharing practices, allows consumers to opt out of the sale of personal information with third parties, and prohibits covered businesses from discriminating against California residents (for example, charging more for services) for exercising any of their rights under the CCPA. The law also provides a private right of action and statutory damages for certain data breaches that result in the loss of personal information. This private right of action is expected to increase the likelihood of, and risks associated with, data breach litigation. However, it remains unclear how various provisions of the CCPA will be interpreted and enforced. Therefore, the CCPA may increase our compliance costs and potential liability.

 

In addition, California voters recently approved the California Privacy Rights Act of 2020 (the “CPRA”) that went into effect on January 1, 2023. The CPRA significantly modifies the CCPA and imposes additional data protection obligations on companies doing business in California, resulting in further complexity. The law, among other things, gives California residents the ability to limit the use of their sensitive information, provides for penalties for CPRA violations concerning California residents under the age of 16, and establishes a new California Privacy Protection Agency to implement and enforce the law. The effects of this legislation are far-reaching and may impact our business. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States, which could increase our potential liability and adversely affect our business, financial condition, results of operations, and prospects.

 

17
 

 

Other jurisdictions in the United States have already passed or are considering laws similar to the CCPA and CPRA, with potentially greater penalties and more rigorous compliance requirements relevant to our business. Many state legislatures have already adopted legislation that regulates how businesses operate online, including measures relating to privacy, data security, data breaches, and the protection of sensitive and personal information. For example, on March 2, 2021, Virginia enacted the Virginia Consumer Data Protection Act (the “CDPA”), a comprehensive privacy statute that shares similarities with the CCPA, CPRA, and legislation proposed in other states. The CDPA required us to incur additional costs and expenses to comply with it before it became effective on January 1, 2023. June 2021, Colorado also enacted a similar law, the Colorado Privacy Act (the “CPA”), which becomes effective on July 1, 2023. Many other states are currently considering proposed comprehensive data privacy legislation and all 50 states have passed at least some form of data privacy legislation (for example, all 50 states have enacted laws requiring disclosure of certain personal data breaches).

 

At the federal level, the United States Congress is also considering various proposals for comprehensive federal data privacy legislation and, while no comprehensive federal data privacy law currently exists, we are subject to applicable existing federal laws and regulations, such as the rules and regulations promulgated under the authority of the FTC, which regulates unfair or deceptive acts or practices, including with respect to data privacy and security. These state statutes, and other similar state or federal laws, may require us to modify our data processing practices and policies and incur substantial compliance-related costs and expenses.

 

We rely on a variety of marketing techniques and practices, including email and social media marketing, online targeted advertising, cookie-based processing, and postal mail to sell our products and services and to attract new consumers, and we and our vendors, are subject to various current and future Data Protection Laws and Data Protection Obligations that govern marketing and advertising practices. Governmental authorities continue to evaluate the privacy implications inherent in the use of third-party “cookies” and other methods of online tracking for behavioral advertising and other purposes, such as by regulating the level of consumer notice and consent required before a company can employ cookies or other electronic tracking tools or the use of data gathered with such tools. Additionally, some providers of consumer devices, web browsers and application stores have implemented, or announced plans to implement, means to make it easier for Internet users to prevent the placement of cookies or to block other tracking technologies, require additional consents, or limit the ability to track user activity, which could if widely adopted result in the use of third-party cookies and other methods of online tracking becoming significantly less effective. Laws and regulations regarding the use of these cookies and other current online tracking and advertising practices or a loss in our ability to make effective use of services that employ such technologies could increase our costs of operations and limit our ability to acquire new consumers on cost-effective terms, which, in turn, could have an adverse effect on our business, financial condition, results of operations, and prospects.

 

Government regulation of the internet and ecommerce is evolving and unfavorable changes or failure by us to comply with these regulations could have an adverse effect on our business, financial condition, results of operations, and prospects.

 

We are subject to general business regulations and laws as well as regulations and laws specifically governing the internet and ecommerce, including consumer protection regulations that regulate retailers and govern the promotion and sale of merchandise. Existing and future regulations and laws could impede the growth of the Internet, ecommerce, or mobile commerce, which could in turn adversely affect our growth. These regulations and laws may involve taxes, tariffs, privacy and data security, anti-spam, content protection, electronic contracts and communications, consumer protection, sales practices, subscription programs, and internet neutrality. It is not clear how existing laws governing issues such as property ownership, sales and other taxes and consumer privacy apply to the Internet as the vast majority of these laws were adopted prior to the advent of the Internet and do not contemplate or address the unique issues raised by the internet or ecommerce. It is possible that general business regulations and laws, or those specifically governing the internet or ecommerce, may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other rules or our practices. We cannot be sure that our practices have complied, comply, or will comply fully with all such laws and regulations. Any failure, or perceived failure, by us to comply with any of these laws or regulations could result in damage to our reputation, a loss in business, and proceedings or actions against us by governmental entities, customers, suppliers or others. Any such proceeding or action could hurt our reputation, force us to spend significant amounts in defense of these proceedings, distract our management, increase our costs of doing business, decrease the use of our website and mobile applications by customers and suppliers, and may result in the imposition of monetary liabilities and burdensome injunctions that could, for example, require changes to our business practices. We may also be contractually liable to indemnify and hold harmless third parties from the costs or consequences of noncompliance with any such laws or regulations. As a result, adverse developments with respect to these laws and regulations could have an adverse effect on our business, financial condition, results of operations, and prospects.

 

(See also “Government Regulations” for additional risks.)

 

18
 

 

Advertising inaccuracies or product mislabeling may have an adverse effect on our business by exposing us to lawsuits, product recalls or regulatory enforcement actions, increasing our operating costs and reducing demand for our product offerings.

 

Many products that we sell are labeled and advertised with claims as to their origin, ingredients, or health, wellness, environmental or other benefits, including, by way of example, the use of the term “natural” or “organic” or similar synonyms or implied statements relating to such benefits. The FTC’s Guides for The Use Of Environmental Marketing Claims (the “Green Guides”) provide guidance on how to use environmental marketing claims, provide specific guidance for certain terms (e.g., “recyclable”), and recommend against using unqualified statements about environmental benefits such as “eco-friendly.” Although the FDA and the USDA each have issued statements regarding the appropriate use of the word “natural,” there is no single, U.S. government regulated definition of the term “natural” for use in the consumer and personal care industry.

 

Consumer class actions, actions from industry groups such as the National Advertising Division of the Better Business Bureau, and public enforcement actions have been brought against numerous companies that market “natural,” “sustainable,” or other ecologically conscious products or ingredients, asserting false, misleading, and deceptive advertising and labeling claims.

 

These suits often identify ingredients or components of a product for which certain marketing claims may not be fully accurate and claim that their presence in the product renders the statements false and deceptive. For example, some actions concerning “natural” claims have focused on the presence of genetically modified and/or synthetic ingredients or components in products, including synthetic forms of otherwise natural ingredients.

 

(See “Government Regulations.”)

 

Many of our products are subject to regulatory enforcement.

 

  - The FDA regulates product labels and other product claims for the consumer products subject to its jurisdiction and has the authority to challenge product labels and claims that it believes are non-compliant or false or misleading, through the use of a variety of enforcement tools (e.g., Warning Letters, untitled letters, and seizure actions). In limited circumstances, the FDA has taken regulatory action against products labeled “natural” but that nonetheless contain synthetic ingredients or components.
     
  - The FTC has the authority to challenge claims made in product advertising and requires that such claims are adequately substantiated prior to use. The FTC similarly has enforcement tools that it uses to challenge advertising claims that it deems non-compliant with the law.
     
  - The USDA enforces federal standards for organic production and use of the term “organic” on product labeling. These laws prohibit a company from selling or labeling products as organic unless they are produced and handled in accordance with the applicable federal law. Failure to comply with these requirements may subject us to liability or regulatory enforcement. Consumers may also pursue state law claims challenging use of the organic label as being intentionally mislabeled or misleading or deceptive to consumers.

 

State and local regulators also have the authority to prosecute false advertising cases, including relating to environmental marketing claims. Current and potential competitors may make similar claims, which may result in action and inquiries to us from state and federal regulators and governments.

 

Should we become subject to actions regarding our branding or product marketing, consumers may avoid purchasing products from us or seek alternatives, even if the basis for the claim is unfounded. Moreover, any regulatory or government enforcement actions may trigger class action lawsuits under state consumer protection laws.

 

19
 

 

Adverse publicity about these matters may discourage consumers from buying our products. The cost of defending against any such claims could be significant and we may incur substantial costs remediating product claims in labeling and advertising if we are unsuccessful in defending such actions. Any loss of confidence on the part of consumers in the truthfulness of our labeling, advertising or ingredient claims would be difficult and costly to overcome and may significantly reduce our brand value. Any of these events could adversely affect our reputation and brand and decrease our sales, which could have an adverse effect on our business, financial condition, results of operations, and prospects.

 

False or misleading marketing claims concerning a product’s registration or its efficacy may also create the risk for challenges under federal or state law.

 

(See “Government Regulations.”)

 

We are subject to a number of other laws and regulations, which could impact our business.

 

We are subject to a broad range of federal, state, local, and foreign laws and regulations intended to protect public and worker health and safety, natural resources, the environment, and consumers. Our operations are subject to regulation by the Occupational Safety and Health Administration (“OSHA”), the FDA, the CPSC, the USDA, the FTC, and by various other federal, state, local and foreign authorities regarding the manufacture, processing, packaging, storage, sale, order fulfillment, advertising, labeling, import and export of our products. In addition, we and our manufacturing partners are subject to additional regulatory requirements, including state, local and foreign environmental, health and safety legislative and regulatory authorities and the National Labor Relations Board, covering such areas as discharges and emissions to air and water, the use, management, disposal and remediation of, and human exposure to, hazardous materials and wastes, and public and worker health and safety, and Current Good Manufacturing Practice requirements (“GMPs”) enforced by the FDA.

 

In addition, as the provider of products with a subscription-based element, a variety of laws and regulations govern the ability of users to cancel subscriptions and auto-payment renewals. California’s automatic renewal law in particular has been the basis for both consumer class actions and government enforcement.

 

Violations of or liability under any of these laws and regulations may result in administrative, civil, or criminal fines, penalties, or sanctions against us, revocation or modification of applicable permits, licenses, or authorizations, environmental, health and safety investigations or remedial activities, voluntary or involuntary product recalls, warning or untitled letters or cease and desist orders against operations that are not in compliance, among other things. Such laws and regulations generally have become more stringent over time and may become more so in the future, and we may incur (directly or indirectly through our manufacturing partners) material costs to comply with current or future laws and regulations or in any required product recalls.

 

Liabilities under, and/or costs of compliance, and the impacts on us of any non-compliance, with or investigations under any such laws and regulations could have an adverse effect on our business, financial condition, results of operations, and prospects.

 

Failure by our network of retail and ecommerce partners, suppliers, or manufacturers to comply with product safety, environmental, or other laws and regulations, or with the specifications and requirements of our products, may disrupt our supply of products and adversely affect our business.

 

If our network of retail and ecommerce partners, suppliers, or manufacturers fail to comply with environmental, health and safety, or other laws and regulations, or face allegations of non-compliance, their operations may be disrupted and our reputation could be harmed. Additionally, our retail and ecommerce partners, suppliers, and manufacturers are required to maintain the quality of our products and to comply with our standards and specifications. In the event of actual or alleged non-compliance, we might be forced to find alternative retail or ecommerce partners, suppliers, or manufacturers and we may be subject to lawsuits and/or regulatory enforcement actions related to such non-compliance by the suppliers and manufacturers. As a result, our supply of products could be disrupted or our costs could increase, which could adversely affect our business, financial condition, results of operations, and prospects. The failure of any partner or manufacturer to produce products that conform to our standards could adversely affect our reputation in the marketplace and result in product recalls, product liability claims, government, or third-party actions, or economic loss. For example, a manufacturer’s failure to meet GMPs could result in the delivery of a product that is subject to a product recall, product liability litigation, or government investigations and enforcement. Additionally, actions we may take to mitigate the impact of any disruption or potential disruption in our supply of materials or finished inventory, including increasing inventory in anticipation of a potential supply or production interruption, could have an adverse effect on our business, financial condition, results of operations, and prospects.

 

20
 

 

Our future financial performance and our ability to commercialize our products and services and to compete effectively will depend, in part, on our ability to manage any future growth effectively.

 

If our operations expand as planned, we will need to manage additional relationships with various strategic partners, suppliers, and other third parties. Our future financial performance and our ability to commercialize our products and services and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts effectively and hire, train, and integrate additional management, administrative and sales and marketing personnel. Our projected growth will place a significant strain on our administrative, operational, and financial resources. If we are unable to successfully manage our future growth, establish and continue to upgrade our operating and financial control systems, recruit and hire necessary personnel, or effectively manage unexpected expansion difficulties, our financial condition and results of operations could be materially and adversely affected.

 

Our operating plan relies in large part upon our assumptions and analyses. If these assumptions or analyses prove to be incorrect, our actual operating results may be materially different from our forecasted results.

 

Whether actual operating results and business developments will be consistent with our expectations and assumptions as reflected in our operating plan depends on a number of factors, many of which are outside our control, including, but not limited to:

 

  whether we can obtain sufficient capital to sustain and grow our business;
     
  our ability to manage our growth;
     
  results of our research and development activity;
     
  demand for our current and proposed products;
     
  competition;
     
  our ability to retain existing key management and consultants, to integrate recent hires, and to attract, retain, and motivate qualified personnel; and
     
  the overall strength and stability of domestic and international economies.

 

Unfavorable changes in any of these or other factors, most of which are beyond our control, could materially and adversely affect our business, results of operations, and financial condition.

 

Acts of war or terrorism may seriously harm our business.

 

Acts of war, any outbreak or escalation of hostilities between the United States and any foreign power, or acts of terrorism may cause disruption to the U.S. economy or the local economies of the markets in which we operate, cause shortages of materials, increase costs associated with obtaining materials, affect job growth and consumer confidence, or cause economic changes that we cannot anticipate, all of which could reduce demand for our products and services and adversely impact our business, prospects, liquidity, financial condition, and results of operations.

 

21
 

 

RISKS RELATED TO OUR ORGANIZATION AND STRUCTURE

 

We have authorized and designated Class A Preferred Convertible Stock, which have voting rights of 60% of our common stock at all times.

 

We have 500,000 shares of our Class A Preferred Convertible Stock authorized and outstanding. The Class A Preferred Convertible Stock have 60% super majority voting rights over our common stock. At this time, all shares of the Class A Preferred Convertible Stock are issued to our CEO, Jaspreet Mathur. Therefore, at all times, our CEO will have voting control over all decisions requiring majority vote or consent.

 

Jaspreet Mathur, our Chief Executive Officer, owns greater than 50% of our voting securities which will cause us to be deemed a “controlled company” under the rules of NYSE American.

 

As a result of his ownership of all issued and outstanding shares of our Class A Preferred Convertible Stock, as well as ownership of our Common Stock, Mr. Mathur, our Chief Executive Officer currently holds approximately 87% of our voting securities (and will continue to own at least 60% of our voting stock at all times, including after our offering), and as such, we are a “controlled company” under the NYSE American Listing Rules. Under these rules, a company of which more than 50% of the voting power is held by an individual, a group, or another company is a “controlled company” and, as such, may elect to be exempt from certain corporate governance requirements.

 

Accordingly, should the interests of Mr. Mathur differ from those of other shareholders, the other shareholders may not have the same protections afforded to shareholders of companies that are subject to all of the NYSE American corporate governance standards. Even if we do not avail ourselves of these exemptions, our status as a controlled company could make our common stock less attractive to some investors or otherwise harm our stock price.

 

Because insiders control our activities, that may cause us to act us in a manner that is most beneficial to them and not to outside shareholder which could cause us not to take actions that outside shareholders might view favorably.

 

Our officers, directors, and holders of 5% or more of our issued and outstanding common stock beneficially own approximately 78.2% of our issued and outstanding common stock and our CEO owns all of the Class A Preferred Convertible Stock. As a result, insiders and particularly our CEO effectively control all matters requiring shareholder approval, including the election of directors, the approval of significant corporate transactions, such as mergers and related party transaction. These insiders also have the ability to delay or perhaps even block, by their ownership of our stock, an unsolicited tender offer. This concentration of ownership could have the effect of delaying, deterring or preventing a change in control that you might view favorably.

 

We are dependent upon our management, founders, key personnel, and consultants to execute our business plan, and many of them have concurrent responsibilities at other companies.

 

Our success is heavily dependent upon the continued active participation of our current executive officers as well as other key personnel and consultants. Many of them have concurrent responsibilities at other entities . Some of the advisors and consultants, and others to whom our ultimate success may be reliant have not signed contracts with us and may not ever do so. Loss of the services of one or more of these individuals could have a material adverse effect upon our business, financial condition, or results of operations. Further, our success and achievement of our growth plans depend on our ability to recruit, hire, train, and retain other highly qualified personnel. Competition for qualified employees and consultants among companies in the applicable industries is intense, and the loss of any of such persons, or an inability to attract, retain, and motivate any additional highly skilled employees and consultants required for the initiation and expansion of our activities, could have a materially adverse effect on it.

 

We do not have any key person life insurance policies on any of our officers or employees.

 

We are dependent upon our officers and key employees to conduct our operations and execute our business plan. However, we have not purchased any life insurance policies for any individuals in the event of their death or disability. Therefore, should any of those officers and key employees die or become disabled, we will not receive any compensation that would assist with such person’s absence. The loss of such person could negatively affect us and our operations.

 

22
 

 

There are limitations on the liability of our directors.

 

Delaware General Corporation Laws exclude personal liability of our directors and our shareholders for monetary damages for breach of fiduciary duty except in certain specified circumstances. Accordingly, we will have a much more limited right of action against our directors than otherwise would be the case. This provision does not affect the liability of any director under federal or applicable state securities laws. Our charter documents also provide for the indemnification of directors to the fullest extent permitted by law and, to the extent permitted by such law, eliminate or limit the personal liability of directors for monetary damages for certain breaches of fiduciary duty. Insofar as indemnification for liabilities arising under the Act may be permitted to directors, officers, or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is therefore unenforceable.

 

We have agreed to indemnification of officers and directors as is allowed by Delaware General Corporation Law.

 

Delaware General Corporation Law provides for the indemnification of our directors, officers, employees, and agents, under certain circumstances, against attorney’s fees and other expenses incurred by them in any litigation to which they become a party arising from their association with us or activities our behalf. We will also bear the expenses of such litigation for any of our directors, officers, employees, or agents, upon such person’s promise to repay us therefore if it is ultimately determined that any such person shall not have been entitled to indemnification. This indemnification policy could result in substantial expenditures by us that we will be unable to recoup.

 

Our officers and directors may have conflicts of interests as to corporate opportunities which we may not be able or allowed to participate in.

 

Presently there is no requirement contained in our charter documents or minutes which requires officers and directors of our business to disclose to us business opportunities which come to their attention. Our officers and directors do, however, have a fiduciary duty of loyalty to us to disclose to us any business opportunities which come to their attention, in their capacity as an officer and/or director or otherwise. Excluded from this duty would be opportunities which the person learns about through his involvement as an officer and director of another company. See Certain Relationships and Related Party Transactions.”

 

RISKS RELATED TO OWNERSHIP OF OUR SECURITIES

 

We can issue future series of shares of preferred stock without shareholder approval which could adversely affect the rights of common shareholders.

 

Our Certificate of Incorporation, as amended, permits our board of directors to establish the rights, privileges, preferences and restrictions, including voting rights, of future series of preferred stock and to issue such stock without approval from our shareholders. The rights of holders of common stock may suffer as a result of the rights granted to holders of preferred stock that may be issued in the future. In addition, we could issue preferred stock to prevent a change in control, depriving common shareholders of an opportunity to sell their stock at a price in excess of the prevailing market price.

 

If we are unable to implement and maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, which could adversely affect the market price of our common stock.

 

We have identified material weaknesses in our internal control over financial reporting. These material weaknesses relate to the fact that we do not maintain a comprehensive policies and procedures manual designed to establish internal controls over financial reporting to reduce the risk of publishing materially misstated financial statements, as well as define responsibilities and segregate incompatible duties to reduce the risk of unauthorized transactions.

 

23
 

 

As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. A material weakness is defined in the standards established by the Public Company Accounting Oversight Board (United States) as a deficiency, or an acquisition of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. The process of designing, implementing and testing the internal control over financial reporting required to comply with this obligation is time consuming, costly, and complex. If we fail to increase and maintain the number and expertise of our staff for our accounting and finance functions and to improve and maintain internal control over financial reporting adequate to meet the demands upon us as a public company, including the requirements of the Sarbanes-Oxley Act, we may be unable to report our financial results accurately and prevent fraud. In addition, we cannot be certain that any such steps we undertake will successfully remediate any material weaknesses or that other material weaknesses and control deficiencies will not be discovered in the future. If our remediation efforts are not successful or other material weaknesses or control deficiencies occur in the future, we may be unable to report our financial results accurately or on a timely basis, which could cause our reported financial results to be materially misstated and result in the loss of investor confidence or delisting and cause our stock price to decline. As a result of such failures, we could also become subject to investigations by any over-the-counter market where our stock may trade, the SEC, or other regulatory authorities, and become subject to litigation from investors and shareholders, any of which could harm our reputation and financial condition, and divert financial and management resources. Even if we are able to report our consolidated financial statements accurately and timely, if we do not make all the necessary improvements to address the material weaknesses, continued disclosure of our material weaknesses will be required in future filings with the SEC, which could reduce investor confidence in our reported results and our cause our stock price to decline.

 

Our stock price may be volatile.

 

Our common stock may be subject to rapid and substantial price volatility. Contributing to this risk of volatility are a number of factors. First, our shares of common stock are likely to be more sporadically and thinly traded than that of larger, more established companies. As a consequence of this lack of liquidity, the trade of relatively small quantities of shares by our shareholders may disproportionately influence the price of those shares in either direction. The price of our common stock could, for example, decline precipitously in the event that a large number of our shares are sold on the market without commensurate demand as compared to a seasoned issuer that could better absorb those sales without adverse impact on its stock price. Second, we are a speculative investment due to our limited operating history, not being profitable, and engaging in a new business strategy with no guarantee of its success. As a consequence of this enhanced risk, shareholders, under the fear of losing all or most of their investment in the event of negative news or lack of progress, be more inclined to sell their shares on the market more quickly and at greater discounts than would be the case with the stock of a larger, more established company that has a relatively large public float.

 

In addition, the market price of our common stock is also subject to significant fluctuations in response to, among other factors:

 

  quarterly variations in our results of operations or those of our competitors;
     
  announcements by us or our competitors of acquisitions, new products, significant contracts, commercial relationships or capital commitments;
     
  disruption to our operations or those of other sources critical to our operations;
     
  the emergence of new competitors or new products;
     
  our ability to develop and market new and enhanced products on a timely basis;
     
  seasonal or other variations in our subscriber base;
     
  commencement of, or our involvement in, litigation;

 

  dilutive issuances of our stock or the stock of our subsidiaries, or the incurrence of additional debt;
     
  changes in our board or management;
     
  adoption of new or different accounting standards;
     
  changes in earnings estimates or recommendations by securities analysts; and
     
  general economic conditions and slow or negative growth of related markets.

 

Many of these factors are beyond our control and may decrease the market price of our common stock. Such volatility, including any stock run-ups, may be unrelated or disproportionate to our actual or expected operating performance and financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our common stock.

 

24
 

 

Furthermore, the stock market in general, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general economic, political and market conditions such as recessions or interest rate changes, may seriously affect the market price of our common stock, regardless of our actual operating performance.

 

Further, in the past, following periods of volatility in the overall market and the market prices of particular companies’ securities, securities class action litigations have often been instituted against these companies. Litigation of this type, if instituted against us, could result in substantial costs and a diversion of our management’s attention and resources. Any adverse determination in any such litigation or any amounts paid to settle any such actual or threatened litigation could require that we make significant payments.

 

There has been a limited public market for our common stock and there is no assurance that a more active, liquid and orderly trading market will develop for our common stock or what the market price of our common stock will be.

 

There is and has been a limited public market for shares of our common stock on the OTCQB. Until our common stock is listed on a national market or a broader exchange, we anticipate that it will remain quoted on the OTCQB. In this venue, investors may find it difficult to obtain accurate quotations as to the market value of our common stock. In addition, if we fail to meet the criteria set forth in SEC regulations, various requirements would be imposed by law on broker-dealers who sell our securities to persons other than established customers and accredited investors. Consequently, such regulations may deter broker-dealers from recommending or selling our common stock, which may further affect liquidity. This could also make it more difficult to raise additional capital.

 

Our stock is thinly traded.

 

The shares of our common stock are thinly-traded. We are a small company which is relatively unknown to stock analysts, stockbrokers, institutional shareholders and others in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons, they tend to be risk-averse and would be reluctant to follow an unproven, early stage company such as ours or purchase or recommend the purchase of any of our securities until such time as we became more seasoned and viable. As a consequence, there may be periods of several days or more when trading activity in our securities is minimal or non-existent, as compared to a seasoned issuer which has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on securities prices. We cannot give you any assurance that a broader or more active public trading market for our securities will develop or be sustained, or that any trading levels will be sustained. Due to these conditions, we can give shareholders no assurance that they will be able to sell their shares at or near ask prices or at all if they need money or otherwise desire to liquidate their securities.

 

Our securities are considered a penny stock, and therefore are subject to the penny stock rules, as such, U.S. broker-dealers may be discouraged from effecting transactions in our securities.

 

Our securities are subject to the penny stock rules under the Exchange Act. The SEC rules define a “penny stock,” as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, Rule 15g-9 requires broker-dealers that derive more than 5% of their customer transaction revenues from transactions in penny stocks to deliver a standardized risk disclosure document that provides information about penny stocks and the nature and level of risks in the penny stock market to any non-institutional customer to whom the broker-dealer recommends a penny stock transaction. The broker-dealer must also provide the customer with the current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson, and monthly account statements showing the market value of each penny stock held in the customer’s account. The bid and offer quotations and the broker-dealer and salesperson compensation information must be given to the customer orally or in writing before completing the transaction and must be given to the customer in writing before or with the customer’s confirmation. In addition, the penny stock rules require that before a transaction, the broker and/or dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. The transaction costs associated with penny stocks are high, reducing the number of broker-dealers who may be willing to engage in the trading of our securities. These additional penny stock disclosure requirements are burdensome and may reduce all the trading activity in the market for our securities. As long as our securities are subject to the penny stock rules, holders of our securities may find it more difficult to sell their securities and cause a decline in the market value of our stock.

 

25
 

 

Our shareholders may suffer future dilution due to issuances of shares for our convertible securities and various considerations in the future.

 

We currently have outstanding notes with the aggregate original principal amount of $12,175,000 with a 6% per annum interest rate, a maturity date of one year from issuance, and an automatic conversion upon the effectiveness of registration of such notes on a registration statement filed with the SEC. Upon conversion of the notes and the potential issuance of 49,065,120 shares of common stock, there will be substantial dilution of the current shareholders. There may also be substantial dilution to our shareholders as a result of future decisions of the board of directors to issue shares without shareholder approval for cash, services, or acquisitions.

 

We have not paid dividends in the past and do not expect to pay dividends in the foreseeable future.

 

We have never paid cash dividends on our securities and do not anticipate paying cash dividends in the foreseeable future. We currently intend to retain our future earnings, if any, to finance the development and expansion of our business. The determination to pay dividends will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements, restrictions contained in any financing instruments, and such other factors as our board of directors deems relevant in its discretion.

 

We rely significantly on information technology and any failure, inadequacy, or security lapse of that technology, including any cybersecurity incidents, could harm us.

 

We believe that companies have been increasingly subject to a wide variety of security incidents, cyberattacks and other attempts to gain unauthorized access. These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-sponsored attack. Cyber threats may be generic, or they may be custom-crafted against our information systems. Over the past few years, cyber-attacks have become more prevalent and much harder to detect and defend against. Several key areas of our business depend on the use of information technologies, including production, manufacturing, marketing, and logistics, as well as clinical and regulatory matters. We also utilize systems that allow for the secure storage and transmission of proprietary or confidential information regarding our customers, employees, and others, including personal information. If we fail to maintain or protect our information systems and data integrity effectively, we could have problems in determining product cost estimates and establishing appropriate pricing, have difficulty preventing, detecting, and controlling fraud, have disputes with physicians, and other health care professionals, have regulatory sanctions or penalties imposed, have increases in operating expenses, incur expenses or lose revenues as a result of a data privacy breach, or suffer other adverse consequences and reputational damages. While we have invested in the protection of data and information technology, there can be no assurance that our efforts or those of our third-party collaborators, if any, or manufacturers, to implement adequate security and quality measures for data processing would be sufficient to protect against data deterioration or loss in the event of a system malfunction, or to prevent data from being stolen or corrupted in the event of a security breach. Any such loss or breach could harm our business, operating results, and financial condition. For a discussion of our management of cybersecurity risks, see Item 1C. “Cybersecurity-Risk Management” and “-Governance.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS.

 

Not applicable.

 

ITEM 1C. CYBERSECURITY.

 

Risks related to Cybersecurity Incidents

 

We face significant risks related to cybersecurity threats, which could adversely affect our business, financial condition, and results of operations. Cybersecurity incidents, including but not limited to unauthorized access, data breaches, and other malicious activities, could result in the loss or theft of sensitive information, disruption of our operations, and damage to our reputation. While we have implemented measures to protect our information systems, there can be no assurance that these measures will effectively prevent all cybersecurity incidents.

 

26
 

 

Specific risks include, but are not limited to:

 

  1. Data Breaches: A breach of our information systems could lead to unauthorized access to customer or employee data, resulting in reputational harm and legal liabilities.
  2. Operational Disruption: Cybersecurity incidents could disrupt our operations, leading to delays in production, delivery, or fulfillment of customer orders.
  3. Intellectual Property Theft: Unauthorized access to our proprietary information could result in intellectual property theft, impacting our competitive position in the market.
  4. Regulatory and Legal Compliance: Cybersecurity incidents may subject us to regulatory investigations, legal claims, and penalties, affecting our compliance with applicable laws and regulations.
  5. Third-Party Relationships: Our reliance on third-party vendors and service providers exposes us to additional cybersecurity risks, and a security breach affecting these entities could impact our operations.

 

Although, to date, cybersecurity incidents have not materially impacted our business strategy, results of operations, or financial condition, there can be no assurances that they will not do so in the future.

 

Refer to “Item 1A. Risk factors” in this Annual Report for additional information about cybersecurity-related risks.

 

Risk Management and Strategy

 

Assessing, Identifying, and Managing Material Cyber Threats

 

We have in place certain infrastructure, systems, policies, and procedures that are designed to proactively and reactively address circumstances that arise when unexpected events such as a cybersecurity incident occur. These include processes for assessing, identifying, and managing material risks from cybersecurity threats. We consult with external parties, such as cybersecurity firms and risk management and governance experts, on risk management and strategy. We use a team of outside vendors and government services specializing in IT and cybersecurity that provide expertise, tools, and methodologies to identify and assess vulnerabilities and potential threats. Automated tools and

 

AI-based user behavior analytics also support identification and management of cyber threats. Response to a broad category of threats is immediate and automatic. Security personnel and members of our management are alerted when cyber threats or anomalies are detected. Persistent threats or issues that, in the opinion of management, are material are immediately brought to the attention of our board of directors.

 

In the event of a detected cyber incident by 24/7 monitoring software or employee notification, our IT and cybersecurity provider performs a detailed assessment of the incident, identifies the source of the problem, and resolves the issue as appropriate. If they are unable to resolve the issue, the problem is escalated to our cybersecurity monitoring and detection software provider for resolution. Events which are not routinely resolved by our IT and cybersecurity provider are brought to the attention of the board.

 

In order to mitigate risks of cybersecurity incidents, critical business and operational data are backed up at night and stored offsite for security purposes and to restore data in the event of a breach. Additionally, we provide cybersecurity awareness training of our employees, incident response personnel, and senior management.

 

Governance

 

Our executive management team is primarily responsible for assessing and managing our material risks from cybersecurity threats. Management supervises both our internal cybersecurity and IT related personnel, as well as our retained external cybersecurity consultants and vendors. Additionally, they supervise efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefing from internal or external security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants or vendors engaged by us; and alerts and reports produced by security tools deployed in our IT environment.

 

27
 

 

Our board of directors provides oversight and oversees management’s processes for identifying and mitigating risks, including cybersecurity risks, to help align our risk exposure with our strategic objectives. Two of our management have received training on cyber risk governance for public companies, regularly brief our board of directors on our cybersecurity and information security posture as well as cybersecurity incidents deemed to have a moderate or higher business impact, even if viewed as immaterial to us. As cyber threats evolve and become more sophisticated, we believe that the board’s involvement in cybersecurity governance ensures that we are adequately focused on resources and protecting the Company’s assets and reputation.

 

Vital aspects of our cybersecurity governance that are currently in process or have been implemented include the following:

 

  Governance and Strategy: Management and the board ensure that our cybersecurity strategy is aligned with our business strategy.
  Risk Management and Oversight: Our board, as part of the board’s enterprise risk management oversight, actively oversee our cybersecurity risk management framework, ensuring that material risks are identified, assessed, and mitigated.
  Resource Allocation:

    Budget Approval: The board reviews and approves cybersecurity budgets and resource allocations to ensure we have adequate resources to implement and maintain effective cybersecurity measures.
    Investment Decisions: The board, based upon recommendation of management or our external vendors and consultants, evaluates and approves significant investments in cybersecurity technologies, training, and talent.

  Compliance and Legal Obligations:

    Regulatory Compliance: Management and the board both play a role in overseeing compliance with relevant cybersecurity regulations and legal requirements.
    Legal Oversight: Management and the board ensure we have appropriate legal counsel to address cybersecurity-related issues, including breach notification requirements.

  Education and Awareness:

    Training and Awareness: Members of management and members of our board take reasonable steps to stay informed about cybersecurity trends, threats, and best practices through ongoing education and training. Management reviews Company employee training programs to ensure employees are being trained appropriately and kept up to date on evolving cyber trends.
    Board Training: Certain of our board members have received training to understand cybersecurity risks and their role in overseeing cybersecurity.

  Reporting and Communication:

    Periodic Updates: The board receives periodic updates from management, responsible staff regarding the Company’s cybersecurity posture, incidents, and risk management efforts.
    Communication Strategy: Management, together with the board, are in the process of establishing a communication strategy for addressing cybersecurity disclosures with stakeholders, including customers, employees, and the public.

  Performance Evaluation: Included in the board’s annual evaluation of the performance of the Company’s chief executive officer is the effectiveness of implementing cybersecurity policy and measures, ensuring that cybersecurity policies and practices are effective and aligned with organizational goals.
  Cybersecurity Culture: The board fosters a cybersecurity-aware culture throughout the organization, supporting management’s efforts to build risk management including cyber into the fabric of the operating culture.

 

Despite these efforts, the rapidly evolving nature of cybersecurity threats requires ongoing vigilance, and there can be no assurance that our efforts will prevent all incidents.

 

In addition to the foregoing, management and the board are evaluating, and intend to implement, further cybersecurity related measures, including without limitation developing a more robust internal policy framework, incident response plan, crisis management planning, and third-party vendor assessments and contractual obligations for third parties that the Company engages with. The Company intends to progress these efforts throughout 2024.

 

ITEM 2. PROPERTIES

 

Our executive offices are located in Beverly Hills, California. We do not own any real property, but lease an office space consisting of approximately 1900 square feet for all of our corporate and subsidiary locations. We believe that substantially all of our property and equipment is in good condition, subject to normal wear and tear, and that our facilities have sufficient capacity to meet the current needs of our business.

 

ITEM 3. LEGAL PROCEEDINGS

 

There are currently no actions, suits, proceedings, inquiries or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect other than disclosed in our financial statements.

 

From time to time, the Company is involved in legal proceedings. The Company records a liability for those legal proceedings when it determines it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The Company also discloses when it is reasonably possible that a material loss may be incurred, however, the amount cannot be reasonably estimated. From time to time, the Company may enter into discussions regarding settlement of these matters, and may enter into settlement agreements, if it believes settlement is in the best interest of the Company and its shareholders.

 

The following is a summary of our current outstanding litigation:

 

Mentom Eyewear Inc. – A legal action was filed in the Los Angeles Superior Court against Limitless X Holdings Inc., four of its officers, and an unrelated company, alleging the breach of an Implied In-Fact Agreement and other causes of action related to that alleged agreement such as conversion, fraud and unjust enrichment, Mentom Eyewear Inc. v. Limitless X Holdings Inc., et al., Case Number 23STCV24681.  We believe that there was no such agreement, and that the plaintiff has no legal standing to bring such a matter against the Company or its officers.  The case is moving into the discovery phase where we believe the true facts will lead to a dismissal; however, if the case continues, we will vigorously defend against such claims as it is our position that the allegations are not supported by the facts.  No liability has been recorded for these litigations because the Company believes that any such liability is not probable and reasonably estimable at this time.

 

Harpo Inc. – A legal action was filed in the Central District of California against Limitless X Inc. and two of its officers along with Emblaze One, Inc., alleging trademark infringement and dilution, unfair competition, false advertising, and violation of the right of publicity, all based on allegations that one of our advertisements contained the unauthorized use of a celebrity’s name and intellectual property, Harpo Inc. and OW Licensing Company LLC v. Emblaze One, Inc., et al., Case Number 2:23-cv-04459 VAP (ASx).  Any exposure stemming from this action would be subject to indemnity from the advertising network responsible for the ads in question.  We have not yet filed a responsive pleading in this action as we are attempting a global settlement; however, if unable to settle we will defend the case vigorously and will attempt a contractual and equitable indemnity claim against the advertiser.  No liability has been recorded for this litigation because the Company believes that any such liability is not reasonably estimable at this time.

 

ITEM 4. MINE SAFETY DISCLOSURE

 

Not applicable.

 

28
 

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Market Information

 

Our common stock is currently trading on the OTCQB under the symbol “VYBE.” The closing price of our common stock on the OTCQB on April 10, 2024 was $0.51.

 

Holders

 

As of the date of this Annual Report, there are approximately 68 record holders of 3,977,497 shares of our common stock and 500,000 shares of Class A Preferred Stock.

 

Transfer Agent and Registrar

 

Our transfer agent is Mountain Share Transfer, Inc., 2030 Powers Ferry Rd. SE, Suite # 212, Atlanta, Georgia 30339. Their telephone number is (404) 474-3110.

 

Performance Graph and Purchases of Equity Securities

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

 

Dividends

 

As of the filing of this Annual Report, we have not paid any dividends to shareholders. There are no restrictions which would limit our current ability to pay dividends on common stock or that are likely to do so in the future. The Delaware General Corporation Law, however, does prohibit us from declaring dividends where, after giving effect to the distribution of the dividend, we would not be able to pay our debts as they become due in the usual course of business, or our total assets would be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of shareholders who have preferential rights superior to those receiving the dividend.

 

Securities Authorized for Issuance Under Equity Compensation Plans.

 

In 2020, we adopted our 2020 Stock Incentive Plan. A total of 2,222 shares of common stock are reserved for the 2020 Stock Incentive Plan.

 

Effective August 9, 2022, we adopted our 2022 Incentive and Nonstatutory Stock Option Plan (the “2022 Stock Option Plan”). Under the 2022 Stock Option Plan, the Board of Directors may grant options to purchase common stock to officers, employees, and other persons who provide services to us. A total of 833,333 shares of common stock is reserved for the 2022 Stock Option Plan. As of the date of this Annual Report, there have been no options granted under the 2022 Stock Option Plan.

 

Effective August 9, 2022, we adopted our 2022 Restricted Stock Plan (the “2022 Restricted Stock Plan”). Under the 2022 Restricted Stock Plan, the Board of Directors may grant restricted stock to officers, directors, and key employees. A total of 833,333 shares of common stock is reserved for the 2022 Restricted Stock Plan. As of the date of this Annual Report, there have been no shares of common stock granted under the 2022 Restricted Stock Plan.

 

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

 

There were no issuer purchases of equity securities during the year ended December 31, 2023.

 

29
 

 

Recent Issuance of Unregistered Securities

 

Other than the below, we had no sales of unregistered securities in 2023 that have not been previously disclosed in a Current Report on Form 8-K or Quarterly Report on Form 10-Q.

 

The Company has received $9,175,000 from 12 accredited investors pursuant to the Convertible Note Offering during 2022 and additional one accredited investor for $500,000 during 2023. The convertible notes have a conversion rate of $0.25 per share of common stock. The notes have maturity dates of one year from issuance. The interest rate of the notes is 6% per annum. The notes are convertible into shares of common stock at the option of the holder. On October 1, 2023, the Company entered into Conversion Agreements with each of the convertible noteholders to convert their respective notes into shares of Class B Preferred Stock. Pursuant to the Conversion Agreements, each noteholder agreed to receive one share of Class B Preferred Stock for each $2.00 of principal and unpaid interest accrued through the closing date of the Conversion Agreement. As of the closing date of the Conversion Agreement, and each of them, no portion of any of the Notes had been converted into shares of the Company’s common stock. On October 23, 2023, pursuant to the Conversion Agreements, the Company planned to issue an aggregate of 10,349,097 shares of Class B Preferred Stock before the completion of this offering and extinguish $9,675,000 of convertible debt including accumulated interest as of October 23, 2023 in the amount of $674,097. As of December 31, 2023, Class B Preferred Stock has not been registered.

 

In connection with each of the following unregistered sales and issuances of securities, except as otherwise provided below, the Company relied upon the exemption from registration provided by Section 4(a)(2) of the Securities Act for transactions not involving a public offering.

 

Reverse Stock Split

 

On December 19, 2022, we filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation effecting a 1-for-30 reverse stock split (the “Reverse Stock Split”).

 

As a result of the Reverse Stock Split, the total number of shares of common stock held by each shareholder was converted automatically into the number of whole shares of common stock equal to (i) the number of shares of common stock held by such shareholder immediately prior to the Reverse Split, divided by (ii) 30, and then rounded up to the nearest whole number. No fractional shares were issued, and no cash or other consideration was paid to any shareholder. Instead, we issued one whole share of the post-Reverse Stock Split common stock to any shareholder who otherwise would have received a fractional share as a result of the Reverse Stock Split.

 

Except for our historical financial statements and unless otherwise stated, all option, share, and per share information gives effect to the Reverse Stock Split.

 

30
 

 

ITEM 6. RESERVED

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements and Associated Risks.

 

This Annual Report contains certain statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this Annual Report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may,” “expect,” “believe,” “anticipate,” “estimate,” or “continue,” or comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within our control. These factors include but are not limited to economic conditions generally and in the industries in which we may participate; competition within our chosen industry, including competition from much larger competitors; technological advances and failure to successfully develop business relationships. (See “Cautionary Note Concerning Forward-Looking Statements.”)

 

OVERVIEW

 

We are a multinational consumer packaged goods company that specializes in developing and offering ‘Look Good, Feel Great’ products, specifically within the nutrition and beauty industry, through direct response advertising and our distinctive and highly successful celebrity-backed brand awareness strategies. We possess unique capabilities to greatly enhance the reputation and impact of brands, due to our extensive knowledge and expertise in digital marketing and our successful track record in launching new consumer products.

 

On May 11, 2022, Bio Lab Naturals, Inc. (“Bio Lab”), entered into a Share Exchange Agreement (the “Share Exchange Agreement”) with Limitless X, Inc., a Nevada corporation (“LimitlessX”), and its 11 shareholders (the “LimitlessX Acquisition”) on May 11, 2022 (the “Merger”). The parties completed and closed the LimitlessX Acquisition on May 20, 2022 by issuing an aggregate of 3,233,334 shares of common stock of Bio Lab to the LimitlessX shareholders (the “Acquisition Closing”). According to the terms of the Share Exchange Agreement, Bio Lab then issued an additional 300,000 shares of common stock to the LimitlessX shareholders pro rata to their interests in approximately six months from the Acquisition Closing as part of the Limitless Acquisition. Concurrently with the LimitlessX Acquisition, Jaspreet Mathur, the founder and principal shareholder of LimitlessX, also purchased from Helion Holdings LLC, 500,000 shares of Bio Lab’s Class A Preferred Convertible Stock, which at all times have a number of votes equal to 60% of all of the issued and outstanding shares of common stock of Bio Lab.

 

For accounting purposes, the Merger was accounted for as a “reverse merger” with LimitlessX as the accounting acquiror (legal acquiree) and Bio Lab as the accounting acquiree (legal acquiror). and, consequently, the transaction was treated as a recapitalization of Bio Lab. Since LimitlessX was deemed to be the accounting acquiror in the Merger, the historical financial information for periods prior to the Merger reflect the financial information and activities solely of LimitlessX and not of Bio Lab. No step-up in basis or intangible assets or goodwill was recorded in this transaction.

 

On June 10, 2022, Bio Lab changed its name to Limitless X Holdings, Inc. (“we,” “us,” or “our”).

 

Reverse Stock Split

 

Effective December 19, 2022, we completed a reverse stock split of our outstanding common stock upon the filing of our Certificate of Amendment of Amended and Restated Certificate of Incorporation effecting a 1-for-30 reverse stock split (the “Reverse Stock Split”). No fractional shares were or will be issued in connection with the reverse stock split, and all such fractional shares resulting from the reverse stock split were and will be rounded up to the nearest whole number. The shares issuable upon the exercise of our outstanding warrants, and the exercise prices of such warrants, have been adjusted to reflect the reverse stock split. Unless otherwise noted, the share and per share information in this Annual Report reflects the reverse stock split.

 

31
 

 

Supply Chain Disruption / COVID-19 Business Update

 

Due to the residual impact of the global COVID-19 pandemic, we have taken measures to secure our research and development activities, while work in facilities has been organized to reduce the risk of COVID-19 transmission. The extent of the impact of the COVID-19 pandemic on our business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on development, manufacturing process, supply chain, and other third parties with whom we do business, as well as its impact on regulatory authorities and our key management personnel. While we are experiencing limited financial impacts at this time, given the global economic slowdown, the overall disruption of global supply chains and the other risks and uncertainties associated with the pandemic, our business, financial condition, and results of operations ultimately could be materially adversely affected. Some of our suppliers have experienced delays in securing critical raw materials; while this has not materially impacted their services, we have observed delays in certain activities. Therefore, we continue to closely monitor the COVID-19 pandemic as we evolve our business continuity plans, clinical development plans and response strategy.

 

General and Administrative Expenses

 

General and administrative expenses consist of administrative functions, as well as fees paid for legal, consulting fees and facilities costs not otherwise included in research and development expense. Legal costs include general corporate legal fees and patent costs. We expect to incur additional expenses as a result of becoming a public company, including expenses related to compliance with the rules and regulations of the SEC and NYSE, additional insurance, investor relations and other administrative expenses and professional services.

 

RESULTS OF OPERATION

 

For the Year Ended December 31, 2023 Compared to the Year Ended December 31, 2022.

 

32
 

 

   Years Ended December 31,     
   2023   2022   Changes 
       % of       % of         
   Amount   Sales   Amount   Sales   Amount   % 
Revenue                        
Product sales  $15,443,148    77.0%  $40,364,955    68.8%  $(24,921,807)   -61.7%
Service revenue   4,597,933    22.9%   18,308,341    31.2%   (13,710,408)   -74.9%
Rentals   15,000    0.1%   15,000    0.0%   -    0.0%
Total revenue   20,056,081    100.0%   58,688,296    100.0%   (38,632,215)   -65.8%
                               
Cost of sales                              
Cost of sales   4,064,933    20.3%   6,942,680    11.8%   (2,877,747)   -41.5%
Cost of sales - other   -    0.0%   358    0.0%   (358)   -100.0%
Total cost of sales   4,064,933    20.3%   6,943,038    11.8%   (2,878,105)   -41.5%
                               
Gross profit   15,991,148    79.7%   51,745,258    88.2%   (35,754,110)   -69.1%
                               
Operating expenses:                              
General and administrative   1,078,532    5.4%   1,938,640    3.3%   (860,108)   -44.4%
Advertising and marketing   19,416,622    96.8%   47,164,700    80.4%   (27,748,078)   -58.8%
Stock compensation for services   141,020    0.7%   1,117,782    1.9%   (976,762)   -87.4%
Transaction fees   1,159,896    5.8%   3,201,599    5.5%   (2,041,703)   -63.8%
Merchant fees   1,147,678    5.7%   2,459,670    4.2%   (1,311,992)   -53.3%
Royalty fees   416,140    2.1%   1,114,403    1.9%   (698,263)   -62.7%
Professional fees   1,515,065    7.6%   1,647,787    2.8%   (132,722)   -8.1%
Payroll and payroll taxes   3,587,300    17.9%   1,306,565    2.2%   2,280,735    174.6%
Rent   159,216    0.8%   205,497    0.4%   (46,281)   -22.5%
Bad debt expense   2,666,835    13.3%   1,300,855    2.2%   1,365,980    105.0%
Consulting fees, related party   10,000    0.0%   43,500    0.1%   (33,500)   -77.0%
Total operating expenses   31,298,304    156.1%   61,500,998    104.8%   (30,202,694)   -49.1%
                               
Income (loss) from operations   (15,307,156)   -76.3%   (9,755,740)   -16.6%   (5,551,416)   56.9%
                               
Other income (expense)                              
Interest expense   (897,287)   -4.5%   (348,017)   -0.6%   (549,270)   157.8%
Loss on debt settlement   (142,551)   -0.7%   -    0.0%   (142,551)   N/A 
Other income   17,056    0.1%   57,756    0.1%   (40,700)   -70.5%
Other expense   (30,000)   -0.1%   -    0.0%   (30,000)   N/A 
Gain on disposal of assets   -    0.0%   28,397    0.0%   (28,397)   -100.0%
Total other income (expense), net   (1,052,782)   -5.2%   (261,864)   -0.4%   (790,918)   302.0%
                               
Income (loss) before income tax provision and gain on deconsolidation   (16,359,938)   -81.6%   (10,017,604)   -17.1%   (6,342,334)   63.3%
                               
Gain on deconsolidation of subsidiaries   241,365    1.2%   -    0.0%   241,365    N/A 
                               
Income (loss) before income tax provision   (16,118,573)   -80.4%   (10,017,604)   -17.1%   (6,100,969)   60.9%
                               
Income tax provision   -    0.0%   6,402    0.0%   (6,402)   -100.0%
                               
Net income (loss)  $(16,118,573)   -80.4%  $(10,024,006)   -17.1%  $(6,094,567)   60.8%

 

Product Sales - Our product sales decreased by $24.9 million to $15.4 million for the year ended December 31, 2023 as compared to $40.4 million for the year ended December 31, 2022. The sales decrease was primarily attributable to changing affiliate marketing strategy to in-house sales through digital marketing. In 2023, there was a shift in our marketing strategies, including strategic advertisement placements with celebrities rather than depending on affiliate marketers who charge significant amount of marketing and affiliate costs.

 

33
 

 

Service Revenue - Our service revenue decreased by $13.7 million to $4.6 million for the year ended December 31, 2023 as compared to $18.3 million for the year ended December 31, 2022. Our service revenue decrease was primarily due to a shift in our marketing strategies which resulted in less digital marketing services from a decrease in number of customer transactions.

 

Cost of Sales

 

Our cost of sales decreased by $2.9 million, 41.5% of sales, to $4.1 million, 20.2% of sales. This increase was primarily due to decrease in product revenue and a result of operations decreasing during the period. The Company’s costs for freight, inventory, and other supplies decreased as well. Going forward, management is expecting both the product sales and service revenue business to steadily improve in terms of volumes and to remain stable.

 

Gross Profit

 

Gross profit for the year ended December 31, 2023 was $16.0 million or 79.7% of total revenue compared to $51.7 million and 88.2% of total revenue for the year ended December 31, 2022. The decrease in gross profit of $35.7 million was primarily due to decrease product and service revenue due to decrease in number of customer transactions and volume resulting from reduction in using affiliate third-party marketing. Our gross margin decrease was primarily due to slight increase in product costs.

 

Operating Expenses

 

During the year ended December 31, 2023, we recognized $31.3 million in operating expenses compared to $61.5 million for the year ended December 31, 2022. The decrease of $30.2 million was due to decrease in advertising and marketing, transaction fees, merchant fees, royalty fees, and bad debt expense.

 

  Our advertising and marketing expense decreased by $27.8 million due to a shift in marketing strategies to bring digital marketing in-house and decrease in spendings to performance marketers (affiliate marketing).
  The decrease in transaction fees and merchant fees are directly related to the increased number of transactions during the year.

 

Income (Loss) from Operations

 

As a result of the above, the Company had net loss from operations of $15.3 million for the year ended December 31, 2023, as compared to a loss from operations of $9.8 million for the year ended December 31, 2022.

 

Other Income (Expense)

 

For the year ended December 31, 2023, the Company incurred other expense of $1.1 million related to interest expense of $0.9 million and loss on debt settlement of $1.4 million compared to $3.5 million of interest expense for the year ended December 31, 2022.

 

Net Income (Loss)

 

As a result of the above, the Company generated a net loss of $16.1 million for the year ended December 31, 2023, as compared to a net loss of $10.0 million for the year ended December 31, 2022.

  

LIQUIDITY AND CAPITAL RESOURCES


 

We have a history of operating losses and negative cash flow in operating activities. We have incurred recurring net losses, including net losses from operations before income taxes of $16.1 million and $10.0 million for the years ended December 31, 2023 and 2022, respectively. We used $0.1 million and $5.8 million of cash for operating activities the year ended December 31, 2023 and 2022, respectively, and we had an accumulated deficit of $12.9 million at December 31, 2023. These factors raise substantial doubt as to our ability to continue as a going concern, and our independent registered public accounting firm has included a going concern uncertainty explanatory paragraph in their report for 2023.

 

Cash Used in Operating Activities

 

During the year ended December 31, 2023, net cash used in operating activities was $6.9 million. The cash used in operating activities was primarily due to net loss of $16.1 million off-set by increase in accounts payable, inventories and accrued expenses of $5.9 million and decrease royalty payable of $1.1 million. During the year ended December 31, 2022 net cash used in operating activities was $9.1 million. The cash used in operating activities was primarily due to net loss of $10.0 million off-set by increase in accounts payable and accrued expenses and royalty payable of $2.9 million and decrease of inventories of $1.9 million.

 

34
 

 

Cash Provided by Investing Activities

 

Net cash used in financing activities for the years ended December 31, 2023 and 2022 was nil.

 

Cash Provided by Financing Activities

 

Net cash provided by financing activities for the year ended December 31, 2023 was $1.2 million. This amount was incurred by increased borrowings from related parties, shareholders, and convertible debt. Net cash provided by financing activities for the year ended December 31, 2022 was $14.9 million. This amount was incurred by increased borrowings from related parties, shareholders, and convertible debt.

 

CRITICAL ACCOUNTING ESTIMATES

 

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make judgments, assumptions and estimates that affect the amounts reported in our financial statements and the accompanying notes. The amounts of assets and liabilities reported on our balance sheet and the amounts of revenues and expenses reported for each of our fiscal periods are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue recognition, stock-based compensation and the valuation of deferred taxes. Actual results could differ from these estimates. The following critical accounting policies are significantly affected by judgments, assumptions and estimates used in the preparation of the financial statements:

 

Revenue Recognition

 

We recognize revenue when performance obligations under the terms of a contract with our customers are satisfied. We have determined that fulfilling and delivering products is a single performance obligation. Revenue is recognized at the point in time when we have satisfied our performance obligation, and the customer has obtained control of the products. This generally occurs when the product is delivered to or picked up by the customer based on applicable shipping terms, which is typically within 15 days. Revenue is measured as the amount of consideration expected to be received in exchange for fulfilled product orders,

 

While customers generally have a right to return defective or non-conforming products, past experience has demonstrated that product returns have been immaterial. Customer remedies for defective or non-conforming products may include a refund or exchange. As a result, the right of return is estimated and recorded as a reduction in revenue at the time of sale, if necessary.

 

Our customer contracts identify product quantity, price, and payment terms. Payment terms are granted consistent with industry standards. Although some payment terms may be more extended, the majority of the our payment terms are less than 30 days. As a result, revenue is not adjusted for the effects of a significant financing component. Amounts billed and due from customers are classified as Accounts Receivables on the Balance Sheet.

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

The consolidated financial statements required by this item begin on page F-1 of this Annual Report and are incorporated herein by reference.

 

35
 

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

No events occurred requiring disclosure under Item 304 of Regulation S-K.

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Our management has evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this Annual Report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer has concluded that, as of December 31, 2023, our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC and (ii) accumulated and communicated to our management, including our principal executive and principal financial and accounting officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

 

Other than the hiring of a new Chief Financial Officer, there have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Annual Report that has materially affected or are reasonably likely to materially affect our internal controls and procedures over financial reporting.

 

MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. Any system of internal control, no matter how well designed, has inherent limitations, including the possibility that a control can be circumvented or overridden and misstatements due to error or fraud may occur and not be detected. Also, because of changes in conditions, internal control effectiveness may vary over time. Accordingly, even an effective system of internal control will provide only reasonable assurance that the objectives of the internal control system are met.

 

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2023, based on the criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on this evaluation, our management concluded that our internal control over financial reporting was ineffective as of December 31, 2023.

 

We have identified material weaknesses in our internal control over financial reporting. These material weaknesses relate to the fact that we do not maintain a comprehensive policies and procedures manual designed to establish internal controls over financial reporting to reduce the risk of publishing materially misstated financial statements, as well as define responsibilities and segregate incompatible duties to reduce the risk of unauthorized transactions. We believe that the hiring of additional personnel who have the technical expertise and knowledge with the non-routine or technical issues we have encountered in the past will result in both proper recording of these transactions and a much more knowledgeable finance department as a whole. Due to the fact that our accounting staff currently consists only of a Chief Financial Officer, additional personnel will also create the proper segregation of duties and provide more checks and balances within the department. Additional personnel can also provide the cross training needed to support us if personnel turnover issues within the department occur. We believe that the hiring of additional accounting and financial personnel will eliminate or greatly decrease any control and procedure issues we may encounter in the future. However, we cannot be certain that any such steps we undertake will successfully remediate any material weaknesses or that other material weaknesses and control deficiencies will not be discovered in the future. We will continue to monitor and evaluate the effectiveness of our disclosure controls and procedures and our internal controls over financial reporting on an ongoing basis and are committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.

 

This Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management’s assessment was not subject to attestation by our independent registered public accounting firm pursuant to rules of the SEC that permit us to provide only management’s assessment in this Annual Report.

 

ITEM 9B. OTHER INFORMATION

 

None.

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

Not applicable.

 

36
 

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE

 

Information About our Executive Officers and Directors

 

Our business and affairs are organized under the direction of our board of directors, which currently consists of nine members. We currently have five independent directors. Our directors will serve for one-year terms or until their successors are duly elected and qualified. There will be no cumulative voting in the election of directors. Consequently, at each annual meeting, the successors to each of our directors will be elected by a plurality of the votes cast at that meeting.

 

Set forth below are the names, ages, and positions of our directors and executive officers as of the date of this Annual Report.

 

Name  Age  Position with the Company  Date Joined the Company
Jaspreet Mathur  37  Chief Executive Officer and Chairman  May 20, 2022
Kenneth Haller  36  President and Director  May 20, 2022
Benjamin Chung  48  Chief Financial Officer  May 20, 2022
Danielle Young  35  Chief Operating Officer  May 20, 2022
Rob Cucher  46  VP of Legal Affairs  May 20, 2022
Bharat Raj Mathur  67  Director  May 20, 2022
Amanda Saccomanno  31  Director  May 20, 2022
Dov Konetz  40  Director  May 20, 2022
Dan Fleyshman  40  Director  October 3, 2022
Leon Anderson  36  Director  October 3, 2022
Michael Braun  38  Director  January 11, 2023
Hassan Iddrissu  45  Director  January 11, 2023

 

Biographical Information

 

Directors and Executive Officers

 

The following is a summary of certain biographical information of our current directors and executive officers.

 

Jaspreet Mathur– Chief Executive Officer and Chairman of the Board of Directors

 

On May 20, 2022, Jaspreet Mathur became our Chairman, Chief Executive Officer, and a member of our Board of Directors. In January 2011, Mr. Mathur launched Kore Fit Living, a chain of retail stores across Canada specializing in sales of vitamins and supplements, sports nutrition, athletic apparel and fitness/MMA training equipment. In 2013, he launched a web agency, Emblaze One, as a full-service interactive agency with global offices to accommodate a consumer market shift from brick and mortar to e-commerce. In November 2018, Mr. Mathur launched the Limitless brand, which manufactures and distributes health and wellness products and offers B2B services for brand development and digital marketing. In January 2022, he teamed up with Dr. Mehmet Oz and a nonprofit organization called HealthCorps to jumpstart health and wellness programs that are targeted to teens and young adults.

 

Kenneth Haller– President and Director

 

On May 20, 2022 Kenneth Haller was appointed our President and a Director of our Board. From January 2021 until April 2022, Mr. Haller was Vice President of Payments at RYVYL Inc. (formerly Greenbox POS) (Nasdaq: RYVL), a software company that designs and develops mobile applications for cash-free e-wallet payments. From May 2013 through May 2022, Mr. Haller was Managing Partner of SKY MIDS, a strategic merchant services company that focuses on high risk and international credit card processing. During this same period until 2021, he was Chief Executive Officer of ChargeSavvy, LLC, a table-side checkout POS system that streamlines information gathering and payment processing.

 

37
 

 

Benjamin Chung- Chief Financial Officer

 

On May 20, 2022, Benjamin Chung was appointed as our Chief Financial Officer. Mr. Chung has been in public accounting for over 24 years. From 1999 through 2004, Mr. Chung was an Audit Manager at PricewaterhouseCoopers. From May 2004 through June 2007, Mr. Chung was an audit manager at Ernst & Young. He then went on to become the Director of Internal Audit for Big 5 Sporting Goods. In January 2012, Mr. Chung was the founder and managing partner at Benjamin & Ko, a public accounting and consulting firm. In May 2021, Mr. Chung became the CFO of RYVYL Inc. (formerly Greenbox POS) (Nasdaq: RYVL). Additionally, over the last five years, Mr. Chung has also served on the board for multiple public companies, the most recent being Franklin Wireless, which trades on Nasdaq. Mr. Chung resigned from that board in December 2019 and currently does not serve on the board of directors of any publicly traded company.

 

Danielle Young- Chief Operating Officer

 

On May 20, 2022, Danielle Young was appointed our Chief Operating Officer. Mrs. Young has been in public accounting for over twelve years. In January 2015, she was hired by Benjamin & Young, LLP, a mid-size CPA firm in Orange County, California as part of their tax department. In May 2019, she left Benjamin & Young and joined Benjamin & Ko, as the Director of Internal Audit, spearheading their operations as well as working with major public companies such as The Habit Burger, Aerovironment, and Ducommun Aerospace. After leaving Benjamin & Ko in July 2021, she started her own consulting firm, Irvine Advisory Services which focuses on IPO readiness preparation, internal audit, Sarbanes-Oxley and corporate management. In June 2022, she was elected to the board of trustees of The Miss America Foundation.

 

Rob Cucher-VP of Legal Affairs

 

On May 20, 2022 Rob Cucher was appointed as our VP of Legal Affairs. Mr. Cucher is a seasoned attorney with 20 years of courtroom practice and experience representing clients on a wide range of legal matters including civil litigation, corporate governance, labor and employment, and commercial transactions, with a concentration in business law and health care. Since April 2017, Mr. Cucher has served as an officer and director of a technology company finding solutions to tracking chronic care and behavioral health conditions for patients throughout California. In February 2010, Mr. Cucher co-founded Sports for All Children, a non-profit providing athletic opportunities for children with special needs. Additionally, Mr. Cucher became a director in May 2019 of Better Housing Solutions, an affordable housing non-profit currently servicing Palmdale, California. Mr. Cucher graduated cum laude from UCLA and Loyola Law School in Los Angeles and is a current member of the California State Bar and United States District Courts.

 

Bharat Raj Mathur- Director

 

Bharat Raj Mathur joined our board of directors on May 20, 2022. Since July 2016, he has been a columnist and featured contributor at www.bizcatalyst360.com. From March 2014 to April 2016, he was chief operating officer at KORE Fit Living. From August 2004 through April 2016, Mr. Mathur was Vice President, Distribution Channel Management at Incredible Entertainment.

 

Amanda Saccomanno- Director

 

Amanda Saccomanno joined our board of directors on May 20, 2022. Ms. Saccomanno is an American professional wrestler, television personality, and fitness and figure competitor. In 2015, Ms. Saccomanno gained major attention from World Wrestling Entertainment (WWE) after scoring second place in its Tough Enough reality show – a competition of contenders vying for a WWE wrestling contract. In May 2015, she signed with the WWE as a Sports Entertainer and starring in their E! Hit Reality Series, Total Divas. Since May 2017, Ms. Saccomanno has developed multiple health platforms and launched an iOS application called “Fit with Mandy.” In 2020, Ms. Saccomanno co-founded and continues to help market and develop a skin care line, with our CEO, Jaspreet Mathur, called Amarose.

 

Dov Konetz- Director

 

For more than the past five years, Dov Konetz has been the Managing Director of DMK Capital, a company engaged in providing valuations in commercial real estate, intangibles and movable assets. Since 2008, Mr. Konetz has served as a Director of Mount Sinai Hospital in Miami, Florida. Mr. Konetz also served on the Miami Beach Police Relations Committee from 2010 through 2012. Mr. Konetz is a valued supporter of The Dream Catcher Foundation, a non-profit that is dedicated to combating human trafficking.

 

38
 

 

Dan Fleyshman- Director

 

Dan Fleyshman is the CIO and a director of Blockchain Consulting Group, Inc. He founded Elevator Studios in 2015 and is currently its CEO. From 2012 through 2015, he was the CEO of One Penny Ad Agency. Between 2010 and 2012, Mr. Fleyshman consulted for a casino in Nevada. He was the CEO of Victory Poker from 2009 through April 2010. From 1999 through 2009, he was the president of WYD, Inc. located in San Diego, California.

 

Leon Starino Anderson- Director

 

From 2002 through 2012, Mr. Anderson became a partner in a London based night club. Mr. Anderson went on to develop public relations and marketing services for major brand deals while in the U.K. for a number of celebrities. Mr. Anderson was recognized for a “first of its kind” buyout on a brand that had no previous history but secured a buyout by ASOS. Since September 2021, Mr. Anderson has continued to run his company, Due Diligence Apparel Ltd.

 

Michael Braun- Director

 

Since 2010, Michael Braun has been the Director of Marketing and Sales of Westbank Pacific Realty Corp., a mixed-use real estate development company. Prior to Westbank, Mr. Braun worked for Rennie, a real estate marketing and sales firm in Vancouver. He graduated from the University of British Columbia in 2007 with a Science Major and Commerce Minor. Mr. Braun holds a real estate license in Vancouver, British Columbia.

 

Hassan Iddrissu- Director

 

Since 2014, Mr. Iddrissu has been the CFO of First Pinnacle Capital Group, Inc., a real estate company in West Los Angeles. Since 2003, Mr. Iddrissu has also been the co-Founder, Chairman, and CEO of RoadStarr Motorsports, a market leader in the auto boutique with various entities across the luxury car industry including an exotic car rental company Starr Auto Rentals. Mr. Iddrissu is also an active mentor and motivational speaker for various inner-city youth, including the Los Angeles Sheriff Foundation. Mr. Iddrissu has his Bachelors of Business Administration from Loyola Marymount University.

 

Family Relationships

 

Except for Bharat Raj Mathur, who is the father of our CEO, Jaspreet Mathur, there are no family relationships with any of the executive officers or directors of the Company and the above referenced individuals. Other than as may be contemplated by the Share Exchange Agreement there are no arrangements or understandings between the above referenced individuals and any other persons pursuant to which he or she was selected as a director.

 

Board Composition

 

Our board of directors currently consists of nine persons.

 

Our board of directors believes its members collectively have the experience, qualifications, attributes and skills to effectively oversee our management, including a high degree of personal and professional integrity, an ability to exercise sound business judgment on a broad range of issues, sufficient experience and background to have an appreciation of the issues facing us, a willingness to devote the necessary time to board duties, a commitment to representing our best interests and the best interests of our shareholders, and a dedication to enhancing shareholder value.

 

We held one board of directors meeting in 2021, two board of directors’ meetings in 2022, and no board of directors’ meetings in 2023. All other board actions were taken by unanimous written consent of the directors.

 

39
 

 

Delinquent Section 16(a) Reports

 

Section 16(a) of the Securities Exchange Act of 1934 (the “Exchange Act”), as amended, requires the Company’s directors and executive officers, and persons who own more than 10% of a registered class of the Company’s equity securities, to file reports of securities ownership and changes in such ownership with the SEC.

 

Based solely upon a review of such forms filed electronically with the SEC or written representations that no Form 5s were required, the Company believes that all Section 16(a) filing requirements were timely met during the year ended December 31, 2023.

 

Director Independence

 

We adhere to the rules of NYSE American in determining whether a director is independent. The NYSE American listing standards generally define an “independent director” as a person, other than an executive officer of a company or any other individual having a relationship which, in the opinion of the issuer’s board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

 

Our board of directors has undertaken a review of the independence of each director and will review the independence of any new directors based on information provided by each director concerning his background, employment, and affiliations, in order to make a determination of independence. Our board of directors has determined that there are five independent directors on our board of directors.

 

Role of Our Board of Directors in Risk Oversight

 

One of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors administers this oversight function directly, along with our Audit Committee, and we plan to have supporting committees, including a Compensation Committee and a Nominating and Corporate Governance Committee, which will then support the board of directors by addressing risks specific to its respective areas of oversight. Until such time as those committees are formed, the board of directors will manage the process. Our Compensation Committee will assess and monitor whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. Our Nominations and Corporate Governance Committee will provide oversight with respect to corporate governance and ethical conduct and monitors the effectiveness of our corporate governance guidelines, including whether such guidelines are successful in preventing illegal or improper liability-creating conduct.

 

Code of Business Conduct and Ethics

 

Our Board has adopted a Code of Business Conduct and Ethics that applies to all of our employees, including our executive officers and directors. Code of Business Conduct and Ethics will be available on our website at www.limitlessx.com, upon the completion of a successful uplisting on the NYSE. If we amend or grant a waiver of one or more of the provisions of our Code of Ethics and Business Conduct, we intend to satisfy the requirements under Item 5.05 of Form 8-K regarding the disclosure of amendments to or waivers from provisions of our Code of Ethics and Business Conduct that apply to our principal executive officer, financial and accounting officers by posting the required information on our website at the above address within four business days of such amendment or waiver. The information on our website is not part of this Annual Report.

 

Our Board, management and all employees of our Company are committed to implementing and adhering to the Code of Business Conduct and Ethics. Therefore, it is up to each individual to comply with the Code of Business Conduct and Ethics and to be in compliance of the Code of Business Conduct and Ethics. If an individual is concerned that there has been a violation of the Code of Business Conduct and Ethics, he or she will be able to report such violation in good faith to his or her superior. While a record of such reports will be kept confidential by our Company for the purposes of investigation, the report may be made anonymously and no individual making such a report will be subject to any form of retribution.

 

Audit Committee

 

We do not currently have an audit committee and we plan to form audit committee in the future.

 

40
 

 

ITEM 11. EXECUTIVE COMPENSATION.

 

Summary Compensation

 

The following table summarizes information regarding the compensation for fiscal years 2023 and 2022 for our named executive officers.

 

Name and Principal Position  Year   Salary
($)
   Stock
Awards
($)
   Option
Awards
($)
   All Other
Compensation
($)
   Total
($)
 
Jaspreet Mathur, Chief Executive Officer   2023    1,000,000    -    -    -    - 
and Chairman of the Board of Directors(1)   2022    291,667    -    -    417    292,084 
Kenneth Haller,   2023    500,000    -    -    -    - 
President and Director(2)   2022    145,833    -    -    5,624    151,457 
Benjamin Chung,   2023    250,000    -    -    -    - 
Chief Financial Officer(3)   2022    113,750    -    -    5,112    118,862 
Danielle Young,   2023    200,000    -    -    -    - 
Chief Operating Officer(4)   2022    91,000    -    -    667    91,667 
Rob Cucher,   2023    250,000    -    -    -    - 
VP of Legal Affairs(5)   2022    116,667    -    -    7,924    124,591 

 

  (1) Mr. Mathur was appointed as CEO on May 20, 2022.
  (2) Mr. Haller was appointed as President on May 20, 2022.
  (3) Mr. Chung was appointed as CFO on May 20, 2022.
  (4) Ms. Young was appointed as COO on May 20, 2022.
  (5) Mr. Cucher was appointed VP of Legal Affairs on August 1, 2022.

 

Executive Compensation

 

We believe that the primary goal of executive compensation is to align the interests of our executive officers with those of our shareholders in a way that allows us to attract and retain the best executive talent.

 

Annual Base Salary. Base salary will be designed to compensate our named executive officers at a fixed level of compensation that will be designed to serve as a retention tool throughout the executive’s career. In determining base salaries, our board of directors (or, when enacted, our compensation committee) considers each executive’s role and responsibility, unique skills, future potential with us, salary levels for similar positions in our market and internal pay equity.
   
Option Plan. We plan to offer option awards to executives and other employees, in the discretion of the board of directors, considering the executive’s role and other compensation.
   
Health/Welfare Plans. All of our full-time employees are eligible to participate in health and welfare plans, including medical, dental and vision benefits, maintained by the Company. The Company pays 100% of health and welfare plans for all executives and 50% of health and welfare plans for all full-time employees.
   
PTO Plan. We offer paid-time off, which can be used for may be used for vacations, rest and relaxation and personal business, and sick days. The PTO varies amongst type of employee and is between two and three weeks.

 

41
 

 

Employment Agreements

 

Jaspreet Mathur, Chief Executive Officer

 

We entered into an employment agreement with Jaspreet Mathur, effective as of May 1, 2022, pursuant to which Mr. Mathur will serve as our Chief Executive Officer. Under his employment agreement, Mr. Mathur has agreed to devote his full business time and effort to the business affairs of the Company. Mr. Mathur employment agreement provides that his employment will be on an at-will basis and can be terminated by either Mr. Mathur or the Company at any time for cause. Under the agreement, Mr. Mathur will receive an initial base salary of $500,000 per year. Thereafter, effective as of January 1, 2023, the Company agreed to increase Mr. Mathur’s annual salary to $1,000,000. In the event that Mr. Mathur’s employment is terminated by our company without “Cause” or is terminated by Mr. Mathur for “Good Reason”, Mr. Mathur will be entitled to a predetermined severance compensation package which will be negotiated in good faith and be incompliance with all SEC regulations. “Cause” is defined to include dishonesty, misappropriation, willful misconduct, breach of the agreement, and other customary matters. “Good Reason” is defined to include a material adverse change in Mr. Mathur’s compensation or duties and level of responsibility. Mr. Mathur will be eligible to participate in Stock Option plans or other incentive plans the Company will offer. The employment agreement also contains customary confidentiality and invention-assignment covenants to which Mr. Mathur is subject.

 

Kenneth Haller, President

 

We entered into an employment agreement with Kenneth Haller, effective as of May 1, 2022, pursuant to which Mr. Haller will serve as our President. Under his employment agreement, Mr. Haller has agreed to devote his full business time and effort to the business affairs of the Company. Mr. Mathur employment agreement provides that his employment will be on an at-will basis and can be terminated by either Mr. Mathur or the Company at any time for cause. Under the agreement, Mr. Mathur will receive an initial base salary of $250,000 per year. Mr. Haller’s employment may be terminated by our company for “Good Reason” or without “Cause.” “Cause” is defined to include dishonesty, misappropriation, willful misconduct, breach of the agreement, and other customary matters. “Good Reason” is defined to include a material adverse change in Mr. Haller’s compensation or duties and level of responsibility. Mr. Haller will be eligible to participate in Stock Option plans or other incentive plans the Company will offer. The employment agreement also contains customary confidentiality and invention-assignment covenants to which Mr. Haller is subject.

 

Rob D. Cucher, Esq., President

 

We entered into an employment agreement with Rob D. Cucher, Esq., effective as of May 1, 2022, pursuant to which Mr. Cucher will serve as our Vice President – Legal Affairs. Under his employment agreement, Mr. Cucher has agreed to devote his full business time and effort to the business affairs of the Company. Mr. Cucher’s employment agreement provides that his employment will be on an at-will basis and can be terminated by either Mr. Cucher or the Company at any time for cause. Under the agreement, Mr. Cucher will receive an initial base salary of $250,000 per year. Mr. Cucher’s employment may be terminated by our company for “Good Reason” or without “Cause.” “Cause” is defined to include dishonesty, misappropriation, willful misconduct, breach of the agreement, and other customary matters. “Good Reason” is defined to include a material adverse change in Mr. Cucher’s compensation or duties and level of responsibility. Mr. Cucher will be eligible to participate in Stock Option plans or other incentive plans the Company will offer. The employment agreement also contains customary confidentiality and invention-assignment covenants to which Mr. Cucher is subject.

 

Karmandeep Munder, Operations Manager

 

We entered into an employment agreement with Karmandeep Munder, effective as of May 1, 2022, pursuant to which Mr. Munder will serve as our Operations Manager. Under his employment agreement, Mr. Munder has agreed to devote his full business time and effort to the business affairs of the Company. Mr. Munder employment agreement provides that his employment will be on an at-will basis and can be terminated by either Mr. Cucher or the Company at any time for cause. Under the agreement, Mr. Munder will receive an initial base salary of $150,000 per year. Mr. Munder’s employment may be terminated by our company for “Good Reason” or without “Cause.” “Cause” is defined to include dishonesty, misappropriation, willful misconduct, breach of the agreement, and other customary matters. “Good Reason” is defined to include a material adverse change in Mr. Munder’s compensation or duties and level of responsibility. Mr. Munder will be eligible to participate in Stock Option plans or other incentive plans the Company will offer. The employment agreement also contains customary confidentiality and invention-assignment covenants to which Mr. Munder is subject.

 

42
 

 

Benjamin Chung, Chief Financial Officer

 

We entered into an employment agreement with Benjamin Chung, effective as of July 27, 2022, pursuant to which Mr. Chung will serve as our Chief Financial officer. Under his employment agreement, Mr. Chung has agreed to devote his full business time and effort to the business affairs of the Company. Mr. Chung employment agreement provides that his employment will be on an at-will basis and can be terminated by either Mr. Chung or the Company at any time for cause. Under the agreement, Mr. Chung will receive an initial base salary of $250,000 per year. Mr. Chung’s employment may be terminated by our company for “Good Reason” or without “Cause.” “Cause” is defined to include dishonesty, misappropriation, willful misconduct, breach of the agreement, and other customary matters. “Good Reason” is defined to include a material adverse change in Mr. Chung’s compensation or duties and level of responsibility. Mr. Chung will be eligible to participate in Stock Option plans or other incentive plans the Company will offer. The employment agreement also contains customary confidentiality and invention-assignment covenants to which Mr. Chung is subject.

 

Danielle Young, Chief Operating Officer

 

We entered into an employment agreement with Danielle Young, effective as of May 1, 2022, pursuant to which Ms. Young will serve as our Chief Operating Officer. Under her employment agreement, Ms. Young has agreed to devote her full business time and effort to the business affairs of the Company. Ms. Young’s employment agreement provides that her employment will be on an at-will basis and can be terminated by either Ms. Young or the Company at any time for cause. Under the agreement, Ms. Young will receive an initial base salary of $200,000 per year. Ms. Young’s employment may be terminated by our company for “Good Reason” or without “Cause.” “Cause” is defined to include dishonesty, misappropriation, willful misconduct, breach of the agreement, and other customary matters. “Good Reason” is defined to include a material adverse change in Ms. Young’s compensation or duties and level of responsibility. Ms. Young will be eligible to participate in Stock Option plans or other incentive plans the Company will offer. The employment agreement also contains customary confidentiality and invention-assignment covenants to which Ms. Young is subject.

 

Base Salaries

 

The base salaries of our employed executive officers are specified in their respective employment agreements, as summarized above.

 

Bonuses

 

We did not pay any bonuses to any of our named executive officers during 2022 or 2023.

 

Equity Compensation

 

Through the date of this Annual Report, none of our officers, directors, or employees have received any equity compensation.

 

Retirement Plans

 

We do not currently maintain any retirement plans for our employees.

 

Director Compensation

 

We did not provide any cash or equity compensation to any of our directors during the year ended December 31, 2023, in their capacity as directors, and we have not yet adopted a compensation program for our directors.

 

Director Agreements

 

We do not have any written agreements with our directors. However, we have agreed to reimburse the directors for any Company-related expenses.

 

Outstanding Equity Awards at Fiscal Year End

 

There were no equity awards held by any of our appointed executive officers and directors as of December 31, 2023.

 

43
 

 

2020 Stock Incentive Plan

 

On January 15, 2020, a Stock Option and Award Incentive Plan (the “2020 Stock Incentive Plan”) was approved by our Board of Directors. There are 2,222 shares of common stock reserved for the 2020 Stock Option Plan. No options or awards were granted under the 2020 Stock Incentive Plan.

 

2022 Stock Option Plan

 

Effective August 9, 2022, we adopted our 2022 Incentive and Nonstatutory Stock Option Plan (the “2022 Stock Option Plan”). Under the 2022 Stock Option Plan, the Board of Directors may grant options to purchase common stock to officers, employees, and other persons who provide services to us. A total of 833,333 shares of common stock is reserved for the 2022 Stock Option Plan. As of the date of this Annual Report, there have been no options granted under the 2022 Stock Option Plan.

 

2022 Restricted Stock Plan

 

Effective August 9, 2022, we adopted our 2022 Restricted Stock Plan (the “2022 Restricted Stock Plan”). Under the 2022 Restricted Stock Plan, the Board of Directors may grant restricted stock to officers, directors, and key employees. A total of 833,333 shares of common stock is reserved for the 2022 Restricted Stock Plan. As of the date of this Annual Report, there have been no shares of common stock granted under the 2022 Restricted Stock Plan.

 

Equity Compensation Plan Information

 

The following table sets forth information as of December 31, 2023 regarding shares of common stock that may be issued under our equity compensation plans, consisting of our 2020 Stock Incentive Plan, 2022 Equity Incentive Plan, and our 2022 Restricted Stock Plan. We do not have any non-shareholder approved equity compensation plans.

 

Plan Category  Number of
securities to be
issued upon
exercise of
outstanding
options, warrants
and rights
   Weighted-average
exercise price of
outstanding
options, warrants
and rights
   Number of securities
remaining available
for future issuance
under equity
compensation plans
(excluding securities
reflected in column (a))
 
    (a)    (b)    (c) 
Equity compensation plans approved by security holders   -   $-    1,668,888(1)
Equity compensation plans not approved by security holders   -    -    - 
Total   0         1,668,888 

 

(1) Includes 2,222 options under the 2020 Stock Incentive Plan; 833,333 options under the 2022 Equity Incentive Plan; and 833,333 shares of common stock under the 2022 Restricted Stock Plan.

 

44
 

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED

 

Security Ownership of Certain Beneficial Owners and Management

 

As of the date of this Annual Report, there are 3,930,333 shares of our common stock outstanding. The following table sets forth the beneficial ownership of our common stock:

 

  each of our directors;
     
  each of our named executive officers;
     
  all of our directors and executive officers as a group; and
     
  each person known by us to be the beneficial owner of 5% or more of our outstanding common stock.

 

Beneficial ownership is determined according to the rules of the SEC. Generally, it means that a person has beneficial ownership of a security if he or she possesses sole or shared voting or investment power of that security and includes options, warrants, and other securities convertible or exercisable into shares of common stock, provided that such securities are currently exercisable or convertible or exercisable or convertible within 60 days of the date hereof. Each director or officer, as the case may be, has furnished us with information with respect to their beneficial ownership. Except as otherwise indicated, all persons listed below have (i) sole voting power and investment power with respect to their stock, except to the extent that authority is shared by spouses under applicable law, and (ii) record and beneficial ownership with respect to their securities.

 

Name and Address (1)  Title  Shares Owned   Percent of
Class (2)
 
Class A Preferred Stock             
              
Jaspreet Mathur  Chief Executive Officer and Chairman   500,000    100%
              
Common Stock             
              
Jaspreet Mathur  Chief Executive Officer and Chairman   2,632,334    66.97%
              
Bharat Raj Mathur  Director   141,334    3.60%
              
Kenneth Haller  President and Director   141,334    3.60%
              
Amanda Saccomanno  Director   106,000    2.70%
              
Benjamin Chung  Chief Financial Officer   35,334    * 
              
Rob Cucher  VP of Legal Affairs   17,667    * 
              
Danielle Young  Chief Operating Officer   -    - 
              
Dov Konetz  Director   -    - 
              
Dan Fleyshman  Director   -    - 
              
Leon Anderson  Director   -    - 
              
Michael Braun  Director   -    - 
              
Hassan Iddrissu  Director   -    - 
              
All executive officers and directors      3,074,003    78.21%

 

* Less than 1%.
   
(1) The mailing address of each of the officers and directors as set forth above is c/o Limitless X Holdings Inc., 9454 Wilshire Blvd. #300, Beverly Hills, California 90212.
   
(2) As of the date hereof, there were 3,930,333 shares of our common stock issued and outstanding and 500,000 shares of our Class A Preferred Stock issued and outstanding.

 

45
 

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

 

The Company has established policies and other procedures regarding approval of transactions between the Company and any employee, officer, director, and certain of their family members and other related persons. These policies and procedures are generally not in writing but are evidenced by long standing principles adhered to by our Board. The disinterested members of the Board review, approve and ratify transactions that involve “related persons” and potential conflicts of interest. Related persons must disclose to the disinterested members of the Board any potential related person transactions and must disclose all material facts with respect to such transaction. All such transactions will be reviewed by the disinterested members of the Board and, in their discretion, approved or ratified. In determining whether to approve or ratify a related person transaction the disinterested members of the Board will consider the relevant facts and circumstances of the transaction, which may include factors such as the relationship of the related person with the Company, the materiality or significance of the transaction to the Company and the related person, the business purpose and reasonableness of the transaction, whether the transaction is comparable to a transaction that could be available to the Company on an arms-length basis, and the impact of the transaction on the Company’s business and operations.

 

We had the following transactions with related parties during the last two fiscal years:

 

Sale of Class A Preferred Convertible Stock

 

Concurrently with the LimitlessX Acquisition, Jaspreet Mathur, our current Chief Executive Officer purchased from Helion Holdings, LLC, a company beneficially owned by our former Chief Executive Officer, 500,000 shares of our Class A Preferred Convertible Stock for consideration of $400,000.

 

Royalty Payables

 

Limitless Performance Inc. (“LPI”), SMILZ INC. (“Smiles”), and DIVATRIM INC. (“Divatrim”), are all companies owned by Jas Mathur, our Chief Executive Officer, Director, and majority shareholder. AMAROSE INC. (“Amarose”) is owned 50% by Mr. Mathur and 50% by Amanda Saccomanno, one of our directors.

 

As of November 1, 2023, we terminated our licensing agreement with Limitless Performance, Inc., Amarose, Inc., Divatrim, Inc., and SMILZ, Inc

 

As of December 31, 2023 and 2022, the royalty payable was $0 and $1,114,403, respectively.

 

Note Payables to Shareholder

 

Notes payable to shareholder consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
         
December 6, 2021 ($50,000)  $50,000   $50,000 
February 11, 2022 ($150,000)   150,000    150,000 
May 8, 2022 ($550,000)   550,000    550,000 
May 9, 2022 ($1,100,000)   1,100,000    1,100,000 
May 16, 2022 ($450,000)   450,000    450,000 
June 1, 2022 ($500,000)   500,000    500,000 
June 30, 2022 ($922,028)   922,028    922,028 
August 25, 2022 ($290,000)   290,000    290,000 
November 15, 2022 ($450,000)   450,000    450,000 
May 16, 2023 ($150,000)   150,000    - 
May 18, 2023 ($50,000)   50,000    - 
June 5, 2023 ($150,000)   150,000    - 
June 20, 2023 ($50,000) – Funding Commitment   50,000    - 
July 13, 2023 ($50,000) – Funding Commitment   50,000    - 
August 1, 2023 ($190,000) – Funding Commitment   190,000    - 
August 7, 2023 ($50,000) – Funding Commitment   50,000    - 
Total notes payable to stockholder (current)  $5,152,028   $4,462,028 

 

46
 

 

  December 6, 2021 – $50,000

 

On December 6, 2021, the Company entered into a Loan Authorization and Agreement for a loan of $50,000 from a shareholder, the proceeds of which were used to be used for working capital purposes. As of September 30, 2023 and December 31, 2022, the principal balance was $50,000 and $50,000, respectively. Beginning on June 1, 2022, the loan required a payment of $4,303 per month, which included principal and interest with an interest rate of 6 % per annum. The total balance of principal and interest of $51,640 was due on May 1, 2023.

 

  February   11, 2022 – $150,000

 

On February 11, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $150,000 from a shareholder, the proceeds of which were to be used for working capital purposes. As of September 30, 2023 and December 31, 2022, the principal balance was $150,000 and $150,000, respectively. Beginning on June 1, 2022, the loan required a payment of $12,910 per month, which included principal and interest with an interest rate of 6% per annum. The total balance of principal and interest of $154,920 was due on May 1, 2023.

 

  May 8, 2022 – $550,000

 

On May 8, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $550,000 from a shareholder, the proceeds of which were to be used for working capital purposes. As of September 30, 2023 and December 31, 2022, the principal balance was $550,000 and $550,000, respectively. Beginning on June 1, 2022, the loan required a payment of $47,337 per month, which included principal and interest with an interest rate of 6% per annum. The total balance of principal and interest of $568,038 was due on May 1, 2023.

 

  May 16, 2022 – $1,100,000

 

On May 16, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $1,100,000 from a shareholder, the proceeds of which were to be used for working capital purposes. As of September 30, 2023 and December 31, 2022, the principal balance was $1,100,000 and $1,100,000, respectively. Interest began accruing at the rate of 8.5% per annum on June 17, 2022 and was due on May 16, 2023.

 

  May 18, 2022 – $450,000

 

On May 18, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $450,000 from a shareholder, the proceeds of which were to be used for working capital purposes. As of September 30, 2023 and December 31, 2022, the principal balance was $450,000 and $450,000, respectively. Interest began accruing at the rate of 8.5% per annum on June 19, 2022 and was due on May 18, 2023.

 

  June 1, 2022 – $500,000

 

On June 1, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $500,000 from a shareholder, the proceeds of which were to be used for working capital purposes. As of September 30, 2023 and December 31, 2022, the principal balance was $500,000 and $500,000, respectively. Beginning on August 1, 2022, the loan required a payment of $43,494 per month, which included principal and interest with an interest rate of 8% per annum. The total balance of principal and interest of $521,931 was due on July 1, 2023.

 

47
 

 

  September 30, 2022 – $922,028

 

On June 30, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $922,028 from a shareholder, the proceeds of which were to be used for working capital purposes. As of September 30, 2023 and December 31, 2022, the principal balance was $922,028 and $922,028, respectively. Beginning on August 1, 2022, the loan required a payment of $80,206 per month, which included principal and interest with an interest rate of 8% per annum. The total balance of principal and interest of $962,469 was due on August 1, 2023.

 

  August 25, 2022 – $290,000

 

On August 25, 2022, the Company entered into a Loan Authorization Agreement for a loan of $290,000 from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of 10% per annum and is due on demand. As of September 30, 2023 and December 31, 2022, the principal balance was $290,000 and $290,000, respectively.

 

  November 15, 2022 – $450,000

 

On November 15, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $450,000 from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of 10% per annum and is due on demand. As of September 30, 2023 and December 31, 2022, the principal balance was $450,000 and $450,000, respectively.

 

  May 16, 2023 – $150,000

 

On May 16, 2023, the Company entered into a Loan Authorization and Agreement for a loan of $150,000 from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of 10% per annum and is due on demand. As of September 30, 2023, the principal balance was $150,000.

 

  May 18, 2023 – $50,000

 

On May 18, 2023, the Company entered into a Loan Authorization and Agreement for a loan of $50,000 from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of 10% per annum and is due on demand. As of September 30, 2023, the principal balance was $50,000.

 

  June 5, 2023 – $150,000

 

On June 5, 2023, the Company entered into a Loan Authorization and Agreement for a loan of $150,000 from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of 10% per annum and is due on demand. As of September 30, 2023, the principal balance was $150,000.

 

  Funding Commitment Agreement

 

On June 3, 2023, the Company entered into a Funding Commitment Agreement (the “Funding Commitment”) with its Chief Executive Officer and Chairman of the Board of Directors, Jaspreet Mathur, wherein Mr. Mathur committed to provide up to $1,000,000 of working capital to the Company over the next six months. Mr. Mathur agreed to the Funding Commitment in exchange for a one year convertible promissory note for each drawdown amount advanced to the Company with an annual interest rate of 10% and a balloon payment of principal and interest due at maturity, unless Mr. Mathur elects to convert the outstanding principal and interest into Class B Preferred Stock of the Company at the conversion price of $1.50 per share; provided, however, Mr. Mathur may only covert each note within the term of the Funding Commitment, in the event of the occurrence of the earlier of a public offering of securities of the Company pursuant to a registration statement filed with the SEC and declared effective pursuant to the Securities Act of 1933, upon completion of which the Company has a class of stock registered under the Securities Exchange Act of 1934 and that stock is listed on a national stock exchange, or a liquidation, merger, acquisition, sale of voting control or sale of substantially all of the assets of the Company in which the shareholders of the Company do not own a majority of the outstanding shares of the surviving corporation. For the avoidance of doubt, a national stock exchange includes Nasdaq, NYSE, and NYSE American, but excludes any over-the-counter quotation systems or trading platforms. The balance of the Funding Commitment are as follows:

 

   December 31, 2023 
     
June 20, 2023 ($50,000)  $50,000 
July 13, 2023 ($50,000)   50,000 
August 1, 2023 ($190,000)   190,000 
August 7, 2023 ($50,000)   50,000 
Total Funding Commitment  $340,000 

 

As of December 31, 2023, the balance of the Funding Commitment was $340,000.

 

48
 

 

Notes Payable to Related Party

 

Notes payable to related party consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
         
May 10, 2022 ($12,500)  $12,500   $12,500 
May 10, 2022 ($12,500)   12,500    12,500 
May 10, 2022 ($20,000)   20,000    20,000 
May 31, 2022 ($5,000)   5,000    5,000 
May 31, 2022 ($15,000)   15,000    15,000 
June 9, 2022 ($15,000)   15,000    15,000 
December 31, 2022 ($929,401)   -    929,401 
           
Total notes payable to related parties (current)  $80,000   $1,247,011 

 

  May 10, 2022 - $12,500

 

On May 10, 2022, a related party of the Company loaned Prime Time Live, Inc. $12,500 in exchange for a promissory note that includes interest at the rate of 10% per annum on the unpaid principal balance, with all unpaid principal and interest due on or before May 10, 2023. Interest began accruing on May 10, 2022. As of September 30, 2023 and December 31, 2022, the principal balance was $12,500 and $12,500, respectively.

 

  May 10, 2022 - $12,500

 

On May 10, 2022, a related party of the Company loaned Prime Time Live, Inc. $12,500 in exchange for a promissory note that includes interest at the rate of 10% per annum on the unpaid principal balance with all unpaid principal and interest due on or before May 10, 2023. Interest began accruing on May 10, 2022. As of September 30, 2023 and December 31, 2022, the principal balance was $12,500 and $12,500, respectively.

 

  May 10, 2022 - $20,000

 

On May 10, 2022, a related party of the Company loaned Prime Time Live, Inc. $20,000 in exchange for a promissory note that included interest at the rate of 10% per annum on the unpaid principal balance with all unpaid principal and interest due on or before May 10, 2023. Interest began accruing on May 10, 2022. As of September 30, 2023 and December 31, 2022, the principal balance was $20,000 and $20,000, respectively.

 

49
 

 

  May 31, 2022 - $5,000

 

On May 31, 2022, a related party of the Company loaned Prime Time Live, Inc. $5,000 in exchange for a promissory note that included interest at the rate of 10% per annum on the unpaid principal balance with all unpaid principal and interest due on or before May 31, 2023. Interest began accruing on May 31, 2022. As of September 30, 2023 and December 31, 2022, the principal balance was $5,000 and $5,000, respectively.

 

  May 31, 2022 - $15,000

 

On May 31, 2022, a related party of the Company loaned Prime Time Live, Inc. $15,000 in exchange for a promissory note that included interest at the rate of 10% per annum on the unpaid principal balance with all unpaid principal and interest due on or before May 31, 2023. Interest began accruing on May 31, 2022. As of September 30, 2023 and December 31, 2022, the principal balance was $15,000 and $15,000, respectively.

 

  June 9, 2022 - $15,000

 

On May 10, 2022, a related party of the Company loaned Prime Time Live, Inc. $15,000 in exchange for a promissory note that included interest at the rate of 10% per annum on the unpaid principal balance with all unpaid principal and interest due on or before May 10, 2023. Interest began accruing on May 10, 2022. As of September 30, 2023 and December 31, 2022, the principal balance was $15,000 and $15,000, respectively.

 

  December 31, 2022 - $929,401

 

On December 31, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $929,401 from Emblaze, the proceeds of which were to be used for working capital purposes. The loan had an interest rate of 8% per annum and was due on December 1, 2023. As of September 30, 2023 and December 31, 2022, the balance was $0 and $929,401, respectively.

 

On June 1, 2023, the Company entered into an Agreement for Purchase and Sale of Stock with Emblaze wherein the Company sold all 5,000 of its shares of common stock of Vybe Labs, as full payment and settlement of a debt in the in the principal amount of $929,401 owed by the Company to Emblaze.

 

Policies and Procedures for Transactions with Related Persons

 

All future related party transactions will be voted upon by the disinterested board of directors. The audit committee of the board of directors is responsible for evaluating each related party transaction and making a recommendation to the disinterested members of the board of directors as to whether the transaction at issue is fair, reasonable and within our policy and whether it should be ratified and approved. If there is no Audit Committee at such time, then the evaluation will also be done by the disinterested board of directors. The board of directors or the audit committee, as applicable, in making its recommendation, will consider various factors, including the benefit of the transaction to us, the terms of the transaction and whether they are at arm’s-length and in the ordinary course of our business, the direct or indirect nature of the related person’s interest in the transaction, the size and expected term of the transaction and other facts and circumstances that bear on the materiality of the related party transaction under applicable law and listing standards. The board of directors or the audit committee will review, at least annually, a summary of our transactions with our directors and officers and with firms that employ our directors, as well as any other related person transactions.

 

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.

 

The following table summarizes the aggregate fees billed to us by BF Borgers CPA, PC, our principal accounts, for professional services during the years ended December 31, 2023 and December 31, 2022:

 

Fees  2023   2022 
Audit Fees (1)  $367,500   $71,000 
All Other Fees   -    - 
Total Fees  $367,500   $70,600 

 

(1) Audit Fees.

 

Fees for audit services billed in 2023 and 2022 consisted of:

 

  Progress billings for the audits of the Company’s financial statements for 2022 and 2023; and

 

  Review of the Company’s quarterly financial statements for 2023 and 2022.

 

Audit fees consists of fees billed for professional services rendered for the audit of our consolidated financial statements, the review of interim consolidated financial statements included in quarterly reports, services that are normally provided in connection with statutory and regulatory filings or engagements and attest services, except those not required by statute or regulation.

 

50
 

 

PART IV

 

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.

 

The following documents are filed as part of this Annual Report on Form 10-K:

 

  a) Financial Statements:

 

Our financial statements and the Report of Independent Registered Public Accounting Firm are included herein on page F-1.

 

  b) Financial Statement Schedules:

 

The financial statement schedules are omitted as they are either not applicable or the information required is presented in the financial statements and notes thereto on page F-1.

 

  c) Exhibits:

 

Exhibit Number   Description   Form   Exhibit   Filing Date   Filed Herewith
3.1   Amended and Restated Certificate of Incorporation filed October 31, 2022   8-K   3.1   11/01/2022    
3.2   Amended and Restated Bylaws   S-1   3.2   02/14/2024    
3.3   Certificate of Amendment of Amended and Restated Certificate of Incorporation filed December 19, 2022   8-K   3.1   12/21/2022    
3.4   Class A Super Majority Convertible Preferred Shares Designation filed February 5, 2020   S-1   4.3   07/02/2020    
3.5   Amended Certificate of Designation of Class A Preferred Convertible Stock   8-K   3.1   05/26/2022    
3.6   Certificate of Designation of Class B Convertible Preferred Stock filed October 23, 2023   8-K   3.1   10/26/2023    
3.7   Amended Certificate of Designation of Class B Preferred Convertible Stock   S-1   3.7   02/14/2024    
4.1   2020 Stock Option Plan   S-1   4.1   07/02/2020    
4.2   2022 Restricted Stock Plan   S-1   4.2   02/14/2024    
4.3   2022 Stock Option Plan   S-1   4.3   02/14/2024    
10.1   Manufacturing & Distributorship License Agreement between Limitless X Inc. and Divatrim Inc., dated December 1, 2021   8-K   10.3   05/26/2022    
10.2   Manufacturing & Distributorship License Agreement between Limitless X Inc. and Smilz Inc., dated December 1, 2021   8-K   10.4   05/26/2022    
10.3   Manufacturing & Distributorship License Agreement between Limitless X Inc. and Limitless Performance Inc., dated December 1, 2021   8-K   10.5   05/26/2022    
10.4   Manufacturing & Distributorship License Agreement between Limitless X Inc. and Amarose Inc., dated December 1, 2021   8-K   10.6   05/26/2022    
10.5   Promissory Note between Limitless X, Inc. and Jaspreet Mathur, dated December 6, 2021   8-K   10.7   05/26/2022    

 

51
 

 

10.6   Promissory Note between Limitless X, Inc. and Jaspreet Mathur, dated February 11, 2022   8-K   10.8   05/26/2022    
10.7   Promissory Note between Limitless X, Inc. and Jaspreet Mathur, dated May 8, 2022   8-K   10.9   05/26/2022    
10.8   Share Exchange Agreement among Bio Lab Naturals, Inc., Limitless X, Inc., and Certain Shareholders, dated May 11, 2022   8-K   2.1   05/26/2022    
10.9   Promissory Note between Limitless X, Inc. and Jaspreet Mathur, dated May 16, 2022   8-K   10.10   05/26/2022    
10.10   Promissory Note between Limitless X, Inc. and Jaspreet Mathur, dated May 18, 2022   8-K   10.11   05/26/2022    
10.11   Amendment to Share Exchange Agreement, dated August 2, 2022   8-K   10.1   08/05/2022    
21.1   List of Subsidiaries    S-1    21.1    02/14/2024    
31.1   Certification of Chief Executive Officer Pursuant to Rule 13a–14(a) or 15d-14(a) of the Securities Exchange Act of 1934               X
31.2   Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934               X
32.1   Certification of Chief Executive Officer under Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002               X
32.2   Certification of Chief Financial Officer under Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002               X
101.INS   Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.                
101.SCH   Inline XBRL Taxonomy Extension Schema Document                
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document                
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document                
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document                
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document                
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained within Exhibit 101)                

 

52
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  LIMITLESS X HOLDINGS, INC.
     
  By: /s/ Jaspreet Mathur
  Name: Jaspreet Mathur
Dated: April 18, 2024 Title: Chief Executive Officer and Chairman of the Board of Directors

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Jaspreet Mathur   Chief Executive Officer and Chairman of the Board of Director   April 18, 2024
Jaspreet Mathur   (Principal Executive Officer)    
         
/s/ Benjamin Chung   Chief Financial Officer   April 18, 2024
Benjamin Chung   (Principal Financial Officer and Principal Accounting Officer)    
         
/s/ Kenneth Haller   Director  

April 18, 2024

Kenneth Haller        
         
/s/ Bharat Raj Mathur   Director   April 18, 2024
Bharat Raj Mathur        
         
/s/ Amanda Saccomanno   Director   April 18, 2024
Amanda Saccomanno        
         
/s/ Dov Konetz   Director   April 18, 2024
Dov Konetz        
         
/s/ Leon Anderson   Director   April 18, 2024
Leon Anderson        
         
/s/ Dan Fleyshman   Director   April 18, 2024
Dan Fleyshman        
         
/s/ Michael Braun   Director   April 18, 2024
Michael Braun        
         
/s/ Hassan Iddrissu   Director   April 18, 2024
Hassan Iddrissu        

 

53
 

 

LIMITLESS X HOLDINGS, INC.

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

Index to Consolidated Financial Statements  
   
Report of Independent Registered Public Accounting Firm (PCAOB ID No. 5041) F-2
   
Consolidated Balance Sheets F-3
   
Consolidated Statements of Operations F-4
   
Consolidated Statement of Changes in Stockholders’ Equity F-5
   
Consolidated Statements of Cash Flows F-6
   
Notes to the Consolidated Financial Statements F-7

 

F-1
 

 

Report of Independent Registered Public Accounting Firm

 

To the shareholders and the board of directors

of Limitless X Holdings Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Limitless X Holdings Inc. as of December 31, 2023 and 2022, the related statements of operations, stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

 

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company’s significant operating losses raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

Critical Audit Matter

 

Critical audit matters are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.

 

We determined that there are no critical audit matters.

 

/S/ BF Borgers CPA PC (PCAOB ID 5041)

We have served as the Company’s auditor since 2022

Lakewood, CO

April 18, 2024

 

F-2
 

 

LIMITLESS X HOLDINGS INC.

CONSOLIDATED BALANCE SHEETS

 

December 31,  2023   2022 
         
ASSETS          
           
Current Assets:          
Cash  $116,100   $5,843,323 
Accounts receivables, net   116,888    895,713 
Holdback receivables, net   -    1,043,991 
Inventories   21,857    3,855,946 
Prepaid expenses   12,500    - 
Total current assets   267,345    11,638,973 
           
Non-Current Assets:          
Operating lease right-of-use asset, net   -    91,032 
Property and equipment, net   29,410    32,256 
Other assets   10,985    78,965 
Total non-current assets   40,395    202,253 
           
Total assets  $307,740   $11,841,226 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
           
Current Liabilities:          
Accounts payable and accrued expenses  $7,318,230   $2,074,576 
Accrued interest   531,149    344,475 
Current portion of operating lease liabilities   -    92,195 
Royalty payable   -    1,114,403 
Refunds payable   41,509    213,930 
Chargebacks payable   20,755    118,288 
Income tax payable   -    17,056 
Note payable   35,000    35,000 
Convertible notes payable   -    9,175,000 
Notes payable to shareholder   5,152,028    4,462,028 
Notes payable to related parties   80,000    1,247,011 
           
Total current liabilities   13,178,671    18,893,962 
Total liabilities   13,178,671    18,893,962 
           
Commitments and contingencies          
           
Stockholders’ deficit          
Preferred Stock A - $0.0001 par value; 30,000,000 authorized shares; 500,000 shares issued and outstanding   50    50 
Preferred Stock B - $0.0001 par value; 30,000,000 authorized shares; 10,349,097 shares issued and outstanding   1,035    - 
Common Stock- $0.0001 par value; 300,000,000 authorized shares; 3,977,497 shares and 3,929,834 issued, respectively   399    394 
Additional paid-in-capital   13,265,500    2,966,162 
Retained earnings   (26,137,915)   (10,019,342)
Total stockholders’ deficit   (12,870,931)   (7,052,736)
           
Total liabilities and stockholders’ deficit  $307,740   $11,841,226 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-3
 

 

LIMITLESS X HOLDINGS INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

 

Years Ended December 31,  2023   2022 
         
Net Revenue          
Product sales  $15,443,148   $40,364,955 
Service revenue   4,597,933    18,308,341 
Rentals   15,000    15,000 
Total net revenue   20,056,081    58,688,296 
           
Cost of Revenue          
Cost of revenue   4,064,933    6,942,680 
Cost of revenue - other   -    358 
Total cost of sales   4,064,933    6,943,038 
           
Gross profit   15,991,148    51,745,258 
           
Operating expenses:          
General and administrative   1,078,532    1,938,640 
Advertising and marketing   19,416,622    47,164,700 
Stock compensation for services   141,020    1,117,782 
Transaction fees   1,159,896    3,201,599 
Merchant fees   1,147,678    2,459,670 
Royalty fees   416,140    1,114,403 
Professional fees   1,515,065    1,647,787 
Payroll and payroll taxes   3,587,300    1,306,565 
Rent   159,216    205,497 
Bad debt expense   2,666,835    1,300,855 
Consulting fees, related party   10,000    43,500 
Total operating expenses   31,298,304    61,500,998 
           
Loss from operations   (15,307,156)   (9,755,740)
           
Other income (expense)          
Interest expense   (897,287)   (348,017)
Loss on debt settlement   (142,551)   - 
Other income   17,056    57,756 
Other expense   (30,000)   - 
Gain on disposal of assets   -    28,397 
Total other income (expense), net   (1,052,782)   (261,864)
           
Loss before income tax provision and gain on deconsolidation   (16,359,938)   (10,017,604)
           
Gain on deconsolidation of subsidiary   241,365    - 
           
Loss before income tax provision   (16,118,573)   (10,017,604)
           
Income tax provision   -    6,402 
           
Net loss  $(16,118,573)  $(10,024,006)
           
Earnings (Loss) Per Share:          
Net loss per common share - basic and diluted  $(4.07)  $(2.71)
Weighted average number of common shares   3,957,486    3,692,740 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-4
 

 

LIMITLESS X HOLDINGS INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

 

                                             
   Preferred Stock A   Preferred Stock B   Common Stock   Common Stock Issuable  

Additional Pain-In

   Retained   Total Stockholder’s 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Earnings   Equity 
                                             
Balance at December 31, 2021   500,000   $50    -   $-    3,496,150   $350    397,000   $40   $1,848,384   $4,664   $1,853,488 
                                                        
Issuance of common stock   -    -    -    -    97,000    10    (97,000)   (10)   -    -    - 
                                                        
Issuance of common stock issuable   -    -    -    -    300,000    30    (300,000)   (30)   -    -    - 
                                                        
Issuance of common stock for services   -    -    -    -    36,684    4    -    -    1,117,778    -    1,117,782 
                                                        
Net loss   -    -    -    -    -    -    -    -    -    (10,024,006)   (10,024,006)
                                                        
Balance at December 31, 2022   500,000   $50    -   $-    3,929,834   $394    -   $-   $2,966,162   $(10,019,342)  $(7,052,736)
                                                        
Issuance of common stock for services   -    -    -    -    47,663    5    -    -    141,015    -    141,020 
                                                        
Vybe deconsolidation   -    -    -    -    -    -    -    -    (189,739)   -    (189,739)
                                                        
Conversion of convertible notes and interest payables   -    -    10,349,097    1,035    -    -    -    -    10,348,062    -    10,349,097 
                                                        
Net loss   -    -    -    -    -    -    -    -    -    (16,118,573)   (16,118,573)
                                                        
Balance at December 31, 2023   500,000   $50   $10,349,097   $1,035    3,977,497   $399    -   $-   $13,265,500   $(26,137,915)  $(12,870,931)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-5
 

 

LIMITLESS X HOLDINGS INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

Years Ended December 31,  2023   2022 
         
Cash flows from operating activities:          
Net loss  $(16,118,573)  $(10,024,006)
           
Adjustments to reconcile net loss to net cash provided by operating activities:          
Depreciation   4,450    5,686 
Common stock issued for professional fees   141,020    1,117,782 
Loss on settlement of debt   142,551    - 
Gain on deconsolidation of subsidiary   (241,365)   - 
Changes in assets and liabilities:          
Accounts receivables, net   300,717    (573,214)
Holdback receivables   1,043,991    (881,765)
Inventories   3,048,179    (1,980,800)
Prepaid expenses   (12,500)   - 
Other assets   67,980    (67,980)
Accounts payable and accrued expenses   5,899,533    1,794,031 
Accrued interest   233,862    344,475 
Refunds payable   (172,421)   6,331 
Royalty payable   (1,114,403)   1,114,403 
Chargebacks payable   (97,533)   17,938 
Income tax payable   -    (5,850)
Net cash used in operating activities   (6,874,512)   (9,132,969)
           
Cash flows from investing activities:          
Purchases of equipment   (1,604)   - 
Proceeds from disposition of asset   -    28,397 
Net cash used in financing activities   (1,604)   28,397 
           
Cash flows from financing activities:          
Proceeds from convertible debt   500,000    - 
Proceeds from borrowings from stockholder   690,000    4,412,028 
Proceeds from borrowings from related parties   -    1,247,011 
Proceeds from borrowing   -    9,210,000 
Net cash provided by financing activities   1,190,000    14,869,039 
           
Net increase(decrease) in cash   (5,686,116)   5,764,467 
           
Deconsolidation - Cash   (41,107)   - 
           
Cash – beginning of period   5,843,323    78,856 
           
Cash – end of period  $116,100   $5,843,323 
           
Supplemental disclosures of cash flow information          
Cash paid during the periods for:          
Interest  $2,334   $1,125 
Income taxes  $-   $5,850 
           
Non-cash investing and financing activities:          
Conversion of convertible notes and interest payables  $10,349,097   $- 
Increase of due to shareholder from asset contribution by shareholder  $988,817      
Decrease in due to Emblaze One, Inc. by Limitless X due to deconsolidation  $(1,167,011)  $- 
Increase in due from Vybe Labs, Inc. by Limitless X due to deconsolidation  $1,356,750   $- 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-6
 

 

LIMITLESS X HOLDINGS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 – ORGANIZATION AND HISTORY

 

On May 11, 2022, Bio Lab Naturals, Inc., a Delaware corporation (“Bio Lab”), entered into a Share Exchange Agreement (the “Share Exchange Agreement”) with Limitless X, Inc., a Nevada corporation (“LimitlessX”), and its 11 shareholders (the “LimitlessX Acquisition”). The parties completed and closed the LimitlessX Acquisition on May 20, 2022 by issuing an aggregate of 3,233,334 shares of common stock of Bio Lab to the LimitlessX shareholders (the “Acquisition Closing”). According to the terms of the Share Exchange Agreement, Bio Lab then issued an additional 300,000 shares of common stock to the LimitlessX shareholders pro rata to their interests approximately six months from the Acquisition Closing as part of the LimitlessX Acquisition. Concurrently with the LimitlessX Acquisition, Jaspreet Mathur, the founder and principal shareholder of LimitlessX, also purchased from Helion Holdings LLC, 500,000 shares of Bio Lab’s Class A Preferred Convertible Stock, which at all times have a number of votes equal to 60% of all of the issued and outstanding shares of common stock of Bio Lab.

 

On June 10, 2022, Bio Lab changed its name to Limitless X Holdings Inc. (“Limitless”).

 

The LimitlessX Acquisition was accounted for as a “reverse merger” following the completion of the transaction. For accounting purposes, LimitlessX was deemed to be the accounting acquirer in the transaction and, consequently, the transaction was treated as a recapitalization of Bio Lab. Accordingly, LimitlessX’s assets, liabilities, and results of operations became the historical financial statements of the registrant. No step-up in basis or intangible assets or goodwill was recorded in this transaction.

 

The Company (as defined below) is a lifestyle brand, focused in the health and wellness industry. Initially, the Company focused on nutritional supplements, wellness studies, and interactive training videos and has since focused its business on performance marketing, sales of digital services, and sales of products. The Company’s mission is to provide businesses a turnkey solution to sell their products. Company teams include sales, marketing, user interface design (UI), user experience design (UX), fulfillment, customer support, labeling, product manufacturing, consulting, retailing, and payment processing, among others.

 

The Company currently offers products online only. The Company has manufacturing and distribution licensing agreements to market, manufacture, sell, and distribute branded products on behalf of its clients. The Company orders products from third party partner manufacturers that make the products according to the Company’s custom formulations, and brands them using the Company’s licensed trademarks. Products are then marketed and sold direct to consumers online. Orders are fulfilled and shipped directly from the Company’s licensors. The Company plans to offer global marketing services across all areas of the sales process, including market research, brand and product development, and digital advertising operating as an integrated marketing agency.

 

The Company operates in the following product and service sectors: (i) health products and (ii) digital marketing services. The health products sector included the sales of health products in two primary vertical markets: (1) health & wellness; and (2) beauty & skincare. The digital marketing service sector includes digital marketing; digital and print design; social media marketing; and direct-to-consumer marketing.

 

F-7
 

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Principles of Consolidation and Reporting

 

The accompanying consolidated financial statements include the accounts of Limitless X Holdings Inc. (a holding company) and its wholly owned operating subsidiaries: Limitless X, Inc., Vybe Lab Inc. (for 2022 and deconsolidated on June 1, 2023), and Prime Time Live, Inc. (collectively, the “Company”). All intercompany balances have been eliminated during consolidation.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $26.1 million at December 31, 2023, and had a net loss of $16.1 million for the year ended December 31, 2023 and net cash used in operating activities of $6.9 million for the year ended December 31, 2023. These matters raise substantial doubt about the Company’s ability to continue as a going concern.

 

To support our existing and planned business model, the Company needs to raise additional capital to fund our future operations. The Company has not experienced any difficulty in raising funds through loans and has not experienced any liquidity problems in settling payables in the normal course of business and repaying loans when they fall due. Successful renewal of our loans, however, is subject to numerous risks and uncertainties. In addition, the increasingly competitive industry conditions under which we operate may negatively impacted our results of operations and cash flows. Additional debt financing is anticipated to fund the Company’s operations in near future. However, there are no current agreements or understandings with regard to the form, time or amount of such financing and there is no assurance that any of this financing can be obtained or that the Company can continue as a going concern.

 

Use of Estimates in the Preparation of Consolidated Financial Statements

 

The preparation of consolidated financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all liquid investments purchased with an initial maturity of three months or less to be cash equivalents. Cash and cash equivalents include demand deposits carried at cost which approximates fair value. The Company maintains its cash in institutions insured by the Federal Deposit Insurance Corporation (“FDIC”).

 

Concentration of Credit Risk

 

The Company offers its services to a small number of clients. This risk of non-payment by these clients is considered minimal and the Company does not generally obtain collateral for sales. The Company continually monitors the credit standing of its clients.

 

Accounts Receivable, net

 

Accounts receivable, net consists primarily of trade receivables, net of allowances for doubtful accounts. The Company sells its products and services for cash or on credit terms, which are established in accordance with local and industry practices and typically require payment within 30 days of delivery. The Company estimates its allowance for doubtful accounts and the related expected credit loss based upon the Company’s historical credit loss experience, adjusted for asset-specific risk characteristics, current economic conditions, and reasonable forecasts. Accounts receivables are written off when determined to be uncollectible. The Company did not require and did not have an allowance for doubtful accounts.

 

F-8
 

 

Holdback Receivables

 

Limitless primarily sells its products online using various third party sales affiliates. These affiliates (online marketing campaign companies) are paid certain commission based on their ability to provide the Company’s products through online sales. All payments are processed through various gateways and are settled through the Company’s payment gateway settler. The Company payment gateway settler is not responsible for settlements that are not paid to processing bank failure. The Company holds responsibility for all the risk in all transactions and processing systems. The payment gateway settler charges a reserve fee to mitigate the risk on their end for any loss of funds or damages.

 

Distributions of the holdback receivables from the third-party payment gateway settler are based on several criteria, such as return and chargeback history, associated risk for the specific business vertical, average transaction amount, and so on. In order to mitigate processing risks, there are policies regarding reserve requirements and payment in arrears in place.

 

The total holdback receivables balance reflects the 0-10% reserve on gross sales and additional reserves by the third-party processor for additional returns and chargebacks if needed. Based on aging of the holdback receivables, the Company has determined that an allowance for doubtful accounts of $1,300,855 or 55% of holdback receivables should be deemed uncollectible recorded as bad debt expense. As of December 31, 2023 and December 31, 2022, the adjusted holdback receivables balance was $NIL and $1,043,991, respectively.

 

Inventories

 

Inventories are valued at the lower-of-cost or net realizable value on a first-in, first-out basis, adjusted for the value of inventory that is determined to be excess, obsolete, expired, or unsaleable. Inventories primarily consisted of finished goods.

 

Advertising and Marketing

 

Advertising and marketing costs are charged to expense as incurred. Advertising and marketing costs were approximately $19,416,622 and $47,164,700 for the years ended December 31, 2023 and 2022, respectively, and are included in operating expenses in the accompanying statements of operations.

 

F-9
 

 

Property and Equipment, net

 

Property and equipment is recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation of property and equipment is over the estimated useful life of five to ten years using the straight-line method.

 

   December 31, 2023   December 31, 2022 
         
Machinery and equipment  $39,067   $37,463 
Total   39,067    37,463 
           
Less: accumulated depreciation   (9,657)   (5,207 
           
Total equipment, net  $29,410   $32,256 

 

Depreciation expense was $4,450 and $5,686 for the years ended December 31, 2023 and 2022, respectively. During the year ended December 31, 2022, the Company reported a gain of $28,397 on the disposal of assets.

 

Revenue Recognition

 

Product Sales

 

The Company recognizes revenue when performance obligations under the terms of a contract with its customer are satisfied. The Company has determined that fulfilling and delivering products is a single performance obligation. Revenue is recognized at the point in time when the Company has satisfied its performance obligation and the customer has obtained control of the products or when the service is fully. This generally occurs when the product is delivered to or picked up by the customer based on applicable shipping terms, which is typically within 15 days. Revenue is measured as the amount of consideration expected to be received in exchange for fulfilled product orders,

 

While customers generally have a right to return defective or non-conforming products, past experience has demonstrated that product returns have been immaterial. Customer remedies for defective or non-conforming products may include a refund or exchange. As a result, the right of return is estimated and recorded as a reduction in revenue at the time of sale, if necessary.

 

The Company’s customer contracts identify product quantity, price, and payment terms. Payment terms are granted consistent with industry standards. Although some payment terms may be more extended, the majority of the Company’s payment terms are less than 30 days. As a result, revenue is not adjusted for the effects of a significant financing component. Amounts billed and due from customers are classified as Accounts Receivables on the Balance Sheet.

 

F-10
 

 

The Company utilizes third-party contract manufacturers for the manufacture of its products. The Company has evaluated whether it is the principal or agent in these relationships. The Company has determined that it is the principal in all cases, as it retains the responsibility for fulfillment and risk of loss, as well as for establishing the price.

 

In accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, the Company has elected the practical expedient to expense the incremental costs to obtain a contract, because the amortization period would be less than one year, and the practical expedient for shipping and handling costs. Shipping and handling costs incurred to deliver products to customers are accounted for as fulfillment activities, rather than a promised service, and as such are included in Cost of Goods Sold in the Statements of Operations.

 

Service Revenue

 

Service revenue consists of digital marketing revenue.

 

Revenue related to digital marketing is recognized over time as services are provided to the customer. We sell digital marketing, digital and print design, social media marketing and direct-to-consumer marketing and thus use standalone selling prices as the basis for revenue. Payment for digital marketing services are typically received at the point when control transfers to the customer or in accordance with payment terms customary to the business. There was no deferred revenue related to services revenue as of December 31, 2023 and 2022.

 

Cost of Sales

 

Cost of goods sold includes the cost of inventory sold during the period as well as certain commission fees, returns, chargebacks, distribution and shipping and handling costs. The amount shown is net of various rebates from third-party vendors in the form of payments.

 

Refunds Payable

 

If customers are not satisfied for any reason, they may request a full refund, processed to the original form of payment, within 30 days from the order date. If the order has already been shipped, the Company charges a 20% restocking fee. The Company’s estimate of the reserve is based upon the Company’s most historical experience of actual customer returns. Additionally, the Company considers other factors in estimating the reserve, such as hiring a new internal team with more resources for the refund process.

 

As of December 31, 2023 and December 31, 2022, refunds payable was $41,509 and $213,930, respectively.

 

F-11
 

 

Chargebacks Payable

 

Once customers successfully dispute chargebacks with the payment processor, the Company returns such funds to the payment processor to return to the customer. As of December 31, 2023 and December 31, 2022, chargebacks payable was $20,755 and $118,288, respectively.

 

Other Comprehensive Loss

 

The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss for the period.

 

Income Taxes

 

The accounting standard on accounting for uncertainty in income taxes addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under that guidance, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

 

Earnings (Loss) per Share

 

The Company calculates earnings per share in accordance with Financial Accounting Standards Board (“FASB”) ASC 260, Earnings Per Share, which requires a dual presentation of basic and diluted earnings per share. Basic earnings per share (“EPS”) is computed by dividing earnings (losses) attributable to common shareholders by the weighted average number of common shares outstanding for the periods. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. The Company had a loss for the years ended December 31, 2023 and 2022.

 

Equity Based Payments

 

The Company accounts for equity-based payment accruals under authoritative guidance as set forth in the Topics of the ASC. The guidance requires all equity-based payments to employees and non-employees, including grants of employee and non-employee stock options and warrants, to be recognized in the consolidated financial statements based at their fair values. The Company applies the provisions of ASC 718, “Compensation - Stock Compensation,” using a modified prospective application, and the Black-Scholes model to value stock options. Under this application, the Company records compensation expense for all awards granted. Compensation costs will be recognized over the period that an employee provides service in exchange for the award. During the year ended December 31, 2023 and the year ended December 31, 2022, the Company granted no options under the 2020 Stock Incentive Plan and 2022 Stock Option Plan.

 

General Concentrations of Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk are accounts receivable and other receivables arising from its normal business activities. The Company has a diversified customer base. The Company controls credit risk related to accounts receivable through credit approvals, credit limits, and monitoring procedures. The Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable related credit risk exposure beyond such allowance is limited.

 

The Company purchases merchandise from 6 suppliers, and the Company’s 3 largest suppliers accounted for 95% of total purchases in fiscal 2022. A significant portion of the Company’s inventory is manufactured abroad in Asia. Foreign imports subject the Company to the risks of changes in, or the imposition of new, import tariffs, duties or quotas, new restrictions on imports, loss of “most favored nation” status with the United States for a particular foreign country, antidumping or countervailing duty orders, retaliatory actions in response to illegal trade practices, work stoppages, delays in shipment, freight expense increases, product cost increases due to foreign currency fluctuations or revaluations, public health issues that could lead to temporary closures of facilities or shipping ports, such as the recent outbreak of COVID-19, and other economic uncertainties. If a disruption of trade were to occur from the countries in which the suppliers of the Company’s vendors are located, the Company may be unable to obtain sufficient quantities of products to satisfy its requirements, or the cost of obtaining products may increase.

 

A substantial amount of the Company’s inventory is manufactured abroad. From time to time, shipping ports experience capacity constraints (such as delays associated with COVID-19), labor strikes, work stoppages or other disruptions that may delay the delivery of imported products. A contract dispute may lead to protracted delays in the movement of the Company’s products, which could further delay the delivery of products to the Company’s stores and impact net sales and profitability. In addition, other conditions outside of the Company’s control, such as adverse weather conditions or acts of terrorism or war, such as the current conflict in Ukraine, could significantly disrupt operations at shipping ports or otherwise impact transportation of the imported merchandise we sell, either through supply chain disruptions, or rising freight and fuel costs.

 

F-12
 

 

Operating Lease

 

In accordance with ASC 842, Leases, the Company determines whether an arrangement contains a lease at inception. A lease is a contract that provides the right to control an identified asset for a period of time in exchange for consideration. For identified leases, the Company determines whether it should be classified as an operating or finance lease. Operating leases are recorded in the balance sheet as: right-of-use asset (“ROU asset”) and operating lease liability. ROU asset represents the Company’s right to use an underlying asset for the lease term and lease liability represents the Company’s obligation to make lease payments arising from the lease. ROU assets and operating lease liabilities are recognized at the commencement date of the lease and measured based on the present value of lease payments over the lease term. The ROU asset also includes deferred rent liabilities. The Company’s lease arrangement generally do not provide an implicit interest rate. As a result, in such situations the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option in the measurement of its ROU asset and liability. Lease expense for the operating lease is recognized on a straight-line basis over the lease term. The Company has a ease agreement with lease and non-lease components, which are accounted for as a single lease component and are month-to-month during the year ended December 31, 2023.

 

Recent Accounting Pronouncements

 

In December 2019, FASB issued Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which amends existing guidance related to the accounting for income taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending existing guidance. This ASU is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company evaluated the effects of adoption of this guidance on the financial statements and did not have any material impact on its consolidated financial statements.

 

In June 2016, the FASB issued an accounting standards update which changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. This update replaces the existing incurred loss impairment model with an expected loss model (referred to as the Current Expected Credit Loss model, or “CECL”). The standard update, and its related amendments, will become effective for the fiscal year beginning on January 1, 2023. The Company evaluated the effects of adoption of this guidance on the financial statements and did not have any material impact on its consolidated financial statements.

 

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA and the SEC did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

 

F-13
 

 

NOTE 3 – FAIR VALUE MEASUREMENTS

 

The Company utilizes ASC 820-10, Fair Value Measurement and Disclosure, for valuing financial assets and liabilities measured on a recurring basis. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value:

 

  Level 1. Observable inputs such as quoted prices in active markets;

 

  Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

 

  Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

 

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. There were no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. There have been no transfers between levels.

 

NOTE 4 – DECONSOLIDATION (Sale of Vybe Labs, Inc.)

 

On June 1, 2023, the Company entered into an Agreement for Purchase and Sale of Stock (the “Vybe Sale Agreement”) with Emblaze One, Inc., a Nevada corporation, (“Emblaze”) wherein the Company sold all 5,000 of its shares of common stock of its wholly owned subsidiary, Vybe Labs, Inc., a Delaware corporation (“Vybe”). Emblaze is a company 100% owned by the Company’s Chief Executive Officer, Chairman of the Board of Directors, and majority shareholder, Jaspreet Mathur.

 

The transaction is recorded as follows at the date of this transaction:

 

   June 1, 
   2023 
     
Total assets and liabilities deconsolidated for Vybe:     
Total assets  $1,156,733 
Total liabilities   (1,356,750)
      
Net assets (liabilities)  $(241,365)
      
Net amount of deconsolidation – Recorded as a Gain on Deconsolidation of Subsidiary  $241,365 

 

NOTE 5 – LOSS ON SETTLEMENT OF DEBT

 

On June 1, 2023, the Company agreed to a settlement of a debt in the amount of $1,167,011 and interest payable of $47,188 owed by the Company to Emblaze, a related party, under two Loan Authorization and Agreements dated April 1, 2022 and December 31, 2022, in the principal amounts of $237,610 and $929,401, respectively, and interest payable of $10,012 and $37,176, respectively, as part of the Vybe Sales Agreement with Emblaze.

 

F-14
 

 

The transaction is recorded as follows at the date of this transaction:

 

SCHEDULE OF DECONSOLIDATION ON LOSS ON SETTLEMENT OF DEBT 

   June 1, 
   2023 
     
Total due to and due from between Limitless X and Vybe before deconsolidation:     
Due to Emblaze One, Inc. by Limitless X  $1,167,011 
Interest payable   47,188 
Due from Vybe Labs, Inc. by Limitless X   (1,356,750)
      
Net due to (from)  $(142,551)
      
Net amount of deconsolidation – Recorded as a Loss on Settlement of Debt  $142,551 

 

NOTE 6 – ROYALTY PAYABLES

 

Limitless Performance Inc. (“LPI”), SMILZ INC. (“Smiles”), DIVATRIM INC. (“Divatrim”), and AMAROSE INC. (“Amarose,” and collectively with LPI, Smiles, and Divatrim, the “Licensors”) are all companies at least 50% owned by a shareholder of the Company. On December 1, 2021, the Company entered into manufacturing and distributorship license agreements (each, a “License Agreement”) with each of the Licensors to distribute each of the Licensors’ respective products and for payments to such Licensor for its product designs and distribution rights. Pursuant to the License Agreements, and each of them, the Company agreed to pay to such Licensors royalty payments equal to 4.00% of gross sales, excluding returns, chargebacks, and other such allowances.

 

As of December 31, 2023 and 2022, the royalty payable was $0 and $1,114,403, respectively.

 

On October 1, 2023, the Company terminated each of the License Agreements; however, the Company maintained its license for NZT-48 with LPI.

 

NOTE 7 – NOTE PAYABLE

 

On March 1, 2021, an individual loaned the predecessor company $35,000 in exchange for an unsecured promissory note that included interest at the rate of 10% per annum on the unpaid principal balance with all unpaid principal and interest due on or before March 1, 2022. The maturity date was extended to December 31, 2022. Interest is due and payable on the first day of each month. As of December 31, 2023, Prime Time Live, Inc. owes $35,000 in principal and accrued interest of $4,595 as of December 31, 2023. As of December 31, 2022, Prime Time Live, Inc. owes $35,000 in principal and accrued interest of $1,095 as of December 31, 2022.

 

F-15
 

 

NOTE 8 – CONVERTIBLE NOTES PAYABLE

 

Convertible notes payable consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
         
August 3, 2022 ($5,000,000)  $        -   $5,000,000 
August 3, 2022 ($1,000,000)   -    1,000,000 
August 22, 2022 ($500,000)   -    500,000 
September 22, 2022 ($250,000)   -    250,000 
September 25, 2022 ($600,000)   -    600,000 
September 25, 2022 ($600,000)   -    600,000 
September 29, 2022 ($50,000)   -    50,000 
September 29, 2022 ($500,000)   -    500,000 
October 10, 2022 ($500,000)   -    500,000 
October 13, 2022 ($750,000)   -    75,000 
October 13, 2022 ($50,000)   -    50,000 
October 14, 2022 ($50,000)   -    50,000 
           
Total convertible note payables (current)  $-   $9,175,000 

 

From August 3, 2022 through November 28, 2022, the Company conducted a convertible note offering for a maximum offering of $15,000,000 and a minimum of $2,000,000 (the “Convertible Note Offering”).

 

Pursuant to the terms of the Convertible Note, the principal amount of the Note that may be outstanding from time to time shall bear interest per annum until paid in full at a rate equal to 6%, compounded annually. The principal and interest of the Note shall be due and payable to the noteholder on the one-year anniversary of the date of the Note (the “Maturity Date”) unless all principal and interest due under the Note had been converted by the Maturity Date.

 

The conversion price shall be equal to $0.25 per share of Common Stock. Any time prior to the Maturity Date, and upon the date of effectiveness of registration of the Notes on a registration statement filed with the Securities and Exchange Commission (the “SEC”), the Note shall automatically convert to shares of common stock of the Company at the Conversion Price (the “Automatic Conversion”); provided however, that in the event that Conversion Shares represent greater than 4.99% of the total Common Shares of the Company (the portion above 4.99% referred to herein as the “Excess Shares”), then the Automatic Conversion shall only apply to such portion of the Note up to 4.99% and not include the Excess Shares. This Note is convertible at the option of the Noteholder, in holder’s sole discretion, in whole or in part, at any time prior to the Maturity Date or payment in full of the Note, whichever occurs first, all or any portion of principal or interest, into shares of Common Stock of the Company at the Conversion Price.

 

The Company analyzed the conversion option in the notes for derivative accounting treatment under ASC Topic 815, “Derivatives and Hedging,” and determined that the instruments do not qualify for derivative accounting.

 

The Company has received $9,175,000 from 12 accredited investors pursuant to the Convertible Note Offering during 2022 and additional one accredited investor for $500,000 during 2023. The Company had $9,675,000 raised through the Convertible Note Offering prior to converting to Class B Preferred Stock on October 23, 2023.

 

On October 1, 2023, the Company entered into Conversion Agreements with each of the convertible noteholders to convert their respective notes into shares of Class B Preferred Stock. Pursuant to the Conversion Agreements, each noteholder agreed to receive one share of Class B Preferred Stock for each $2.00 of principal and unpaid interest accrued through the closing date of the Conversion Agreement. As of the closing date of the Conversion Agreement, and each of them, no portion of any of the Notes had been converted into shares of the Company’s common stock.

 


On October 23, 2023, pursuant to the Conversion Agreements, the Company planned to issue an aggregate of 10,349,097 shares of Class B Preferred Stock before the completion of this offering and extinguish $9,675,000 of convertible debt including accumulated interest as of October 23, 2023 in the amount of $674,097.

 

F-16
 

 

NOTE 9 – NOTES PAYABLE TO SHAREHOLDER

 

Notes payable to shareholder consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
         
December 6, 2021 ($50,000)  $50,000   $50,000 
February 11, 2022 ($150,000)   150,000    150,000 
May 8, 2022 ($550,000)   550,000    550,000 
May 9, 2022 ($1,100,000)   1,100,000    1,100,000 
May 16, 2022 ($450,000)   450,000    450,000 
June 1, 2022 ($500,000)   500,000    500,000 
June 30, 2022 ($922,028)   922,028    922,028 
August 25, 2022 ($290,000)   290,000    290,000 
November 15, 2022 ($450,000)   450,000    450,000 
May 16, 2023 ($150,000)   150,000    - 
May 18, 2023 ($50,000)   50,000    - 
June 5, 2023 ($150,000)   150,000    - 
June 20, 2023 ($50,000) – Funding Commitment   50,000    - 
July 13, 2023 ($50,000) – Funding Commitment   50,000    - 
August 1, 2023 ($190,000) – Funding Commitment   190,000    - 
August 7, 2023 ($50,000) – Funding Commitment   50,000    - 
Total notes payable to stockholder (current)  $5,152,028   $4,462,028 

 

  December 6, 2021 – $50,000

 

On December 6, 2021, the Company entered into a Loan Authorization and Agreement for a loan of $50,000 from a shareholder, the proceeds of which were used to be used for working capital purposes. Beginning on June 1, 2022, the loan required a payment of $4,303 per month, which included principal and interest with an interest rate of 6 % per annum. The total balance of principal and interest was due on May 1, 2023. As of December 31, 2023, the loan is due upon demand.

 

  February 11, 2022 – $150,000

 

On February 11, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $150,000 from a shareholder, the proceeds of which were to be used for working capital purposes. Beginning on June 1, 2022, the loan required a payment of $12,910 per month, which included principal and interest with an interest rate of 6% per annum. The total balance of principal and interest was due on May 1, 2023. As of December 31, 2023, the loan is due upon demand.

 

  May 8, 2022 – $550,000

 

On May 8, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $550,000 from a shareholder, the proceeds of which were to be used for working capital purposes. As of September 30, 2023 and December 31, 2022, the principal balance was $550,000 and $550,000, respectively. Beginning on June 1, 2022, the loan required a payment of $47,337 per month, which included principal and interest with an interest rate of 6% per annum. The total balance of principal and interest was due on May 1, 2023. As of December 31, 2023, the loan is due upon demand.

 

F-17
 

 

  May 16, 2022 – $1,100,000

 

On May 16, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $1,100,000 from a shareholder, the proceeds of which were to be used for working capital purposes. Interest began accruing at the rate of 8.5% per annum on June 17, 2022 and was due on May 16, 2023. As of December 31, 2023, the loan is due upon demand.

 

  May 18, 2022 – $450,000

 

On May 18, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $450,000 from a shareholder, the proceeds of which were to be used for working capital purposes. Interest began accruing at the rate of 8.5% per annum on June 19, 2022 and was due on May 18, 2023. As of December 31, 2023, the loan is due upon demand.

 

  June 1, 2022 – $500,000

 

On June 1, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $500,000 from a shareholder, the proceeds of which were to be used for working capital purposes. Beginning on August 1, 2022, the loan required a payment of $43,494 per month, which included principal and interest with an interest rate of 8% per annum. The total balance of principal and interest was due on July 1, 2023. As of December 31, 2023, the loan is due upon demand.

 

  September 30, 2022 – $922,028

 

On June 30, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $922,028 from a shareholder, the proceeds of which were to be used for working capital purposes. Beginning on August 1, 2022, the loan required a payment of $80,206 per month, which included principal and interest with an interest rate of 8% per annum. The total balance of principal and interest was due on August 1, 2023. As of December 31, 2023, the loan is due upon demand.

 

  August 25, 2022 – $290,000

 

On August 25, 2022, the Company entered into a Loan Authorization Agreement for a loan of $290,000 from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of 10% per annum and is due on demand.

 

  November 15, 2022 – $450,000

 

On November 15, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $450,000 from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of 10% per annum and is due on demand.

 

  May 16, 2023 – $150,000

 

On May 16, 2023, the Company entered into a Loan Authorization and Agreement for a loan of $150,000 from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of 10% per annum and is due on demand.

 

  May 18, 2023 – $50,000

 

On May 18, 2023, the Company entered into a Loan Authorization and Agreement for a loan of $50,000 from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of 10% per annum and is due on demand.

 

F-18
 

 

  June 5, 2023 – $150,000

 

On June 5, 2023, the Company entered into a Loan Authorization and Agreement for a loan of $150,000 from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of 10% per annum and is due on demand.

 

  Funding Commitment Agreement

 

On June 3, 2023, the Company entered into a Funding Commitment Agreement (the “Funding Commitment”) with its Chief Executive Officer and Chairman of the Board of Directors, Jaspreet Mathur, wherein Mr. Mathur committed to provide up to $1,000,000 of working capital to the Company over the next six months. Mr. Mathur agreed to the Funding Commitment in exchange for a one year convertible promissory note for each drawdown amount advanced to the Company with an annual interest rate of 10% and a balloon payment of principal and interest due at maturity, unless Mr. Mathur elects to convert the outstanding principal and interest into Class B Preferred Stock of the Company at the conversion price of $1.50 per share; provided, however, Mr. Mathur may only covert each note within the term of the Funding Commitment, in the event of the occurrence of the earlier of a public offering of securities of the Company pursuant to a registration statement filed with the SEC and declared effective pursuant to the Securities Act of 1933, upon completion of which the Company has a class of stock registered under the Securities Exchange Act of 1934 and that stock is listed on a national stock exchange, or a liquidation, merger, acquisition, sale of voting control or sale of substantially all of the assets of the Company in which the shareholders of the Company do not own a majority of the outstanding shares of the surviving corporation. For the avoidance of doubt, a national stock exchange includes Nasdaq, NYSE, and NYSE American, but excludes any over-the-counter quotation systems or trading platforms. The balance of the Funding Commitment are as follows:

 

   December 31, 2023 
     
June 20, 2023 ($50,000)  $50,000 
July 13, 2023 ($50,000)   50,000 
August 1, 2023 ($190,000)   190,000 
August 7, 2023 ($50,000)   50,000 
Total Funding Commitment  $340,000 

 

As of December 31, 2023, the balance of notes payable to shareholder under the Funding Commitment was $340,000.

 

Total accrued interest related to notes payable to shareholder as of December 31, 2023 and 2022 was $508,524 and $132,938, respectively. Interest expense related to notes payable to shareholder for the year ended December 31, 2023 was $375,586.

 

NOTE 10 – NOTES PAYABLE TO RELATED PARTIES

 

Notes payable to related party consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
         
May 10, 2022 ($12,500)  $12,500   $12,500 
May 10, 2022 ($12,500)   12,500    12,500 
May 10, 2022 ($20,000)   20,000    20,000 
May 31, 2022 ($5,000)   5,000    5,000 
May 31, 2022 ($15,000)   15,000    15,000 
June 9, 2022 ($15,000)   15,000    15,000 
December 31, 2022 ($929,401)   -    929,401 
           
Total notes payable to related parties (current)  $80,000   $1,247,011 

 

F-19
 

 

  May 10, 2022 - $12,500

 

On May 10, 2022, a related party of the Company loaned Prime Time Live, Inc. $12,500 in exchange for a promissory note that includes interest at the rate of 10% per annum on the unpaid principal balance, with all unpaid principal and interest due on or before May 10, 2023. Interest began accruing on May 10, 2022. As of December 31, 2023, the loan is due upon demand.

 

  May 10, 2022 - $12,500

 

On May 10, 2022, a related party of the Company loaned Prime Time Live, Inc. $12,500 in exchange for a promissory note that includes interest at the rate of 10% per annum on the unpaid principal balance with all unpaid principal and interest due on or before May 10, 2023. Interest began accruing on May 10, 2022. As of December 31, 2023, the loan is due upon demand.

 

  May 10, 2022 - $20,000

 

On May 10, 2022, a related party of the Company loaned Prime Time Live, Inc. $20,000 in exchange for a promissory note that included interest at the rate of 10% per annum on the unpaid principal balance with all unpaid principal and interest due on or before May 10, 2023. Interest began accruing on May 10, 2022. As of December 31, 2023, the loan is due upon demand.

 

  May 31, 2022 - $5,000

 

On May 31, 2022, a related party of the Company loaned Prime Time Live, Inc. $5,000 in exchange for a promissory note that included interest at the rate of 10% per annum on the unpaid principal balance with all unpaid principal and interest due on or before May 31, 2023. Interest began accruing on May 31, 2022. As of December 31, 2023, the loan is due upon demand.

 

  May 31, 2022 - $15,000

 

On May 31, 2022, a related party of the Company loaned Prime Time Live, Inc. $15,000 in exchange for a promissory note that included interest at the rate of 10% per annum on the unpaid principal balance with all unpaid principal and interest due on or before May 31, 2023. Interest began accruing on May 31, 2022. As of December 31, 2023, the loan is due upon demand.

 

  June 9, 2022 - $15,000

 

On May 10, 2022, a related party of the Company loaned Prime Time Live, Inc. $15,000 in exchange for a promissory note that included interest at the rate of 10% per annum on the unpaid principal balance with all unpaid principal and interest due on or before May 10, 2023. Interest began accruing on May 10, 2022. As of December 31, 2023, the loan is due upon demand.

 

  December 31, 2022 - $929,401

 

On December 31, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $929,401 from Emblaze, the proceeds of which were to be used for working capital purposes. The loan had an interest rate of 8% per annum and was due on December 1, 2023. On June 1, 2023, the Company entered into an Agreement for Purchase and Sale of Stock with Emblaze wherein the Company sold all 5,000 of its shares of common stock of Vybe Labs, as full payment and settlement of a debt in the in the principal amount of $929,401 owed by the Company to Emblaze.

 

Total accrued interest related to notes payable to shareholder as of December 31, 2023 and 2022 was $11,127 and $3,127, respectively. Interest expense related to notes payable to shareholder for the year ended December 31, 2023 was $8,000.

 

F-20
 

 

NOTE 11 – STOCKHOLDERS’ EQUITY

 

Common Stock

 

As of December 31, 2023 and 2022, the Company had 300,000,000 authorized shares of common stock par value $0.0001 per share and had 3,977,497 shares and 3,929,834 shares issued and outstanding, respectively.

 

Common Stock Issued for Services – On May 31, 2023, the Company issued approximately 47,000 shares of common stock for services provided to the Company. These shares were valued at fair value at the time of issuance and recorded stock compensation expense of $141,020, for the year ended December 31, 2023.

 

Common Stock Issued for Services – On May 10, 2022 and June 10, 2022, the Company issued 36,000 and 684 shares of common stock, respectively, for services provided to the Company. These shares were valued at fair value at the time of issuance and recorded stock compensation expense of $1,117,782 for the year ended December 31, 2022.

 

Preferred Stock

 

As of December 31, 2023 and 2022, the Company has authorized 30,000,000 shares of preferred stock, 500,000 shares of which were designated as Class A Convertible Preferred Stock (“Class A Preferred Stock”).

 

Class A Convertible Stock – As of December 31, 2023 and 2022, there were a total of 500,000 shares of Class A Preferred Stock issued and outstanding. The Class A Preferred Stock, when voting as a single class, has the votes of at least 60% of the voting power of the Company. Further, the holder of the Class A Preferred Stock can convert one share of Class A Preferred Stock into two shares of the Company’s common stock, subject to adjustment. In addition, the holder of the Class A Preferred Stock is entitled to a liquidation preference of the Company senior to all other securities of the Company.

 

Class B Convertible Stock – On October 23, 2023, pursuant to certain Conversion Agreements, the Company issued an aggregate of 10,349,097 shares of Class B Preferred Stock and extinguished $9,675,000 of convertible debt including accumulated interest as of October 23, 2023 in the amount of $674,097. The holders of the Class B Preferred Stock are entitled to a liquidation preference senior to common stock and junior to the Class A Preferred Stock at a liquidation price of $3.00 per share of Class B Preferred Stock. The Class B Preferred Stock also has conversion rights, whereby each share of Class B Preferred Stock is convertible into two shares of Common Stock at the discretion of the holder, subject to beneficial ownership limitations. The holders of the Class B Preferred Stock have no voting rights, unless otherwise provided for in its Certificate of Designation or by law.

 

F-21
 

 

Common Stock and Recapitalization

 

As a result of the LimitlessX Acquisition and LimitlessX being the acquirer, the Company retrospectively restated its common stock as if the transaction occurred at the beginning of the period. The following is the reconciliation of retrospectively restated common stock:

 

             
   December 31, 2021 
   Issued   Issuable   Total 
             
Common stock – Limitless X Inc. – as original   1,616,667    50,000    1,666,667 
Common stock split (1 to 1.94) – Limitless X Inc.   1,519,366    47,000    1,566,366 
Common stock issuable (additional stock split) – Limitless X Inc.   -    300,000    300,000 
Common stock (Bio Lab) – prior to reverse merger   360,117    -    360,117 
                
Total as of December 31, 2021 – as retrospectively restated   3,496,150    397,000    3,893,150 

 

NOTE 12 – EQUITY BASED PAYMENTS

 

The Company had the following equity-based plan:

 

Stock Incentive Plans

 

Effective January 15, 2020, the Company adopted its 2020 Stock Option and Award Plan (the “2020 Stock Incentive Plan”). Under the 2020 Stock Incentive Plan, the Board of Directors may grant options or purchase rights to purchase common stock to officers, employees, and other persons who provide services to the Company or any related company. The participants to whom awards are granted, the type of awards granted, the number of shares covered for each award, and the purchase price, conditions and other terms of each award are determined by the Board of Directors, except that the term of the options shall not exceed ten years. A total of 2,222 shares of the Company’s common stock is reserved for the 2020 Stock Incentive Plan. The shares issued for the 2020 Stock Incentive Plan may be either treasury or authorized and unissued shares. During the year ended December 31, 2023 and the year ended December 31, 2022, the Company granted no options under the 2020 Stock Incentive Plan.

 

Effective August 9, 2022, the Company adopted its 2022 Incentive and Non-statutory Stock Option Plan (the “2022 Stock Option Plan”). Under the 2022 Stock Option Plan, the Board of Directors may grant options to purchase common stock to officers, employees, and other persons who provide services to the Company. A total of 833,333 shares of the Company’s common stock is reserved for the 2022 Stock Option Plan. During the year ended December 31, 2023 and the year ended December 31, 2022, the Company granted no options under the 2022 Stock Option Plan.

 

Effective August 9, 2022, we adopted our 2022 Restricted Stock Plan (the “2022 Restricted Stock Plan”). Under the 2022 Restricted Stock Plan, the Board of Directors may grant restricted stock to officers, directors, and key employees. A total of 833,333 shares of common stock is reserved for the 2022 Stock Option Plan. During the year ended December 31, 2023 and the year ended December 31, 2022, there have been no shares of common stock granted under the 2022 Restricted Stock Plan.

 

NOTE 13 – RELATED PARTY TRANSACTIONS

 

The Company had the following related party transactions:

 

Royalty Payables – Limitless Performance Inc. (“LPI”), SMILZ INC. (“Smiles”), DIVATRIM INC. (“Divatrim”), and AMAROSE INC. (“Amarose,” and collectively with LPI, Smiles, and Divatrim, the “Licensors”) are all companies at least 50% owned by a shareholder of the Company. On December 1, 2021, the Company entered into manufacturing and distributorship license agreements (each, a “License Agreement”) with each of the Licensors to distribute each of the Licensors’ respective products and for payments to such Licensor for its product designs and distribution rights. Pursuant to the License Agreements, and each of them, the Company agreed to pay to such Licensors royalty payments equal to 4.00% of gross sales, excluding returns, chargebacks, and other such allowances. As of December 31, 2023 and 2022, the royalty payable was $0 and $1,114,403, respectively. On October 1, 2023, the Company terminated each of the License Agreements; however, the Company maintained its license for NZT-48 with LPI.

 

F-22
 

 

Notes Payable to Shareholder – The Company had various notes payable with its shareholder who is the Chief Executive Officer of the Company. As of December 31, 2023 and 2022, the Company had $5,152,028 and $4,462,028 outstanding, respectively. Refer to Note 9.

 

Notes Payable to Related Parties – The Company entered into various notes payable with shareholders of the Company. As of December 31, 2023 and 2022, the Company had $80,000 outstanding. Refer to Note 10.

 

Consulting Fees – During the year ended December 31, 2023, the Company incurred consulting fees in the amount of $0 to an officer and an officer of one of its affiliates. During the year ended December 31, 2022, the Company incurred consulting fees in the amount of $32,500 to an officer and an officer of one of its affiliates.

 

NOTE 14 – COMMITMENTS AND CONTINGENCIES

 

Commitments

 

Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives. The Company’s variable lease payments primarily consist of maintenance and other operating expenses from their real estate leases. Variable lease payments are excluded from the ROU assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

 

The Company has lease agreements with lease and non-lease components. The Company has elected to account for these lease and non-lease components as a single lease component.

 

F-23
 

 

In accordance with ASC 842, the components of lease expense were as follows:

 

   For the   For the 
   year ended   year ended 
   December 31, 2023   December 31, 2022 
Operating lease expense  $-   $138,108 
Total lease expense  $-   $138,108 

 

In accordance with ASC 842, other information related to leases was as follows:

 

   For the   For the 
   year ended   year ended 
   December 31, 2023   December 31, 2022 
Operating cash flows from operating leases  $-   $137,138 
Cash paid for amounts included in the measurement of lease liabilities  $-   $137,138 

 

Weighted-average remaining lease term—operating leases  Years 
Weighted-average discount rate—operating leases   3%

 

Total rent expense was $160,379 and $204,527 for the years ended December 31, 2023 and 2022, respectively.

 

Contingencies

 

From time to time, the Company is involved in legal proceedings. The Company records a liability for those legal proceedings when it determines it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The Company also discloses when it is reasonably possible that a material loss may be incurred, however, the amount cannot be reasonably estimated. From time to time, the Company may enter into discussions regarding settlement of these matters, and may enter into settlement agreements, if it believes settlement is in the best interest of the Company and its shareholders.

 

The following is a summary of our current outstanding litigation:

 

Mentom Eyewear Inc. – A legal action was filed in the Los Angeles Superior Court against Limitless X Holdings Inc., four of its officers, and an unrelated company, alleging the breach of an Implied In-Fact Agreement and other causes of action related to that alleged agreement such as conversion, fraud and unjust enrichment, Mentom Eyewear Inc. v. Limitless X Holdings Inc., et al., Case Number 23STCV24681.  We believe that there was no such agreement, and that the plaintiff has no legal standing to bring such a matter against the Company or its officers.  The case is moving into the discovery phase where we believe the true facts will lead to a dismissal; however, if the case continues, we will vigorously defend against such claims as it is our position that the allegations are not supported by the facts.  No liability has been recorded for these litigations because the Company believes that any such liability is not probable and reasonably estimable at this time.

 

Harpo Inc. – A legal action was filed in the Central District of California against Limitless X Inc. and two of its officers along with Emblaze One, Inc., alleging trademark infringement and dilution, unfair competition, false advertising, and violation of the right of publicity, all based on allegations that one of our advertisements contained the unauthorized use of a celebrity’s name and intellectual property, Harpo Inc. and OW Licensing Company LLC v. Emblaze One, Inc., et al., Case Number 2:23-cv-04459 VAP (ASx).  Any exposure stemming from this action would be subject to indemnity from the advertising network responsible for the ads in question.  We have not yet filed a responsive pleading in this action as we are attempting a global settlement; however, if unable to settle we will defend the case vigorously and will attempt a contractual and equitable indemnity claim against the advertiser.  No liability has been recorded for this litigation because the Company believes that any such liability is not reasonably estimable at this time.

 

NOTE 15 – SUBSEQUENT EVENTS

 

The Company evaluated all events or transactions that occurred after December 31, 2023. During this period, the Company did not have any material recognizable subsequent events required to be disclosed.

 

F-24

 

EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

Certification of Principal Executive Officer

Pursuant to Rule 13a-14(a) and 15d-14(a) Under the Securities Exchange Act of 1934, As Amended

As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act

 

I, Jaspreet Mathur, certify that:

 

  1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2023 of Limitless X Holdings Inc.;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  By: /s/ Jaspreet Mathur
    Jaspreet Mathur
    Chief Executive Officer
    (Principal Executive Officer)
     
Date: April 18, 2024    

 

 

 

EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

Certification of Chief Financial Officer

Pursuant to Rule 13a-14(a) and 15d-14(a) Under the Securities Exchange Act of 1934, As Amended

As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act

 

I, Benjamin Chung, certify that:

 

  1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2023 of Limitless X Holdings Inc.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  By: /s/ Benjamin Chung
    Benjamin Chung
    Chief Financial Officer
    (Principal Financial Officer and Principal Accounting Officer)
     
Date: April 18, 2024    

 

 

 

EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

Certification of Principal Executive Officer Pursuant to

18 U.S.C. Section 1350 As Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act

 

In connection with the Annual Report of Limitless X Holdings Inc. (the “Company”) on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jaspreet Mathur, in the capacity and on the date indicated below, certify that, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  By: /s/ Jaspreet Mathur
  Name: Jaspreet Mathur
  Title: Chief Executive Officer
    (Principal Executive Officer)

 

Date: April 18, 2024

 

 

 

EX-32.2 5 ex32-2.htm

 

Exhibit 32.2

 

Certification of Principal Financial and Accounting Officer Pursuant to

18 U.S.C. Section 1350 As Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act

 

In connection with the Annual Report of Limitless X Holdings Inc. (the “Company”) on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Benjamin Chung, in the capacity and on the date indicated below, certify that, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  By: /s/ Benjamin Chung
    Benjamin Chung
    Chief Financial Officer
    (Principal Financial Officer and Principal Accounting Officer)

 

Date: April 18, 2024

 

 

 

EX-101.SCH 6 vybe-20231231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION AND HISTORY link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - DECONSOLIDATION (Sale of Vybe Labs, Inc.) link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - LOSS ON SETTLEMENT OF DEBT link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - ROYALTY PAYABLES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - NOTE PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - NOTES PAYABLE TO SHAREHOLDER link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - NOTES PAYABLE TO RELATED PARTIES link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - EQUITY BASED PAYMENTS link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - DECONSOLIDATION (Sale of Vybe Labs, Inc.) (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - LOSS ON SETTLEMENT OF DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - NOTES PAYABLE TO SHAREHOLDER (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - NOTES PAYABLE TO RELATED PARTIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - STOCKHOLDERS’ EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - ORGANIZATION AND HISTORY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SCHEDULE OF DECONSOLIDATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - DECONSOLIDATION (Sale of Vybe Labs, Inc.) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SCHEDULE OF DECONSOLIDATION ON LOSS ON SETTLEMENT OF DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - LOSS ON SETTLEMENT OF DEBT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - ROYALTY PAYABLES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - NOTE PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - SCHEDULE OF CONVERTIBLE NOTE PAYABLES (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - SCHEDULE OF CONVERTIBLE NOTE PAYABLES (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - SCHEDULE OF NOTES PAYABLE TO SHAREHOLDER (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - SCHEDULE OF NOTES PAYABLE TO SHAREHOLDER (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - SCHEDULE OF FUNDING COMMITMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - SCHEDULE OF FUNDING COMMITMENT (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - NOTES PAYABLE TO SHAREHOLDER (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - SCHEDULE OF NOTES PAYABLE TO RELATED PARTIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - SCHEDULE OF NOTES PAYABLE TO RELATED PARTIES (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - NOTES PAYABLE TO RELATED PARTIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - SCHEDULE OF RECONCILIATION OF RESTATED COMMON STOCK (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - EQUITY BASED PAYMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - SCHEDULE OF LEASE COST (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 vybe-20231231_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 vybe-20231231_def.xml XBRL DEFINITION FILE EX-101.LAB 9 vybe-20231231_lab.xml XBRL LABEL FILE Related Party, Type [Axis] Nonrelated Party [Member] Related Party [Member] Class of Stock [Axis] Preferred Class A [Member] Preferred Class B [Member] Product and Service [Axis] Product [Member] Service [Member] Rentals [Member] Cost Of Revenue [Member] Cost Of Revenue Other [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Common Stock Issuable [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Legal Entity [Axis] Bio Lab Naturals, Inc [Member] Limitless X Shareholders [Member] Class A Convertible Preferred Stock [Member] Helion Holdings LLC [Member] Jaspreet Mathur [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Related Party Transaction [Axis] Three Largest Suppliers [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Accounts Receivable [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Vybe Sale Agreement [Member] Investment, Name [Axis] Emblaze One, Inc. [Member] Two Loan Authorization And Agreements [Member] Vybe Labs Inc [Member] Limitless Performance Inc [Member] Title of Individual [Axis] Individual Counterparty [Member] Prime Time Live Inc [Member] Debt Instrument [Axis] Unsecured Convertible Promissory Note [Member] Long-Term Debt, Type [Axis] August 3, 2022 ($5,000,000) [Member] August 3, 2022 ($1,000,000) [Member] August 22, 2022 ($500,000) [Member] September 22, 2022 ($250,000) [Member] September 25, 2022 ($600,000) [Member] September 25, 2022 ($600,000) [Member] September 29, 2022 ($50,000) [Member] September 29, 2022 ($500,000) [Member] October 10, 2022 ($500,000) [Member] October 13, 2022 ($750,000) [Member] October 13, 2022 ($50,000) [Member] October 14, 2022 ($50,000) [Member] Convertible Note Offering [Member] 12 Accredited Investors [Member] Class B Preferred Stock [Member] Shareholder [Member] December 6, 2021 - $50,000 [Member] February 11, 2022 - $150,000 [Member] May 8, 2022 - $550,000 May 9, 2022 - $1,100,000 [Member] May 16, 2022 - $450,000 [Member] June 1, 2022 - $500,000 [Member] June 30, 2022 - $922,028 [Member] August 25, 2022 - $290,000 [Member] November 15, 2022 - $450,000 [Member] May 16, 2023 - $150,000 [Member] May 18, 2023 - $50,000 [Member] June 5, 2023 - $150,000 [Member] June 20, 2023 - $50,000 [Member] July 13, 2023 -$50,000 [Member] August 1, 2023 - $190,000 [Member] August 7, 2023 - $50,000 [Member] May 18, 2022 – $450,000 [Member] Funding Commitment [Member] Chief Executive Officer [Member] Notes Payables[ Member] May 10, 2022 ($12,500) [Member] May 10, 2022 ($12,500) [Member] May 10, 2022 ($20,000) [Member] May 31, 2022 ($5,000) [Member] May 31, 2022 ($15,000) [Member] June 9, 2022 ($15,000) [Member] December 31, 2022 ($929,401) [Member] Vybe Labs [Member] Notes Payables One [Member] Shareholder One [Member] Class B Convertible Preferred Stock [Member] Issued [Member] Issuable [Member] Plan Name [Axis] 2020 Stock Incentive Plan [Member] 2022 Stock Option Plan [Member] 2022 Restricted Stock Plan [Member] Officer [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated By Reference ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location Statement [Table] Statement [Line Items] ASSETS Current Assets: Cash Accounts receivables, net Holdback receivables, net Inventories Prepaid expenses Total current assets Non-Current Assets: Operating lease right-of-use asset, net Property and equipment, net Other assets Total non-current assets Total assets LIABILITIES AND STOCKHOLDERS’ DEFICIT Current Liabilities: Accounts payable and accrued expenses Accrued interest Current portion of operating lease liabilities Royalty payable Refunds payable Chargebacks payable Income tax payable Notes payable Convertible notes payable Notes payable to shareholder Total current liabilities Total liabilities Commitments and contingencies Stockholders’ deficit Preferred Stock value Common Stock- $0.0001 par value; 300,000,000 authorized shares; 3,977,497 shares and 3,929,834 issued, respectively Additional paid-in-capital Retained earnings Total stockholders’ deficit Total liabilities and stockholders’ deficit Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Net Revenue Total net revenue Cost of Revenue Total cost of sales Gross profit Operating expenses: General and administrative Advertising and marketing Stock compensation for services Transaction fees Merchant fees Royalty fees Professional fees Payroll and payroll taxes Rent Bad debt expense Consulting fees, related party Total operating expenses Loss from operations Other income (expense) Interest expense Loss on debt settlement Other income Other expense Gain on disposal of assets Total other income (expense), net Loss before income tax provision and gain on deconsolidation Gain on deconsolidation of subsidiary Loss before income tax provision Income tax provision Net loss Earnings (Loss) Per Share: Net loss per common share - basic Net loss per common share - diluted Weighted average number of common shares - basic Weighted average number of common shares - diluted Balance Balance, shares Issuance of common stock Issuance of common stock, shares Issuance of common stock issuable Issuance of common stock issuable, shares Issuance of common stock for services Issuance of common stock for services, shares Net loss Vybe deconsolidation Conversion of convertible notes and interest payables Conversion of convertible notes and interest payables, shares Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation Common stock issued for professional fees Loss on settlement of debt Gain on deconsolidation of subsidiary Changes in assets and liabilities: Accounts receivables, net Holdback receivables Inventories Prepaid expenses Other assets Accounts payable and accrued expenses Accrued interest Refunds payable Royalty payable Chargebacks payable Income tax payable Net cash used in operating activities Cash flows from investing activities: Purchases of equipment Proceeds from disposition of asset Net cash used in financing activities Cash flows from financing activities: Proceeds from convertible debt Proceeds from borrowings from stockholder Proceeds from borrowings from related parties Proceeds from borrowing Net cash provided by financing activities Net increase(decrease) in cash Deconsolidation - Cash Cash – beginning of period Cash – end of period Supplemental disclosures of cash flow information Interest Income taxes Non-cash investing and financing activities: Conversion of convertible notes and interest payables Increase of due to shareholder from asset contribution by shareholder Decrease in due to Emblaze One, Inc. by Limitless X due to deconsolidation Increase in due from Vybe Labs, Inc. by Limitless X due to deconsolidation Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND HISTORY Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Fair Value Disclosures [Abstract] FAIR VALUE MEASUREMENTS Deconsolidation DECONSOLIDATION (Sale of Vybe Labs, Inc.) Loss On Settlement Of Debt LOSS ON SETTLEMENT OF DEBT Royalty Payables ROYALTY PAYABLES Note Payable NOTE PAYABLE Debt Disclosure [Abstract] CONVERTIBLE NOTES PAYABLE Notes Payable To Shareholder NOTES PAYABLE TO SHAREHOLDER Notes Payable To Related Parties NOTES PAYABLE TO RELATED PARTIES Equity [Abstract] STOCKHOLDERS’ EQUITY Share-Based Payment Arrangement [Abstract] EQUITY BASED PAYMENTS Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Subsequent Events [Abstract] SUBSEQUENT EVENTS Principles of Consolidation and Reporting Going Concern Use of Estimates in the Preparation of Consolidated Financial Statements Cash and Cash Equivalents Concentration of Credit Risk Accounts Receivable, net Holdback Receivables Inventories Advertising and Marketing Property and Equipment, net Revenue Recognition Service Revenue Cost of Sales Refunds Payable Chargebacks Payable Other Comprehensive Loss Income Taxes Earnings (Loss) per Share Equity Based Payments General Concentrations of Risk Operating Lease Recent Accounting Pronouncements SCHEDULE OF PROPERTY AND EQUIPMENT, NET Deconsolidation Sale Of Vybe Labs Inc. SCHEDULE OF DECONSOLIDATION SCHEDULE OF DECONSOLIDATION ON LOSS ON SETTLEMENT OF DEBT SCHEDULE OF CONVERTIBLE NOTE PAYABLES Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] SCHEDULE OF NOTES PAYABLE TO SHAREHOLDER SCHEDULE OF FUNDING COMMITMENT SCHEDULE OF NOTES PAYABLE TO RELATED PARTIES SCHEDULE OF RECONCILIATION OF RESTATED COMMON STOCK SCHEDULE OF LEASE COST SCHEDULE OF OTHER INFORMATION RELATED TO LEASES Number of shares acquisitions Number of additional shares issued Preferred stock shares issued Outstanding shares percentage Machinery and equipment Total Less: accumulated depreciation Total equipment, net Schedule of Product Information [Table] Product Information [Line Items] Accumulated deficit Net income (loss) Net cash used in operating activities Hold receivables percentage Hold receivables, allowance for doubtful accounts Holdback receivables Advertising and marketing cost Depreciation expense Gain of disposal of assets Deferred revenue Refunds payable percentage Income taxes likelihood Concentration risk, percentage Schedule Of Deconsolidation Total assets Total liabilities Net assets (liabilities) Net amount of deconsolidation – Recorded as a Gain on Deconsolidation of Subsidiary Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Number of shares sold Ownership percentage Due to Emblaze One, Inc. by Limitless X Interest payable Due from Vybe Labs, Inc. by Limitless X Net due to (from) Net amount of deconsolidation – Recorded as a Loss on Settlement of Debt Settlement of debt amount Principal amount Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Royalty payables percentage Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Note payable Interest rate Note payable, maturity date Accrued interest Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Total convertible note payables (current) Debt face amount Debt face amount Debt bear interest rate Conversion price, per share Debt instrumen, description Convertible notes payable Convertible preferred stock amount Share price Number of shares issued Extinguish convertible debt Accumulated interest Total notes payable to stockholder (current) Total Funding Commitment Funding commitment amount Long-term debt Payments for loans Debt interest rate Debt instrument maturity date Funding commitment Working capital Conversion price Interest expense Total notes payable to related parties (current) Common stock shares sold Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Common stock – Limitless X Inc. – as original Common stock split (1 to 1.94) – Limitless X Inc. Common stock issuable (additional stock split) – Limitless X Inc. Common stock (Bio Lab) – prior to reverse merger Total as of December 31, 2021 – as retrospectively restated Schedule of Stock by Class [Table] Class of Stock [Line Items] Common stock, shares outstanding Number of shares issued for services Stock compensation expense Preferred stock, voting rights Shares issued Extinguishment convertible debt Convertible debt including accumulated interest Preferred stock liquidation price Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common stock reserved shares Options granted Notes payable outstanding Consulting fees Operating lease expense Total lease expense Operating cash flows from operating leases Cash paid for amounts included in the measurement of lease liabilities Weighted average discount rate Operating leases Rent expense Bio Lab Naturals, Inc [Member] Limitless X Shareholders [Member] Holdback receivables net current. Number of additional shares issued during acquisitions. Class A Convertible Preferred Stock [Member] Helion Holdings LLC [Member] Jaspreet Mathur [Member] Royalty payable. Refunds payable. Chargebacks payable. Holdback receivables percentage. Hold receivables, allowance for doubtful accounts. Refunds Payable [Policy Text Block] Chargebacks Payable [Policy Text Block] Three Largest Suppliers [Member] Concentrations of Credit Risk [Policy Text Block] Deconsolidation Disclosure [Text Block] Vybe Sale Agreement [Member] Emblaze One, Inc. [Member] Schedule Of Deconsolidation [Table Text Block] Net assets liabilities. Gain on deconsolidation of subsidiary. Loss On Settlement Of Debt [Text Block] Two Loan Authorization And Agreements [Member] Schedule Of Deconsolidation Loss On Settlement Of Debt [Table Text Block] Vybe Labs Inc [Member] Royalty payables percentage. Limitless Performance Inc [Member] Royalty Payables [Text Block] Prime Time Live Inc [Member] Unsecured Convertible Promissory Note [Member] Amount of transaction fees. Merchant fees. Rent expense. Consulting fees related party. Loss on debt settlement. Gain on deconsolidation of subsidiary. August 3, 2022 ($5,000,000) [Member] August 3, 2022 ($1,000,000) [Member] August 22, 2022 ($500,000) [Member] September 22, 2022 ($250,000) [Member] September 25, 2022 ($600,000) [Member] September 25, 2022 ($600,000) [Member] September 29, 2022 ($50,000) [Member] September 29, 2022 ($500,000) [Member] October 10, 2022 ($500,000) [Member] October 13, 2022 ($750,000) [Member] October 13, 2022 ($50,000) [Member] October 14, 2022 ($50,000) [Member] Common Stock Issuable [Member] Convertible Note Offering [Member] 12 Accredited Investors [Member] Class B Preferred Stock [Member] Increase Decrease In Chargebacks Payable. Deconsolidation cash. Conversion of convertible notes and interest payables. Increase of due to shareholder from asset contribution by shareholder. Decrease due to deconsolidation. Increase due to deconsolidation. Notes Payable to Shareholder [Text Block] December 6, 2021 - $50,000 [Member] February 11, 2022 - $150,000 [Member] May 8, 2022 - $550,000 May 9, 2022 - $1,100,000 [Member] May 16, 2022 - $450,000 [Member] June 1, 2022 - $500,000 [Member] June 30, 2022 - $922,028 [Member] August 25, 2022 - $290,000 [Member] November 15, 2022 - $450,000 [Member] May 16, 2023 - $150,000 [Member] May 18, 2023 - $50,000 [Member] June 5, 2023 - $150,000 [Member] June 20, 2023 - $50,000 [Member] July 13, 2023 -$50,000 [Member] August 1, 2023 - $190,000 [Member] August 7, 2023 - $50,000 [Member] Accrued interest. Increase decrease in accrued interest. Working capital. Funding Commitment [Member] Funding Commitment [Table Text Block] Cost of revenue [Member] Cost of revenue other [Member] Loss before income tax provision and gain on deconsolidation. Notes Payables[ Member] Shareholder [Member] Notes Payable to Related Parties [Text Block] May 10, 2022 ($12,500) [Member] May 10, 2022 ($12,500) [Member] May 10, 2022 ($20,000) [Member] May 31, 2022 ($5,000) [Member] May 31, 2022 ($15,000) [Member] June 9, 2022 ($15,000) [Member] December 31, 2022 ($929,401) [Member] Vybe Labs [Member] Notes Payables One [Member] Shareholder One [Member] Class B Convertible Preferred Stock [Member] Convertible debt including accumulated interest. Issued [Member] Issuable [Member] Common stock – Limitless X Inc. – as original. Common stock split (1 to 1.94) – Limitless X Inc. Common stock issuable (additional stock split) – Limitless X Inc. Common stock (Bio Lab) – prior to reverse merger. Total retrospectively restated. 2020 Stock Incentive Plan [Member] 2022 Stock Option Plan [Member] 2022 Restricted Stock Plan [Member] Schedule of Other information Related to Leases [Table Text Block] May 18, 2022 – $450,000 [Member] Going concern policy [Text Block] September 25, 2022 ($600,000) [Member] [Default Label] May 10, 2022 ($12,500) [Member] [Default Label] Assets, Current Assets, Noncurrent Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) LossOnDebtSettlement Other Nonoperating Expense Nonoperating Income (Expense) LossBeforeIncomeTaxProvisionAndGainOnDeconsolidation Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding Increase (Decrease) in Accounts Receivable Increase (Decrease) in Accounts Receivable and Other Operating Assets Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense Increase (Decrease) in Other Noncurrent Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities IncreaseDecreaseInAccruedInterest Increase (Decrease) in Retainage Payable Increase (Decrease) in Royalties Payable Increase Decrease In Chargebacks Payable Increase (Decrease) in Income Taxes Net Cash Provided by (Used in) Operating Activities Payments to Acquire Productive Assets Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations ConversionOfConvertibleNotesAndInterestPayables Inventory, Policy [Policy Text Block] Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment NetAssetsLiabilities Other Receivables, Net, Current Related Party Transaction, Amounts of Transaction Debt Instrument, Increase, Accrued Interest Convertible Notes Payable Lease, Cost EX-101.PRE 10 vybe-20231231_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover - USD ($)
12 Months Ended
Dec. 31, 2023
Mar. 29, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2023    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Current Fiscal Year End Date --12-31    
Entity File Number 000-56453    
Entity Registrant Name LIMITLESS X HOLDINGS, INC.    
Entity Central Index Key 0001803977    
Entity Tax Identification Number 81-1034163    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 9454 Wilshire Blvd. #300    
Entity Address, City or Town Beverly Hills    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 90212    
City Area Code (855)    
Local Phone Number 413-7030    
Title of 12(g) Security Common Stock    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 3,899,529
Entity Common Stock, Shares Outstanding   3,977,497  
Documents Incorporated By Reference None    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 5041    
Auditor Name BF Borgers CPA PC    
Auditor Location Lakewood, CO    
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current Assets:    
Cash $ 116,100 $ 5,843,323
Accounts receivables, net 116,888 895,713
Holdback receivables, net 1,043,991
Inventories 21,857 3,855,946
Prepaid expenses 12,500
Total current assets 267,345 11,638,973
Non-Current Assets:    
Operating lease right-of-use asset, net 91,032
Property and equipment, net 29,410 32,256
Other assets 10,985 78,965
Total non-current assets 40,395 202,253
Total assets 307,740 11,841,226
Current Liabilities:    
Accounts payable and accrued expenses 7,318,230 2,074,576
Accrued interest 531,149 344,475
Current portion of operating lease liabilities 92,195
Royalty payable 1,114,403
Refunds payable 41,509 213,930
Chargebacks payable 20,755 118,288
Income tax payable 17,056
Convertible notes payable 9,175,000
Notes payable to shareholder 5,152,028 4,462,028
Total current liabilities 13,178,671 18,893,962
Total liabilities 13,178,671 18,893,962
Stockholders’ deficit    
Common Stock- $0.0001 par value; 300,000,000 authorized shares; 3,977,497 shares and 3,929,834 issued, respectively 399 394
Additional paid-in-capital 13,265,500 2,966,162
Retained earnings (26,137,915) (10,019,342)
Total stockholders’ deficit (12,870,931) (7,052,736)
Total liabilities and stockholders’ deficit 307,740 11,841,226
Preferred Class A [Member]    
Stockholders’ deficit    
Preferred Stock value 50 50
Preferred Class B [Member]    
Stockholders’ deficit    
Preferred Stock value 1,035
Nonrelated Party [Member]    
Current Liabilities:    
Notes payable 35,000 35,000
Related Party [Member]    
Current Liabilities:    
Notes payable $ 80,000 $ 1,247,011
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 300,000,000 300,000,000
Common stock, shares issued 3,977,497 3,929,834
Preferred Class A [Member]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 30,000,000 30,000,000
Preferred stock, shares issued 500,000 500,000
Preferred stock, shares outstanding 500,000 500,000
Preferred Class B [Member]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 30,000,000 30,000,000
Preferred stock, shares issued 10,349,097 10,349,097
Preferred stock, shares outstanding 10,349,097 10,349,097
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Net Revenue    
Total net revenue $ 20,056,081 $ 58,688,296
Cost of Revenue    
Total cost of sales 4,064,933 6,943,038
Gross profit 15,991,148 51,745,258
Operating expenses:    
General and administrative 1,078,532 1,938,640
Advertising and marketing 19,416,622 47,164,700
Stock compensation for services 141,020 1,117,782
Transaction fees 1,159,896 3,201,599
Merchant fees 1,147,678 2,459,670
Royalty fees 416,140 1,114,403
Professional fees 1,515,065 1,647,787
Payroll and payroll taxes 3,587,300 1,306,565
Rent 159,216 205,497
Bad debt expense 2,666,835 1,300,855
Consulting fees, related party 10,000 43,500
Total operating expenses 31,298,304 61,500,998
Loss from operations (15,307,156) (9,755,740)
Other income (expense)    
Interest expense (897,287) (348,017)
Loss on debt settlement (142,551)
Other income 17,056 57,756
Other expense (30,000)
Gain on disposal of assets 28,397
Total other income (expense), net (1,052,782) (261,864)
Loss before income tax provision and gain on deconsolidation (16,359,938) (10,017,604)
Gain on deconsolidation of subsidiary 241,365
Loss before income tax provision (16,118,573) (10,017,604)
Income tax provision 6,402
Net loss $ (16,118,573) $ (10,024,006)
Earnings (Loss) Per Share:    
Net loss per common share - basic $ (4.07) $ (2.71)
Net loss per common share - diluted $ (4.07) $ (2.71)
Weighted average number of common shares - basic 3,957,486 3,692,740
Weighted average number of common shares - diluted 3,957,486 3,692,740
Product [Member]    
Net Revenue    
Total net revenue $ 15,443,148 $ 40,364,955
Service [Member]    
Net Revenue    
Total net revenue 4,597,933 18,308,341
Rentals [Member]    
Net Revenue    
Total net revenue 15,000 15,000
Cost Of Revenue [Member]    
Cost of Revenue    
Total cost of sales 4,064,933 6,942,680
Cost Of Revenue Other [Member]    
Cost of Revenue    
Total cost of sales $ 358
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Stockholders' Equity - USD ($)
Preferred Stock [Member]
Preferred Class A [Member]
Preferred Stock [Member]
Preferred Class B [Member]
Common Stock [Member]
Common Stock Issuable [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2021 $ 50 $ 350 $ 40 $ 1,848,384 $ 4,664 $ 1,853,488
Balance, shares at Dec. 31, 2021 500,000 3,496,150 397,000      
Issuance of common stock $ 10 $ (10)
Issuance of common stock, shares     97,000 (97,000)      
Issuance of common stock issuable $ 30 $ (30)
Issuance of common stock issuable, shares   300,000 (300,000)      
Issuance of common stock for services $ 4 1,117,778 1,117,782
Issuance of common stock for services, shares     36,684        
Net loss (10,024,006) (10,024,006)
Balance at Dec. 31, 2022 $ 50 $ 394 2,966,162 (10,019,342) (7,052,736)
Balance, shares at Dec. 31, 2022 500,000 3,929,834      
Issuance of common stock for services $ 5 141,015 141,020
Issuance of common stock for services, shares     47,663        
Net loss (16,118,573) (16,118,573)
Vybe deconsolidation (189,739) (189,739)
Conversion of convertible notes and interest payables $ 1,035 10,348,062 10,349,097
Conversion of convertible notes and interest payables, shares   10,349,097        
Balance at Dec. 31, 2023 $ 50 $ 1,035 $ 399 $ 13,265,500 $ (26,137,915) $ (12,870,931)
Balance, shares at Dec. 31, 2023 500,000 10,349,097 3,977,497      
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:    
Net loss $ (16,118,573) $ (10,024,006)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation 4,450 5,686
Common stock issued for professional fees 141,020 1,117,782
Loss on settlement of debt 142,551
Gain on deconsolidation of subsidiary (241,365)
Changes in assets and liabilities:    
Accounts receivables, net 300,717 (573,214)
Holdback receivables 1,043,991 (881,765)
Inventories 3,048,179 (1,980,800)
Prepaid expenses (12,500)
Other assets 67,980 (67,980)
Accounts payable and accrued expenses 5,899,533 1,794,031
Accrued interest 233,862 344,475
Refunds payable (172,421) 6,331
Royalty payable (1,114,403) 1,114,403
Chargebacks payable (97,533) 17,938
Income tax payable (5,850)
Net cash used in operating activities (6,874,512) (9,132,969)
Cash flows from investing activities:    
Purchases of equipment (1,604)
Proceeds from disposition of asset 28,397
Net cash used in financing activities (1,604) 28,397
Cash flows from financing activities:    
Proceeds from convertible debt 500,000
Proceeds from borrowings from stockholder 690,000 4,412,028
Proceeds from borrowings from related parties 1,247,011
Proceeds from borrowing 9,210,000
Net cash provided by financing activities 1,190,000 14,869,039
Net increase(decrease) in cash (5,686,116) 5,764,467
Deconsolidation - Cash (41,107)
Cash – beginning of period 5,843,323 78,856
Cash – end of period 116,100 5,843,323
Supplemental disclosures of cash flow information    
Interest 2,334 1,125
Income taxes 5,850
Non-cash investing and financing activities:    
Conversion of convertible notes and interest payables 10,349,097
Increase of due to shareholder from asset contribution by shareholder 988,817  
Decrease in due to Emblaze One, Inc. by Limitless X due to deconsolidation (1,167,011)
Increase in due from Vybe Labs, Inc. by Limitless X due to deconsolidation $ 1,356,750
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ORGANIZATION AND HISTORY
12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND HISTORY

NOTE 1 – ORGANIZATION AND HISTORY

 

On May 11, 2022, Bio Lab Naturals, Inc., a Delaware corporation (“Bio Lab”), entered into a Share Exchange Agreement (the “Share Exchange Agreement”) with Limitless X, Inc., a Nevada corporation (“LimitlessX”), and its 11 shareholders (the “LimitlessX Acquisition”). The parties completed and closed the LimitlessX Acquisition on May 20, 2022 by issuing an aggregate of 3,233,334 shares of common stock of Bio Lab to the LimitlessX shareholders (the “Acquisition Closing”). According to the terms of the Share Exchange Agreement, Bio Lab then issued an additional 300,000 shares of common stock to the LimitlessX shareholders pro rata to their interests approximately six months from the Acquisition Closing as part of the LimitlessX Acquisition. Concurrently with the LimitlessX Acquisition, Jaspreet Mathur, the founder and principal shareholder of LimitlessX, also purchased from Helion Holdings LLC, 500,000 shares of Bio Lab’s Class A Preferred Convertible Stock, which at all times have a number of votes equal to 60% of all of the issued and outstanding shares of common stock of Bio Lab.

 

On June 10, 2022, Bio Lab changed its name to Limitless X Holdings Inc. (“Limitless”).

 

The LimitlessX Acquisition was accounted for as a “reverse merger” following the completion of the transaction. For accounting purposes, LimitlessX was deemed to be the accounting acquirer in the transaction and, consequently, the transaction was treated as a recapitalization of Bio Lab. Accordingly, LimitlessX’s assets, liabilities, and results of operations became the historical financial statements of the registrant. No step-up in basis or intangible assets or goodwill was recorded in this transaction.

 

The Company (as defined below) is a lifestyle brand, focused in the health and wellness industry. Initially, the Company focused on nutritional supplements, wellness studies, and interactive training videos and has since focused its business on performance marketing, sales of digital services, and sales of products. The Company’s mission is to provide businesses a turnkey solution to sell their products. Company teams include sales, marketing, user interface design (UI), user experience design (UX), fulfillment, customer support, labeling, product manufacturing, consulting, retailing, and payment processing, among others.

 

The Company currently offers products online only. The Company has manufacturing and distribution licensing agreements to market, manufacture, sell, and distribute branded products on behalf of its clients. The Company orders products from third party partner manufacturers that make the products according to the Company’s custom formulations, and brands them using the Company’s licensed trademarks. Products are then marketed and sold direct to consumers online. Orders are fulfilled and shipped directly from the Company’s licensors. The Company plans to offer global marketing services across all areas of the sales process, including market research, brand and product development, and digital advertising operating as an integrated marketing agency.

 

The Company operates in the following product and service sectors: (i) health products and (ii) digital marketing services. The health products sector included the sales of health products in two primary vertical markets: (1) health & wellness; and (2) beauty & skincare. The digital marketing service sector includes digital marketing; digital and print design; social media marketing; and direct-to-consumer marketing.

 

 

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Principles of Consolidation and Reporting

 

The accompanying consolidated financial statements include the accounts of Limitless X Holdings Inc. (a holding company) and its wholly owned operating subsidiaries: Limitless X, Inc., Vybe Lab Inc. (for 2022 and deconsolidated on June 1, 2023), and Prime Time Live, Inc. (collectively, the “Company”). All intercompany balances have been eliminated during consolidation.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $26.1 million at December 31, 2023, and had a net loss of $16.1 million for the year ended December 31, 2023 and net cash used in operating activities of $6.9 million for the year ended December 31, 2023. These matters raise substantial doubt about the Company’s ability to continue as a going concern.

 

To support our existing and planned business model, the Company needs to raise additional capital to fund our future operations. The Company has not experienced any difficulty in raising funds through loans and has not experienced any liquidity problems in settling payables in the normal course of business and repaying loans when they fall due. Successful renewal of our loans, however, is subject to numerous risks and uncertainties. In addition, the increasingly competitive industry conditions under which we operate may negatively impacted our results of operations and cash flows. Additional debt financing is anticipated to fund the Company’s operations in near future. However, there are no current agreements or understandings with regard to the form, time or amount of such financing and there is no assurance that any of this financing can be obtained or that the Company can continue as a going concern.

 

Use of Estimates in the Preparation of Consolidated Financial Statements

 

The preparation of consolidated financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all liquid investments purchased with an initial maturity of three months or less to be cash equivalents. Cash and cash equivalents include demand deposits carried at cost which approximates fair value. The Company maintains its cash in institutions insured by the Federal Deposit Insurance Corporation (“FDIC”).

 

Concentration of Credit Risk

 

The Company offers its services to a small number of clients. This risk of non-payment by these clients is considered minimal and the Company does not generally obtain collateral for sales. The Company continually monitors the credit standing of its clients.

 

Accounts Receivable, net

 

Accounts receivable, net consists primarily of trade receivables, net of allowances for doubtful accounts. The Company sells its products and services for cash or on credit terms, which are established in accordance with local and industry practices and typically require payment within 30 days of delivery. The Company estimates its allowance for doubtful accounts and the related expected credit loss based upon the Company’s historical credit loss experience, adjusted for asset-specific risk characteristics, current economic conditions, and reasonable forecasts. Accounts receivables are written off when determined to be uncollectible. The Company did not require and did not have an allowance for doubtful accounts.

 

 

Holdback Receivables

 

Limitless primarily sells its products online using various third party sales affiliates. These affiliates (online marketing campaign companies) are paid certain commission based on their ability to provide the Company’s products through online sales. All payments are processed through various gateways and are settled through the Company’s payment gateway settler. The Company payment gateway settler is not responsible for settlements that are not paid to processing bank failure. The Company holds responsibility for all the risk in all transactions and processing systems. The payment gateway settler charges a reserve fee to mitigate the risk on their end for any loss of funds or damages.

 

Distributions of the holdback receivables from the third-party payment gateway settler are based on several criteria, such as return and chargeback history, associated risk for the specific business vertical, average transaction amount, and so on. In order to mitigate processing risks, there are policies regarding reserve requirements and payment in arrears in place.

 

The total holdback receivables balance reflects the 0-10% reserve on gross sales and additional reserves by the third-party processor for additional returns and chargebacks if needed. Based on aging of the holdback receivables, the Company has determined that an allowance for doubtful accounts of $1,300,855 or 55% of holdback receivables should be deemed uncollectible recorded as bad debt expense. As of December 31, 2023 and December 31, 2022, the adjusted holdback receivables balance was $NIL and $1,043,991, respectively.

 

Inventories

 

Inventories are valued at the lower-of-cost or net realizable value on a first-in, first-out basis, adjusted for the value of inventory that is determined to be excess, obsolete, expired, or unsaleable. Inventories primarily consisted of finished goods.

 

Advertising and Marketing

 

Advertising and marketing costs are charged to expense as incurred. Advertising and marketing costs were approximately $19,416,622 and $47,164,700 for the years ended December 31, 2023 and 2022, respectively, and are included in operating expenses in the accompanying statements of operations.

 

 

Property and Equipment, net

 

Property and equipment is recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation of property and equipment is over the estimated useful life of five to ten years using the straight-line method.

 

   December 31, 2023   December 31, 2022 
         
Machinery and equipment  $39,067   $37,463 
Total   39,067    37,463 
           
Less: accumulated depreciation   (9,657)   (5,207 
           
Total equipment, net  $29,410   $32,256 

 

Depreciation expense was $4,450 and $5,686 for the years ended December 31, 2023 and 2022, respectively. During the year ended December 31, 2022, the Company reported a gain of $28,397 on the disposal of assets.

 

Revenue Recognition

 

Product Sales

 

The Company recognizes revenue when performance obligations under the terms of a contract with its customer are satisfied. The Company has determined that fulfilling and delivering products is a single performance obligation. Revenue is recognized at the point in time when the Company has satisfied its performance obligation and the customer has obtained control of the products or when the service is fully. This generally occurs when the product is delivered to or picked up by the customer based on applicable shipping terms, which is typically within 15 days. Revenue is measured as the amount of consideration expected to be received in exchange for fulfilled product orders,

 

While customers generally have a right to return defective or non-conforming products, past experience has demonstrated that product returns have been immaterial. Customer remedies for defective or non-conforming products may include a refund or exchange. As a result, the right of return is estimated and recorded as a reduction in revenue at the time of sale, if necessary.

 

The Company’s customer contracts identify product quantity, price, and payment terms. Payment terms are granted consistent with industry standards. Although some payment terms may be more extended, the majority of the Company’s payment terms are less than 30 days. As a result, revenue is not adjusted for the effects of a significant financing component. Amounts billed and due from customers are classified as Accounts Receivables on the Balance Sheet.

 

 

The Company utilizes third-party contract manufacturers for the manufacture of its products. The Company has evaluated whether it is the principal or agent in these relationships. The Company has determined that it is the principal in all cases, as it retains the responsibility for fulfillment and risk of loss, as well as for establishing the price.

 

In accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, the Company has elected the practical expedient to expense the incremental costs to obtain a contract, because the amortization period would be less than one year, and the practical expedient for shipping and handling costs. Shipping and handling costs incurred to deliver products to customers are accounted for as fulfillment activities, rather than a promised service, and as such are included in Cost of Goods Sold in the Statements of Operations.

 

Service Revenue

 

Service revenue consists of digital marketing revenue.

 

Revenue related to digital marketing is recognized over time as services are provided to the customer. We sell digital marketing, digital and print design, social media marketing and direct-to-consumer marketing and thus use standalone selling prices as the basis for revenue. Payment for digital marketing services are typically received at the point when control transfers to the customer or in accordance with payment terms customary to the business. There was no deferred revenue related to services revenue as of December 31, 2023 and 2022.

 

Cost of Sales

 

Cost of goods sold includes the cost of inventory sold during the period as well as certain commission fees, returns, chargebacks, distribution and shipping and handling costs. The amount shown is net of various rebates from third-party vendors in the form of payments.

 

Refunds Payable

 

If customers are not satisfied for any reason, they may request a full refund, processed to the original form of payment, within 30 days from the order date. If the order has already been shipped, the Company charges a 20% restocking fee. The Company’s estimate of the reserve is based upon the Company’s most historical experience of actual customer returns. Additionally, the Company considers other factors in estimating the reserve, such as hiring a new internal team with more resources for the refund process.

 

As of December 31, 2023 and December 31, 2022, refunds payable was $41,509 and $213,930, respectively.

 

 

Chargebacks Payable

 

Once customers successfully dispute chargebacks with the payment processor, the Company returns such funds to the payment processor to return to the customer. As of December 31, 2023 and December 31, 2022, chargebacks payable was $20,755 and $118,288, respectively.

 

Other Comprehensive Loss

 

The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss for the period.

 

Income Taxes

 

The accounting standard on accounting for uncertainty in income taxes addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under that guidance, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

 

Earnings (Loss) per Share

 

The Company calculates earnings per share in accordance with Financial Accounting Standards Board (“FASB”) ASC 260, Earnings Per Share, which requires a dual presentation of basic and diluted earnings per share. Basic earnings per share (“EPS”) is computed by dividing earnings (losses) attributable to common shareholders by the weighted average number of common shares outstanding for the periods. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. The Company had a loss for the years ended December 31, 2023 and 2022.

 

Equity Based Payments

 

The Company accounts for equity-based payment accruals under authoritative guidance as set forth in the Topics of the ASC. The guidance requires all equity-based payments to employees and non-employees, including grants of employee and non-employee stock options and warrants, to be recognized in the consolidated financial statements based at their fair values. The Company applies the provisions of ASC 718, “Compensation - Stock Compensation,” using a modified prospective application, and the Black-Scholes model to value stock options. Under this application, the Company records compensation expense for all awards granted. Compensation costs will be recognized over the period that an employee provides service in exchange for the award. During the year ended December 31, 2023 and the year ended December 31, 2022, the Company granted no options under the 2020 Stock Incentive Plan and 2022 Stock Option Plan.

 

General Concentrations of Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk are accounts receivable and other receivables arising from its normal business activities. The Company has a diversified customer base. The Company controls credit risk related to accounts receivable through credit approvals, credit limits, and monitoring procedures. The Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable related credit risk exposure beyond such allowance is limited.

 

The Company purchases merchandise from 6 suppliers, and the Company’s 3 largest suppliers accounted for 95% of total purchases in fiscal 2022. A significant portion of the Company’s inventory is manufactured abroad in Asia. Foreign imports subject the Company to the risks of changes in, or the imposition of new, import tariffs, duties or quotas, new restrictions on imports, loss of “most favored nation” status with the United States for a particular foreign country, antidumping or countervailing duty orders, retaliatory actions in response to illegal trade practices, work stoppages, delays in shipment, freight expense increases, product cost increases due to foreign currency fluctuations or revaluations, public health issues that could lead to temporary closures of facilities or shipping ports, such as the recent outbreak of COVID-19, and other economic uncertainties. If a disruption of trade were to occur from the countries in which the suppliers of the Company’s vendors are located, the Company may be unable to obtain sufficient quantities of products to satisfy its requirements, or the cost of obtaining products may increase.

 

A substantial amount of the Company’s inventory is manufactured abroad. From time to time, shipping ports experience capacity constraints (such as delays associated with COVID-19), labor strikes, work stoppages or other disruptions that may delay the delivery of imported products. A contract dispute may lead to protracted delays in the movement of the Company’s products, which could further delay the delivery of products to the Company’s stores and impact net sales and profitability. In addition, other conditions outside of the Company’s control, such as adverse weather conditions or acts of terrorism or war, such as the current conflict in Ukraine, could significantly disrupt operations at shipping ports or otherwise impact transportation of the imported merchandise we sell, either through supply chain disruptions, or rising freight and fuel costs.

 

 

Operating Lease

 

In accordance with ASC 842, Leases, the Company determines whether an arrangement contains a lease at inception. A lease is a contract that provides the right to control an identified asset for a period of time in exchange for consideration. For identified leases, the Company determines whether it should be classified as an operating or finance lease. Operating leases are recorded in the balance sheet as: right-of-use asset (“ROU asset”) and operating lease liability. ROU asset represents the Company’s right to use an underlying asset for the lease term and lease liability represents the Company’s obligation to make lease payments arising from the lease. ROU assets and operating lease liabilities are recognized at the commencement date of the lease and measured based on the present value of lease payments over the lease term. The ROU asset also includes deferred rent liabilities. The Company’s lease arrangement generally do not provide an implicit interest rate. As a result, in such situations the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option in the measurement of its ROU asset and liability. Lease expense for the operating lease is recognized on a straight-line basis over the lease term. The Company has a ease agreement with lease and non-lease components, which are accounted for as a single lease component and are month-to-month during the year ended December 31, 2023.

 

Recent Accounting Pronouncements

 

In December 2019, FASB issued Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which amends existing guidance related to the accounting for income taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending existing guidance. This ASU is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company evaluated the effects of adoption of this guidance on the financial statements and did not have any material impact on its consolidated financial statements.

 

In June 2016, the FASB issued an accounting standards update which changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. This update replaces the existing incurred loss impairment model with an expected loss model (referred to as the Current Expected Credit Loss model, or “CECL”). The standard update, and its related amendments, will become effective for the fiscal year beginning on January 1, 2023. The Company evaluated the effects of adoption of this guidance on the financial statements and did not have any material impact on its consolidated financial statements.

 

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA and the SEC did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

 

 

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE MEASUREMENTS
12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS

NOTE 3 – FAIR VALUE MEASUREMENTS

 

The Company utilizes ASC 820-10, Fair Value Measurement and Disclosure, for valuing financial assets and liabilities measured on a recurring basis. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value:

 

  Level 1. Observable inputs such as quoted prices in active markets;

 

  Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

 

  Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

 

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. There were no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. There have been no transfers between levels.

 

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DECONSOLIDATION (Sale of Vybe Labs, Inc.)
12 Months Ended
Dec. 31, 2023
Deconsolidation  
DECONSOLIDATION (Sale of Vybe Labs, Inc.)

NOTE 4 – DECONSOLIDATION (Sale of Vybe Labs, Inc.)

 

On June 1, 2023, the Company entered into an Agreement for Purchase and Sale of Stock (the “Vybe Sale Agreement”) with Emblaze One, Inc., a Nevada corporation, (“Emblaze”) wherein the Company sold all 5,000 of its shares of common stock of its wholly owned subsidiary, Vybe Labs, Inc., a Delaware corporation (“Vybe”). Emblaze is a company 100% owned by the Company’s Chief Executive Officer, Chairman of the Board of Directors, and majority shareholder, Jaspreet Mathur.

 

The transaction is recorded as follows at the date of this transaction:

 

   June 1, 
   2023 
     
Total assets and liabilities deconsolidated for Vybe:     
Total assets  $1,156,733 
Total liabilities   (1,356,750)
      
Net assets (liabilities)  $(241,365)
      
Net amount of deconsolidation – Recorded as a Gain on Deconsolidation of Subsidiary  $241,365 

 

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LOSS ON SETTLEMENT OF DEBT
12 Months Ended
Dec. 31, 2023
Loss On Settlement Of Debt  
LOSS ON SETTLEMENT OF DEBT

NOTE 5 – LOSS ON SETTLEMENT OF DEBT

 

On June 1, 2023, the Company agreed to a settlement of a debt in the amount of $1,167,011 and interest payable of $47,188 owed by the Company to Emblaze, a related party, under two Loan Authorization and Agreements dated April 1, 2022 and December 31, 2022, in the principal amounts of $237,610 and $929,401, respectively, and interest payable of $10,012 and $37,176, respectively, as part of the Vybe Sales Agreement with Emblaze.

 

 

The transaction is recorded as follows at the date of this transaction:

 

SCHEDULE OF DECONSOLIDATION ON LOSS ON SETTLEMENT OF DEBT 

   June 1, 
   2023 
     
Total due to and due from between Limitless X and Vybe before deconsolidation:     
Due to Emblaze One, Inc. by Limitless X  $1,167,011 
Interest payable   47,188 
Due from Vybe Labs, Inc. by Limitless X   (1,356,750)
      
Net due to (from)  $(142,551)
      
Net amount of deconsolidation – Recorded as a Loss on Settlement of Debt  $142,551 

 

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ROYALTY PAYABLES
12 Months Ended
Dec. 31, 2023
Royalty Payables  
ROYALTY PAYABLES

NOTE 6 – ROYALTY PAYABLES

 

Limitless Performance Inc. (“LPI”), SMILZ INC. (“Smiles”), DIVATRIM INC. (“Divatrim”), and AMAROSE INC. (“Amarose,” and collectively with LPI, Smiles, and Divatrim, the “Licensors”) are all companies at least 50% owned by a shareholder of the Company. On December 1, 2021, the Company entered into manufacturing and distributorship license agreements (each, a “License Agreement”) with each of the Licensors to distribute each of the Licensors’ respective products and for payments to such Licensor for its product designs and distribution rights. Pursuant to the License Agreements, and each of them, the Company agreed to pay to such Licensors royalty payments equal to 4.00% of gross sales, excluding returns, chargebacks, and other such allowances.

 

As of December 31, 2023 and 2022, the royalty payable was $0 and $1,114,403, respectively.

 

On October 1, 2023, the Company terminated each of the License Agreements; however, the Company maintained its license for NZT-48 with LPI.

 

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NOTE PAYABLE
12 Months Ended
Dec. 31, 2023
Note Payable  
NOTE PAYABLE

NOTE 7 – NOTE PAYABLE

 

On March 1, 2021, an individual loaned the predecessor company $35,000 in exchange for an unsecured promissory note that included interest at the rate of 10% per annum on the unpaid principal balance with all unpaid principal and interest due on or before March 1, 2022. The maturity date was extended to December 31, 2022. Interest is due and payable on the first day of each month. As of December 31, 2023, Prime Time Live, Inc. owes $35,000 in principal and accrued interest of $4,595 as of December 31, 2023. As of December 31, 2022, Prime Time Live, Inc. owes $35,000 in principal and accrued interest of $1,095 as of December 31, 2022.

 

 

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONVERTIBLE NOTES PAYABLE
12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
CONVERTIBLE NOTES PAYABLE

NOTE 8 – CONVERTIBLE NOTES PAYABLE

 

Convertible notes payable consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
         
August 3, 2022 ($5,000,000)  $        -   $5,000,000 
August 3, 2022 ($1,000,000)   -    1,000,000 
August 22, 2022 ($500,000)   -    500,000 
September 22, 2022 ($250,000)   -    250,000 
September 25, 2022 ($600,000)   -    600,000 
September 25, 2022 ($600,000)   -    600,000 
September 29, 2022 ($50,000)   -    50,000 
September 29, 2022 ($500,000)   -    500,000 
October 10, 2022 ($500,000)   -    500,000 
October 13, 2022 ($750,000)   -    75,000 
October 13, 2022 ($50,000)   -    50,000 
October 14, 2022 ($50,000)   -    50,000 
           
Total convertible note payables (current)  $-   $9,175,000 

 

From August 3, 2022 through November 28, 2022, the Company conducted a convertible note offering for a maximum offering of $15,000,000 and a minimum of $2,000,000 (the “Convertible Note Offering”).

 

Pursuant to the terms of the Convertible Note, the principal amount of the Note that may be outstanding from time to time shall bear interest per annum until paid in full at a rate equal to 6%, compounded annually. The principal and interest of the Note shall be due and payable to the noteholder on the one-year anniversary of the date of the Note (the “Maturity Date”) unless all principal and interest due under the Note had been converted by the Maturity Date.

 

The conversion price shall be equal to $0.25 per share of Common Stock. Any time prior to the Maturity Date, and upon the date of effectiveness of registration of the Notes on a registration statement filed with the Securities and Exchange Commission (the “SEC”), the Note shall automatically convert to shares of common stock of the Company at the Conversion Price (the “Automatic Conversion”); provided however, that in the event that Conversion Shares represent greater than 4.99% of the total Common Shares of the Company (the portion above 4.99% referred to herein as the “Excess Shares”), then the Automatic Conversion shall only apply to such portion of the Note up to 4.99% and not include the Excess Shares. This Note is convertible at the option of the Noteholder, in holder’s sole discretion, in whole or in part, at any time prior to the Maturity Date or payment in full of the Note, whichever occurs first, all or any portion of principal or interest, into shares of Common Stock of the Company at the Conversion Price.

 

The Company analyzed the conversion option in the notes for derivative accounting treatment under ASC Topic 815, “Derivatives and Hedging,” and determined that the instruments do not qualify for derivative accounting.

 

The Company has received $9,175,000 from 12 accredited investors pursuant to the Convertible Note Offering during 2022 and additional one accredited investor for $500,000 during 2023. The Company had $9,675,000 raised through the Convertible Note Offering prior to converting to Class B Preferred Stock on October 23, 2023.

 

On October 1, 2023, the Company entered into Conversion Agreements with each of the convertible noteholders to convert their respective notes into shares of Class B Preferred Stock. Pursuant to the Conversion Agreements, each noteholder agreed to receive one share of Class B Preferred Stock for each $2.00 of principal and unpaid interest accrued through the closing date of the Conversion Agreement. As of the closing date of the Conversion Agreement, and each of them, no portion of any of the Notes had been converted into shares of the Company’s common stock.

 


On October 23, 2023, pursuant to the Conversion Agreements, the Company planned to issue an aggregate of 10,349,097 shares of Class B Preferred Stock before the completion of this offering and extinguish $9,675,000 of convertible debt including accumulated interest as of October 23, 2023 in the amount of $674,097.

 

 

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NOTES PAYABLE TO SHAREHOLDER
12 Months Ended
Dec. 31, 2023
Notes Payable To Shareholder  
NOTES PAYABLE TO SHAREHOLDER

NOTE 9 – NOTES PAYABLE TO SHAREHOLDER

 

Notes payable to shareholder consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
         
December 6, 2021 ($50,000)  $50,000   $50,000 
February 11, 2022 ($150,000)   150,000    150,000 
May 8, 2022 ($550,000)   550,000    550,000 
May 9, 2022 ($1,100,000)   1,100,000    1,100,000 
May 16, 2022 ($450,000)   450,000    450,000 
June 1, 2022 ($500,000)   500,000    500,000 
June 30, 2022 ($922,028)   922,028    922,028 
August 25, 2022 ($290,000)   290,000    290,000 
November 15, 2022 ($450,000)   450,000    450,000 
May 16, 2023 ($150,000)   150,000    - 
May 18, 2023 ($50,000)   50,000    - 
June 5, 2023 ($150,000)   150,000    - 
June 20, 2023 ($50,000) – Funding Commitment   50,000    - 
July 13, 2023 ($50,000) – Funding Commitment   50,000    - 
August 1, 2023 ($190,000) – Funding Commitment   190,000    - 
August 7, 2023 ($50,000) – Funding Commitment   50,000    - 
Total notes payable to stockholder (current)  $5,152,028   $4,462,028 

 

  December 6, 2021 – $50,000

 

On December 6, 2021, the Company entered into a Loan Authorization and Agreement for a loan of $50,000 from a shareholder, the proceeds of which were used to be used for working capital purposes. Beginning on June 1, 2022, the loan required a payment of $4,303 per month, which included principal and interest with an interest rate of 6 % per annum. The total balance of principal and interest was due on May 1, 2023. As of December 31, 2023, the loan is due upon demand.

 

  February 11, 2022 – $150,000

 

On February 11, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $150,000 from a shareholder, the proceeds of which were to be used for working capital purposes. Beginning on June 1, 2022, the loan required a payment of $12,910 per month, which included principal and interest with an interest rate of 6% per annum. The total balance of principal and interest was due on May 1, 2023. As of December 31, 2023, the loan is due upon demand.

 

  May 8, 2022 – $550,000

 

On May 8, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $550,000 from a shareholder, the proceeds of which were to be used for working capital purposes. As of September 30, 2023 and December 31, 2022, the principal balance was $550,000 and $550,000, respectively. Beginning on June 1, 2022, the loan required a payment of $47,337 per month, which included principal and interest with an interest rate of 6% per annum. The total balance of principal and interest was due on May 1, 2023. As of December 31, 2023, the loan is due upon demand.

 

 

  May 16, 2022 – $1,100,000

 

On May 16, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $1,100,000 from a shareholder, the proceeds of which were to be used for working capital purposes. Interest began accruing at the rate of 8.5% per annum on June 17, 2022 and was due on May 16, 2023. As of December 31, 2023, the loan is due upon demand.

 

  May 18, 2022 – $450,000

 

On May 18, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $450,000 from a shareholder, the proceeds of which were to be used for working capital purposes. Interest began accruing at the rate of 8.5% per annum on June 19, 2022 and was due on May 18, 2023. As of December 31, 2023, the loan is due upon demand.

 

  June 1, 2022 – $500,000

 

On June 1, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $500,000 from a shareholder, the proceeds of which were to be used for working capital purposes. Beginning on August 1, 2022, the loan required a payment of $43,494 per month, which included principal and interest with an interest rate of 8% per annum. The total balance of principal and interest was due on July 1, 2023. As of December 31, 2023, the loan is due upon demand.

 

  September 30, 2022 – $922,028

 

On June 30, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $922,028 from a shareholder, the proceeds of which were to be used for working capital purposes. Beginning on August 1, 2022, the loan required a payment of $80,206 per month, which included principal and interest with an interest rate of 8% per annum. The total balance of principal and interest was due on August 1, 2023. As of December 31, 2023, the loan is due upon demand.

 

  August 25, 2022 – $290,000

 

On August 25, 2022, the Company entered into a Loan Authorization Agreement for a loan of $290,000 from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of 10% per annum and is due on demand.

 

  November 15, 2022 – $450,000

 

On November 15, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $450,000 from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of 10% per annum and is due on demand.

 

  May 16, 2023 – $150,000

 

On May 16, 2023, the Company entered into a Loan Authorization and Agreement for a loan of $150,000 from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of 10% per annum and is due on demand.

 

  May 18, 2023 – $50,000

 

On May 18, 2023, the Company entered into a Loan Authorization and Agreement for a loan of $50,000 from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of 10% per annum and is due on demand.

 

 

  June 5, 2023 – $150,000

 

On June 5, 2023, the Company entered into a Loan Authorization and Agreement for a loan of $150,000 from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of 10% per annum and is due on demand.

 

  Funding Commitment Agreement

 

On June 3, 2023, the Company entered into a Funding Commitment Agreement (the “Funding Commitment”) with its Chief Executive Officer and Chairman of the Board of Directors, Jaspreet Mathur, wherein Mr. Mathur committed to provide up to $1,000,000 of working capital to the Company over the next six months. Mr. Mathur agreed to the Funding Commitment in exchange for a one year convertible promissory note for each drawdown amount advanced to the Company with an annual interest rate of 10% and a balloon payment of principal and interest due at maturity, unless Mr. Mathur elects to convert the outstanding principal and interest into Class B Preferred Stock of the Company at the conversion price of $1.50 per share; provided, however, Mr. Mathur may only covert each note within the term of the Funding Commitment, in the event of the occurrence of the earlier of a public offering of securities of the Company pursuant to a registration statement filed with the SEC and declared effective pursuant to the Securities Act of 1933, upon completion of which the Company has a class of stock registered under the Securities Exchange Act of 1934 and that stock is listed on a national stock exchange, or a liquidation, merger, acquisition, sale of voting control or sale of substantially all of the assets of the Company in which the shareholders of the Company do not own a majority of the outstanding shares of the surviving corporation. For the avoidance of doubt, a national stock exchange includes Nasdaq, NYSE, and NYSE American, but excludes any over-the-counter quotation systems or trading platforms. The balance of the Funding Commitment are as follows:

 

   December 31, 2023 
     
June 20, 2023 ($50,000)  $50,000 
July 13, 2023 ($50,000)   50,000 
August 1, 2023 ($190,000)   190,000 
August 7, 2023 ($50,000)   50,000 
Total Funding Commitment  $340,000 

 

As of December 31, 2023, the balance of notes payable to shareholder under the Funding Commitment was $340,000.

 

Total accrued interest related to notes payable to shareholder as of December 31, 2023 and 2022 was $508,524 and $132,938, respectively. Interest expense related to notes payable to shareholder for the year ended December 31, 2023 was $375,586.

 

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NOTES PAYABLE TO RELATED PARTIES
12 Months Ended
Dec. 31, 2023
Notes Payable To Related Parties  
NOTES PAYABLE TO RELATED PARTIES

NOTE 10 – NOTES PAYABLE TO RELATED PARTIES

 

Notes payable to related party consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
         
May 10, 2022 ($12,500)  $12,500   $12,500 
May 10, 2022 ($12,500)   12,500    12,500 
May 10, 2022 ($20,000)   20,000    20,000 
May 31, 2022 ($5,000)   5,000    5,000 
May 31, 2022 ($15,000)   15,000    15,000 
June 9, 2022 ($15,000)   15,000    15,000 
December 31, 2022 ($929,401)   -    929,401 
           
Total notes payable to related parties (current)  $80,000   $1,247,011 

 

 

  May 10, 2022 - $12,500

 

On May 10, 2022, a related party of the Company loaned Prime Time Live, Inc. $12,500 in exchange for a promissory note that includes interest at the rate of 10% per annum on the unpaid principal balance, with all unpaid principal and interest due on or before May 10, 2023. Interest began accruing on May 10, 2022. As of December 31, 2023, the loan is due upon demand.

 

  May 10, 2022 - $12,500

 

On May 10, 2022, a related party of the Company loaned Prime Time Live, Inc. $12,500 in exchange for a promissory note that includes interest at the rate of 10% per annum on the unpaid principal balance with all unpaid principal and interest due on or before May 10, 2023. Interest began accruing on May 10, 2022. As of December 31, 2023, the loan is due upon demand.

 

  May 10, 2022 - $20,000

 

On May 10, 2022, a related party of the Company loaned Prime Time Live, Inc. $20,000 in exchange for a promissory note that included interest at the rate of 10% per annum on the unpaid principal balance with all unpaid principal and interest due on or before May 10, 2023. Interest began accruing on May 10, 2022. As of December 31, 2023, the loan is due upon demand.

 

  May 31, 2022 - $5,000

 

On May 31, 2022, a related party of the Company loaned Prime Time Live, Inc. $5,000 in exchange for a promissory note that included interest at the rate of 10% per annum on the unpaid principal balance with all unpaid principal and interest due on or before May 31, 2023. Interest began accruing on May 31, 2022. As of December 31, 2023, the loan is due upon demand.

 

  May 31, 2022 - $15,000

 

On May 31, 2022, a related party of the Company loaned Prime Time Live, Inc. $15,000 in exchange for a promissory note that included interest at the rate of 10% per annum on the unpaid principal balance with all unpaid principal and interest due on or before May 31, 2023. Interest began accruing on May 31, 2022. As of December 31, 2023, the loan is due upon demand.

 

  June 9, 2022 - $15,000

 

On May 10, 2022, a related party of the Company loaned Prime Time Live, Inc. $15,000 in exchange for a promissory note that included interest at the rate of 10% per annum on the unpaid principal balance with all unpaid principal and interest due on or before May 10, 2023. Interest began accruing on May 10, 2022. As of December 31, 2023, the loan is due upon demand.

 

  December 31, 2022 - $929,401

 

On December 31, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $929,401 from Emblaze, the proceeds of which were to be used for working capital purposes. The loan had an interest rate of 8% per annum and was due on December 1, 2023. On June 1, 2023, the Company entered into an Agreement for Purchase and Sale of Stock with Emblaze wherein the Company sold all 5,000 of its shares of common stock of Vybe Labs, as full payment and settlement of a debt in the in the principal amount of $929,401 owed by the Company to Emblaze.

 

Total accrued interest related to notes payable to shareholder as of December 31, 2023 and 2022 was $11,127 and $3,127, respectively. Interest expense related to notes payable to shareholder for the year ended December 31, 2023 was $8,000.

 

 

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCKHOLDERS’ EQUITY
12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 11 – STOCKHOLDERS’ EQUITY

 

Common Stock

 

As of December 31, 2023 and 2022, the Company had 300,000,000 authorized shares of common stock par value $0.0001 per share and had 3,977,497 shares and 3,929,834 shares issued and outstanding, respectively.

 

Common Stock Issued for Services – On May 31, 2023, the Company issued approximately 47,000 shares of common stock for services provided to the Company. These shares were valued at fair value at the time of issuance and recorded stock compensation expense of $141,020, for the year ended December 31, 2023.

 

Common Stock Issued for Services – On May 10, 2022 and June 10, 2022, the Company issued 36,000 and 684 shares of common stock, respectively, for services provided to the Company. These shares were valued at fair value at the time of issuance and recorded stock compensation expense of $1,117,782 for the year ended December 31, 2022.

 

Preferred Stock

 

As of December 31, 2023 and 2022, the Company has authorized 30,000,000 shares of preferred stock, 500,000 shares of which were designated as Class A Convertible Preferred Stock (“Class A Preferred Stock”).

 

Class A Convertible Stock – As of December 31, 2023 and 2022, there were a total of 500,000 shares of Class A Preferred Stock issued and outstanding. The Class A Preferred Stock, when voting as a single class, has the votes of at least 60% of the voting power of the Company. Further, the holder of the Class A Preferred Stock can convert one share of Class A Preferred Stock into two shares of the Company’s common stock, subject to adjustment. In addition, the holder of the Class A Preferred Stock is entitled to a liquidation preference of the Company senior to all other securities of the Company.

 

Class B Convertible Stock – On October 23, 2023, pursuant to certain Conversion Agreements, the Company issued an aggregate of 10,349,097 shares of Class B Preferred Stock and extinguished $9,675,000 of convertible debt including accumulated interest as of October 23, 2023 in the amount of $674,097. The holders of the Class B Preferred Stock are entitled to a liquidation preference senior to common stock and junior to the Class A Preferred Stock at a liquidation price of $3.00 per share of Class B Preferred Stock. The Class B Preferred Stock also has conversion rights, whereby each share of Class B Preferred Stock is convertible into two shares of Common Stock at the discretion of the holder, subject to beneficial ownership limitations. The holders of the Class B Preferred Stock have no voting rights, unless otherwise provided for in its Certificate of Designation or by law.

 

 

Common Stock and Recapitalization

 

As a result of the LimitlessX Acquisition and LimitlessX being the acquirer, the Company retrospectively restated its common stock as if the transaction occurred at the beginning of the period. The following is the reconciliation of retrospectively restated common stock:

 

             
   December 31, 2021 
   Issued   Issuable   Total 
             
Common stock – Limitless X Inc. – as original   1,616,667    50,000    1,666,667 
Common stock split (1 to 1.94) – Limitless X Inc.   1,519,366    47,000    1,566,366 
Common stock issuable (additional stock split) – Limitless X Inc.   -    300,000    300,000 
Common stock (Bio Lab) – prior to reverse merger   360,117    -    360,117 
                
Total as of December 31, 2021 – as retrospectively restated   3,496,150    397,000    3,893,150 

 

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
EQUITY BASED PAYMENTS
12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
EQUITY BASED PAYMENTS

NOTE 12 – EQUITY BASED PAYMENTS

 

The Company had the following equity-based plan:

 

Stock Incentive Plans

 

Effective January 15, 2020, the Company adopted its 2020 Stock Option and Award Plan (the “2020 Stock Incentive Plan”). Under the 2020 Stock Incentive Plan, the Board of Directors may grant options or purchase rights to purchase common stock to officers, employees, and other persons who provide services to the Company or any related company. The participants to whom awards are granted, the type of awards granted, the number of shares covered for each award, and the purchase price, conditions and other terms of each award are determined by the Board of Directors, except that the term of the options shall not exceed ten years. A total of 2,222 shares of the Company’s common stock is reserved for the 2020 Stock Incentive Plan. The shares issued for the 2020 Stock Incentive Plan may be either treasury or authorized and unissued shares. During the year ended December 31, 2023 and the year ended December 31, 2022, the Company granted no options under the 2020 Stock Incentive Plan.

 

Effective August 9, 2022, the Company adopted its 2022 Incentive and Non-statutory Stock Option Plan (the “2022 Stock Option Plan”). Under the 2022 Stock Option Plan, the Board of Directors may grant options to purchase common stock to officers, employees, and other persons who provide services to the Company. A total of 833,333 shares of the Company’s common stock is reserved for the 2022 Stock Option Plan. During the year ended December 31, 2023 and the year ended December 31, 2022, the Company granted no options under the 2022 Stock Option Plan.

 

Effective August 9, 2022, we adopted our 2022 Restricted Stock Plan (the “2022 Restricted Stock Plan”). Under the 2022 Restricted Stock Plan, the Board of Directors may grant restricted stock to officers, directors, and key employees. A total of 833,333 shares of common stock is reserved for the 2022 Stock Option Plan. During the year ended December 31, 2023 and the year ended December 31, 2022, there have been no shares of common stock granted under the 2022 Restricted Stock Plan.

 

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
RELATED PARTY TRANSACTIONS
12 Months Ended
Dec. 31, 2023
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 13 – RELATED PARTY TRANSACTIONS

 

The Company had the following related party transactions:

 

Royalty Payables – Limitless Performance Inc. (“LPI”), SMILZ INC. (“Smiles”), DIVATRIM INC. (“Divatrim”), and AMAROSE INC. (“Amarose,” and collectively with LPI, Smiles, and Divatrim, the “Licensors”) are all companies at least 50% owned by a shareholder of the Company. On December 1, 2021, the Company entered into manufacturing and distributorship license agreements (each, a “License Agreement”) with each of the Licensors to distribute each of the Licensors’ respective products and for payments to such Licensor for its product designs and distribution rights. Pursuant to the License Agreements, and each of them, the Company agreed to pay to such Licensors royalty payments equal to 4.00% of gross sales, excluding returns, chargebacks, and other such allowances. As of December 31, 2023 and 2022, the royalty payable was $0 and $1,114,403, respectively. On October 1, 2023, the Company terminated each of the License Agreements; however, the Company maintained its license for NZT-48 with LPI.

 

 

Notes Payable to Shareholder – The Company had various notes payable with its shareholder who is the Chief Executive Officer of the Company. As of December 31, 2023 and 2022, the Company had $5,152,028 and $4,462,028 outstanding, respectively. Refer to Note 9.

 

Notes Payable to Related Parties – The Company entered into various notes payable with shareholders of the Company. As of December 31, 2023 and 2022, the Company had $80,000 outstanding. Refer to Note 10.

 

Consulting Fees – During the year ended December 31, 2023, the Company incurred consulting fees in the amount of $0 to an officer and an officer of one of its affiliates. During the year ended December 31, 2022, the Company incurred consulting fees in the amount of $32,500 to an officer and an officer of one of its affiliates.

 

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES
12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 14 – COMMITMENTS AND CONTINGENCIES

 

Commitments

 

Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives. The Company’s variable lease payments primarily consist of maintenance and other operating expenses from their real estate leases. Variable lease payments are excluded from the ROU assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

 

The Company has lease agreements with lease and non-lease components. The Company has elected to account for these lease and non-lease components as a single lease component.

 

 

In accordance with ASC 842, the components of lease expense were as follows:

 

   For the   For the 
   year ended   year ended 
   December 31, 2023   December 31, 2022 
Operating lease expense  $-   $138,108 
Total lease expense  $-   $138,108 

 

In accordance with ASC 842, other information related to leases was as follows:

 

   For the   For the 
   year ended   year ended 
   December 31, 2023   December 31, 2022 
Operating cash flows from operating leases  $-   $137,138 
Cash paid for amounts included in the measurement of lease liabilities  $-   $137,138 

 

Weighted-average remaining lease term—operating leases  Years 
Weighted-average discount rate—operating leases   3%

 

Total rent expense was $160,379 and $204,527 for the years ended December 31, 2023 and 2022, respectively.

 

Contingencies

 

From time to time, the Company is involved in legal proceedings. The Company records a liability for those legal proceedings when it determines it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The Company also discloses when it is reasonably possible that a material loss may be incurred, however, the amount cannot be reasonably estimated. From time to time, the Company may enter into discussions regarding settlement of these matters, and may enter into settlement agreements, if it believes settlement is in the best interest of the Company and its shareholders.

 

The following is a summary of our current outstanding litigation:

 

Mentom Eyewear Inc. – A legal action was filed in the Los Angeles Superior Court against Limitless X Holdings Inc., four of its officers, and an unrelated company, alleging the breach of an Implied In-Fact Agreement and other causes of action related to that alleged agreement such as conversion, fraud and unjust enrichment, Mentom Eyewear Inc. v. Limitless X Holdings Inc., et al., Case Number 23STCV24681.  We believe that there was no such agreement, and that the plaintiff has no legal standing to bring such a matter against the Company or its officers.  The case is moving into the discovery phase where we believe the true facts will lead to a dismissal; however, if the case continues, we will vigorously defend against such claims as it is our position that the allegations are not supported by the facts.  No liability has been recorded for these litigations because the Company believes that any such liability is not probable and reasonably estimable at this time.

 

Harpo Inc. – A legal action was filed in the Central District of California against Limitless X Inc. and two of its officers along with Emblaze One, Inc., alleging trademark infringement and dilution, unfair competition, false advertising, and violation of the right of publicity, all based on allegations that one of our advertisements contained the unauthorized use of a celebrity’s name and intellectual property, Harpo Inc. and OW Licensing Company LLC v. Emblaze One, Inc., et al., Case Number 2:23-cv-04459 VAP (ASx).  Any exposure stemming from this action would be subject to indemnity from the advertising network responsible for the ads in question.  We have not yet filed a responsive pleading in this action as we are attempting a global settlement; however, if unable to settle we will defend the case vigorously and will attempt a contractual and equitable indemnity claim against the advertiser.  No liability has been recorded for this litigation because the Company believes that any such liability is not reasonably estimable at this time.

 

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUBSEQUENT EVENTS
12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 15 – SUBSEQUENT EVENTS

 

The Company evaluated all events or transactions that occurred after December 31, 2023. During this period, the Company did not have any material recognizable subsequent events required to be disclosed.

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Principles of Consolidation and Reporting

Principles of Consolidation and Reporting

 

The accompanying consolidated financial statements include the accounts of Limitless X Holdings Inc. (a holding company) and its wholly owned operating subsidiaries: Limitless X, Inc., Vybe Lab Inc. (for 2022 and deconsolidated on June 1, 2023), and Prime Time Live, Inc. (collectively, the “Company”). All intercompany balances have been eliminated during consolidation.

 

Going Concern

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $26.1 million at December 31, 2023, and had a net loss of $16.1 million for the year ended December 31, 2023 and net cash used in operating activities of $6.9 million for the year ended December 31, 2023. These matters raise substantial doubt about the Company’s ability to continue as a going concern.

 

To support our existing and planned business model, the Company needs to raise additional capital to fund our future operations. The Company has not experienced any difficulty in raising funds through loans and has not experienced any liquidity problems in settling payables in the normal course of business and repaying loans when they fall due. Successful renewal of our loans, however, is subject to numerous risks and uncertainties. In addition, the increasingly competitive industry conditions under which we operate may negatively impacted our results of operations and cash flows. Additional debt financing is anticipated to fund the Company’s operations in near future. However, there are no current agreements or understandings with regard to the form, time or amount of such financing and there is no assurance that any of this financing can be obtained or that the Company can continue as a going concern.

 

Use of Estimates in the Preparation of Consolidated Financial Statements

Use of Estimates in the Preparation of Consolidated Financial Statements

 

The preparation of consolidated financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all liquid investments purchased with an initial maturity of three months or less to be cash equivalents. Cash and cash equivalents include demand deposits carried at cost which approximates fair value. The Company maintains its cash in institutions insured by the Federal Deposit Insurance Corporation (“FDIC”).

 

Concentration of Credit Risk

Concentration of Credit Risk

 

The Company offers its services to a small number of clients. This risk of non-payment by these clients is considered minimal and the Company does not generally obtain collateral for sales. The Company continually monitors the credit standing of its clients.

 

Accounts Receivable, net

Accounts Receivable, net

 

Accounts receivable, net consists primarily of trade receivables, net of allowances for doubtful accounts. The Company sells its products and services for cash or on credit terms, which are established in accordance with local and industry practices and typically require payment within 30 days of delivery. The Company estimates its allowance for doubtful accounts and the related expected credit loss based upon the Company’s historical credit loss experience, adjusted for asset-specific risk characteristics, current economic conditions, and reasonable forecasts. Accounts receivables are written off when determined to be uncollectible. The Company did not require and did not have an allowance for doubtful accounts.

 

 

Holdback Receivables

Holdback Receivables

 

Limitless primarily sells its products online using various third party sales affiliates. These affiliates (online marketing campaign companies) are paid certain commission based on their ability to provide the Company’s products through online sales. All payments are processed through various gateways and are settled through the Company’s payment gateway settler. The Company payment gateway settler is not responsible for settlements that are not paid to processing bank failure. The Company holds responsibility for all the risk in all transactions and processing systems. The payment gateway settler charges a reserve fee to mitigate the risk on their end for any loss of funds or damages.

 

Distributions of the holdback receivables from the third-party payment gateway settler are based on several criteria, such as return and chargeback history, associated risk for the specific business vertical, average transaction amount, and so on. In order to mitigate processing risks, there are policies regarding reserve requirements and payment in arrears in place.

 

The total holdback receivables balance reflects the 0-10% reserve on gross sales and additional reserves by the third-party processor for additional returns and chargebacks if needed. Based on aging of the holdback receivables, the Company has determined that an allowance for doubtful accounts of $1,300,855 or 55% of holdback receivables should be deemed uncollectible recorded as bad debt expense. As of December 31, 2023 and December 31, 2022, the adjusted holdback receivables balance was $NIL and $1,043,991, respectively.

 

Inventories

Inventories

 

Inventories are valued at the lower-of-cost or net realizable value on a first-in, first-out basis, adjusted for the value of inventory that is determined to be excess, obsolete, expired, or unsaleable. Inventories primarily consisted of finished goods.

 

Advertising and Marketing

Advertising and Marketing

 

Advertising and marketing costs are charged to expense as incurred. Advertising and marketing costs were approximately $19,416,622 and $47,164,700 for the years ended December 31, 2023 and 2022, respectively, and are included in operating expenses in the accompanying statements of operations.

 

 

Property and Equipment, net

Property and Equipment, net

 

Property and equipment is recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation of property and equipment is over the estimated useful life of five to ten years using the straight-line method.

 

   December 31, 2023   December 31, 2022 
         
Machinery and equipment  $39,067   $37,463 
Total   39,067    37,463 
           
Less: accumulated depreciation   (9,657)   (5,207 
           
Total equipment, net  $29,410   $32,256 

 

Depreciation expense was $4,450 and $5,686 for the years ended December 31, 2023 and 2022, respectively. During the year ended December 31, 2022, the Company reported a gain of $28,397 on the disposal of assets.

 

Revenue Recognition

Revenue Recognition

 

Product Sales

 

The Company recognizes revenue when performance obligations under the terms of a contract with its customer are satisfied. The Company has determined that fulfilling and delivering products is a single performance obligation. Revenue is recognized at the point in time when the Company has satisfied its performance obligation and the customer has obtained control of the products or when the service is fully. This generally occurs when the product is delivered to or picked up by the customer based on applicable shipping terms, which is typically within 15 days. Revenue is measured as the amount of consideration expected to be received in exchange for fulfilled product orders,

 

While customers generally have a right to return defective or non-conforming products, past experience has demonstrated that product returns have been immaterial. Customer remedies for defective or non-conforming products may include a refund or exchange. As a result, the right of return is estimated and recorded as a reduction in revenue at the time of sale, if necessary.

 

The Company’s customer contracts identify product quantity, price, and payment terms. Payment terms are granted consistent with industry standards. Although some payment terms may be more extended, the majority of the Company’s payment terms are less than 30 days. As a result, revenue is not adjusted for the effects of a significant financing component. Amounts billed and due from customers are classified as Accounts Receivables on the Balance Sheet.

 

 

The Company utilizes third-party contract manufacturers for the manufacture of its products. The Company has evaluated whether it is the principal or agent in these relationships. The Company has determined that it is the principal in all cases, as it retains the responsibility for fulfillment and risk of loss, as well as for establishing the price.

 

In accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, the Company has elected the practical expedient to expense the incremental costs to obtain a contract, because the amortization period would be less than one year, and the practical expedient for shipping and handling costs. Shipping and handling costs incurred to deliver products to customers are accounted for as fulfillment activities, rather than a promised service, and as such are included in Cost of Goods Sold in the Statements of Operations.

 

Service Revenue

Service Revenue

 

Service revenue consists of digital marketing revenue.

 

Revenue related to digital marketing is recognized over time as services are provided to the customer. We sell digital marketing, digital and print design, social media marketing and direct-to-consumer marketing and thus use standalone selling prices as the basis for revenue. Payment for digital marketing services are typically received at the point when control transfers to the customer or in accordance with payment terms customary to the business. There was no deferred revenue related to services revenue as of December 31, 2023 and 2022.

 

Cost of Sales

Cost of Sales

 

Cost of goods sold includes the cost of inventory sold during the period as well as certain commission fees, returns, chargebacks, distribution and shipping and handling costs. The amount shown is net of various rebates from third-party vendors in the form of payments.

 

Refunds Payable

Refunds Payable

 

If customers are not satisfied for any reason, they may request a full refund, processed to the original form of payment, within 30 days from the order date. If the order has already been shipped, the Company charges a 20% restocking fee. The Company’s estimate of the reserve is based upon the Company’s most historical experience of actual customer returns. Additionally, the Company considers other factors in estimating the reserve, such as hiring a new internal team with more resources for the refund process.

 

As of December 31, 2023 and December 31, 2022, refunds payable was $41,509 and $213,930, respectively.

 

 

Chargebacks Payable

Chargebacks Payable

 

Once customers successfully dispute chargebacks with the payment processor, the Company returns such funds to the payment processor to return to the customer. As of December 31, 2023 and December 31, 2022, chargebacks payable was $20,755 and $118,288, respectively.

 

Other Comprehensive Loss

Other Comprehensive Loss

 

The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss for the period.

 

Income Taxes

Income Taxes

 

The accounting standard on accounting for uncertainty in income taxes addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under that guidance, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

 

Earnings (Loss) per Share

Earnings (Loss) per Share

 

The Company calculates earnings per share in accordance with Financial Accounting Standards Board (“FASB”) ASC 260, Earnings Per Share, which requires a dual presentation of basic and diluted earnings per share. Basic earnings per share (“EPS”) is computed by dividing earnings (losses) attributable to common shareholders by the weighted average number of common shares outstanding for the periods. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. The Company had a loss for the years ended December 31, 2023 and 2022.

 

Equity Based Payments

Equity Based Payments

 

The Company accounts for equity-based payment accruals under authoritative guidance as set forth in the Topics of the ASC. The guidance requires all equity-based payments to employees and non-employees, including grants of employee and non-employee stock options and warrants, to be recognized in the consolidated financial statements based at their fair values. The Company applies the provisions of ASC 718, “Compensation - Stock Compensation,” using a modified prospective application, and the Black-Scholes model to value stock options. Under this application, the Company records compensation expense for all awards granted. Compensation costs will be recognized over the period that an employee provides service in exchange for the award. During the year ended December 31, 2023 and the year ended December 31, 2022, the Company granted no options under the 2020 Stock Incentive Plan and 2022 Stock Option Plan.

 

General Concentrations of Risk

General Concentrations of Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk are accounts receivable and other receivables arising from its normal business activities. The Company has a diversified customer base. The Company controls credit risk related to accounts receivable through credit approvals, credit limits, and monitoring procedures. The Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable related credit risk exposure beyond such allowance is limited.

 

The Company purchases merchandise from 6 suppliers, and the Company’s 3 largest suppliers accounted for 95% of total purchases in fiscal 2022. A significant portion of the Company’s inventory is manufactured abroad in Asia. Foreign imports subject the Company to the risks of changes in, or the imposition of new, import tariffs, duties or quotas, new restrictions on imports, loss of “most favored nation” status with the United States for a particular foreign country, antidumping or countervailing duty orders, retaliatory actions in response to illegal trade practices, work stoppages, delays in shipment, freight expense increases, product cost increases due to foreign currency fluctuations or revaluations, public health issues that could lead to temporary closures of facilities or shipping ports, such as the recent outbreak of COVID-19, and other economic uncertainties. If a disruption of trade were to occur from the countries in which the suppliers of the Company’s vendors are located, the Company may be unable to obtain sufficient quantities of products to satisfy its requirements, or the cost of obtaining products may increase.

 

A substantial amount of the Company’s inventory is manufactured abroad. From time to time, shipping ports experience capacity constraints (such as delays associated with COVID-19), labor strikes, work stoppages or other disruptions that may delay the delivery of imported products. A contract dispute may lead to protracted delays in the movement of the Company’s products, which could further delay the delivery of products to the Company’s stores and impact net sales and profitability. In addition, other conditions outside of the Company’s control, such as adverse weather conditions or acts of terrorism or war, such as the current conflict in Ukraine, could significantly disrupt operations at shipping ports or otherwise impact transportation of the imported merchandise we sell, either through supply chain disruptions, or rising freight and fuel costs.

 

 

Operating Lease

Operating Lease

 

In accordance with ASC 842, Leases, the Company determines whether an arrangement contains a lease at inception. A lease is a contract that provides the right to control an identified asset for a period of time in exchange for consideration. For identified leases, the Company determines whether it should be classified as an operating or finance lease. Operating leases are recorded in the balance sheet as: right-of-use asset (“ROU asset”) and operating lease liability. ROU asset represents the Company’s right to use an underlying asset for the lease term and lease liability represents the Company’s obligation to make lease payments arising from the lease. ROU assets and operating lease liabilities are recognized at the commencement date of the lease and measured based on the present value of lease payments over the lease term. The ROU asset also includes deferred rent liabilities. The Company’s lease arrangement generally do not provide an implicit interest rate. As a result, in such situations the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option in the measurement of its ROU asset and liability. Lease expense for the operating lease is recognized on a straight-line basis over the lease term. The Company has a ease agreement with lease and non-lease components, which are accounted for as a single lease component and are month-to-month during the year ended December 31, 2023.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In December 2019, FASB issued Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which amends existing guidance related to the accounting for income taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending existing guidance. This ASU is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company evaluated the effects of adoption of this guidance on the financial statements and did not have any material impact on its consolidated financial statements.

 

In June 2016, the FASB issued an accounting standards update which changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. This update replaces the existing incurred loss impairment model with an expected loss model (referred to as the Current Expected Credit Loss model, or “CECL”). The standard update, and its related amendments, will become effective for the fiscal year beginning on January 1, 2023. The Company evaluated the effects of adoption of this guidance on the financial statements and did not have any material impact on its consolidated financial statements.

 

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA and the SEC did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

 

 

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
SCHEDULE OF PROPERTY AND EQUIPMENT, NET

   December 31, 2023   December 31, 2022 
         
Machinery and equipment  $39,067   $37,463 
Total   39,067    37,463 
           
Less: accumulated depreciation   (9,657)   (5,207 
           
Total equipment, net  $29,410   $32,256 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DECONSOLIDATION (Sale of Vybe Labs, Inc.) (Tables)
12 Months Ended
Dec. 31, 2023
Deconsolidation  
SCHEDULE OF DECONSOLIDATION

The transaction is recorded as follows at the date of this transaction:

 

   June 1, 
   2023 
     
Total assets and liabilities deconsolidated for Vybe:     
Total assets  $1,156,733 
Total liabilities   (1,356,750)
      
Net assets (liabilities)  $(241,365)
      
Net amount of deconsolidation – Recorded as a Gain on Deconsolidation of Subsidiary  $241,365 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LOSS ON SETTLEMENT OF DEBT (Tables)
12 Months Ended
Dec. 31, 2023
Loss On Settlement Of Debt  
SCHEDULE OF DECONSOLIDATION ON LOSS ON SETTLEMENT OF DEBT

The transaction is recorded as follows at the date of this transaction:

 

SCHEDULE OF DECONSOLIDATION ON LOSS ON SETTLEMENT OF DEBT 

   June 1, 
   2023 
     
Total due to and due from between Limitless X and Vybe before deconsolidation:     
Due to Emblaze One, Inc. by Limitless X  $1,167,011 
Interest payable   47,188 
Due from Vybe Labs, Inc. by Limitless X   (1,356,750)
      
Net due to (from)  $(142,551)
      
Net amount of deconsolidation – Recorded as a Loss on Settlement of Debt  $142,551 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONVERTIBLE NOTES PAYABLE (Tables)
12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
SCHEDULE OF CONVERTIBLE NOTE PAYABLES

Convertible notes payable consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
         
August 3, 2022 ($5,000,000)  $        -   $5,000,000 
August 3, 2022 ($1,000,000)   -    1,000,000 
August 22, 2022 ($500,000)   -    500,000 
September 22, 2022 ($250,000)   -    250,000 
September 25, 2022 ($600,000)   -    600,000 
September 25, 2022 ($600,000)   -    600,000 
September 29, 2022 ($50,000)   -    50,000 
September 29, 2022 ($500,000)   -    500,000 
October 10, 2022 ($500,000)   -    500,000 
October 13, 2022 ($750,000)   -    75,000 
October 13, 2022 ($50,000)   -    50,000 
October 14, 2022 ($50,000)   -    50,000 
           
Total convertible note payables (current)  $-   $9,175,000 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NOTES PAYABLE TO SHAREHOLDER (Tables) - Shareholder [Member]
12 Months Ended
Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]  
SCHEDULE OF NOTES PAYABLE TO SHAREHOLDER

Notes payable to shareholder consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
         
December 6, 2021 ($50,000)  $50,000   $50,000 
February 11, 2022 ($150,000)   150,000    150,000 
May 8, 2022 ($550,000)   550,000    550,000 
May 9, 2022 ($1,100,000)   1,100,000    1,100,000 
May 16, 2022 ($450,000)   450,000    450,000 
June 1, 2022 ($500,000)   500,000    500,000 
June 30, 2022 ($922,028)   922,028    922,028 
August 25, 2022 ($290,000)   290,000    290,000 
November 15, 2022 ($450,000)   450,000    450,000 
May 16, 2023 ($150,000)   150,000    - 
May 18, 2023 ($50,000)   50,000    - 
June 5, 2023 ($150,000)   150,000    - 
June 20, 2023 ($50,000) – Funding Commitment   50,000    - 
July 13, 2023 ($50,000) – Funding Commitment   50,000    - 
August 1, 2023 ($190,000) – Funding Commitment   190,000    - 
August 7, 2023 ($50,000) – Funding Commitment   50,000    - 
Total notes payable to stockholder (current)  $5,152,028   $4,462,028 
SCHEDULE OF FUNDING COMMITMENT

   December 31, 2023 
     
June 20, 2023 ($50,000)  $50,000 
July 13, 2023 ($50,000)   50,000 
August 1, 2023 ($190,000)   190,000 
August 7, 2023 ($50,000)   50,000 
Total Funding Commitment  $340,000 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NOTES PAYABLE TO RELATED PARTIES (Tables)
12 Months Ended
Dec. 31, 2023
Related Party [Member]  
Defined Benefit Plan Disclosure [Line Items]  
SCHEDULE OF NOTES PAYABLE TO RELATED PARTIES

Notes payable to related party consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
         
May 10, 2022 ($12,500)  $12,500   $12,500 
May 10, 2022 ($12,500)   12,500    12,500 
May 10, 2022 ($20,000)   20,000    20,000 
May 31, 2022 ($5,000)   5,000    5,000 
May 31, 2022 ($15,000)   15,000    15,000 
June 9, 2022 ($15,000)   15,000    15,000 
December 31, 2022 ($929,401)   -    929,401 
           
Total notes payable to related parties (current)  $80,000   $1,247,011 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCKHOLDERS’ EQUITY (Tables)
12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
SCHEDULE OF RECONCILIATION OF RESTATED COMMON STOCK

             
   December 31, 2021 
   Issued   Issuable   Total 
             
Common stock – Limitless X Inc. – as original   1,616,667    50,000    1,666,667 
Common stock split (1 to 1.94) – Limitless X Inc.   1,519,366    47,000    1,566,366 
Common stock issuable (additional stock split) – Limitless X Inc.   -    300,000    300,000 
Common stock (Bio Lab) – prior to reverse merger   360,117    -    360,117 
                
Total as of December 31, 2021 – as retrospectively restated   3,496,150    397,000    3,893,150 

 

XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES (Tables)
12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
SCHEDULE OF LEASE COST

In accordance with ASC 842, the components of lease expense were as follows:

 

   For the   For the 
   year ended   year ended 
   December 31, 2023   December 31, 2022 
Operating lease expense  $-   $138,108 
Total lease expense  $-   $138,108 
SCHEDULE OF OTHER INFORMATION RELATED TO LEASES

In accordance with ASC 842, other information related to leases was as follows:

 

   For the   For the 
   year ended   year ended 
   December 31, 2023   December 31, 2022 
Operating cash flows from operating leases  $-   $137,138 
Cash paid for amounts included in the measurement of lease liabilities  $-   $137,138 

 

Weighted-average remaining lease term—operating leases  Years 
Weighted-average discount rate—operating leases   3%
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ORGANIZATION AND HISTORY (Details Narrative) - shares
May 20, 2022
Dec. 31, 2023
Dec. 31, 2022
Class A Convertible Preferred Stock [Member]      
Preferred stock shares issued   500,000 500,000
Helion Holdings LLC [Member] | Jaspreet Mathur [Member] | Class A Convertible Preferred Stock [Member]      
Preferred stock shares issued 500,000    
Common Stock [Member] | Bio Lab Naturals, Inc [Member]      
Outstanding shares percentage 60.00%    
Common Stock [Member] | Bio Lab Naturals, Inc [Member] | Limitless X Shareholders [Member]      
Number of shares acquisitions 3,233,334    
Number of additional shares issued 300,000    
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Machinery and equipment $ 39,067 $ 37,463
Total 39,067 37,463
Less: accumulated depreciation (9,657) (5,207)
Total equipment, net $ 29,410 $ 32,256
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Product Information [Line Items]    
Accumulated deficit $ 26,137,915 $ 10,019,342
Net income (loss) 16,118,573 10,024,006
Net cash used in operating activities $ 6,874,512 9,132,969
Hold receivables percentage 55.00%  
Hold receivables, allowance for doubtful accounts $ 1,300,855  
Holdback receivables 1,043,991
Advertising and marketing cost 19,416,622 47,164,700
Depreciation expense 4,450 5,686
Gain of disposal of assets 28,397
Deferred revenue $ 0 0
Refunds payable percentage 20.00%  
Refunds payable $ 41,509 213,930
Chargebacks payable $ 20,755 $ 118,288
Income taxes likelihood greater than 50% likelihood  
Three Largest Suppliers [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]    
Product Information [Line Items]    
Concentration risk, percentage 95.00%  
Minimum [Member]    
Product Information [Line Items]    
Hold receivables percentage 0.00%  
Maximum [Member]    
Product Information [Line Items]    
Hold receivables percentage 10.00%  
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SCHEDULE OF DECONSOLIDATION (Details) - USD ($)
Dec. 31, 2023
Jun. 01, 2023
Dec. 31, 2022
Deconsolidation      
Total assets $ 307,740 $ 1,156,733 $ 11,841,226
Total liabilities $ (13,178,671) (1,356,750) $ (18,893,962)
Net assets (liabilities)   (241,365)  
Net amount of deconsolidation – Recorded as a Gain on Deconsolidation of Subsidiary   $ 241,365  
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DECONSOLIDATION (Sale of Vybe Labs, Inc.) (Details Narrative) - Vybe Sale Agreement [Member] - Emblaze One, Inc. [Member]
Jun. 01, 2023
shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Number of shares sold 5,000
Ownership percentage 100.00%
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SCHEDULE OF DECONSOLIDATION ON LOSS ON SETTLEMENT OF DEBT (Details) - USD ($)
12 Months Ended
Jun. 01, 2023
Dec. 31, 2023
Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]      
Net due to (from) $ (142,551)    
Net amount of deconsolidation – Recorded as a Loss on Settlement of Debt 142,551 $ (142,551)
Emblaze One, Inc. [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Due to Emblaze One, Inc. by Limitless X 1,167,011    
Interest payable 47,188    
Vybe Labs Inc [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Due from Vybe Labs, Inc. by Limitless X $ (1,356,750)    
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LOSS ON SETTLEMENT OF DEBT (Details Narrative) - USD ($)
Jun. 01, 2023
Dec. 31, 2022
Apr. 01, 2022
Two Loan Authorization And Agreements [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Interest payable   $ 37,176 $ 10,012
Principal amount   $ 929,401 $ 237,610
Emblaze One, Inc. [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Settlement of debt amount $ 1,167,011    
Interest payable $ 47,188    
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ROYALTY PAYABLES (Details Narrative) - USD ($)
Dec. 01, 2021
Dec. 31, 2023
Dec. 31, 2022
Related Party Transaction [Line Items]      
Royalty payable   $ 1,114,403
Limitless Performance Inc [Member]      
Related Party Transaction [Line Items]      
Royalty payables percentage 4.00%    
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NOTE PAYABLE (Details Narrative) - Prime Time Live Inc [Member] - USD ($)
12 Months Ended
Mar. 01, 2021
Dec. 31, 2023
Dec. 31, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Note payable   $ 35,000 $ 35,000
Accrued interest   $ 4,595 $ 1,095
Individual Counterparty [Member] | Unsecured Convertible Promissory Note [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Note payable $ 35,000    
Interest rate 10.00%    
Note payable, maturity date Dec. 31, 2022    
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SCHEDULE OF CONVERTIBLE NOTE PAYABLES (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Total convertible note payables (current) $ 9,175,000
August 3, 2022 ($5,000,000) [Member]    
Debt Instrument [Line Items]    
Total convertible note payables (current) 5,000,000
August 3, 2022 ($1,000,000) [Member]    
Debt Instrument [Line Items]    
Total convertible note payables (current) 1,000,000
August 22, 2022 ($500,000) [Member]    
Debt Instrument [Line Items]    
Total convertible note payables (current) 500,000
September 22, 2022 ($250,000) [Member]    
Debt Instrument [Line Items]    
Total convertible note payables (current) 250,000
September 25, 2022 ($600,000) [Member]    
Debt Instrument [Line Items]    
Total convertible note payables (current) 600,000
September 25, 2022 ($600,000) [Member]    
Debt Instrument [Line Items]    
Total convertible note payables (current) 600,000
September 29, 2022 ($50,000) [Member]    
Debt Instrument [Line Items]    
Total convertible note payables (current) 50,000
September 29, 2022 ($500,000) [Member]    
Debt Instrument [Line Items]    
Total convertible note payables (current) 500,000
October 10, 2022 ($500,000) [Member]    
Debt Instrument [Line Items]    
Total convertible note payables (current) 500,000
October 13, 2022 ($750,000) [Member]    
Debt Instrument [Line Items]    
Total convertible note payables (current) 75,000
October 13, 2022 ($50,000) [Member]    
Debt Instrument [Line Items]    
Total convertible note payables (current) 50,000
October 14, 2022 ($50,000) [Member]    
Debt Instrument [Line Items]    
Total convertible note payables (current) $ 50,000
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SCHEDULE OF CONVERTIBLE NOTE PAYABLES (Details) (Parenthetical)
Dec. 31, 2023
USD ($)
August 3, 2022 ($5,000,000) [Member]  
Debt Instrument [Line Items]  
Debt face amount $ 5,000,000
August 3, 2022 ($1,000,000) [Member]  
Debt Instrument [Line Items]  
Debt face amount 1,000,000
August 22, 2022 ($500,000) [Member]  
Debt Instrument [Line Items]  
Debt face amount 500,000
September 22, 2022 ($250,000) [Member]  
Debt Instrument [Line Items]  
Debt face amount 250,000
September 25, 2022 ($600,000) [Member]  
Debt Instrument [Line Items]  
Debt face amount 600,000
September 25, 2022 ($600,000) [Member]  
Debt Instrument [Line Items]  
Debt face amount 600,000
September 29, 2022 ($50,000) [Member]  
Debt Instrument [Line Items]  
Debt face amount 50,000
September 29, 2022 ($500,000) [Member]  
Debt Instrument [Line Items]  
Debt face amount 500,000
October 10, 2022 ($500,000) [Member]  
Debt Instrument [Line Items]  
Debt face amount 500,000
October 13, 2022 ($750,000) [Member]  
Debt Instrument [Line Items]  
Debt face amount 750,000
October 13, 2022 ($50,000) [Member]  
Debt Instrument [Line Items]  
Debt face amount 50,000
October 14, 2022 ($50,000) [Member]  
Debt Instrument [Line Items]  
Debt face amount $ 50,000
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)
12 Months Ended
Oct. 23, 2023
Jun. 01, 2023
Dec. 31, 2023
Dec. 31, 2022
Oct. 01, 2023
Nov. 28, 2022
Debt Instrument [Line Items]            
Debt face amount     $ 9,175,000    
Debt bear interest rate     6.00%      
Debt instrumen, description     Any time prior to the Maturity Date, and upon the date of effectiveness of registration of the Notes on a registration statement filed with the Securities and Exchange Commission (the “SEC”), the Note shall automatically convert to shares of common stock of the Company at the Conversion Price (the “Automatic Conversion”); provided however, that in the event that Conversion Shares represent greater than 4.99% of the total Common Shares of the Company (the portion above 4.99% referred to herein as the “Excess Shares”), then the Automatic Conversion shall only apply to such portion of the Note up to 4.99% and not include the Excess Shares.      
Extinguish convertible debt   $ 142,551 $ (142,551)    
Class B Preferred Stock [Member]            
Debt Instrument [Line Items]            
Convertible preferred stock amount $ 9,675,000          
Number of shares issued 10,349,097          
Extinguish convertible debt $ 9,675,000          
Accumulated interest $ 674,097          
Common Stock [Member]            
Debt Instrument [Line Items]            
Conversion price, per share     $ 0.25      
Share price         $ 2.00  
Number of shares issued       97,000    
Convertible Note Offering [Member] | 12 Accredited Investors [Member]            
Debt Instrument [Line Items]            
Convertible notes payable     $ 500,000 $ 9,175,000    
Convertible Note Offering [Member] | Minimum [Member]            
Debt Instrument [Line Items]            
Debt face amount           $ 15,000,000
Convertible Note Offering [Member] | Maximum [Member]            
Debt Instrument [Line Items]            
Debt face amount           $ 2,000,000
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SCHEDULE OF NOTES PAYABLE TO SHAREHOLDER (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]    
Total notes payable to stockholder (current) $ 5,152,028 $ 4,462,028
December 6, 2021 - $50,000 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Total notes payable to stockholder (current) 50,000 50,000
February 11, 2022 - $150,000 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Total notes payable to stockholder (current) 150,000 150,000
May 8, 2022 - $550,000    
Defined Benefit Plan Disclosure [Line Items]    
Total notes payable to stockholder (current) 550,000 550,000
May 9, 2022 - $1,100,000 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Total notes payable to stockholder (current) 1,100,000 1,100,000
May 16, 2022 - $450,000 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Total notes payable to stockholder (current) 450,000 450,000
June 1, 2022 - $500,000 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Total notes payable to stockholder (current) 500,000 500,000
June 30, 2022 - $922,028 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Total notes payable to stockholder (current) 922,028 922,028
August 25, 2022 - $290,000 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Total notes payable to stockholder (current) 290,000 290,000
November 15, 2022 - $450,000 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Total notes payable to stockholder (current) 450,000 450,000
May 16, 2023 - $150,000 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Total notes payable to stockholder (current) 150,000
May 18, 2023 - $50,000 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Total notes payable to stockholder (current) 50,000
June 5, 2023 - $150,000 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Total notes payable to stockholder (current) 150,000
June 20, 2023 - $50,000 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Total notes payable to stockholder (current) 50,000
July 13, 2023 -$50,000 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Total notes payable to stockholder (current) 50,000
August 1, 2023 - $190,000 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Total notes payable to stockholder (current) 190,000
August 7, 2023 - $50,000 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Total notes payable to stockholder (current) $ 50,000
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SCHEDULE OF NOTES PAYABLE TO SHAREHOLDER (Details) (Parenthetical)
Dec. 31, 2023
USD ($)
December 6, 2021 - $50,000 [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Debt face amount $ 50,000
February 11, 2022 - $150,000 [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Debt face amount 150,000
May 8, 2022 - $550,000  
Defined Benefit Plan Disclosure [Line Items]  
Debt face amount 550,000
May 9, 2022 - $1,100,000 [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Debt face amount 1,100,000
May 16, 2022 - $450,000 [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Debt face amount 450,000
June 1, 2022 - $500,000 [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Debt face amount 500,000
June 30, 2022 - $922,028 [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Debt face amount 922,028
August 25, 2022 - $290,000 [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Debt face amount 290,000
November 15, 2022 - $450,000 [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Debt face amount 450,000
May 16, 2023 - $150,000 [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Debt face amount 150,000
May 18, 2023 - $50,000 [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Debt face amount 50,000
June 5, 2023 - $150,000 [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Debt face amount 150,000
June 20, 2023 - $50,000 [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Debt face amount 50,000
July 13, 2023 -$50,000 [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Debt face amount 50,000
August 1, 2023 - $190,000 [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Debt face amount 190,000
August 7, 2023 - $50,000 [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Debt face amount $ 50,000
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SCHEDULE OF FUNDING COMMITMENT (Details) - Funding Commitment [Member]
Dec. 31, 2023
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Total Funding Commitment $ 340,000
June 20, 2023 - $50,000 [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Total Funding Commitment 50,000
July 13, 2023 -$50,000 [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Total Funding Commitment 50,000
August 1, 2023 - $190,000 [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Total Funding Commitment 190,000
August 7, 2023 - $50,000 [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Total Funding Commitment $ 50,000
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SCHEDULE OF FUNDING COMMITMENT (Details) (Parenthetical) - Funding Commitment [Member]
Dec. 31, 2023
USD ($)
June 20, 2023 - $50,000 [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Funding commitment amount $ 50,000
July 13, 2023 -$50,000 [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Funding commitment amount 50,000
August 1, 2023 - $190,000 [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Funding commitment amount 190,000
August 7, 2023 - $50,000 [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Funding commitment amount $ 50,000
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NOTES PAYABLE TO SHAREHOLDER (Details Narrative) - USD ($)
12 Months Ended
Aug. 01, 2022
Jun. 30, 2022
Jun. 01, 2022
May 18, 2022
May 16, 2022
May 08, 2022
Feb. 11, 2022
Dec. 06, 2021
Dec. 31, 2023
Dec. 31, 2022
Sep. 30, 2023
Jun. 05, 2023
Jun. 03, 2023
May 18, 2023
May 16, 2023
Nov. 15, 2022
Aug. 25, 2022
Jun. 19, 2022
Jun. 17, 2022
Defined Benefit Plan Disclosure [Line Items]                                      
Interest expense                 $ 897,287 $ 348,017                  
Funding Commitment [Member]                                      
Defined Benefit Plan Disclosure [Line Items]                                      
Funding commitment                 340,000                    
Funding Commitment [Member] | Chief Executive Officer [Member]                                      
Defined Benefit Plan Disclosure [Line Items]                                      
Debt interest rate                         10.00%            
Working capital                         $ 1,000,000            
Funding Commitment [Member] | Chief Executive Officer [Member] | Preferred Class B [Member]                                      
Defined Benefit Plan Disclosure [Line Items]                                      
Conversion price                         $ 1.50            
December 6, 2021 - $50,000 [Member]                                      
Defined Benefit Plan Disclosure [Line Items]                                      
Long-term debt               $ 50,000                      
Payments for loans     $ 4,303                                
Debt interest rate     6.00%                                
Debt instrument maturity date               May 01, 2023                      
February 11, 2022 - $150,000 [Member]                                      
Defined Benefit Plan Disclosure [Line Items]                                      
Long-term debt             $ 150,000                        
Payments for loans     $ 12,910                                
Debt interest rate     6.00%                                
Debt instrument maturity date             May 01, 2023                        
May 8, 2022 - $550,000                                      
Defined Benefit Plan Disclosure [Line Items]                                      
Long-term debt           $ 550,000                          
Payments for loans     $ 47,337                                
Debt interest rate     6.00%                                
Debt instrument maturity date           May 01, 2023                          
Funding commitment                   550,000 $ 550,000                
May 16, 2022 - $450,000 [Member]                                      
Defined Benefit Plan Disclosure [Line Items]                                      
Long-term debt         $ 1,100,000                            
Debt interest rate                                     8.50%
Debt instrument maturity date         May 16, 2023                            
May 18, 2022 – $450,000 [Member]                                      
Defined Benefit Plan Disclosure [Line Items]                                      
Long-term debt       $ 450,000                              
Debt interest rate                                   8.50%  
Debt instrument maturity date       May 18, 2023                              
June 1, 2022 - $500,000 [Member]                                      
Defined Benefit Plan Disclosure [Line Items]                                      
Long-term debt     $ 500,000                                
Payments for loans $ 43,494                                    
Debt interest rate 8.00%                                    
Debt instrument maturity date     Jul. 01, 2023                                
June 30, 2022 - $922,028 [Member]                                      
Defined Benefit Plan Disclosure [Line Items]                                      
Long-term debt   $ 922,028                                  
Payments for loans $ 80,206                                    
Debt interest rate 8.00%                                    
Debt instrument maturity date   Aug. 01, 2023                                  
August 25, 2022 - $290,000 [Member]                                      
Defined Benefit Plan Disclosure [Line Items]                                      
Long-term debt                                 $ 290,000    
Debt interest rate                                 10.00%    
November 15, 2022 - $450,000 [Member]                                      
Defined Benefit Plan Disclosure [Line Items]                                      
Long-term debt                               $ 450,000      
Debt interest rate                               10.00%      
May 16, 2023 - $150,000 [Member]                                      
Defined Benefit Plan Disclosure [Line Items]                                      
Long-term debt                             $ 150,000        
Debt interest rate                             10.00%        
May 18, 2023 - $50,000 [Member]                                      
Defined Benefit Plan Disclosure [Line Items]                                      
Long-term debt                           $ 50,000          
Debt interest rate                           10.00%          
June 5, 2023 - $150,000 [Member]                                      
Defined Benefit Plan Disclosure [Line Items]                                      
Long-term debt                       $ 150,000              
Debt interest rate                       10.00%              
Shareholder [Member] | Notes Payables[ Member]                                      
Defined Benefit Plan Disclosure [Line Items]                                      
Accrued interest                 508,524 $ 132,938                  
Interest expense                 $ 375,586                    
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SCHEDULE OF NOTES PAYABLE TO RELATED PARTIES (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Jun. 09, 2022
May 31, 2022
May 10, 2022
May 10, 2022 ($12,500) [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Total notes payable to related parties (current) $ 12,500 $ 12,500     $ 12,500
May 10, 2022 ($12,500) [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Total notes payable to related parties (current) 12,500 12,500     12,500
May 10, 2022 ($20,000) [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Total notes payable to related parties (current) 20,000 20,000     $ 20,000
May 31, 2022 ($5,000) [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Total notes payable to related parties (current) 5,000 5,000   $ 5,000  
May 31, 2022 ($15,000) [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Total notes payable to related parties (current) 15,000 15,000   $ 15,000  
June 9, 2022 ($15,000) [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Total notes payable to related parties (current) 15,000 15,000 $ 15,000    
December 31, 2022 ($929,401) [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Total notes payable to related parties (current) 929,401      
Related Party [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Total notes payable to related parties (current) $ 80,000 $ 1,247,011      
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SCHEDULE OF NOTES PAYABLE TO RELATED PARTIES (Details) (Parenthetical) - USD ($)
Dec. 31, 2023
Jun. 01, 2023
May 10, 2022 ($12,500) [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Debt face amount $ 12,500  
May 10, 2022 ($12,500) [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Debt face amount 12,500  
May 10, 2022 ($20,000) [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Debt face amount 20,000  
May 31, 2022 ($5,000) [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Debt face amount 5,000  
May 31, 2022 ($15,000) [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Debt face amount 15,000  
June 9, 2022 ($15,000) [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Debt face amount 15,000  
December 31, 2022 ($929,401) [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Debt face amount $ 929,401 $ 929,401
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NOTES PAYABLE TO RELATED PARTIES (Details Narrative) - USD ($)
12 Months Ended
Jun. 01, 2023
Jun. 09, 2022
May 31, 2022
May 10, 2022
Dec. 31, 2023
Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]            
Interest expense         $ 897,287 $ 348,017
May 10, 2022 ($12,500) [Member]            
Defined Benefit Plan Disclosure [Line Items]            
Notes payable       $ 12,500 12,500 12,500
Debt interest rate       10.00%    
Debt instrument maturity date       May 10, 2023    
Debt face amount         12,500  
May 10, 2022 ($12,500) [Member]            
Defined Benefit Plan Disclosure [Line Items]            
Notes payable       $ 12,500 12,500 12,500
Debt interest rate       10.00%    
Debt instrument maturity date       May 10, 2023    
Debt face amount         12,500  
May 10, 2022 ($20,000) [Member]            
Defined Benefit Plan Disclosure [Line Items]            
Notes payable       $ 20,000 20,000 20,000
Debt interest rate       10.00%    
Debt instrument maturity date       May 10, 2023    
Debt face amount         20,000  
May 31, 2022 ($5,000) [Member]            
Defined Benefit Plan Disclosure [Line Items]            
Notes payable     $ 5,000   5,000 5,000
Debt interest rate     10.00%      
Debt instrument maturity date     May 31, 2023      
Debt face amount         5,000  
May 31, 2022 ($15,000) [Member]            
Defined Benefit Plan Disclosure [Line Items]            
Notes payable     $ 15,000   15,000 15,000
Debt interest rate     10.00%      
Debt instrument maturity date     May 31, 2023      
Debt face amount         15,000  
June 9, 2022 ($15,000) [Member]            
Defined Benefit Plan Disclosure [Line Items]            
Notes payable   $ 15,000     15,000 15,000
Debt interest rate   10.00%        
Debt instrument maturity date   May 10, 2023        
Debt face amount         15,000  
December 31, 2022 ($929,401) [Member]            
Defined Benefit Plan Disclosure [Line Items]            
Notes payable         $ 929,401
Debt interest rate           8.00%
Debt face amount $ 929,401       929,401  
Vybe Labs [Member]            
Defined Benefit Plan Disclosure [Line Items]            
Common stock shares sold 5,000          
Shareholder One [Member] | Notes Payables One [Member]            
Defined Benefit Plan Disclosure [Line Items]            
Accrued interest         11,127 $ 3,127
Interest expense         $ 8,000  
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SCHEDULE OF RECONCILIATION OF RESTATED COMMON STOCK (Details)
12 Months Ended
Dec. 31, 2021
shares
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Common stock – Limitless X Inc. – as original 1,666,667
Common stock split (1 to 1.94) – Limitless X Inc. 1,566,366
Common stock issuable (additional stock split) – Limitless X Inc. 300,000
Common stock (Bio Lab) – prior to reverse merger 360,117
Total as of December 31, 2021 – as retrospectively restated 3,893,150
Issued [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Common stock – Limitless X Inc. – as original 1,616,667
Common stock split (1 to 1.94) – Limitless X Inc. 1,519,366
Common stock issuable (additional stock split) – Limitless X Inc.
Common stock (Bio Lab) – prior to reverse merger 360,117
Total as of December 31, 2021 – as retrospectively restated 3,496,150
Issuable [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Common stock – Limitless X Inc. – as original 50,000
Common stock split (1 to 1.94) – Limitless X Inc. 47,000
Common stock issuable (additional stock split) – Limitless X Inc. 300,000
Common stock (Bio Lab) – prior to reverse merger
Total as of December 31, 2021 – as retrospectively restated 397,000
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
12 Months Ended
Oct. 23, 2023
May 31, 2023
Jun. 10, 2022
May 10, 2022
Dec. 31, 2023
Dec. 31, 2022
Class of Stock [Line Items]            
Common stock, shares authorized         300,000,000 300,000,000
Common stock, par value         $ 0.0001 $ 0.0001
Common stock, shares issued         3,977,497 3,929,834
Common stock, shares outstanding         3,977,497 3,929,834
Number of shares issued for services   47,000 684 36,000    
Stock compensation expense         $ 141,020 $ 1,117,782
Preferred Class A [Member]            
Class of Stock [Line Items]            
Preferred stock, shares authorized         30,000,000 30,000,000
Preferred stock, shares issued         500,000 500,000
Preferred stock, shares outstanding         500,000 500,000
Class A Convertible Preferred Stock [Member]            
Class of Stock [Line Items]            
Preferred stock, shares authorized         500,000  
Preferred stock, shares issued         500,000 500,000
Preferred stock, shares outstanding         500,000 500,000
Preferred stock, voting rights         The Class A Preferred Stock, when voting as a single class, has the votes of at least 60% of the voting power of the Company.  
Class B Convertible Preferred Stock [Member]            
Class of Stock [Line Items]            
Shares issued 10,349,097          
Extinguishment convertible debt $ 9,675,000          
Convertible debt including accumulated interest $ 674,097          
Preferred stock liquidation price $ 3.00          
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
EQUITY BASED PAYMENTS (Details Narrative) - shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Aug. 09, 2022
Jan. 15, 2020
2020 Stock Incentive Plan [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Common stock reserved shares       2,222
Options granted 0 0    
2022 Stock Option Plan [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Common stock reserved shares     833,333  
Options granted 0 0    
2022 Restricted Stock Plan [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Common stock reserved shares     833,333  
Options granted 0 0    
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
12 Months Ended
Dec. 01, 2021
Dec. 31, 2023
Dec. 31, 2022
Related Party Transaction [Line Items]      
Royalty payable   $ 1,114,403
Notes payable outstanding   5,152,028 4,462,028
Consulting fees   1,515,065 1,647,787
Officer [Member]      
Related Party Transaction [Line Items]      
Consulting fees   0 32,500
Related Party [Member]      
Related Party Transaction [Line Items]      
Notes payable   80,000 1,247,011
Notes Payables[ Member] | Shareholder [Member]      
Related Party Transaction [Line Items]      
Notes payable outstanding   5,152,028 $ 4,462,028
Notes Payables[ Member] | Related Party [Member]      
Related Party Transaction [Line Items]      
Notes payable   $ 80,000  
Limitless Performance Inc [Member]      
Related Party Transaction [Line Items]      
Royalty payables percentage 4.00%    
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SCHEDULE OF LEASE COST (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
Operating lease expense $ 138,108
Total lease expense $ 138,108
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
Operating cash flows from operating leases $ 137,138
Cash paid for amounts included in the measurement of lease liabilities $ 137,138
Weighted average discount rate Operating leases   3.00%
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
Rent expense $ 160,379 $ 204,527
EXCEL 69 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 71 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 73 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 238 248 1 false 86 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://biolabnaturals.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://biolabnaturals.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://biolabnaturals.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://biolabnaturals.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://biolabnaturals.com/role/StatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows Sheet http://biolabnaturals.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION AND HISTORY Sheet http://biolabnaturals.com/role/OrganizationAndHistory ORGANIZATION AND HISTORY Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://biolabnaturals.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://biolabnaturals.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS Notes 9 false false R10.htm 00000010 - Disclosure - DECONSOLIDATION (Sale of Vybe Labs, Inc.) Sheet http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc. DECONSOLIDATION (Sale of Vybe Labs, Inc.) Notes 10 false false R11.htm 00000011 - Disclosure - LOSS ON SETTLEMENT OF DEBT Sheet http://biolabnaturals.com/role/LossOnSettlementOfDebt LOSS ON SETTLEMENT OF DEBT Notes 11 false false R12.htm 00000012 - Disclosure - ROYALTY PAYABLES Sheet http://biolabnaturals.com/role/RoyaltyPayables ROYALTY PAYABLES Notes 12 false false R13.htm 00000013 - Disclosure - NOTE PAYABLE Sheet http://biolabnaturals.com/role/NotePayable NOTE PAYABLE Notes 13 false false R14.htm 00000014 - Disclosure - CONVERTIBLE NOTES PAYABLE Notes http://biolabnaturals.com/role/ConvertibleNotesPayable CONVERTIBLE NOTES PAYABLE Notes 14 false false R15.htm 00000015 - Disclosure - NOTES PAYABLE TO SHAREHOLDER Notes http://biolabnaturals.com/role/NotesPayableToShareholder NOTES PAYABLE TO SHAREHOLDER Notes 15 false false R16.htm 00000016 - Disclosure - NOTES PAYABLE TO RELATED PARTIES Notes http://biolabnaturals.com/role/NotesPayableToRelatedParties NOTES PAYABLE TO RELATED PARTIES Notes 16 false false R17.htm 00000017 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://biolabnaturals.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 17 false false R18.htm 00000018 - Disclosure - EQUITY BASED PAYMENTS Sheet http://biolabnaturals.com/role/EquityBasedPayments EQUITY BASED PAYMENTS Notes 18 false false R19.htm 00000019 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://biolabnaturals.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 19 false false R20.htm 00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://biolabnaturals.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 20 false false R21.htm 00000021 - Disclosure - SUBSEQUENT EVENTS Sheet http://biolabnaturals.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 21 false false R22.htm 00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 22 false false R23.htm 00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://biolabnaturals.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - DECONSOLIDATION (Sale of Vybe Labs, Inc.) (Tables) Sheet http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc.Tables DECONSOLIDATION (Sale of Vybe Labs, Inc.) (Tables) Tables http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc. 24 false false R25.htm 00000025 - Disclosure - LOSS ON SETTLEMENT OF DEBT (Tables) Sheet http://biolabnaturals.com/role/LossOnSettlementOfDebtTables LOSS ON SETTLEMENT OF DEBT (Tables) Tables http://biolabnaturals.com/role/LossOnSettlementOfDebt 25 false false R26.htm 00000026 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables) Notes http://biolabnaturals.com/role/ConvertibleNotesPayableTables CONVERTIBLE NOTES PAYABLE (Tables) Tables http://biolabnaturals.com/role/ConvertibleNotesPayable 26 false false R27.htm 00000027 - Disclosure - NOTES PAYABLE TO SHAREHOLDER (Tables) Notes http://biolabnaturals.com/role/NotesPayableToShareholderTables NOTES PAYABLE TO SHAREHOLDER (Tables) Tables http://biolabnaturals.com/role/NotesPayableToShareholder 27 false false R28.htm 00000028 - Disclosure - NOTES PAYABLE TO RELATED PARTIES (Tables) Notes http://biolabnaturals.com/role/NotesPayableToRelatedPartiesTables NOTES PAYABLE TO RELATED PARTIES (Tables) Tables http://biolabnaturals.com/role/NotesPayableToRelatedParties 28 false false R29.htm 00000029 - Disclosure - STOCKHOLDERS??? EQUITY (Tables) Sheet http://biolabnaturals.com/role/StockholdersEquityTables STOCKHOLDERS??? EQUITY (Tables) Tables http://biolabnaturals.com/role/StockholdersEquity 29 false false R30.htm 00000030 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://biolabnaturals.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://biolabnaturals.com/role/CommitmentsAndContingencies 30 false false R31.htm 00000031 - Disclosure - ORGANIZATION AND HISTORY (Details Narrative) Sheet http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative ORGANIZATION AND HISTORY (Details Narrative) Details http://biolabnaturals.com/role/OrganizationAndHistory 31 false false R32.htm 00000032 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details) Sheet http://biolabnaturals.com/role/ScheduleOfPropertyAndEquipmentNetDetails SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details) Details 32 false false R33.htm 00000033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesTables 33 false false R34.htm 00000034 - Disclosure - SCHEDULE OF DECONSOLIDATION (Details) Sheet http://biolabnaturals.com/role/ScheduleOfDeconsolidationDetails SCHEDULE OF DECONSOLIDATION (Details) Details 34 false false R35.htm 00000035 - Disclosure - DECONSOLIDATION (Sale of Vybe Labs, Inc.) (Details Narrative) Sheet http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc.DetailsNarrative DECONSOLIDATION (Sale of Vybe Labs, Inc.) (Details Narrative) Details http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc.Tables 35 false false R36.htm 00000036 - Disclosure - SCHEDULE OF DECONSOLIDATION ON LOSS ON SETTLEMENT OF DEBT (Details) Sheet http://biolabnaturals.com/role/ScheduleOfDeconsolidationOnLossOnSettlementOfDebtDetails SCHEDULE OF DECONSOLIDATION ON LOSS ON SETTLEMENT OF DEBT (Details) Details 36 false false R37.htm 00000037 - Disclosure - LOSS ON SETTLEMENT OF DEBT (Details Narrative) Sheet http://biolabnaturals.com/role/LossOnSettlementOfDebtDetailsNarrative LOSS ON SETTLEMENT OF DEBT (Details Narrative) Details http://biolabnaturals.com/role/LossOnSettlementOfDebtTables 37 false false R38.htm 00000038 - Disclosure - ROYALTY PAYABLES (Details Narrative) Sheet http://biolabnaturals.com/role/RoyaltyPayablesDetailsNarrative ROYALTY PAYABLES (Details Narrative) Details http://biolabnaturals.com/role/RoyaltyPayables 38 false false R39.htm 00000039 - Disclosure - NOTE PAYABLE (Details Narrative) Sheet http://biolabnaturals.com/role/NotePayableDetailsNarrative NOTE PAYABLE (Details Narrative) Details http://biolabnaturals.com/role/NotePayable 39 false false R40.htm 00000040 - Disclosure - SCHEDULE OF CONVERTIBLE NOTE PAYABLES (Details) Sheet http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails SCHEDULE OF CONVERTIBLE NOTE PAYABLES (Details) Details 40 false false R41.htm 00000041 - Disclosure - SCHEDULE OF CONVERTIBLE NOTE PAYABLES (Details) (Parenthetical) Sheet http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical SCHEDULE OF CONVERTIBLE NOTE PAYABLES (Details) (Parenthetical) Details 41 false false R42.htm 00000042 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) Notes http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative CONVERTIBLE NOTES PAYABLE (Details Narrative) Details http://biolabnaturals.com/role/ConvertibleNotesPayableTables 42 false false R43.htm 00000043 - Disclosure - SCHEDULE OF NOTES PAYABLE TO SHAREHOLDER (Details) Notes http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails SCHEDULE OF NOTES PAYABLE TO SHAREHOLDER (Details) Details 43 false false R44.htm 00000044 - Disclosure - SCHEDULE OF NOTES PAYABLE TO SHAREHOLDER (Details) (Parenthetical) Notes http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical SCHEDULE OF NOTES PAYABLE TO SHAREHOLDER (Details) (Parenthetical) Details 44 false false R45.htm 00000045 - Disclosure - SCHEDULE OF FUNDING COMMITMENT (Details) Sheet http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetails SCHEDULE OF FUNDING COMMITMENT (Details) Details 45 false false R46.htm 00000046 - Disclosure - SCHEDULE OF FUNDING COMMITMENT (Details) (Parenthetical) Sheet http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetailsParenthetical SCHEDULE OF FUNDING COMMITMENT (Details) (Parenthetical) Details 46 false false R47.htm 00000047 - Disclosure - NOTES PAYABLE TO SHAREHOLDER (Details Narrative) Notes http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative NOTES PAYABLE TO SHAREHOLDER (Details Narrative) Details http://biolabnaturals.com/role/NotesPayableToShareholderTables 47 false false R48.htm 00000048 - Disclosure - SCHEDULE OF NOTES PAYABLE TO RELATED PARTIES (Details) Notes http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetails SCHEDULE OF NOTES PAYABLE TO RELATED PARTIES (Details) Details 48 false false R49.htm 00000049 - Disclosure - SCHEDULE OF NOTES PAYABLE TO RELATED PARTIES (Details) (Parenthetical) Notes http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetailsParenthetical SCHEDULE OF NOTES PAYABLE TO RELATED PARTIES (Details) (Parenthetical) Details 49 false false R50.htm 00000050 - Disclosure - NOTES PAYABLE TO RELATED PARTIES (Details Narrative) Notes http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative NOTES PAYABLE TO RELATED PARTIES (Details Narrative) Details http://biolabnaturals.com/role/NotesPayableToRelatedPartiesTables 50 false false R51.htm 00000051 - Disclosure - SCHEDULE OF RECONCILIATION OF RESTATED COMMON STOCK (Details) Sheet http://biolabnaturals.com/role/ScheduleOfReconciliationOfRestatedCommonStockDetails SCHEDULE OF RECONCILIATION OF RESTATED COMMON STOCK (Details) Details 51 false false R52.htm 00000052 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://biolabnaturals.com/role/StockholdersEquityTables 52 false false R53.htm 00000053 - Disclosure - EQUITY BASED PAYMENTS (Details Narrative) Sheet http://biolabnaturals.com/role/EquityBasedPaymentsDetailsNarrative EQUITY BASED PAYMENTS (Details Narrative) Details http://biolabnaturals.com/role/EquityBasedPayments 53 false false R54.htm 00000054 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://biolabnaturals.com/role/RelatedPartyTransactions 54 false false R55.htm 00000055 - Disclosure - SCHEDULE OF LEASE COST (Details) Sheet http://biolabnaturals.com/role/ScheduleOfLeaseCostDetails SCHEDULE OF LEASE COST (Details) Details 55 false false R56.htm 00000056 - Disclosure - SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details) Sheet http://biolabnaturals.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details) Details 56 false false R57.htm 00000057 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://biolabnaturals.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://biolabnaturals.com/role/CommitmentsAndContingenciesTables 57 false false All Reports Book All Reports [DQC.US.0099.9533] The following elements are in the presentation linkbase of http://biolabnaturals.com/role/StatementsOfCashFlows but are not included in any calculation relationship in the filing. CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseDeconsolidationCash All elements appearing in the face of the financial statements should be included in a calculation relationship somewhere in the filing. Items not included in the financial statement calculations but included in the presentation are referred to as parenthetical items. These usually appear as a referenced item, or as a value in parenthesis describing that the value reported includes another specific amount. These values should be reported in a seperate link role for parenthetical items. This rule will produce an error irrespective of a fact value being entered for the item(s) listed above. If the item is an additional disclosure in the cash flow statement then make sure that is included as a child of one of the following abstract items: {nonCFabstracts} - form10-k.htm - form10-k.htm form10-k.htm vybe-20231231.xsd vybe-20231231_cal.xml vybe-20231231_def.xml vybe-20231231_lab.xml vybe-20231231_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-k.htm": { "nsprefix": "VYBE", "nsuri": "http://biolabnaturals.com/20231231", "dts": { "inline": { "local": [ "form10-k.htm" ] }, "schema": { "local": [ "vybe-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "vybe-20231231_cal.xml" ] }, "definitionLink": { "local": [ "vybe-20231231_def.xml" ] }, "labelLink": { "local": [ "vybe-20231231_lab.xml" ] }, "presentationLink": { "local": [ "vybe-20231231_pre.xml" ] } }, "keyStandard": 203, "keyCustom": 45, "axisStandard": 15, "axisCustom": 0, "memberStandard": 17, "memberCustom": 68, "hidden": { "total": 115, "http://biolabnaturals.com/20231231": 14, "http://fasb.org/us-gaap/2023": 98, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 238, "entityCount": 1, "segmentCount": 86, "elementCount": 449, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 640, "http://xbrl.sec.gov/dei/2023": 37 }, "report": { "R1": { "role": "http://biolabnaturals.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R2": { "role": "http://biolabnaturals.com/role/BalanceSheets", "longName": "00000002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R3": { "role": "http://biolabnaturals.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_PreferredClassAMember", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R4": { "role": "http://biolabnaturals.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R5": { "role": "http://biolabnaturals.com/role/StatementsOfStockholdersEquity", "longName": "00000005 - Statement - Consolidated Statements of Stockholders' Equity", "shortName": "Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_PreferredClassAMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_PreferredClassAMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R6": { "role": "http://biolabnaturals.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DepreciationAmortizationAndAccretionNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R7": { "role": "http://biolabnaturals.com/role/OrganizationAndHistory", "longName": "00000007 - Disclosure - ORGANIZATION AND HISTORY", "shortName": "ORGANIZATION AND HISTORY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R8": { "role": "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPolicies", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R9": { "role": "http://biolabnaturals.com/role/FairValueMeasurements", "longName": "00000009 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R10": { "role": "http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc.", "longName": "00000010 - Disclosure - DECONSOLIDATION (Sale of Vybe Labs, Inc.)", "shortName": "DECONSOLIDATION (Sale of Vybe Labs, Inc.)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "VYBE:DeconsolidationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "VYBE:DeconsolidationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R11": { "role": "http://biolabnaturals.com/role/LossOnSettlementOfDebt", "longName": "00000011 - Disclosure - LOSS ON SETTLEMENT OF DEBT", "shortName": "LOSS ON SETTLEMENT OF DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "VYBE:LossOnSettlementOfDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "VYBE:LossOnSettlementOfDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R12": { "role": "http://biolabnaturals.com/role/RoyaltyPayables", "longName": "00000012 - Disclosure - ROYALTY PAYABLES", "shortName": "ROYALTY PAYABLES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "VYBE:RoyaltyPayablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "VYBE:RoyaltyPayablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R13": { "role": "http://biolabnaturals.com/role/NotePayable", "longName": "00000013 - Disclosure - NOTE PAYABLE", "shortName": "NOTE PAYABLE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R14": { "role": "http://biolabnaturals.com/role/ConvertibleNotesPayable", "longName": "00000014 - Disclosure - CONVERTIBLE NOTES PAYABLE", "shortName": "CONVERTIBLE NOTES PAYABLE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R15": { "role": "http://biolabnaturals.com/role/NotesPayableToShareholder", "longName": "00000015 - Disclosure - NOTES PAYABLE TO SHAREHOLDER", "shortName": "NOTES PAYABLE TO SHAREHOLDER", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "VYBE:NotesPayableToShareholderTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "VYBE:NotesPayableToShareholderTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R16": { "role": "http://biolabnaturals.com/role/NotesPayableToRelatedParties", "longName": "00000016 - Disclosure - NOTES PAYABLE TO RELATED PARTIES", "shortName": "NOTES PAYABLE TO RELATED PARTIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "VYBE:NotesPayableToRelatedPartiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "VYBE:NotesPayableToRelatedPartiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R17": { "role": "http://biolabnaturals.com/role/StockholdersEquity", "longName": "00000017 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "shortName": "STOCKHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R18": { "role": "http://biolabnaturals.com/role/EquityBasedPayments", "longName": "00000018 - Disclosure - EQUITY BASED PAYMENTS", "shortName": "EQUITY BASED PAYMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R19": { "role": "http://biolabnaturals.com/role/RelatedPartyTransactions", "longName": "00000019 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R20": { "role": "http://biolabnaturals.com/role/CommitmentsAndContingencies", "longName": "00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R21": { "role": "http://biolabnaturals.com/role/SubsequentEvents", "longName": "00000021 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R22": { "role": "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R23": { "role": "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R24": { "role": "http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc.Tables", "longName": "00000024 - Disclosure - DECONSOLIDATION (Sale of Vybe Labs, Inc.) (Tables)", "shortName": "DECONSOLIDATION (Sale of Vybe Labs, Inc.) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "VYBE:ScheduleOfDeconsolidationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "VYBE:DeconsolidationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "VYBE:ScheduleOfDeconsolidationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "VYBE:DeconsolidationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R25": { "role": "http://biolabnaturals.com/role/LossOnSettlementOfDebtTables", "longName": "00000025 - Disclosure - LOSS ON SETTLEMENT OF DEBT (Tables)", "shortName": "LOSS ON SETTLEMENT OF DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "VYBE:ScheduleOfDeconsolidationLossOnSettlementOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "VYBE:LossOnSettlementOfDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "VYBE:ScheduleOfDeconsolidationLossOnSettlementOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "VYBE:LossOnSettlementOfDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R26": { "role": "http://biolabnaturals.com/role/ConvertibleNotesPayableTables", "longName": "00000026 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables)", "shortName": "CONVERTIBLE NOTES PAYABLE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R27": { "role": "http://biolabnaturals.com/role/NotesPayableToShareholderTables", "longName": "00000027 - Disclosure - NOTES PAYABLE TO SHAREHOLDER (Tables)", "shortName": "NOTES PAYABLE TO SHAREHOLDER (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_custom_ShareholderMember", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "VYBE:NotesPayableToShareholderTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_ShareholderMember", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "VYBE:NotesPayableToShareholderTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R28": { "role": "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesTables", "longName": "00000028 - Disclosure - NOTES PAYABLE TO RELATED PARTIES (Tables)", "shortName": "NOTES PAYABLE TO RELATED PARTIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_RelatedPartyMember", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "VYBE:NotesPayableToRelatedPartiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_RelatedPartyMember", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "VYBE:NotesPayableToRelatedPartiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R29": { "role": "http://biolabnaturals.com/role/StockholdersEquityTables", "longName": "00000029 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)", "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R30": { "role": "http://biolabnaturals.com/role/CommitmentsAndContingenciesTables", "longName": "00000030 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R31": { "role": "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative", "longName": "00000031 - Disclosure - ORGANIZATION AND HISTORY (Details Narrative)", "shortName": "ORGANIZATION AND HISTORY (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2023-12-31_custom_ClassAConvertiblePreferredStockMember", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "span", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-05-20_custom_ClassAConvertiblePreferredStockMember_custom_HelionHoldingsLLCMember_custom_JaspreetMathurMember", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R32": { "role": "http://biolabnaturals.com/role/ScheduleOfPropertyAndEquipmentNetDetails", "longName": "00000032 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)", "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:MachineryAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:MachineryAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R33": { "role": "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "VYBE:HoldbackReceivablesPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:FinanceLoanAndLeaseReceivablesHeldForInvestmentPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R34": { "role": "http://biolabnaturals.com/role/ScheduleOfDeconsolidationDetails", "longName": "00000034 - Disclosure - SCHEDULE OF DECONSOLIDATION (Details)", "shortName": "SCHEDULE OF DECONSOLIDATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Assets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-01", "name": "us-gaap:Assets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "VYBE:ScheduleOfDeconsolidationTableTextBlock", "VYBE:DeconsolidationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R35": { "role": "http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc.DetailsNarrative", "longName": "00000035 - Disclosure - DECONSOLIDATION (Sale of Vybe Labs, Inc.) (Details Narrative)", "shortName": "DECONSOLIDATION (Sale of Vybe Labs, Inc.) (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2023-06-012023-06-01_custom_VybeSaleAgreementMember_custom_EmblazeOneIncMember", "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "VYBE:DeconsolidationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-06-012023-06-01_custom_VybeSaleAgreementMember_custom_EmblazeOneIncMember", "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "VYBE:DeconsolidationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R36": { "role": "http://biolabnaturals.com/role/ScheduleOfDeconsolidationOnLossOnSettlementOfDebtDetails", "longName": "00000036 - Disclosure - SCHEDULE OF DECONSOLIDATION ON LOSS ON SETTLEMENT OF DEBT (Details)", "shortName": "SCHEDULE OF DECONSOLIDATION ON LOSS ON SETTLEMENT OF DEBT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "From2023-06-012023-06-01", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "VYBE:ScheduleOfDeconsolidationLossOnSettlementOfDebtTableTextBlock", "VYBE:LossOnSettlementOfDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-06-012023-06-01", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "VYBE:ScheduleOfDeconsolidationLossOnSettlementOfDebtTableTextBlock", "VYBE:LossOnSettlementOfDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R37": { "role": "http://biolabnaturals.com/role/LossOnSettlementOfDebtDetailsNarrative", "longName": "00000037 - Disclosure - LOSS ON SETTLEMENT OF DEBT (Details Narrative)", "shortName": "LOSS ON SETTLEMENT OF DEBT (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2022-12-31_custom_TwoLoanAuthorizationAndAgreementsMember", "name": "us-gaap:InterestPayableCurrentAndNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "VYBE:LossOnSettlementOfDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_custom_TwoLoanAuthorizationAndAgreementsMember", "name": "us-gaap:InterestPayableCurrentAndNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "VYBE:LossOnSettlementOfDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R38": { "role": "http://biolabnaturals.com/role/RoyaltyPayablesDetailsNarrative", "longName": "00000038 - Disclosure - ROYALTY PAYABLES (Details Narrative)", "shortName": "ROYALTY PAYABLES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "VYBE:RoyaltyPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R39": { "role": "http://biolabnaturals.com/role/NotePayableDetailsNarrative", "longName": "00000039 - Disclosure - NOTE PAYABLE (Details Narrative)", "shortName": "NOTE PAYABLE (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2023-12-31_custom_PrimeTimeLiveIncMember", "name": "us-gaap:NotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_custom_PrimeTimeLiveIncMember", "name": "us-gaap:NotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R40": { "role": "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails", "longName": "00000040 - Disclosure - SCHEDULE OF CONVERTIBLE NOTE PAYABLES (Details)", "shortName": "SCHEDULE OF CONVERTIBLE NOTE PAYABLES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ConvertibleNotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_custom_ConvertibleNotesPayableOneMember", "name": "us-gaap:ConvertibleNotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R41": { "role": "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical", "longName": "00000041 - Disclosure - SCHEDULE OF CONVERTIBLE NOTE PAYABLES (Details) (Parenthetical)", "shortName": "SCHEDULE OF CONVERTIBLE NOTE PAYABLES (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "AsOf2023-12-31_custom_ConvertibleNotesPayableOneMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_custom_ConvertibleNotesPayableOneMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R42": { "role": "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "longName": "00000042 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative)", "shortName": "CONVERTIBLE NOTES PAYABLE (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ConvertibleNotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R43": { "role": "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "longName": "00000043 - Disclosure - SCHEDULE OF NOTES PAYABLE TO SHAREHOLDER (Details)", "shortName": "SCHEDULE OF NOTES PAYABLE TO SHAREHOLDER (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LoansPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_custom_LoanPayableToShareholderOneMember", "name": "us-gaap:LoansPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "VYBE:NotesPayableToShareholderTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R44": { "role": "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical", "longName": "00000044 - Disclosure - SCHEDULE OF NOTES PAYABLE TO SHAREHOLDER (Details) (Parenthetical)", "shortName": "SCHEDULE OF NOTES PAYABLE TO SHAREHOLDER (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "AsOf2023-12-31_custom_LoanPayableToShareholderOneMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "VYBE:NotesPayableToShareholderTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_custom_LoanPayableToShareholderOneMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "VYBE:NotesPayableToShareholderTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R45": { "role": "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetails", "longName": "00000045 - Disclosure - SCHEDULE OF FUNDING COMMITMENT (Details)", "shortName": "SCHEDULE OF FUNDING COMMITMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "AsOf2023-12-31_custom_FundingCommitmentMember", "name": "us-gaap:DebtCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "VYBE:FundingCommitmentTableTextBlock", "VYBE:NotesPayableToShareholderTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_custom_FundingCommitmentMember_custom_LoanPayableToShareholderThirteenMember", "name": "us-gaap:DebtCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "VYBE:FundingCommitmentTableTextBlock", "VYBE:NotesPayableToShareholderTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R46": { "role": "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetailsParenthetical", "longName": "00000046 - Disclosure - SCHEDULE OF FUNDING COMMITMENT (Details) (Parenthetical)", "shortName": "SCHEDULE OF FUNDING COMMITMENT (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "AsOf2023-12-31_custom_FundingCommitmentMember_custom_LoanPayableToShareholderThirteenMember", "name": "us-gaap:LongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "VYBE:FundingCommitmentTableTextBlock", "VYBE:NotesPayableToShareholderTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_custom_FundingCommitmentMember_custom_LoanPayableToShareholderThirteenMember", "name": "us-gaap:LongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "VYBE:FundingCommitmentTableTextBlock", "VYBE:NotesPayableToShareholderTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R47": { "role": "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "longName": "00000047 - Disclosure - NOTES PAYABLE TO SHAREHOLDER (Details Narrative)", "shortName": "NOTES PAYABLE TO SHAREHOLDER (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:InterestExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-03_custom_FundingCommitmentMember_srt_ChiefExecutiveOfficerMember", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "VYBE:NotesPayableToShareholderTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R48": { "role": "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetails", "longName": "00000048 - Disclosure - SCHEDULE OF NOTES PAYABLE TO RELATED PARTIES (Details)", "shortName": "SCHEDULE OF NOTES PAYABLE TO RELATED PARTIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "AsOf2023-12-31_custom_NotePayablesToRelatedPartiesOneMember", "name": "us-gaap:NotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "VYBE:NotesPayableToRelatedPartiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R49": { "role": "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetailsParenthetical", "longName": "00000049 - Disclosure - SCHEDULE OF NOTES PAYABLE TO RELATED PARTIES (Details) (Parenthetical)", "shortName": "SCHEDULE OF NOTES PAYABLE TO RELATED PARTIES (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "AsOf2023-12-31_custom_NotePayablesToRelatedPartiesOneMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "VYBE:NotesPayableToRelatedPartiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "longName": "00000050 - Disclosure - NOTES PAYABLE TO RELATED PARTIES (Details Narrative)", "shortName": "NOTES PAYABLE TO RELATED PARTIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:InterestExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-05-10_custom_NotePayablesToRelatedPartiesOneMember", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "VYBE:NotesPayableToRelatedPartiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R51": { "role": "http://biolabnaturals.com/role/ScheduleOfReconciliationOfRestatedCommonStockDetails", "longName": "00000051 - Disclosure - SCHEDULE OF RECONCILIATION OF RESTATED COMMON STOCK (Details)", "shortName": "SCHEDULE OF RECONCILIATION OF RESTATED COMMON STOCK (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "From2021-01-012021-12-31", "name": "VYBE:CommonStock", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2021-01-012021-12-31", "name": "VYBE:CommonStock", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R52": { "role": "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative", "longName": "00000052 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockSharesIssued", "span", "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R53": { "role": "http://biolabnaturals.com/role/EquityBasedPaymentsDetailsNarrative", "longName": "00000053 - Disclosure - EQUITY BASED PAYMENTS (Details Narrative)", "shortName": "EQUITY BASED PAYMENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "AsOf2020-01-15_custom_TwoThousandTwentyStockIncentivePlanMember", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2020-01-15_custom_TwoThousandTwentyStockIncentivePlanMember", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R54": { "role": "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "00000054 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "VYBE:RoyaltyPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_srt_OfficerMember", "name": "us-gaap:ProfessionalFees", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R55": { "role": "http://biolabnaturals.com/role/ScheduleOfLeaseCostDetails", "longName": "00000055 - Disclosure - SCHEDULE OF LEASE COST (Details)", "shortName": "SCHEDULE OF LEASE COST (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R56": { "role": "http://biolabnaturals.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails", "longName": "00000056 - Disclosure - SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details)", "shortName": "SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "VYBE:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "VYBE:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R57": { "role": "http://biolabnaturals.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "00000057 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PaymentsForRent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PaymentsForRent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r10" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r531" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivables, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r212", "r213" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Income tax payable", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r68", "r105" ] }, "VYBE_AccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "AccruedInterest", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued interest", "documentation": "Accrued interest." } } }, "auth_ref": [] }, "us-gaap_AccumulatedCapitalizedInterestCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedCapitalizedInterestCosts", "crdr": "debit", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated interest", "documentation": "Amount of accumulated interest costs capitalized as part of property, plant and equipment cost basis." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/ScheduleOfPropertyAndEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://biolabnaturals.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r35", "r136", "r413" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfReconciliationOfRestatedCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r150", "r151", "r358", "r359", "r360", "r361", "r362", "r363" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfReconciliationOfRestatedCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r150", "r151", "r358", "r359", "r360", "r361", "r362", "r363" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in-capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r71", "r556", "r669" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r328", "r329", "r330", "r444", "r606", "r607", "r608", "r650", "r673" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Vybe deconsolidation", "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash provided by operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Advertising and Marketing", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r119" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r584" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc.DetailsNarrative", "http://biolabnaturals.com/role/LossOnSettlementOfDebtDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetails", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetailsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r341" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/ScheduleOfDeconsolidationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r103", "r138", "r165", "r195", "r202", "r206", "r220", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r342", "r344", "r357", "r405", "r480", "r556", "r569", "r616", "r617", "r656" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r132", "r146", "r165", "r220", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r342", "r344", "r357", "r556", "r616", "r617", "r656" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r165", "r220", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r342", "r344", "r357", "r616", "r617", "r656" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-Current Assets:" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r584" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r581", "r583", "r584" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r581", "r583", "r584" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r581", "r583", "r584" ] }, "VYBE_BioLabNaturalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "BioLabNaturalsIncMember", "presentation": [ "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Bio Lab Naturals, Inc [Member]", "documentation": "Bio Lab Naturals, Inc [Member]" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r117", "r407", "r455", "r475", "r556", "r569", "r595" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r22" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash \u2013 beginning of period", "periodEndLabel": "Cash \u2013 end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r21", "r85", "r161" ] }, "VYBE_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseDeconsolidationCash": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseDeconsolidationCash", "crdr": "debit", "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deconsolidation - Cash", "documentation": "Deconsolidation cash." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net increase(decrease) in cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r85" ] }, "VYBE_ChargebacksPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ChargebacksPayable", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chargebacks payable", "documentation": "Chargebacks payable." } } }, "auth_ref": [] }, "VYBE_ChargebacksPayablePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ChargebacksPayablePolicyTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Chargebacks Payable", "documentation": "Chargebacks Payable [Policy Text Block]" } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [ "r610" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "VYBE_ClassAConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ClassAConvertiblePreferredStockMember", "presentation": [ "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative", "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class A Convertible Preferred Stock [Member]", "documentation": "Class A Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "VYBE_ClassBConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ClassBConvertiblePreferredStockMember", "presentation": [ "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class B Convertible Preferred Stock [Member]", "documentation": "Class B Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "VYBE_ClassBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ClassBPreferredStockMember", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class B Preferred Stock [Member]", "documentation": "Class B Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/BalanceSheetsParenthetical", "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative", "http://biolabnaturals.com/role/StatementsOfStockholdersEquity", "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r129", "r140", "r141", "r142", "r165", "r184", "r185", "r187", "r189", "r193", "r194", "r220", "r235", "r237", "r238", "r239", "r242", "r243", "r274", "r275", "r278", "r281", "r288", "r357", "r436", "r437", "r438", "r439", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r456", "r467", "r489", "r512", "r525", "r526", "r527", "r528", "r529", "r591", "r601", "r609" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r140", "r141", "r142", "r193", "r274", "r275", "r276", "r278", "r281", "r286", "r288", "r436", "r437", "r438", "r439", "r551", "r591", "r601" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc.DetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetails", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r341" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r16", "r62", "r406", "r466" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://biolabnaturals.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r92", "r229", "r230", "r532", "r613" ] }, "VYBE_CommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "CommonStock", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfReconciliationOfRestatedCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Common stock \u2013 Limitless X Inc. \u2013 as original", "documentation": "Common stock \u2013 Limitless X Inc. \u2013 as original." } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://biolabnaturals.com/role/EquityBasedPaymentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock reserved shares", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r17" ] }, "VYBE_CommonStockIssuableAdditionalStockSplit": { "xbrltype": "sharesItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "CommonStockIssuableAdditionalStockSplit", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfReconciliationOfRestatedCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Common stock issuable (additional stock split) \u2013 Limitless X Inc.", "documentation": "Common stock issuable (additional stock split) \u2013 Limitless X Inc." } } }, "auth_ref": [] }, "VYBE_CommonStockIssuableMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "CommonStockIssuableMember", "presentation": [ "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock Issuable [Member]", "documentation": "Common Stock Issuable [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative", "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r559", "r560", "r561", "r563", "r564", "r565", "r566", "r606", "r607", "r650", "r667", "r673" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://biolabnaturals.com/role/BalanceSheetsParenthetical", "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r70" ] }, "VYBE_CommonStockPriorToReverseMerger": { "xbrltype": "sharesItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "CommonStockPriorToReverseMerger", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfReconciliationOfRestatedCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Common stock (Bio Lab) \u2013 prior to reverse merger", "documentation": "Common stock (Bio Lab) \u2013 prior to reverse merger." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://biolabnaturals.com/role/BalanceSheetsParenthetical", "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r70", "r467" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://biolabnaturals.com/role/BalanceSheetsParenthetical", "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r70" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r8", "r70", "r467", "r486", "r673", "r674" ] }, "VYBE_CommonStockSplit": { "xbrltype": "sharesItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "CommonStockSplit", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfReconciliationOfRestatedCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Common stock split (1 to 1.94) \u2013 Limitless X Inc.", "documentation": "Common stock split (1 to 1.94) \u2013 Limitless X Inc." } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock- $0.0001 par value; 300,000,000 authorized shares; 3,977,497 shares and 3,929,834 issued, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r70", "r409", "r556" ] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Loss", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r28", "r30", "r53", "r54", "r210", "r531" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r28", "r30", "r53", "r54", "r210", "r431", "r531" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r28", "r30", "r53", "r54", "r210", "r531", "r592" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r65", "r122" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration risk, percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r28", "r30", "r53", "r54", "r210" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r28", "r30", "r53", "r54", "r210", "r531" ] }, "VYBE_ConcentrationsOfCreditRiskPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ConcentrationsOfCreditRiskPolicyTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "General Concentrations of Risk", "documentation": "Concentrations of Credit Risk [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of Consolidation and Reporting", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r52", "r539" ] }, "VYBE_ConsultingFeesRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ConsultingFeesRelatedParty", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Consulting fees, related party", "documentation": "Consulting fees related party." } } }, "auth_ref": [] }, "VYBE_ConversionOfConvertibleNotesAndInterestPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ConversionOfConvertibleNotesAndInterestPayables", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Conversion of convertible notes and interest payables", "documentation": "Conversion of convertible notes and interest payables.", "label": "ConversionOfConvertibleNotesAndInterestPayables" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible notes payable", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r67" ] }, "VYBE_ConvertibleDebtIncludingAccumulatedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ConvertibleDebtIncludingAccumulatedInterest", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible debt including accumulated interest", "documentation": "Convertible debt including accumulated interest." } } }, "auth_ref": [] }, "VYBE_ConvertibleNoteOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ConvertibleNoteOfferingMember", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Note Offering [Member]", "documentation": "Convertible Note Offering [Member]" } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Convertible notes payable", "label": "Convertible Notes Payable", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r9", "r106", "r665" ] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails" ], "lang": { "en-us": { "role": { "label": "Total convertible note payables (current)", "verboseLabel": "Debt face amount", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r12" ] }, "VYBE_ConvertibleNotesPayableEightMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ConvertibleNotesPayableEightMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "September 29, 2022 ($500,000) [Member]", "documentation": "September 29, 2022 ($500,000) [Member]" } } }, "auth_ref": [] }, "VYBE_ConvertibleNotesPayableElevenMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ConvertibleNotesPayableElevenMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "October 13, 2022 ($50,000) [Member]", "documentation": "October 13, 2022 ($50,000) [Member]" } } }, "auth_ref": [] }, "VYBE_ConvertibleNotesPayableFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ConvertibleNotesPayableFiveMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "September 25, 2022 ($600,000) [Member]", "documentation": "September 25, 2022 ($600,000) [Member]" } } }, "auth_ref": [] }, "VYBE_ConvertibleNotesPayableFourMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ConvertibleNotesPayableFourMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "September 22, 2022 ($250,000) [Member]", "documentation": "September 22, 2022 ($250,000) [Member]" } } }, "auth_ref": [] }, "VYBE_ConvertibleNotesPayableNineMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ConvertibleNotesPayableNineMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "October 10, 2022 ($500,000) [Member]", "documentation": "October 10, 2022 ($500,000) [Member]" } } }, "auth_ref": [] }, "VYBE_ConvertibleNotesPayableOneMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ConvertibleNotesPayableOneMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "August 3, 2022 ($5,000,000) [Member]", "documentation": "August 3, 2022 ($5,000,000) [Member]" } } }, "auth_ref": [] }, "VYBE_ConvertibleNotesPayableSevenMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ConvertibleNotesPayableSevenMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "September 29, 2022 ($50,000) [Member]", "documentation": "September 29, 2022 ($50,000) [Member]" } } }, "auth_ref": [] }, "VYBE_ConvertibleNotesPayableSixMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ConvertibleNotesPayableSixMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "September 25, 2022 ($600,000) [Member]", "documentation": "September 25, 2022 ($600,000) [Member]", "label": "September 25, 2022 ($600,000) [Member] [Default Label]" } } }, "auth_ref": [] }, "VYBE_ConvertibleNotesPayableTenMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ConvertibleNotesPayableTenMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "October 13, 2022 ($750,000) [Member]", "documentation": "October 13, 2022 ($750,000) [Member]" } } }, "auth_ref": [] }, "VYBE_ConvertibleNotesPayableThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ConvertibleNotesPayableThreeMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "August 22, 2022 ($500,000) [Member]", "documentation": "August 22, 2022 ($500,000) [Member]" } } }, "auth_ref": [] }, "VYBE_ConvertibleNotesPayableTwelveMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ConvertibleNotesPayableTwelveMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "October 14, 2022 ($50,000) [Member]", "documentation": "October 14, 2022 ($50,000) [Member]" } } }, "auth_ref": [] }, "VYBE_ConvertibleNotesPayableTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ConvertibleNotesPayableTwoMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "August 3, 2022 ($1,000,000) [Member]", "documentation": "August 3, 2022 ($1,000,000) [Member]" } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Total cost of sales", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r79", "r165", "r220", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r357", "r616" ] }, "us-gaap_CostOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenueAbstract", "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of Revenue" } } }, "auth_ref": [] }, "VYBE_CostOfRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "CostOfRevenueMember", "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost Of Revenue [Member]", "documentation": "Cost of revenue [Member]" } } }, "auth_ref": [] }, "VYBE_CostOfRevenueOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "CostOfRevenueOtherMember", "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost Of Revenue Other [Member]", "documentation": "Cost of revenue other [Member]" } } }, "auth_ref": [] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cost of Sales", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r594" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r29", "r210" ] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares sold", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r24", "r25" ] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtCurrent", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetails" ], "lang": { "en-us": { "role": { "label": "Total Funding Commitment", "verboseLabel": "Funding commitment", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r139" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayable" ], "lang": { "en-us": { "role": { "label": "CONVERTIBLE NOTES PAYABLE", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r93", "r163", "r244", "r250", "r251", "r252", "r253", "r254", "r255", "r260", "r267", "r268", "r270" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://biolabnaturals.com/role/NotePayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r9", "r67", "r68", "r104", "r106", "r168", "r245", "r246", "r247", "r248", "r249", "r251", "r256", "r257", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r266", "r365", "r546", "r547", "r548", "r549", "r550", "r602" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion price, per share", "verboseLabel": "Conversion price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r94", "r247" ] }, "us-gaap_DebtInstrumentCovenantDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCovenantDescription", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrumen, description", "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants." } } }, "auth_ref": [ "r9", "r64" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/LossOnSettlementOfDebtDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetailsParenthetical", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Principal amount", "verboseLabel": "Debt face amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r56", "r58", "r245", "r365", "r547", "r548" ] }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentIncreaseAccruedInterest", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/NotePayableDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued interest", "label": "Debt Instrument, Increase, Accrued Interest", "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period." } } }, "auth_ref": [ "r602" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt bear interest rate", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r14", "r56", "r272", "r365" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://biolabnaturals.com/role/NotePayableDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate", "verboseLabel": "Debt interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r14", "r246" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r168", "r245", "r246", "r247", "r248", "r249", "r251", "r256", "r257", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r266", "r269", "r365", "r546", "r547", "r548", "r549", "r550", "r602" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://biolabnaturals.com/role/NotePayableDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Note payable, maturity date", "verboseLabel": "Debt instrument maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r128", "r546", "r651" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://biolabnaturals.com/role/NotePayableDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r15", "r168", "r245", "r246", "r247", "r248", "r249", "r251", "r256", "r257", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r266", "r365", "r546", "r547", "r548", "r549", "r550", "r602" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r15", "r42", "r45", "r55", "r56", "r58", "r63", "r96", "r97", "r168", "r245", "r246", "r247", "r248", "r249", "r251", "r256", "r257", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r266", "r269", "r365", "r546", "r547", "r548", "r549", "r550", "r602" ] }, "VYBE_DeconsolidationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "DeconsolidationDisclosureTextBlock", "presentation": [ "http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc." ], "lang": { "en-us": { "role": { "label": "DECONSOLIDATION (Sale of Vybe Labs, Inc.)", "documentation": "Deconsolidation Disclosure [Text Block]" } } }, "auth_ref": [] }, "VYBE_DeconsolidationGainOrLossAmountOfSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "DeconsolidationGainOrLossAmountOfSubsidiary", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows", "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gain on deconsolidation of subsidiary", "negatedLabel": "Gain on deconsolidation of subsidiary", "documentation": "Gain on deconsolidation of subsidiary." } } }, "auth_ref": [] }, "VYBE_DecreaseInDueToDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "DecreaseInDueToDeconsolidation", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Decrease in due to Emblaze One, Inc. by Limitless X due to deconsolidation", "documentation": "Decrease due to deconsolidation." } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "presentation": [ "http://biolabnaturals.com/role/NotePayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenue", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r596" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://biolabnaturals.com/role/LossOnSettlementOfDebtDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesTables", "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToShareholderTables", "http://biolabnaturals.com/role/ScheduleOfDeconsolidationOnLossOnSettlementOfDebtDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetailsParenthetical", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r34" ] }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAmortizationAndAccretionNet", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r5" ] }, "VYBE_DisclosureDeconsolidationSaleOfVybeLabsInc.Abstract": { "xbrltype": "stringItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "DisclosureDeconsolidationSaleOfVybeLabsInc.Abstract", "lang": { "en-us": { "role": { "label": "Deconsolidation", "verboseLabel": "Deconsolidation Sale Of Vybe Labs Inc.", "terseLabel": "Schedule Of Deconsolidation" } } }, "auth_ref": [] }, "VYBE_DisclosureLossOnSettlementOfDebtAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "DisclosureLossOnSettlementOfDebtAbstract", "lang": { "en-us": { "role": { "label": "Loss On Settlement Of Debt" } } }, "auth_ref": [] }, "VYBE_DisclosureNotesPayableToRelatedPartiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "DisclosureNotesPayableToRelatedPartiesAbstract", "lang": { "en-us": { "role": { "label": "Notes Payable To Related Parties" } } }, "auth_ref": [] }, "VYBE_DisclosureNotesPayableToShareholderAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "DisclosureNotesPayableToShareholderAbstract", "lang": { "en-us": { "role": { "label": "Notes Payable To Shareholder" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://biolabnaturals.com/role/EquityBasedPayments" ], "lang": { "en-us": { "role": { "label": "EQUITY BASED PAYMENTS", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r295", "r298", "r325", "r326", "r327", "r554" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "VYBE_DisclosureRoyaltyPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "DisclosureRoyaltyPayablesAbstract", "lang": { "en-us": { "role": { "label": "Royalty Payables" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r583" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r581", "r583", "r584" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r581", "r583", "r584", "r586" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r582" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r570" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r583" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r583" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r585" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated By Reference", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r573" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings (Loss) Per Share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per common share - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r154", "r174", "r175", "r176", "r177", "r178", "r182", "r184", "r187", "r188", "r189", "r190", "r354", "r355", "r402", "r417", "r542" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per common share - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r154", "r174", "r175", "r176", "r177", "r178", "r184", "r187", "r188", "r189", "r190", "r354", "r355", "r402", "r417", "r542" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings (Loss) per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r26", "r27" ] }, "VYBE_EmblazeOneIncMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "EmblazeOneIncMember", "presentation": [ "http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc.DetailsNarrative", "http://biolabnaturals.com/role/LossOnSettlementOfDebtDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfDeconsolidationOnLossOnSettlementOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Emblaze One, Inc. [Member]", "documentation": "Emblaze One, Inc. [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r576" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r572" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://biolabnaturals.com/role/NotePayableDetailsNarrative", "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r572" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r590" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r572" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r587" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r584" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r572" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r572" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r572" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r572" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r588" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfReconciliationOfRestatedCommonStockDetails", "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r8", "r130", "r150", "r151", "r152", "r169", "r170", "r171", "r173", "r179", "r181", "r192", "r221", "r222", "r289", "r328", "r329", "r330", "r338", "r339", "r346", "r347", "r348", "r349", "r350", "r351", "r353", "r358", "r359", "r360", "r361", "r362", "r363", "r375", "r426", "r427", "r428", "r444", "r512" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc.DetailsNarrative" ], "auth_ref": [ "r217", "r218", "r219" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ownership percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r217" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_ExtinguishmentOfDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExtinguishmentOfDebtAmount", "crdr": "debit", "presentation": [ "http://biolabnaturals.com/role/LossOnSettlementOfDebtDetailsNarrative", "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Settlement of debt amount", "verboseLabel": "Extinguishment convertible debt", "documentation": "Gross amount of debt extinguished." } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://biolabnaturals.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "FAIR VALUE MEASUREMENTS", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r356" ] }, "us-gaap_FinanceLoanAndLeaseReceivablesHeldForInvestmentPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLoanAndLeaseReceivablesHeldForInvestmentPolicy", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Holdback Receivables", "documentation": "Disclosure of accounting policy for financing receivable classified as held-for-investment." } } }, "auth_ref": [ "r90", "r111", "r112", "r114", "r214", "r215" ] }, "VYBE_FundingCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "FundingCommitmentMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetails", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Funding Commitment [Member]", "documentation": "Funding Commitment [Member]" } } }, "auth_ref": [] }, "VYBE_FundingCommitmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "FundingCommitmentTableTextBlock", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF FUNDING COMMITMENT", "documentation": "Funding Commitment [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations", "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gain on disposal of assets", "verboseLabel": "Gain of disposal of assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r600" ] }, "VYBE_GainOnDeconsolidationOfSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "GainOnDeconsolidationOfSubsidiary", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfDeconsolidationDetails" ], "lang": { "en-us": { "role": { "label": "Net amount of deconsolidation \u2013 Recorded as a Gain on Deconsolidation of Subsidiary", "documentation": "Gain on deconsolidation of subsidiary." } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfDeconsolidationOnLossOnSettlementOfDebtDetails", "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on settlement of debt", "totalLabel": "Net amount of deconsolidation \u2013 Recorded as a Loss on Settlement of Debt", "label": "Extinguish convertible debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r5", "r37", "r38" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r81", "r491" ] }, "VYBE_GoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "GoingConcernPolicyTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Going Concern", "documentation": "Going concern policy [Text Block]" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r78", "r165", "r195", "r201", "r205", "r207", "r220", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r357", "r544", "r616" ] }, "VYBE_HelionHoldingsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "HelionHoldingsLLCMember", "presentation": [ "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Helion Holdings LLC [Member]", "documentation": "Helion Holdings LLC [Member]" } } }, "auth_ref": [] }, "VYBE_HoldReceivablesAllowanceForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "HoldReceivablesAllowanceForDoubtfulAccounts", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Hold receivables, allowance for doubtful accounts", "documentation": "Hold receivables, allowance for doubtful accounts." } } }, "auth_ref": [] }, "VYBE_HoldbackReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "HoldbackReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Holdback receivables, net", "verboseLabel": "Holdback receivables", "documentation": "Holdback receivables net current." } } }, "auth_ref": [] }, "VYBE_HoldbackReceivablesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "HoldbackReceivablesPercentage", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Hold receivables percentage", "documentation": "Holdback receivables percentage." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r581", "r583", "r584" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income tax provision", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r76", "r108", "r195", "r201", "r205", "r207", "r403", "r415", "r544" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "auth_ref": [] }, "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income taxes likelihood", "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority." } } }, "auth_ref": [ "r51", "r101" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income tax provision", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r116", "r127", "r180", "r181", "r199", "r333", "r340", "r418" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r149", "r331", "r332", "r334", "r335", "r336", "r337", "r435" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r23" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivables, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Holdback receivables", "label": "Increase (Decrease) in Accounts Receivable and Other Operating Assets", "documentation": "Amount of increase (decrease) in receivables, and operating assets classified as other." } } }, "auth_ref": [ "r599" ] }, "VYBE_IncreaseDecreaseInAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "IncreaseDecreaseInAccruedInterest", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued interest", "documentation": "Increase decrease in accrued interest.", "label": "IncreaseDecreaseInAccruedInterest" } } }, "auth_ref": [] }, "VYBE_IncreaseDecreaseInChargebacksPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "IncreaseDecreaseInChargebacksPayable", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Chargebacks payable", "documentation": "Increase Decrease In Chargebacks Payable.", "label": "Increase Decrease In Chargebacks Payable" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInIncomeTaxes", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Income tax payable", "label": "Increase (Decrease) in Income Taxes", "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets." } } }, "auth_ref": [ "r599" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r599" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInRetainagePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInRetainagePayable", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Refunds payable", "label": "Increase (Decrease) in Retainage Payable", "documentation": "The increase (decrease) during the reporting period in retainage obligations due by the reporting entity that are payable within one year (or one business cycle)." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInRoyaltiesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInRoyaltiesPayable", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Royalty payable", "label": "Increase (Decrease) in Royalties Payable", "documentation": "The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction." } } }, "auth_ref": [ "r4" ] }, "VYBE_IncreaseInDueToDecomsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "IncreaseInDueToDecomsolidation", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase in due from Vybe Labs, Inc. by Limitless X due to deconsolidation", "documentation": "Increase due to deconsolidation." } } }, "auth_ref": [] }, "VYBE_IncreaseOfDueToShareholderFromAssetContributionByShareholder": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "IncreaseOfDueToShareholderFromAssetContributionByShareholder", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase of due to shareholder from asset contribution by shareholder", "documentation": "Increase of due to shareholder from asset contribution by shareholder." } } }, "auth_ref": [] }, "us-gaap_IndividualMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndividualMember", "presentation": [ "http://biolabnaturals.com/role/NotePayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Individual Counterparty [Member]", "documentation": "Individual person that is legally permitted to enter into a contract and be sued if that person fails to meet the obligations imposed by a contract." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r57", "r110", "r153", "r198", "r364", "r497", "r567", "r670" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r157", "r159", "r160" ] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/LossOnSettlementOfDebtDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfDeconsolidationOnLossOnSettlementOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Interest payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": [ "r61", "r664" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r144", "r537", "r556" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r118", "r134", "r143", "r224", "r225", "r226", "r388", "r540" ] }, "VYBE_IssuableMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "IssuableMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfReconciliationOfRestatedCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Issuable [Member]", "documentation": "Issuable [Member]" } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Common stock issued for professional fees", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r5" ] }, "VYBE_IssuedMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "IssuedMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfReconciliationOfRestatedCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Issued [Member]", "documentation": "Issued [Member]" } } }, "auth_ref": [] }, "VYBE_JaspreetMathurMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "JaspreetMathurMember", "presentation": [ "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Jaspreet Mathur [Member]", "documentation": "Jaspreet Mathur [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/ScheduleOfLeaseCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biolabnaturals.com/role/ScheduleOfLeaseCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease expense", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r370", "r555" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://biolabnaturals.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF LEASE COST", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r653" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://biolabnaturals.com/role/NotePayableDetailsNarrative", "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Operating Lease", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r369" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/ScheduleOfDeconsolidationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "negatedLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r11", "r165", "r220", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r343", "r344", "r345", "r357", "r465", "r543", "r569", "r616", "r656", "r657" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 deficit", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r75", "r107", "r411", "r556", "r603", "r611", "r652" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r13", "r133", "r165", "r220", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r343", "r344", "r345", "r357", "r556", "r616", "r656", "r657" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "auth_ref": [] }, "VYBE_LimitlessPerformanceIncMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LimitlessPerformanceIncMember", "presentation": [ "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative", "http://biolabnaturals.com/role/RoyaltyPayablesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Limitless Performance Inc [Member]", "documentation": "Limitless Performance Inc [Member]" } } }, "auth_ref": [] }, "VYBE_LimitlessXShareholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LimitlessXShareholdersMember", "presentation": [ "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Limitless X Shareholders [Member]", "documentation": "Limitless X Shareholders [Member]" } } }, "auth_ref": [] }, "VYBE_LoanPayableToShareholderEightMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LoanPayableToShareholderEightMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "August 25, 2022 - $290,000 [Member]", "documentation": "August 25, 2022 - $290,000 [Member]" } } }, "auth_ref": [] }, "VYBE_LoanPayableToShareholderElevenMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LoanPayableToShareholderElevenMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "May 18, 2023 - $50,000 [Member]", "documentation": "May 18, 2023 - $50,000 [Member]" } } }, "auth_ref": [] }, "VYBE_LoanPayableToShareholderFifteenMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LoanPayableToShareholderFifteenMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetails", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetailsParenthetical", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "August 1, 2023 - $190,000 [Member]", "documentation": "August 1, 2023 - $190,000 [Member]" } } }, "auth_ref": [] }, "VYBE_LoanPayableToShareholderFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LoanPayableToShareholderFiveMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "May 16, 2022 - $450,000 [Member]", "documentation": "May 16, 2022 - $450,000 [Member]" } } }, "auth_ref": [] }, "VYBE_LoanPayableToShareholderFourMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LoanPayableToShareholderFourMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "May 9, 2022 - $1,100,000 [Member]", "documentation": "May 9, 2022 - $1,100,000 [Member]" } } }, "auth_ref": [] }, "VYBE_LoanPayableToShareholderFourteenMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LoanPayableToShareholderFourteenMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetails", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetailsParenthetical", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "July 13, 2023 -$50,000 [Member]", "documentation": "July 13, 2023 -$50,000 [Member]" } } }, "auth_ref": [] }, "VYBE_LoanPayableToShareholderNineMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LoanPayableToShareholderNineMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "November 15, 2022 - $450,000 [Member]", "documentation": "November 15, 2022 - $450,000 [Member]" } } }, "auth_ref": [] }, "VYBE_LoanPayableToShareholderOneMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LoanPayableToShareholderOneMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "December 6, 2021 - $50,000 [Member]", "documentation": "December 6, 2021 - $50,000 [Member]" } } }, "auth_ref": [] }, "VYBE_LoanPayableToShareholderSevenMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LoanPayableToShareholderSevenMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "June 30, 2022 - $922,028 [Member]", "documentation": "June 30, 2022 - $922,028 [Member]" } } }, "auth_ref": [] }, "VYBE_LoanPayableToShareholderSeventeenMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LoanPayableToShareholderSeventeenMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "May 18, 2022 \u0096 $450,000 [Member]", "documentation": "May 18, 2022 \u2013 $450,000 [Member]" } } }, "auth_ref": [] }, "VYBE_LoanPayableToShareholderSixMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LoanPayableToShareholderSixMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "June 1, 2022 - $500,000 [Member]", "documentation": "June 1, 2022 - $500,000 [Member]" } } }, "auth_ref": [] }, "VYBE_LoanPayableToShareholderSixteenMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LoanPayableToShareholderSixteenMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetails", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetailsParenthetical", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "August 7, 2023 - $50,000 [Member]", "documentation": "August 7, 2023 - $50,000 [Member]" } } }, "auth_ref": [] }, "VYBE_LoanPayableToShareholderTenMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LoanPayableToShareholderTenMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "May 16, 2023 - $150,000 [Member]", "documentation": "May 16, 2023 - $150,000 [Member]" } } }, "auth_ref": [] }, "VYBE_LoanPayableToShareholderThirteenMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LoanPayableToShareholderThirteenMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetails", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetailsParenthetical", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "June 20, 2023 - $50,000 [Member]", "documentation": "June 20, 2023 - $50,000 [Member]" } } }, "auth_ref": [] }, "VYBE_LoanPayableToShareholderThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LoanPayableToShareholderThreeMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "May 8, 2022 - $550,000", "documentation": "May 8, 2022 - $550,000" } } }, "auth_ref": [] }, "VYBE_LoanPayableToShareholderTwelveMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LoanPayableToShareholderTwelveMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "June 5, 2023 - $150,000 [Member]", "documentation": "June 5, 2023 - $150,000 [Member]" } } }, "auth_ref": [] }, "VYBE_LoanPayableToShareholderTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LoanPayableToShareholderTwoMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "February 11, 2022 - $150,000 [Member]", "documentation": "February 11, 2022 - $150,000 [Member]" } } }, "auth_ref": [] }, "us-gaap_LoansPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayableCurrent", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails" ], "lang": { "en-us": { "role": { "label": "Notes payable to shareholder", "verboseLabel": "Total notes payable to stockholder (current)", "terseLabel": "Notes payable outstanding", "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r12" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Funding commitment amount", "verboseLabel": "Long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r9", "r106", "r257", "r271", "r547", "r548", "r665" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://biolabnaturals.com/role/NotePayable" ], "lang": { "en-us": { "role": { "label": "NOTE PAYABLE", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r93" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r15" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetails", "http://biolabnaturals.com/role/ScheduleOfConvertibleNotePayablesDetailsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r15", "r36" ] }, "VYBE_LossBeforeIncomeTaxProvisionAndGainOnDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LossBeforeIncomeTaxProvisionAndGainOnDeconsolidation", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income tax provision and gain on deconsolidation", "documentation": "Loss before income tax provision and gain on deconsolidation.", "label": "LossBeforeIncomeTaxProvisionAndGainOnDeconsolidation" } } }, "auth_ref": [] }, "VYBE_LossOnDebtSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LossOnDebtSettlement", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on debt settlement", "documentation": "Loss on debt settlement.", "label": "LossOnDebtSettlement" } } }, "auth_ref": [] }, "VYBE_LossOnSettlementOfDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "LossOnSettlementOfDebtTextBlock", "presentation": [ "http://biolabnaturals.com/role/LossOnSettlementOfDebt" ], "lang": { "en-us": { "role": { "label": "LOSS ON SETTLEMENT OF DEBT", "documentation": "Loss On Settlement Of Debt [Text Block]" } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentGross", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/ScheduleOfPropertyAndEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Machinery and equipment", "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [ "r91" ] }, "us-gaap_MarketingAndAdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketingAndAdvertisingExpense", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations", "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Advertising and marketing", "verboseLabel": "Advertising and marketing cost", "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising." } } }, "auth_ref": [ "r81" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r231", "r232", "r233", "r234", "r294", "r387", "r425", "r457", "r458", "r520", "r521", "r522", "r523", "r524", "r533", "r534", "r545", "r551", "r553", "r558", "r618", "r658", "r659", "r660", "r661", "r662", "r663" ] }, "VYBE_MerchantFees": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "MerchantFees", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Merchant fees", "documentation": "Merchant fees." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r231", "r232", "r233", "r234", "r294", "r387", "r425", "r457", "r458", "r520", "r521", "r522", "r523", "r524", "r533", "r534", "r545", "r551", "r553", "r558", "r618", "r658", "r659", "r660", "r661", "r662", "r663" ] }, "VYBE_NetAssetsLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "NetAssetsLiabilities", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfDeconsolidationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net assets (liabilities)", "documentation": "Net assets liabilities.", "label": "NetAssetsLiabilities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r158" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r158" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows", "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "negatedLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r85", "r86", "r87" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows", "http://biolabnaturals.com/role/StatementsOfOperations", "http://biolabnaturals.com/role/StatementsOfStockholdersEquity", "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "negatedLabel": "Net income (loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r77", "r87", "r109", "r131", "r147", "r148", "r152", "r165", "r172", "r174", "r175", "r176", "r177", "r180", "r181", "r186", "r195", "r201", "r205", "r207", "r220", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r355", "r357", "r416", "r488", "r510", "r511", "r544", "r567", "r616" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities:" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "VYBE_LossBeforeIncomeTaxProvisionAndGainOnDeconsolidation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r82" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrelatedPartyMember", "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r604", "r605" ] }, "VYBE_NotePayableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "NotePayableAbstract", "lang": { "en-us": { "role": { "label": "Note Payable" } } }, "auth_ref": [] }, "VYBE_NotePayablesToRelatedPartiesFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "NotePayablesToRelatedPartiesFiveMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "May 31, 2022 ($15,000) [Member]", "documentation": "May 31, 2022 ($15,000) [Member]" } } }, "auth_ref": [] }, "VYBE_NotePayablesToRelatedPartiesFourMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "NotePayablesToRelatedPartiesFourMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "May 31, 2022 ($5,000) [Member]", "documentation": "May 31, 2022 ($5,000) [Member]" } } }, "auth_ref": [] }, "VYBE_NotePayablesToRelatedPartiesOneMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "NotePayablesToRelatedPartiesOneMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "May 10, 2022 ($12,500) [Member]", "documentation": "May 10, 2022 ($12,500) [Member]" } } }, "auth_ref": [] }, "VYBE_NotePayablesToRelatedPartiesSevenMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "NotePayablesToRelatedPartiesSevenMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "December 31, 2022 ($929,401) [Member]", "documentation": "December 31, 2022 ($929,401) [Member]" } } }, "auth_ref": [] }, "VYBE_NotePayablesToRelatedPartiesSixMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "NotePayablesToRelatedPartiesSixMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "June 9, 2022 ($15,000) [Member]", "documentation": "June 9, 2022 ($15,000) [Member]" } } }, "auth_ref": [] }, "VYBE_NotePayablesToRelatedPartiesThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "NotePayablesToRelatedPartiesThreeMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "May 10, 2022 ($20,000) [Member]", "documentation": "May 10, 2022 ($20,000) [Member]" } } }, "auth_ref": [] }, "VYBE_NotePayablesToRelatedPartiesTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "NotePayablesToRelatedPartiesTwoMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetailsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "May 10, 2022 ($12,500) [Member]", "documentation": "May 10, 2022 ($12,500) [Member]", "label": "May 10, 2022 ($12,500) [Member] [Default Label]" } } }, "auth_ref": [] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/NotePayableDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Notes payable", "verboseLabel": "Note payable", "terseLabel": "Total notes payable to related parties (current)", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r10" ] }, "VYBE_NotesPayableToRelatedPartiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "NotesPayableToRelatedPartiesTextBlock", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToRelatedParties" ], "lang": { "en-us": { "role": { "label": "NOTES PAYABLE TO RELATED PARTIES", "documentation": "Notes Payable to Related Parties [Text Block]" } } }, "auth_ref": [] }, "VYBE_NotesPayableToShareholderTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "NotesPayableToShareholderTextBlock", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholder" ], "lang": { "en-us": { "role": { "label": "NOTES PAYABLE TO SHAREHOLDER", "documentation": "Notes Payable to Shareholder [Text Block]" } } }, "auth_ref": [] }, "VYBE_NotesPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "NotesPayablesMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notes Payables[ Member]", "documentation": "Notes Payables[ Member]" } } }, "auth_ref": [] }, "VYBE_NotesPayablesOneMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "NotesPayablesOneMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notes Payables One [Member]", "documentation": "Notes Payables One [Member]" } } }, "auth_ref": [] }, "VYBE_NumberOfAdditionalSharesIssuedDuringAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "NumberOfAdditionalSharesIssuedDuringAcquisitions", "presentation": [ "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of additional shares issued", "documentation": "Number of additional shares issued during acquisitions." } } }, "auth_ref": [] }, "srt_OfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OfficerMember", "presentation": [ "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Officer [Member]" } } }, "auth_ref": [ "r211", "r668" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "VYBE_LossBeforeIncomeTaxProvisionAndGainOnDeconsolidation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r195", "r201", "r205", "r207", "r544" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/ScheduleOfLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/ScheduleOfLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease expense", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r371", "r555" ] }, "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncomeLeasePayments", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Cash paid for amounts included in the measurement of lease liabilities", "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": [ "r191", "r374" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current portion of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r367" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r368", "r372" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use asset, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r366" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average discount rate Operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r373", "r555" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://biolabnaturals.com/role/OrganizationAndHistory" ], "lang": { "en-us": { "role": { "label": "ORGANIZATION AND HISTORY", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r66", "r102", "r432", "r433" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r137" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfDeconsolidationOnLossOnSettlementOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Due to Emblaze One, Inc. by Limitless X", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r12", "r556" ] }, "us-gaap_OtherNonoperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingExpense", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Other expense", "label": "Other Nonoperating Expense", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r83" ] }, "us-gaap_OtherNonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncome", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income", "documentation": "Amount of income related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r156" ] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfDeconsolidationOnLossOnSettlementOfDebtDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Due from Vybe Labs, Inc. by Limitless X", "label": "Other Receivables, Net, Current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r583" ] }, "us-gaap_PaymentsForLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForLoans", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payments for loans", "documentation": "Cash payments for and related to principal collection on loans related to operating activities." } } }, "auth_ref": [ "r3" ] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRent", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Rent expense", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": [ "r3" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of equipment", "label": "Payments to Acquire Productive Assets", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r115", "r647", "r648", "r649" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://biolabnaturals.com/role/EquityBasedPaymentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://biolabnaturals.com/role/EquityBasedPaymentsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r577" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r578" ] }, "us-gaap_PreferredClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredClassAMember", "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/BalanceSheetsParenthetical", "http://biolabnaturals.com/role/StatementsOfStockholdersEquity", "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred Class A [Member]", "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer." } } }, "auth_ref": [] }, "us-gaap_PreferredClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredClassBMember", "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/BalanceSheetsParenthetical", "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Preferred Class B [Member]", "documentation": "Outstanding nonredeemable preferred class B stock or outstanding preferred class B stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer." } } }, "auth_ref": [] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockLiquidationPreference", "presentation": [ "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock liquidation price", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": [ "r42", "r43", "r69", "r601", "r619" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r559", "r560", "r563", "r564", "r565", "r566", "r667", "r673" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://biolabnaturals.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r69", "r274" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://biolabnaturals.com/role/BalanceSheetsParenthetical", "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r69", "r467" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://biolabnaturals.com/role/BalanceSheetsParenthetical", "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative", "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "verboseLabel": "Preferred stock shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r69", "r274" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://biolabnaturals.com/role/BalanceSheetsParenthetical", "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r69", "r467", "r486", "r673", "r674" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred Stock value", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r69", "r408", "r556" ] }, "us-gaap_PreferredStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockVotingRights", "presentation": [ "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, voting rights", "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": [ "r42", "r69" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r145", "r227", "r228", "r538" ] }, "VYBE_PrimeTimeLiveIncMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "PrimeTimeLiveIncMember", "presentation": [ "http://biolabnaturals.com/role/NotePayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prime Time Live Inc [Member]", "documentation": "Prime Time Live Inc [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from convertible debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "crdr": "debit", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible preferred stock amount", "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from borrowing", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r598" ] }, "us-gaap_ProceedsFromOtherDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromOtherDebt", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from borrowings from stockholder", "documentation": "Amount of cash inflow from debt classified as other." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from borrowings from related parties", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from disposition of asset", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r84" ] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductInformationLineItems", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r552" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r208", "r389", "r419", "r420", "r421", "r422", "r423", "r424", "r536", "r552", "r557", "r593", "r614", "r615", "r620", "r666" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "auth_ref": [ "r208", "r389", "r419", "r420", "r421", "r422", "r423", "r424", "r536", "r552", "r557", "r593", "r614", "r615", "r620", "r666" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfessionalFees", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative", "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Professional fees", "verboseLabel": "Consulting fees", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r567", "r671", "r672" ] }, "us-gaap_PropertyManagementFeePercentFee": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyManagementFeePercentFee", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Refunds payable percentage", "documentation": "The percentage charged for managing real estate properties." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/ScheduleOfPropertyAndEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r91", "r135", "r414" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 }, "http://biolabnaturals.com/role/ScheduleOfPropertyAndEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/ScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Total equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r404", "r414", "r556" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property and Equipment, net", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r6", "r123", "r126", "r412" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF PROPERTY AND EQUIPMENT, NET", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Bad debt expense", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r155", "r223" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r231", "r232", "r233", "r234", "r292", "r294", "r321", "r322", "r323", "r386", "r387", "r425", "r457", "r458", "r520", "r521", "r522", "r523", "r524", "r533", "r534", "r545", "r551", "r553", "r558", "r561", "r612", "r618", "r659", "r660", "r661", "r662", "r663" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r231", "r232", "r233", "r234", "r292", "r294", "r321", "r322", "r323", "r386", "r387", "r425", "r457", "r458", "r520", "r521", "r522", "r523", "r524", "r533", "r534", "r545", "r551", "r553", "r558", "r561", "r612", "r618", "r659", "r660", "r661", "r662", "r663" ] }, "VYBE_RefundsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "RefundsPayable", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Refunds payable", "documentation": "Refunds payable." } } }, "auth_ref": [] }, "VYBE_RefundsPayablePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "RefundsPayablePolicyTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Refunds Payable", "documentation": "Refunds Payable [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/LossOnSettlementOfDebtDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesTables", "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToShareholderTables", "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative", "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfDeconsolidationOnLossOnSettlementOfDebtDetails", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetails", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetailsParenthetical", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetailsParenthetical", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r293", "r379", "r380", "r460", "r461", "r462", "r463", "r464", "r485", "r487", "r519" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesTables", "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r166", "r167", "r379", "r380", "r381", "r382", "r460", "r461", "r462", "r463", "r464", "r485", "r487", "r519" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfDeconsolidationOnLossOnSettlementOfDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net due to (from)", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r60", "r379" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative", "http://biolabnaturals.com/role/RoyaltyPayablesDetailsNarrative", "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r379", "r380", "r655" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative", "http://biolabnaturals.com/role/RoyaltyPayablesDetailsNarrative", "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative", "http://biolabnaturals.com/role/RoyaltyPayablesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r492", "r493", "r496" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/LossOnSettlementOfDebtDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesTables", "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToShareholderTables", "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative", "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfDeconsolidationOnLossOnSettlementOfDebtDetails", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetails", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetailsParenthetical", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetailsParenthetical", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r293", "r379", "r380", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r460", "r461", "r462", "r463", "r464", "r485", "r487", "r519", "r655" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://biolabnaturals.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r376", "r377", "r378", "r380", "r383", "r441", "r442", "r443", "r494", "r495", "r496", "r516", "r518" ] }, "VYBE_RentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "RentExpense", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Rent", "documentation": "Rent expense." } } }, "auth_ref": [] }, "VYBE_RentalsMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "RentalsMember", "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Rentals [Member]" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Retained earnings", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r72", "r98", "r410", "r429", "r430", "r440", "r468", "r556" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r130", "r169", "r170", "r171", "r173", "r179", "r181", "r221", "r222", "r328", "r329", "r330", "r338", "r339", "r346", "r348", "r349", "r351", "r353", "r426", "r428", "r444", "r673" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Total net revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r196", "r197", "r200", "r203", "r204", "r208", "r209", "r210", "r290", "r291", "r389" ] }, "us-gaap_RevenueRecognitionDeferredRevenue": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionDeferredRevenue", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Service Revenue", "documentation": "Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services." } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r490", "r535", "r541" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Revenue" } } }, "auth_ref": [] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyExpense", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Royalty fees", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": [ "r80" ] }, "VYBE_RoyaltyPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "RoyaltyPayable", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative", "http://biolabnaturals.com/role/RoyaltyPayablesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Royalty payable", "documentation": "Royalty payable." } } }, "auth_ref": [] }, "VYBE_RoyaltyPayablesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "RoyaltyPayablesPercentage", "presentation": [ "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative", "http://biolabnaturals.com/role/RoyaltyPayablesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Royalty payables percentage", "documentation": "Royalty payables percentage." } } }, "auth_ref": [] }, "VYBE_RoyaltyPayablesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "RoyaltyPayablesTextBlock", "presentation": [ "http://biolabnaturals.com/role/RoyaltyPayables" ], "lang": { "en-us": { "role": { "label": "ROYALTY PAYABLES", "documentation": "Royalty Payables [Text Block]" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock shares sold", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc.DetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetails", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r341" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF CONVERTIBLE NOTE PAYABLES", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "VYBE_ScheduleOfDeconsolidationLossOnSettlementOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ScheduleOfDeconsolidationLossOnSettlementOfDebtTableTextBlock", "presentation": [ "http://biolabnaturals.com/role/LossOnSettlementOfDebtTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF DECONSOLIDATION ON LOSS ON SETTLEMENT OF DEBT", "documentation": "Schedule Of Deconsolidation Loss On Settlement Of Debt [Table Text Block]" } } }, "auth_ref": [] }, "VYBE_ScheduleOfDeconsolidationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ScheduleOfDeconsolidationTableTextBlock", "presentation": [ "http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc.Tables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF DECONSOLIDATION", "documentation": "Schedule Of Deconsolidation [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "presentation": [ "http://biolabnaturals.com/role/NotePayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]", "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability." } } }, "auth_ref": [ "r46", "r99" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://biolabnaturals.com/role/LossOnSettlementOfDebtDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesTables", "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToShareholderTables", "http://biolabnaturals.com/role/ScheduleOfDeconsolidationOnLossOnSettlementOfDebtDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToRelatedPartiesDetailsParenthetical", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetails", "http://biolabnaturals.com/role/ScheduleOfNotesPayableToShareholderDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r7", "r47", "r48", "r49", "r50" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r217", "r218", "r219" ] }, "VYBE_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ScheduleOfOtherInformationRelatedToLeasesTableTextBlock", "presentation": [ "http://biolabnaturals.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF OTHER INFORMATION RELATED TO LEASES", "documentation": "Schedule of Other information Related to Leases [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Product Information [Table]", "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative", "http://biolabnaturals.com/role/RoyaltyPayablesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r59", "r60", "r492", "r493", "r496" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesTables", "http://biolabnaturals.com/role/NotesPayableToShareholderTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF NOTES PAYABLE TO SHAREHOLDER", "verboseLabel": "SCHEDULE OF NOTES PAYABLE TO RELATED PARTIES", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://biolabnaturals.com/role/EquityBasedPaymentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r39", "r40", "r41", "r42", "r43", "r44", "r45", "r96", "r97", "r98", "r140", "r141", "r142", "r193", "r274", "r275", "r276", "r278", "r281", "r286", "r288", "r436", "r437", "r438", "r439", "r551", "r591", "r601" ] }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityTableTextBlock", "presentation": [ "http://biolabnaturals.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF RECONCILIATION OF RESTATED COMMON STOCK", "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r571" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r575" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r574" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r579" ] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServiceMember", "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r552" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations", "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock compensation for services", "verboseLabel": "Stock compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://biolabnaturals.com/role/EquityBasedPaymentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://biolabnaturals.com/role/EquityBasedPaymentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r306" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Outstanding shares percentage", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "VYBE_ShareholderMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ShareholderMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToShareholderTables", "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shareholder [Member]", "documentation": "Shareholder [Member]" } } }, "auth_ref": [] }, "VYBE_ShareholderOneMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ShareholderOneMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shareholder One [Member]", "documentation": "Shareholder One [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Equity Based Payments", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": [ "r95", "r100" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share price", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r88", "r162" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r580" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/BalanceSheetsParenthetical", "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative", "http://biolabnaturals.com/role/StatementsOfStockholdersEquity", "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r129", "r140", "r141", "r142", "r165", "r184", "r185", "r187", "r189", "r193", "r194", "r220", "r235", "r237", "r238", "r239", "r242", "r243", "r274", "r275", "r278", "r281", "r288", "r357", "r436", "r437", "r438", "r439", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r456", "r467", "r489", "r512", "r525", "r526", "r527", "r528", "r529", "r591", "r601", "r609" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfReconciliationOfRestatedCommonStockDetails", "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r8", "r19", "r130", "r150", "r151", "r152", "r169", "r170", "r171", "r173", "r179", "r181", "r192", "r221", "r222", "r289", "r328", "r329", "r330", "r338", "r339", "r346", "r347", "r348", "r349", "r350", "r351", "r353", "r358", "r359", "r360", "r361", "r362", "r363", "r375", "r426", "r427", "r428", "r444", "r512" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/BalanceSheetsParenthetical", "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative", "http://biolabnaturals.com/role/StatementsOfOperations", "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r169", "r170", "r171", "r192", "r389", "r434", "r456", "r459", "r460", "r461", "r462", "r463", "r464", "r467", "r470", "r471", "r472", "r473", "r474", "r476", "r477", "r478", "r479", "r481", "r482", "r483", "r484", "r485", "r487", "r490", "r491", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r512", "r562" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/BalanceSheetsParenthetical", "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative", "http://biolabnaturals.com/role/StatementsOfOperations", "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r169", "r170", "r171", "r192", "r389", "r434", "r456", "r459", "r460", "r461", "r462", "r463", "r464", "r467", "r470", "r471", "r472", "r473", "r474", "r476", "r477", "r478", "r479", "r481", "r482", "r483", "r484", "r485", "r487", "r490", "r491", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r512", "r562" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://biolabnaturals.com/role/OrganizationAndHistoryDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r69", "r70", "r98" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Conversion of convertible notes and interest payables, shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r8", "r18", "r42", "r98", "r261" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://biolabnaturals.com/role/StatementsOfStockholdersEquity", "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for services, shares", "verboseLabel": "Number of shares issued for services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/StatementsOfStockholdersEquity", "http://biolabnaturals.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock, shares", "verboseLabel": "Number of shares issued", "terseLabel": "Shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r8", "r69", "r70", "r98", "r436", "r512", "r526" ] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock issuable, shares", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Conversion of convertible notes and interest payables", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r8", "r19", "r98" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r8", "r69", "r70", "r98", "r444", "r512", "r526", "r568" ] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock issuable", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://biolabnaturals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biolabnaturals.com/role/BalanceSheets", "http://biolabnaturals.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 deficit", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r70", "r73", "r74", "r89", "r469", "r486", "r513", "r514", "r556", "r569", "r603", "r611", "r652", "r673" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://biolabnaturals.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 deficit" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://biolabnaturals.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r95", "r164", "r273", "r275", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r287", "r289", "r352", "r515", "r517", "r530" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://biolabnaturals.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r384", "r385" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://biolabnaturals.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of cash flow information" } } }, "auth_ref": [] }, "us-gaap_TaxesExcludingIncomeAndExciseTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesExcludingIncomeAndExciseTaxes", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Payroll and payroll taxes", "documentation": "All taxes not related to income of the entity or excise or sales taxes levied on the revenue of the entity that are not reported elsewhere. These taxes could include production, real estate, personal property, and pump tax." } } }, "auth_ref": [ "r597" ] }, "VYBE_ThreeLargestSuppliersMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "ThreeLargestSuppliersMember", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Three Largest Suppliers [Member]", "documentation": "Three Largest Suppliers [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/NotePayableDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r610", "r654" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biolabnaturals.com/role/NotePayableDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/RelatedPartyTransactionsDetailsNarrative" ], "auth_ref": [] }, "VYBE_TotalRetrospectivelyRestated": { "xbrltype": "sharesItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "TotalRetrospectivelyRestated", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfReconciliationOfRestatedCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Total as of December 31, 2021 \u2013 as retrospectively restated", "documentation": "Total retrospectively restated." } } }, "auth_ref": [] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, net", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r111", "r113", "r114", "r214", "r215", "r216" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "VYBE_TransactionFees": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "TransactionFees", "crdr": "debit", "calculation": { "http://biolabnaturals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Transaction fees", "documentation": "Amount of transaction fees." } } }, "auth_ref": [] }, "VYBE_TwelveAccreditedInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "TwelveAccreditedInvestorsMember", "presentation": [ "http://biolabnaturals.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "12 Accredited Investors [Member]", "documentation": "12 Accredited Investors [Member]" } } }, "auth_ref": [] }, "VYBE_TwoLoanAuthorizationAndAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "TwoLoanAuthorizationAndAgreementsMember", "presentation": [ "http://biolabnaturals.com/role/LossOnSettlementOfDebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Two Loan Authorization And Agreements [Member]", "documentation": "Two Loan Authorization And Agreements [Member]" } } }, "auth_ref": [] }, "VYBE_TwoThousandTwentyStockIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "TwoThousandTwentyStockIncentivePlanMember", "presentation": [ "http://biolabnaturals.com/role/EquityBasedPaymentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2020 Stock Incentive Plan [Member]", "documentation": "2020 Stock Incentive Plan [Member]" } } }, "auth_ref": [] }, "VYBE_TwoThousandTwentyTwoRestrictedStockPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "TwoThousandTwentyTwoRestrictedStockPlanMember", "presentation": [ "http://biolabnaturals.com/role/EquityBasedPaymentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2022 Restricted Stock Plan [Member]", "documentation": "2022 Restricted Stock Plan [Member]" } } }, "auth_ref": [] }, "VYBE_TwoThousandTwentyTwoStockOptionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "TwoThousandTwentyTwoStockOptionPlanMember", "presentation": [ "http://biolabnaturals.com/role/EquityBasedPaymentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2022 Stock Option Plan [Member]", "documentation": "2022 Stock Option Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc.DetailsNarrative", "http://biolabnaturals.com/role/LossOnSettlementOfDebtDetailsNarrative", "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetails", "http://biolabnaturals.com/role/ScheduleOfFundingCommitmentDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r341" ] }, "VYBE_UnsecuredConvertiblePromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "UnsecuredConvertiblePromissoryNoteMember", "presentation": [ "http://biolabnaturals.com/role/NotePayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unsecured Convertible Promissory Note [Member]", "documentation": "Unsecured Convertible Promissory Note [Member]" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://biolabnaturals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates in the Preparation of Consolidated Financial Statements", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r31", "r32", "r33", "r120", "r121", "r124", "r125" ] }, "VYBE_VybeLabsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "VybeLabsIncMember", "presentation": [ "http://biolabnaturals.com/role/ScheduleOfDeconsolidationOnLossOnSettlementOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Vybe Labs Inc [Member]", "documentation": "Vybe Labs Inc [Member]" } } }, "auth_ref": [] }, "VYBE_VybeLabsMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "VybeLabsMember", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToRelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vybe Labs [Member]", "documentation": "Vybe Labs [Member]" } } }, "auth_ref": [] }, "VYBE_VybeSaleAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "VybeSaleAgreementMember", "presentation": [ "http://biolabnaturals.com/role/DeconsolidationSaleOfVybeLabsInc.DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vybe Sale Agreement [Member]", "documentation": "Vybe Sale Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r183", "r189" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://biolabnaturals.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares - basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r182", "r189" ] }, "VYBE_WorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://biolabnaturals.com/20231231", "localname": "WorkingCapital", "crdr": "credit", "presentation": [ "http://biolabnaturals.com/role/NotesPayableToShareholderDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Working capital", "documentation": "Working capital." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://biolabnaturals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r589" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "25", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482669/740-10-15-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r591": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org//705/tableOfContent" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 77 0001493152-24-015181-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-015181-xbrl.zip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m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end XML 79 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001803977 2023-01-01 2023-12-31 0001803977 2023-06-30 0001803977 2024-03-29 0001803977 2023-12-31 0001803977 2022-12-31 0001803977 us-gaap:NonrelatedPartyMember 2023-12-31 0001803977 us-gaap:NonrelatedPartyMember 2022-12-31 0001803977 us-gaap:RelatedPartyMember 2023-12-31 0001803977 us-gaap:RelatedPartyMember 2022-12-31 0001803977 us-gaap:PreferredClassAMember 2023-12-31 0001803977 us-gaap:PreferredClassAMember 2022-12-31 0001803977 us-gaap:PreferredClassBMember 2023-12-31 0001803977 us-gaap:PreferredClassBMember 2022-12-31 0001803977 2022-01-01 2022-12-31 0001803977 us-gaap:ProductMember 2023-01-01 2023-12-31 0001803977 us-gaap:ProductMember 2022-01-01 2022-12-31 0001803977 us-gaap:ServiceMember 2023-01-01 2023-12-31 0001803977 us-gaap:ServiceMember 2022-01-01 2022-12-31 0001803977 VYBE:RentalsMember 2023-01-01 2023-12-31 0001803977 VYBE:RentalsMember 2022-01-01 2022-12-31 0001803977 VYBE:CostOfRevenueMember 2023-01-01 2023-12-31 0001803977 VYBE:CostOfRevenueMember 2022-01-01 2022-12-31 0001803977 VYBE:CostOfRevenueOtherMember 2023-01-01 2023-12-31 0001803977 VYBE:CostOfRevenueOtherMember 2022-01-01 2022-12-31 0001803977 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2021-12-31 0001803977 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2021-12-31 0001803977 us-gaap:CommonStockMember 2021-12-31 0001803977 VYBE:CommonStockIssuableMember 2021-12-31 0001803977 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001803977 us-gaap:RetainedEarningsMember 2021-12-31 0001803977 2021-12-31 0001803977 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2022-12-31 0001803977 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2022-12-31 0001803977 us-gaap:CommonStockMember 2022-12-31 0001803977 VYBE:CommonStockIssuableMember 2022-12-31 0001803977 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001803977 us-gaap:RetainedEarningsMember 2022-12-31 0001803977 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001803977 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001803977 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001803977 VYBE:CommonStockIssuableMember 2022-01-01 2022-12-31 0001803977 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001803977 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001803977 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001803977 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001803977 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001803977 VYBE:CommonStockIssuableMember 2023-01-01 2023-12-31 0001803977 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001803977 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001803977 us-gaap:PreferredClassAMember us-gaap:PreferredStockMember 2023-12-31 0001803977 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2023-12-31 0001803977 us-gaap:CommonStockMember 2023-12-31 0001803977 VYBE:CommonStockIssuableMember 2023-12-31 0001803977 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001803977 us-gaap:RetainedEarningsMember 2023-12-31 0001803977 VYBE:LimitlessXShareholdersMember us-gaap:CommonStockMember VYBE:BioLabNaturalsIncMember 2022-05-20 2022-05-20 0001803977 VYBE:JaspreetMathurMember VYBE:ClassAConvertiblePreferredStockMember VYBE:HelionHoldingsLLCMember 2022-05-20 0001803977 us-gaap:CommonStockMember VYBE:BioLabNaturalsIncMember 2022-05-20 2022-05-20 0001803977 srt:MinimumMember 2023-12-31 0001803977 srt:MaximumMember 2023-12-31 0001803977 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember VYBE:ThreeLargestSuppliersMember 2023-01-01 2023-12-31 0001803977 VYBE:EmblazeOneIncMember VYBE:VybeSaleAgreementMember 2023-06-01 2023-06-01 0001803977 VYBE:EmblazeOneIncMember VYBE:VybeSaleAgreementMember 2023-06-01 0001803977 2023-06-01 0001803977 VYBE:EmblazeOneIncMember 2023-06-01 2023-06-01 0001803977 VYBE:EmblazeOneIncMember 2023-06-01 0001803977 VYBE:TwoLoanAuthorizationAndAgreementsMember 2022-04-01 0001803977 VYBE:TwoLoanAuthorizationAndAgreementsMember 2022-12-31 0001803977 VYBE:VybeLabsIncMember 2023-06-01 0001803977 2023-06-01 2023-06-01 0001803977 VYBE:LimitlessPerformanceIncMember 2021-12-01 2021-12-01 0001803977 us-gaap:IndividualMember VYBE:UnsecuredConvertiblePromissoryNoteMember VYBE:PrimeTimeLiveIncMember 2021-03-01 0001803977 us-gaap:IndividualMember VYBE:UnsecuredConvertiblePromissoryNoteMember VYBE:PrimeTimeLiveIncMember 2021-02-28 2021-03-01 0001803977 VYBE:PrimeTimeLiveIncMember 2023-12-31 0001803977 VYBE:PrimeTimeLiveIncMember 2023-01-01 2023-12-31 0001803977 VYBE:PrimeTimeLiveIncMember 2022-12-31 0001803977 VYBE:PrimeTimeLiveIncMember 2022-01-01 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableOneMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableOneMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableTwoMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableTwoMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableThreeMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableThreeMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableFourMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableFourMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableFiveMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableFiveMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableSixMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableSixMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableSevenMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableSevenMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableEightMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableEightMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableNineMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableNineMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableTenMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableTenMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableElevenMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableElevenMember 2022-12-31 0001803977 VYBE:ConvertibleNotesPayableTwelveMember 2023-12-31 0001803977 VYBE:ConvertibleNotesPayableTwelveMember 2022-12-31 0001803977 srt:MinimumMember VYBE:ConvertibleNoteOfferingMember 2022-11-28 0001803977 srt:MaximumMember VYBE:ConvertibleNoteOfferingMember 2022-11-28 0001803977 VYBE:TwelveAccreditedInvestorsMember VYBE:ConvertibleNoteOfferingMember 2022-12-31 0001803977 VYBE:TwelveAccreditedInvestorsMember VYBE:ConvertibleNoteOfferingMember 2023-12-31 0001803977 VYBE:ClassBPreferredStockMember 2023-10-23 2023-10-23 0001803977 us-gaap:CommonStockMember 2023-10-01 0001803977 VYBE:ClassBPreferredStockMember 2023-10-23 0001803977 VYBE:ShareholderMember 2023-01-01 2023-12-31 0001803977 VYBE:LoanPayableToShareholderOneMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderOneMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderTwoMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderTwoMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderThreeMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderThreeMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderFourMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderFourMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderFiveMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderFiveMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderSixMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderSixMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderSevenMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderSevenMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderEightMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderEightMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderNineMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderNineMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderTenMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderTenMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderElevenMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderElevenMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderTwelveMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderTwelveMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderThirteenMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderThirteenMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderFourteenMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderFourteenMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderFifteenMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderFifteenMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderSixteenMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderSixteenMember 2022-12-31 0001803977 VYBE:LoanPayableToShareholderOneMember 2021-12-06 0001803977 VYBE:LoanPayableToShareholderOneMember 2022-05-30 2022-06-01 0001803977 VYBE:LoanPayableToShareholderOneMember 2022-06-01 0001803977 VYBE:LoanPayableToShareholderOneMember 2021-12-05 2021-12-06 0001803977 VYBE:LoanPayableToShareholderTwoMember 2022-02-11 0001803977 VYBE:LoanPayableToShareholderTwoMember 2022-05-30 2022-06-01 0001803977 VYBE:LoanPayableToShareholderTwoMember 2022-06-01 0001803977 VYBE:LoanPayableToShareholderTwoMember 2022-02-10 2022-02-11 0001803977 VYBE:LoanPayableToShareholderThreeMember 2022-05-08 0001803977 VYBE:LoanPayableToShareholderThreeMember 2023-09-30 0001803977 VYBE:LoanPayableToShareholderThreeMember 2022-05-30 2022-06-01 0001803977 VYBE:LoanPayableToShareholderThreeMember 2022-06-01 0001803977 VYBE:LoanPayableToShareholderThreeMember 2022-05-07 2022-05-08 0001803977 VYBE:LoanPayableToShareholderFiveMember 2022-05-16 0001803977 VYBE:LoanPayableToShareholderFiveMember 2022-06-17 0001803977 VYBE:LoanPayableToShareholderFiveMember 2022-05-14 2022-05-16 0001803977 VYBE:LoanPayableToShareholderSeventeenMember 2022-05-18 0001803977 VYBE:LoanPayableToShareholderSeventeenMember 2022-06-19 0001803977 VYBE:LoanPayableToShareholderSeventeenMember 2022-05-18 2022-05-18 0001803977 VYBE:LoanPayableToShareholderSixMember 2022-06-01 0001803977 VYBE:LoanPayableToShareholderSixMember 2022-07-31 2022-08-01 0001803977 VYBE:LoanPayableToShareholderSixMember 2022-08-01 0001803977 VYBE:LoanPayableToShareholderSixMember 2022-05-30 2022-06-01 0001803977 VYBE:LoanPayableToShareholderSevenMember 2022-06-30 0001803977 VYBE:LoanPayableToShareholderSevenMember 2022-07-31 2022-08-01 0001803977 VYBE:LoanPayableToShareholderSevenMember 2022-08-01 0001803977 VYBE:LoanPayableToShareholderSevenMember 2022-06-30 2022-06-30 0001803977 VYBE:LoanPayableToShareholderEightMember 2022-08-25 0001803977 VYBE:LoanPayableToShareholderNineMember 2022-11-15 0001803977 VYBE:LoanPayableToShareholderTenMember 2023-05-16 0001803977 VYBE:LoanPayableToShareholderElevenMember 2023-05-18 0001803977 VYBE:LoanPayableToShareholderTwelveMember 2023-06-05 0001803977 srt:ChiefExecutiveOfficerMember VYBE:FundingCommitmentMember 2023-06-03 0001803977 srt:ChiefExecutiveOfficerMember us-gaap:PreferredClassBMember VYBE:FundingCommitmentMember 2023-06-03 0001803977 VYBE:FundingCommitmentMember 2023-12-31 0001803977 VYBE:NotesPayablesMember VYBE:ShareholderMember 2023-01-01 2023-12-31 0001803977 VYBE:NotesPayablesMember VYBE:ShareholderMember 2022-01-01 2022-12-31 0001803977 VYBE:LoanPayableToShareholderThirteenMember VYBE:FundingCommitmentMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderFourteenMember VYBE:FundingCommitmentMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderFifteenMember VYBE:FundingCommitmentMember 2023-12-31 0001803977 VYBE:LoanPayableToShareholderSixteenMember VYBE:FundingCommitmentMember 2023-12-31 0001803977 us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesOneMember 2023-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesOneMember 2022-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesTwoMember 2023-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesTwoMember 2022-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesThreeMember 2023-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesThreeMember 2022-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesFourMember 2023-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesFourMember 2022-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesFiveMember 2023-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesFiveMember 2022-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesSixMember 2023-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesSixMember 2022-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesSevenMember 2023-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesSevenMember 2022-12-31 0001803977 VYBE:NotePayablesToRelatedPartiesOneMember 2022-05-10 0001803977 VYBE:NotePayablesToRelatedPartiesOneMember 2022-05-09 2022-05-10 0001803977 VYBE:NotePayablesToRelatedPartiesTwoMember 2022-05-10 0001803977 VYBE:NotePayablesToRelatedPartiesTwoMember 2022-05-09 2022-05-10 0001803977 VYBE:NotePayablesToRelatedPartiesThreeMember 2022-05-10 0001803977 VYBE:NotePayablesToRelatedPartiesThreeMember 2022-05-09 2022-05-10 0001803977 VYBE:NotePayablesToRelatedPartiesFourMember 2022-05-31 0001803977 VYBE:NotePayablesToRelatedPartiesFourMember 2022-05-31 2022-05-31 0001803977 VYBE:NotePayablesToRelatedPartiesFiveMember 2022-05-31 0001803977 VYBE:NotePayablesToRelatedPartiesFiveMember 2022-05-31 2022-05-31 0001803977 VYBE:NotePayablesToRelatedPartiesSixMember 2022-06-09 0001803977 VYBE:NotePayablesToRelatedPartiesSixMember 2022-06-08 2022-06-09 0001803977 VYBE:VybeLabsMember 2023-06-01 2023-06-01 0001803977 VYBE:NotePayablesToRelatedPartiesSevenMember 2023-06-01 0001803977 VYBE:NotesPayablesOneMember VYBE:ShareholderOneMember 2023-01-01 2023-12-31 0001803977 VYBE:NotesPayablesOneMember VYBE:ShareholderOneMember 2022-01-01 2022-12-31 0001803977 2023-05-31 2023-05-31 0001803977 2022-05-10 2022-05-10 0001803977 2022-06-10 2022-06-10 0001803977 VYBE:ClassAConvertiblePreferredStockMember 2023-12-31 0001803977 VYBE:ClassAConvertiblePreferredStockMember 2022-12-31 0001803977 VYBE:ClassAConvertiblePreferredStockMember 2023-01-01 2023-12-31 0001803977 VYBE:ClassBConvertiblePreferredStockMember 2023-10-23 2023-10-23 0001803977 VYBE:ClassBConvertiblePreferredStockMember 2023-10-23 0001803977 VYBE:IssuedMember 2021-01-01 2021-12-31 0001803977 VYBE:IssuableMember 2021-01-01 2021-12-31 0001803977 2021-01-01 2021-12-31 0001803977 VYBE:TwoThousandTwentyStockIncentivePlanMember 2020-01-15 0001803977 VYBE:TwoThousandTwentyStockIncentivePlanMember 2023-01-01 2023-12-31 0001803977 VYBE:TwoThousandTwentyStockIncentivePlanMember 2022-01-01 2022-12-31 0001803977 VYBE:TwoThousandTwentyTwoStockOptionPlanMember 2022-08-09 0001803977 VYBE:TwoThousandTwentyTwoStockOptionPlanMember 2023-01-01 2023-12-31 0001803977 VYBE:TwoThousandTwentyTwoStockOptionPlanMember 2022-01-01 2022-12-31 0001803977 VYBE:TwoThousandTwentyTwoRestrictedStockPlanMember 2022-08-09 0001803977 VYBE:TwoThousandTwentyTwoRestrictedStockPlanMember 2023-01-01 2023-12-31 0001803977 VYBE:TwoThousandTwentyTwoRestrictedStockPlanMember 2022-01-01 2022-12-31 0001803977 VYBE:NotesPayablesMember VYBE:ShareholderMember 2023-12-31 0001803977 VYBE:NotesPayablesMember VYBE:ShareholderMember 2022-12-31 0001803977 VYBE:NotesPayablesMember us-gaap:RelatedPartyMember 2023-12-31 0001803977 srt:OfficerMember 2023-01-01 2023-12-31 0001803977 srt:OfficerMember 2022-01-01 2022-12-31 iso4217:USD shares iso4217:USD shares pure false FY 0001803977 10-K true 2023-12-31 --12-31 2023 false 000-56453 LIMITLESS X HOLDINGS, INC. DE 81-1034163 9454 Wilshire Blvd. #300 Beverly Hills CA 90212 (855) 413-7030 Common Stock No No Yes Yes Non-accelerated Filer true false false false false 3899529 3977497 None 5041 BF Borgers CPA PC 5041 Lakewood, CO 116100 5843323 116888 895713 1043991 21857 3855946 12500 267345 11638973 91032 29410 32256 10985 78965 40395 202253 307740 11841226 7318230 2074576 531149 344475 92195 1114403 41509 213930 20755 118288 17056 35000 35000 9175000 5152028 4462028 80000 1247011 80000 1247011 13178671 18893962 13178671 18893962 0.0001 0.0001 30000000 30000000 500000 500000 500000 500000 50 50 0.0001 0.0001 30000000 30000000 10349097 10349097 10349097 10349097 1035 1035 0.0001 0.0001 300000000 300000000 3977497 3929834 399 394 13265500 2966162 -26137915 -10019342 -12870931 -7052736 307740 11841226 15443148 40364955 4597933 18308341 15000 15000 20056081 58688296 4064933 6942680 358 4064933 6943038 15991148 51745258 1078532 1938640 19416622 47164700 141020 1117782 1159896 3201599 1147678 2459670 416140 1114403 1515065 1647787 3587300 1306565 159216 205497 2666835 1300855 10000 43500 31298304 61500998 -15307156 -9755740 897287 348017 142551 17056 57756 30000 28397 -1052782 -261864 -16359938 -10017604 241365 -16118573 -10017604 6402 -16118573 -10024006 -4.07 -4.07 -2.71 -2.71 3957486 3957486 3692740 3692740 500000 50 3496150 350 397000 40 1848384 4664 1853488 97000 10 -97000 -10 300000 30 -300000 -30 36684 4 1117778 1117782 -10024006 -10024006 500000 50 3929834 394 2966162 -10019342 -7052736 500000 50 3929834 394 2966162 -10019342 -7052736 47663 5 141015 141020 -189739 -189739 10349097 1035 10348062 10349097 -16118573 -16118573 500000 50 10349097 1035 3977497 399 13265500 -26137915 -12870931 500000 50 10349097 1035 3977497 399 13265500 -26137915 -12870931 -16118573 -10024006 4450 5686 141020 1117782 -142551 241365 -300717 573214 -1043991 881765 -3048179 1980800 12500 -67980 67980 5899533 1794031 233862 344475 -172421 6331 -1114403 1114403 -97533 17938 -5850 -6874512 -9132969 1604 28397 -1604 28397 500000 690000 4412028 1247011 9210000 1190000 14869039 -5686116 5764467 -41107 5843323 78856 116100 5843323 2334 1125 5850 10349097 988817 -1167011 1356750 <p id="xdx_808_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zdDiSJYuwQq6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_827_zxqyaDIuPdgg">ORGANIZATION AND HISTORY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 11, 2022, Bio Lab Naturals, Inc., a Delaware corporation (“Bio Lab”), entered into a Share Exchange Agreement (the “Share Exchange Agreement”) with Limitless X, Inc., a Nevada corporation (“LimitlessX”), and its 11 shareholders (the “LimitlessX Acquisition”). The parties completed and closed the LimitlessX Acquisition on May 20, 2022 by issuing an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220520__20220520__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BioLabNaturalsIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LimitlessXShareholdersMember_z98Rslwh6ibk" title="Number of shares acquisitions">3,233,334</span> shares of common stock of Bio Lab to the LimitlessX shareholders (the “Acquisition Closing”). According to the terms of the Share Exchange Agreement, Bio Lab then issued an additional <span id="xdx_90B_ecustom--NumberOfAdditionalSharesIssuedDuringAcquisitions_c20220520__20220520__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BioLabNaturalsIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LimitlessXShareholdersMember_zhtRtmplSsVc" title="Number of additional shares issued">300,000</span> shares of common stock to the LimitlessX shareholders pro rata to their interests approximately six months from the Acquisition Closing as part of the LimitlessX Acquisition. Concurrently with the LimitlessX Acquisition, Jaspreet Mathur, the founder and principal shareholder of LimitlessX, also purchased from Helion Holdings LLC, <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_c20220520__us-gaap--StatementClassOfStockAxis__custom--ClassAConvertiblePreferredStockMember__dei--LegalEntityAxis__custom--HelionHoldingsLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JaspreetMathurMember_zGY9FgQxTN81" title="Preferred stock shares issued">500,000</span> shares of Bio Lab’s Class A Preferred Convertible Stock, which at all times have a number of votes equal to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_dp_uPure_c20220520__20220520__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BioLabNaturalsIncMember_zUfSOKWsMzkk" title="Outstanding shares percentage">60</span>% of all of the issued and outstanding shares of common stock of Bio Lab.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 10, 2022, Bio Lab changed its name to Limitless X Holdings Inc. (“Limitless”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The LimitlessX Acquisition was accounted for as a “reverse merger” following the completion of the transaction. For accounting purposes, LimitlessX was deemed to be the accounting acquirer in the transaction and, consequently, the transaction was treated as a recapitalization of Bio Lab. Accordingly, LimitlessX’s assets, liabilities, and results of operations became the historical financial statements of the registrant. No step-up in basis or intangible assets or goodwill was recorded in this transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company (as defined below) is a lifestyle brand, focused in the health and wellness industry. Initially, the Company focused on nutritional supplements, wellness studies, and interactive training videos and has since focused its business on performance marketing, sales of digital services, and sales of products. The Company’s mission is to provide businesses a turnkey solution to sell their products. Company teams include sales, marketing, user interface design (UI), user experience design (UX), fulfillment, customer support, labeling, product manufacturing, consulting, retailing, and payment processing, among others.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently offers products online only. The Company has manufacturing and distribution licensing agreements to market, manufacture, sell, and distribute branded products on behalf of its clients. The Company orders products from third party partner manufacturers that make the products according to the Company’s custom formulations, and brands them using the Company’s licensed trademarks. Products are then marketed and sold direct to consumers online. Orders are fulfilled and shipped directly from the Company’s licensors. The Company plans to offer global marketing services across all areas of the sales process, including market research, brand and product development, and digital advertising operating as an integrated marketing agency.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in the following product and service sectors: (i) health products and (ii) digital marketing services. The health products sector included the sales of health products in two primary vertical markets: (1) health &amp; wellness; and (2) beauty &amp; skincare. The digital marketing service sector includes digital marketing; digital and print design; social media marketing; and direct-to-consumer marketing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 3233334 300000 500000 0.60 <p id="xdx_801_eus-gaap--SignificantAccountingPoliciesTextBlock_za1a3Gch4SX5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_821_zSvbOxiNLZLb">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zVseFmlwVCJ2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zODOsXAzL9N4">Principles of Consolidation and Reporting</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements include the accounts of Limitless X Holdings Inc. (a holding company) and its wholly owned operating subsidiaries: Limitless X, Inc., Vybe Lab Inc. (for 2022 and deconsolidated on June 1, 2023), and Prime Time Live, Inc. (collectively, the “Company”). All intercompany balances have been eliminated during consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p id="xdx_840_ecustom--GoingConcernPolicyTextBlock_zGptflsv3Wwb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white"><b><i><span id="xdx_86E_zcqNvrjGReBd">Going Concern</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20231231_zn1NTzlq5J63" title="Accumulated deficit">26.1</span> million at December 31, 2023, and had a net loss of $<span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20231231_zWC8w0TEXPKg" title="Net income (loss)">16.1</span> million for the year ended December 31, 2023 and net cash used in operating activities of $<span id="xdx_90A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20231231_zuFXzOyarpPb" title="Net cash used in operating activities">6.9 </span>million for the year ended December 31, 2023. These matters raise substantial doubt about the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">To support our existing and planned business model, the Company needs to raise additional capital to fund our future operations. The Company has not experienced any difficulty in raising funds through loans and has not experienced any liquidity problems in settling payables in the normal course of business and repaying loans when they fall due. Successful renewal of our loans, however, is subject to numerous risks and uncertainties. In addition, the increasingly competitive industry conditions under which we operate may negatively impacted our results of operations and cash flows. Additional debt financing is anticipated to fund the Company’s operations in near future. However, there are no current agreements or understandings with regard to the form, time or amount of such financing and there is no assurance that any of this financing can be obtained or that the Company can continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--UseOfEstimates_zQhDa5wowSq7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zbNrH3Q5XBfb">Use of Estimates in the Preparation of Consolidated Financial Statements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zWnAXdaJsaHf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash and Cash Equivalents</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all liquid investments purchased with an initial maturity of three months or less to be cash equivalents. Cash and cash equivalents include demand deposits carried at cost which approximates fair value. The Company maintains its cash in institutions insured by the Federal Deposit Insurance Corporation (“FDIC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zVZuEMkbHcx6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration of Credit Risk</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company offers its services to a small number of clients. This risk of non-payment by these clients is considered minimal and the Company does not generally obtain collateral for sales. The Company continually monitors the credit standing of its clients.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zWkVbmZDNcBl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zcFT36J2MpEi">Accounts Receivable, net</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable, net consists primarily of trade receivables, net of allowances for doubtful accounts. The Company sells its products and services for cash or on credit terms, which are established in accordance with local and industry practices and typically require payment within 30 days of delivery. The Company estimates its allowance for doubtful accounts and the related expected credit loss based upon the Company’s historical credit loss experience, adjusted for asset-specific risk characteristics, current economic conditions, and reasonable forecasts. Accounts receivables are written off when determined to be uncollectible. The Company did not require and did not have an allowance for doubtful accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_849_eus-gaap--FinanceLoanAndLeaseReceivablesHeldForInvestmentPolicy_zeBLCEawBPl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Holdback Receivables</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitless primarily sells its products online using various third party sales affiliates. These affiliates (online marketing campaign companies) are paid certain commission based on their ability to provide the Company’s products through online sales. All payments are processed through various gateways and are settled through the Company’s payment gateway settler. The Company payment gateway settler is not responsible for settlements that are not paid to processing bank failure. The Company holds responsibility for all the risk in all transactions and processing systems. The payment gateway settler charges a reserve fee to mitigate the risk on their end for any loss of funds or damages.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distributions of the holdback receivables from the third-party payment gateway settler are based on several criteria, such as return and chargeback history, associated risk for the specific business vertical, average transaction amount, and so on. In order to mitigate processing risks, there are policies regarding reserve requirements and payment in arrears in place.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total holdback receivables balance reflects the <span id="xdx_908_ecustom--HoldbackReceivablesPercentage_iI_dp_uPure_c20231231__srt--RangeAxis__srt--MinimumMember_zWz609eemccc" title="Owned percentage">0</span>-<span id="xdx_900_ecustom--HoldbackReceivablesPercentage_iI_dp_uPure_c20231231__srt--RangeAxis__srt--MaximumMember_zVU8yPXHlf93" title="Owned percentage">10</span>% reserve on gross sales and additional reserves by the third-party processor for additional returns and chargebacks if needed. Based on aging of the holdback receivables, the Company has determined that an allowance for doubtful accounts of $<span id="xdx_90A_ecustom--HoldReceivablesAllowanceForDoubtfulAccounts_iI_c20231231_zals0EoE396k" title="Hold receivables, allowance for doubtful accounts">1,300,855</span> or <span id="xdx_900_ecustom--HoldbackReceivablesPercentage_iI_dp_uPure_c20231231_zgLIJLvjPTvd" title="Hold receivables percentage">55</span>% of holdback receivables should be deemed uncollectible recorded as bad debt expense. As of December 31, 2023 and December 31, 2022, the adjusted holdback receivables balance was $<span id="xdx_905_ecustom--HoldbackReceivablesNetCurrent_iI_dxL_c20231231_z3WwDej19ZPj" title="Holdback receivables::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0668">NIL</span></span> and $<span id="xdx_90F_ecustom--HoldbackReceivablesNetCurrent_iI_c20221231_zfAuTbYTwhza" title="Holdback receivables">1,043,991</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--InventoryPolicyTextBlock_zSkSAZopzWUc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inventories</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are valued at the lower-of-cost or net realizable value on a first-in, first-out basis, adjusted for the value of inventory that is determined to be excess, obsolete, expired, or unsaleable. Inventories primarily consisted of finished goods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--AdvertisingCostsPolicyTextBlock_zRa4swW2qvab" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advertising and Marketing</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising and marketing costs are charged to expense as incurred. Advertising and marketing costs were approximately $<span id="xdx_90C_eus-gaap--MarketingAndAdvertisingExpense_c20230101__20231231_zPFT7cDSUR58" title="Advertising and marketing cost">19,416,622</span> and $<span id="xdx_909_eus-gaap--MarketingAndAdvertisingExpense_c20220101__20221231_zfycn8PKEwlc" title="Advertising and marketing cost">47,164,700</span> for the years ended December 31, 2023 and 2022, respectively, and are included in operating expenses in the accompanying statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z9i2vWrqYxp" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property and Equipment, net</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment is recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation of property and equipment is over the estimated useful life of five to ten years using the straight-line method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zXIjNZW8nu4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zr3kNumwSEUc" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT, NET</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20231231_zeF6Vr3NzvFl" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231_zfgCqgbD5y2k" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--MachineryAndEquipmentGross_iI_maPPAEOz76w_zzPSkGxw4fB7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Machinery and equipment</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">39,067</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">37,463</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEOz76w_maPPAENzrUK_zgvAWi0WSOO7" style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,067</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,463</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzrUK_zRa5sXYmWkJk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,657</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,207</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzrUK_ztbA8QJsVdm" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total equipment, net</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">29,410</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">32,256</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zfdhGVkJpIIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense was $<span id="xdx_900_eus-gaap--Depreciation_c20230101__20231231_zuIpI9H5Ovd9" title="Depreciation expense">4,450</span> and $<span id="xdx_906_eus-gaap--Depreciation_c20220101__20221231_zUho4mIqmdk1" title="Depreciation expense">5,686</span> for the years ended December 31, 2023 and 2022, respectively. During the year ended December 31, 2022, the Company reported a gain of $<span id="xdx_903_eus-gaap--GainLossOnDispositionOfAssets1_c20220101__20221231_zQUYTphmiyxe" title="Gain of disposal of assets">28,397</span> on the disposal of assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--RevenueRecognitionPolicyTextBlock_zmrnzQgWjBa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zo5HZDtLc5k8">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Product Sales</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue when performance obligations under the terms of a contract with its customer are satisfied. The Company has determined that fulfilling and delivering products is a single performance obligation. Revenue is recognized at the point in time when the Company has satisfied its performance obligation and the customer has obtained control of the products or when the service is fully. This generally occurs when the product is delivered to or picked up by the customer based on applicable shipping terms, which is typically within 15 days. Revenue is measured as the amount of consideration expected to be received in exchange for fulfilled product orders,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While customers generally have a right to return defective or non-conforming products, past experience has demonstrated that product returns have been immaterial. Customer remedies for defective or non-conforming products may include a refund or exchange. As a result, the right of return is estimated and recorded as a reduction in revenue at the time of sale, if necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s customer contracts identify product quantity, price, and payment terms. Payment terms are granted consistent with industry standards. Although some payment terms may be more extended, the majority of the Company’s payment terms are less than 30 days. As a result, revenue is not adjusted for the effects of a significant financing component. Amounts billed and due from customers are classified as Accounts Receivables on the Balance Sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilizes third-party contract manufacturers for the manufacture of its products. The Company has evaluated whether it is the principal or agent in these relationships. The Company has determined that it is the principal in all cases, as it retains the responsibility for fulfillment and risk of loss, as well as for establishing the price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, the Company has elected the practical expedient to expense the incremental costs to obtain a contract, because the amortization period would be less than one year, and the practical expedient for shipping and handling costs. Shipping and handling costs incurred to deliver products to customers are accounted for as fulfillment activities, rather than a promised service, and as such are included in Cost of Goods Sold in the Statements of Operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_849_eus-gaap--RevenueRecognitionDeferredRevenue_zygbhc75xWOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_z7UJsimVQwkj">Service Revenue</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service revenue consists of digital marketing revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue related to digital marketing is recognized over time as services are provided to the customer. We sell digital marketing, digital and print design, social media marketing and direct-to-consumer marketing and thus use standalone selling prices as the basis for revenue. Payment for digital marketing services are typically received at the point when control transfers to the customer or in accordance with payment terms customary to the business. There was <span id="xdx_909_eus-gaap--DeferredRevenue_iI_do_c20231231_zOiRTTrq64Rj" title="Deferred revenue"><span id="xdx_901_eus-gaap--DeferredRevenue_iI_do_c20221231_zrsVajFp42v2" title="Deferred revenue">no</span></span> deferred revenue related to services revenue as of December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_841_eus-gaap--CostOfSalesPolicyTextBlock_zMgaPpbKnmvj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cost of Sales</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of goods sold includes the cost of inventory sold during the period as well as certain commission fees, returns, chargebacks, distribution and shipping and handling costs. The amount shown is net of various rebates from third-party vendors in the form of payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_ecustom--RefundsPayablePolicyTextBlock_ztONvZmVk1S3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Refunds Payable</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If customers are not satisfied for any reason, they may request a full refund, processed to the original form of payment, within 30 days from the order date. If the order has already been shipped, the Company charges a <span id="xdx_903_eus-gaap--PropertyManagementFeePercentFee_dp_uPure_c20230101__20231231_zoEEwzvuVWod" title="Refunds payable percentage">20</span>% restocking fee. The Company’s estimate of the reserve is based upon the Company’s most historical experience of actual customer returns. Additionally, the Company considers other factors in estimating the reserve, such as hiring a new internal team with more resources for the refund process.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and December 31, 2022, refunds payable was $<span id="xdx_904_ecustom--RefundsPayable_iI_c20231231_zFaacDdCsGv7" title="Refunds payable">41,509</span> and $<span id="xdx_903_ecustom--RefundsPayable_iI_c20221231_z6kJDGtYBbzi" title="Refunds payable">213,930</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_ecustom--ChargebacksPayablePolicyTextBlock_zofe5rhUi4e7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Chargebacks Payable</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once customers successfully dispute chargebacks with the payment processor, the Company returns such funds to the payment processor to return to the customer. As of December 31, 2023 and December 31, 2022, chargebacks payable was $<span id="xdx_90A_ecustom--ChargebacksPayable_iI_c20231231_zqByakvxHU7h" title="Chargebacks payable">20,755</span> and $<span id="xdx_90A_ecustom--ChargebacksPayable_iI_c20221231_zDOmdXuWveBb" title="Chargebacks payable">118,288</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84F_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zlPuiMbBlx4g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other Comprehensive Loss</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss for the period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zZjeBrFXT8Y7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income Taxes</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounting standard on accounting for uncertainty in income taxes addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under that guidance, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a <span id="xdx_907_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20230101__20231231_zyF1dwZeHPfl" title="Income taxes likelihood">greater than 50% likelihood</span> of being realized upon ultimate settlement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zoUnD3SfnDb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Earnings (Loss) per Share</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company calculates earnings per share in accordance with Financial Accounting Standards Board (“FASB”) ASC 260, Earnings Per Share, which requires a dual presentation of basic and diluted earnings per share. Basic earnings per share (“EPS”) is computed by dividing earnings (losses) attributable to common shareholders by the weighted average number of common shares outstanding for the periods. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. The Company had a loss for the years ended December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_845_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zLvyaWiGB9Lb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity Based Payments</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for equity-based payment accruals under authoritative guidance as set forth in the Topics of the ASC. The guidance requires all equity-based payments to employees and non-employees, including grants of employee and non-employee stock options and warrants, to be recognized in the consolidated financial statements based at their fair values. The Company applies the provisions of ASC 718, “Compensation - Stock Compensation,” using a modified prospective application, and the Black-Scholes model to value stock options. Under this application, the Company records compensation expense for all awards granted. Compensation costs will be recognized over the period that an employee provides service in exchange for the award. During the year ended December 31, 2023 and the year ended December 31, 2022, the Company granted no options under the 2020 Stock Incentive Plan and 2022 Stock Option Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_ecustom--ConcentrationsOfCreditRiskPolicyTextBlock_zYaYXgRKzJ4g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General Concentrations of Risk</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk are accounts receivable and other receivables arising from its normal business activities. The Company has a diversified customer base. The Company controls credit risk related to accounts receivable through credit approvals, credit limits, and monitoring procedures. The Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable related credit risk exposure beyond such allowance is limited.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company purchases merchandise from 6 suppliers, and the Company’s 3 largest suppliers accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--ThreeLargestSuppliersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z5f18Gq2TXhb" title="Concentration risk, percentage">95</span>% of total purchases in fiscal 2022. A significant portion of the Company’s inventory is manufactured abroad in Asia. Foreign imports subject the Company to the risks of changes in, or the imposition of new, import tariffs, duties or quotas, new restrictions on imports, loss of “most favored nation” status with the United States for a particular foreign country, antidumping or countervailing duty orders, retaliatory actions in response to illegal trade practices, work stoppages, delays in shipment, freight expense increases, product cost increases due to foreign currency fluctuations or revaluations, public health issues that could lead to temporary closures of facilities or shipping ports, such as the recent outbreak of COVID-19, and other economic uncertainties. If a disruption of trade were to occur from the countries in which the suppliers of the Company’s vendors are located, the Company may be unable to obtain sufficient quantities of products to satisfy its requirements, or the cost of obtaining products may increase.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A substantial amount of the Company’s inventory is manufactured abroad. From time to time, shipping ports experience capacity constraints (such as delays associated with COVID-19), labor strikes, work stoppages or other disruptions that may delay the delivery of imported products. A contract dispute may lead to protracted delays in the movement of the Company’s products, which could further delay the delivery of products to the Company’s stores and impact net sales and profitability. In addition, other conditions outside of the Company’s control, such as adverse weather conditions or acts of terrorism or war, such as the current conflict in Ukraine, could significantly disrupt operations at shipping ports or otherwise impact transportation of the imported merchandise we sell, either through supply chain disruptions, or rising freight and fuel costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--LesseeLeasesPolicyTextBlock_zpNFB4bWtSMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating Lease</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 842, Leases, the Company determines whether an arrangement contains a lease at inception. A lease is a contract that provides the right to control an identified asset for a period of time in exchange for consideration. For identified leases, the Company determines whether it should be classified as an operating or finance lease. Operating leases are recorded in the balance sheet as: right-of-use asset (“ROU asset”) and operating lease liability. ROU asset represents the Company’s right to use an underlying asset for the lease term and lease liability represents the Company’s obligation to make lease payments arising from the lease. ROU assets and operating lease liabilities are recognized at the commencement date of the lease and measured based on the present value of lease payments over the lease term. The ROU asset also includes deferred rent liabilities. The Company’s lease arrangement generally do not provide an implicit interest rate. As a result, in such situations the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option in the measurement of its ROU asset and liability. Lease expense for the operating lease is recognized on a straight-line basis over the lease term. The Company has a ease agreement with lease and non-lease components, which are accounted for as a single lease component and are month-to-month during the year ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zU64dY74xhEb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent Accounting Pronouncements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, FASB issued Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which amends existing guidance related to the accounting for income taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending existing guidance. This ASU is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company evaluated the effects of adoption of this guidance on the financial statements and did not have any material impact on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued an accounting standards update which changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. This update replaces the existing incurred loss impairment model with an expected loss model (referred to as the Current Expected Credit Loss model, or “CECL”). The standard update, and its related amendments, will become effective for the fiscal year beginning on January 1, 2023. The Company evaluated the effects of adoption of this guidance on the financial statements and did not have any material impact on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA and the SEC did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zVseFmlwVCJ2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zODOsXAzL9N4">Principles of Consolidation and Reporting</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements include the accounts of Limitless X Holdings Inc. (a holding company) and its wholly owned operating subsidiaries: Limitless X, Inc., Vybe Lab Inc. (for 2022 and deconsolidated on June 1, 2023), and Prime Time Live, Inc. (collectively, the “Company”). All intercompany balances have been eliminated during consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p id="xdx_840_ecustom--GoingConcernPolicyTextBlock_zGptflsv3Wwb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white"><b><i><span id="xdx_86E_zcqNvrjGReBd">Going Concern</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20231231_zn1NTzlq5J63" title="Accumulated deficit">26.1</span> million at December 31, 2023, and had a net loss of $<span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20231231_zWC8w0TEXPKg" title="Net income (loss)">16.1</span> million for the year ended December 31, 2023 and net cash used in operating activities of $<span id="xdx_90A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20231231_zuFXzOyarpPb" title="Net cash used in operating activities">6.9 </span>million for the year ended December 31, 2023. These matters raise substantial doubt about the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">To support our existing and planned business model, the Company needs to raise additional capital to fund our future operations. The Company has not experienced any difficulty in raising funds through loans and has not experienced any liquidity problems in settling payables in the normal course of business and repaying loans when they fall due. Successful renewal of our loans, however, is subject to numerous risks and uncertainties. In addition, the increasingly competitive industry conditions under which we operate may negatively impacted our results of operations and cash flows. Additional debt financing is anticipated to fund the Company’s operations in near future. However, there are no current agreements or understandings with regard to the form, time or amount of such financing and there is no assurance that any of this financing can be obtained or that the Company can continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -26100000 -16100000 -6900000 <p id="xdx_844_eus-gaap--UseOfEstimates_zQhDa5wowSq7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zbNrH3Q5XBfb">Use of Estimates in the Preparation of Consolidated Financial Statements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zWnAXdaJsaHf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash and Cash Equivalents</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all liquid investments purchased with an initial maturity of three months or less to be cash equivalents. Cash and cash equivalents include demand deposits carried at cost which approximates fair value. The Company maintains its cash in institutions insured by the Federal Deposit Insurance Corporation (“FDIC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zVZuEMkbHcx6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration of Credit Risk</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company offers its services to a small number of clients. This risk of non-payment by these clients is considered minimal and the Company does not generally obtain collateral for sales. The Company continually monitors the credit standing of its clients.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zWkVbmZDNcBl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zcFT36J2MpEi">Accounts Receivable, net</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable, net consists primarily of trade receivables, net of allowances for doubtful accounts. The Company sells its products and services for cash or on credit terms, which are established in accordance with local and industry practices and typically require payment within 30 days of delivery. The Company estimates its allowance for doubtful accounts and the related expected credit loss based upon the Company’s historical credit loss experience, adjusted for asset-specific risk characteristics, current economic conditions, and reasonable forecasts. Accounts receivables are written off when determined to be uncollectible. The Company did not require and did not have an allowance for doubtful accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_849_eus-gaap--FinanceLoanAndLeaseReceivablesHeldForInvestmentPolicy_zeBLCEawBPl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Holdback Receivables</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitless primarily sells its products online using various third party sales affiliates. These affiliates (online marketing campaign companies) are paid certain commission based on their ability to provide the Company’s products through online sales. All payments are processed through various gateways and are settled through the Company’s payment gateway settler. The Company payment gateway settler is not responsible for settlements that are not paid to processing bank failure. The Company holds responsibility for all the risk in all transactions and processing systems. The payment gateway settler charges a reserve fee to mitigate the risk on their end for any loss of funds or damages.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distributions of the holdback receivables from the third-party payment gateway settler are based on several criteria, such as return and chargeback history, associated risk for the specific business vertical, average transaction amount, and so on. In order to mitigate processing risks, there are policies regarding reserve requirements and payment in arrears in place.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total holdback receivables balance reflects the <span id="xdx_908_ecustom--HoldbackReceivablesPercentage_iI_dp_uPure_c20231231__srt--RangeAxis__srt--MinimumMember_zWz609eemccc" title="Owned percentage">0</span>-<span id="xdx_900_ecustom--HoldbackReceivablesPercentage_iI_dp_uPure_c20231231__srt--RangeAxis__srt--MaximumMember_zVU8yPXHlf93" title="Owned percentage">10</span>% reserve on gross sales and additional reserves by the third-party processor for additional returns and chargebacks if needed. Based on aging of the holdback receivables, the Company has determined that an allowance for doubtful accounts of $<span id="xdx_90A_ecustom--HoldReceivablesAllowanceForDoubtfulAccounts_iI_c20231231_zals0EoE396k" title="Hold receivables, allowance for doubtful accounts">1,300,855</span> or <span id="xdx_900_ecustom--HoldbackReceivablesPercentage_iI_dp_uPure_c20231231_zgLIJLvjPTvd" title="Hold receivables percentage">55</span>% of holdback receivables should be deemed uncollectible recorded as bad debt expense. As of December 31, 2023 and December 31, 2022, the adjusted holdback receivables balance was $<span id="xdx_905_ecustom--HoldbackReceivablesNetCurrent_iI_dxL_c20231231_z3WwDej19ZPj" title="Holdback receivables::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0668">NIL</span></span> and $<span id="xdx_90F_ecustom--HoldbackReceivablesNetCurrent_iI_c20221231_zfAuTbYTwhza" title="Holdback receivables">1,043,991</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0.10 1300855 0.55 1043991 <p id="xdx_841_eus-gaap--InventoryPolicyTextBlock_zSkSAZopzWUc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inventories</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are valued at the lower-of-cost or net realizable value on a first-in, first-out basis, adjusted for the value of inventory that is determined to be excess, obsolete, expired, or unsaleable. Inventories primarily consisted of finished goods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--AdvertisingCostsPolicyTextBlock_zRa4swW2qvab" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advertising and Marketing</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising and marketing costs are charged to expense as incurred. Advertising and marketing costs were approximately $<span id="xdx_90C_eus-gaap--MarketingAndAdvertisingExpense_c20230101__20231231_zPFT7cDSUR58" title="Advertising and marketing cost">19,416,622</span> and $<span id="xdx_909_eus-gaap--MarketingAndAdvertisingExpense_c20220101__20221231_zfycn8PKEwlc" title="Advertising and marketing cost">47,164,700</span> for the years ended December 31, 2023 and 2022, respectively, and are included in operating expenses in the accompanying statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> 19416622 47164700 <p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z9i2vWrqYxp" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property and Equipment, net</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment is recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation of property and equipment is over the estimated useful life of five to ten years using the straight-line method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zXIjNZW8nu4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zr3kNumwSEUc" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT, NET</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20231231_zeF6Vr3NzvFl" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231_zfgCqgbD5y2k" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--MachineryAndEquipmentGross_iI_maPPAEOz76w_zzPSkGxw4fB7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Machinery and equipment</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">39,067</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">37,463</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEOz76w_maPPAENzrUK_zgvAWi0WSOO7" style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,067</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,463</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzrUK_zRa5sXYmWkJk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,657</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,207</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzrUK_ztbA8QJsVdm" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total equipment, net</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">29,410</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">32,256</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zfdhGVkJpIIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense was $<span id="xdx_900_eus-gaap--Depreciation_c20230101__20231231_zuIpI9H5Ovd9" title="Depreciation expense">4,450</span> and $<span id="xdx_906_eus-gaap--Depreciation_c20220101__20221231_zUho4mIqmdk1" title="Depreciation expense">5,686</span> for the years ended December 31, 2023 and 2022, respectively. During the year ended December 31, 2022, the Company reported a gain of $<span id="xdx_903_eus-gaap--GainLossOnDispositionOfAssets1_c20220101__20221231_zQUYTphmiyxe" title="Gain of disposal of assets">28,397</span> on the disposal of assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zXIjNZW8nu4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zr3kNumwSEUc" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT, NET</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20231231_zeF6Vr3NzvFl" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231_zfgCqgbD5y2k" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--MachineryAndEquipmentGross_iI_maPPAEOz76w_zzPSkGxw4fB7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Machinery and equipment</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">39,067</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">37,463</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEOz76w_maPPAENzrUK_zgvAWi0WSOO7" style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,067</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,463</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzrUK_zRa5sXYmWkJk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,657</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,207</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzrUK_ztbA8QJsVdm" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total equipment, net</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">29,410</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">32,256</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 39067 37463 39067 37463 9657 5207 29410 32256 4450 5686 28397 <p id="xdx_84F_eus-gaap--RevenueRecognitionPolicyTextBlock_zmrnzQgWjBa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zo5HZDtLc5k8">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Product Sales</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue when performance obligations under the terms of a contract with its customer are satisfied. The Company has determined that fulfilling and delivering products is a single performance obligation. Revenue is recognized at the point in time when the Company has satisfied its performance obligation and the customer has obtained control of the products or when the service is fully. This generally occurs when the product is delivered to or picked up by the customer based on applicable shipping terms, which is typically within 15 days. Revenue is measured as the amount of consideration expected to be received in exchange for fulfilled product orders,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While customers generally have a right to return defective or non-conforming products, past experience has demonstrated that product returns have been immaterial. Customer remedies for defective or non-conforming products may include a refund or exchange. As a result, the right of return is estimated and recorded as a reduction in revenue at the time of sale, if necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s customer contracts identify product quantity, price, and payment terms. Payment terms are granted consistent with industry standards. Although some payment terms may be more extended, the majority of the Company’s payment terms are less than 30 days. As a result, revenue is not adjusted for the effects of a significant financing component. Amounts billed and due from customers are classified as Accounts Receivables on the Balance Sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilizes third-party contract manufacturers for the manufacture of its products. The Company has evaluated whether it is the principal or agent in these relationships. The Company has determined that it is the principal in all cases, as it retains the responsibility for fulfillment and risk of loss, as well as for establishing the price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, the Company has elected the practical expedient to expense the incremental costs to obtain a contract, because the amortization period would be less than one year, and the practical expedient for shipping and handling costs. Shipping and handling costs incurred to deliver products to customers are accounted for as fulfillment activities, rather than a promised service, and as such are included in Cost of Goods Sold in the Statements of Operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_849_eus-gaap--RevenueRecognitionDeferredRevenue_zygbhc75xWOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_z7UJsimVQwkj">Service Revenue</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service revenue consists of digital marketing revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue related to digital marketing is recognized over time as services are provided to the customer. We sell digital marketing, digital and print design, social media marketing and direct-to-consumer marketing and thus use standalone selling prices as the basis for revenue. Payment for digital marketing services are typically received at the point when control transfers to the customer or in accordance with payment terms customary to the business. There was <span id="xdx_909_eus-gaap--DeferredRevenue_iI_do_c20231231_zOiRTTrq64Rj" title="Deferred revenue"><span id="xdx_901_eus-gaap--DeferredRevenue_iI_do_c20221231_zrsVajFp42v2" title="Deferred revenue">no</span></span> deferred revenue related to services revenue as of December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> 0 0 <p id="xdx_841_eus-gaap--CostOfSalesPolicyTextBlock_zMgaPpbKnmvj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cost of Sales</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of goods sold includes the cost of inventory sold during the period as well as certain commission fees, returns, chargebacks, distribution and shipping and handling costs. The amount shown is net of various rebates from third-party vendors in the form of payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_ecustom--RefundsPayablePolicyTextBlock_ztONvZmVk1S3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Refunds Payable</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If customers are not satisfied for any reason, they may request a full refund, processed to the original form of payment, within 30 days from the order date. If the order has already been shipped, the Company charges a <span id="xdx_903_eus-gaap--PropertyManagementFeePercentFee_dp_uPure_c20230101__20231231_zoEEwzvuVWod" title="Refunds payable percentage">20</span>% restocking fee. The Company’s estimate of the reserve is based upon the Company’s most historical experience of actual customer returns. Additionally, the Company considers other factors in estimating the reserve, such as hiring a new internal team with more resources for the refund process.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and December 31, 2022, refunds payable was $<span id="xdx_904_ecustom--RefundsPayable_iI_c20231231_zFaacDdCsGv7" title="Refunds payable">41,509</span> and $<span id="xdx_903_ecustom--RefundsPayable_iI_c20221231_z6kJDGtYBbzi" title="Refunds payable">213,930</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.20 41509 213930 <p id="xdx_841_ecustom--ChargebacksPayablePolicyTextBlock_zofe5rhUi4e7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Chargebacks Payable</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once customers successfully dispute chargebacks with the payment processor, the Company returns such funds to the payment processor to return to the customer. As of December 31, 2023 and December 31, 2022, chargebacks payable was $<span id="xdx_90A_ecustom--ChargebacksPayable_iI_c20231231_zqByakvxHU7h" title="Chargebacks payable">20,755</span> and $<span id="xdx_90A_ecustom--ChargebacksPayable_iI_c20221231_zDOmdXuWveBb" title="Chargebacks payable">118,288</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> 20755 118288 <p id="xdx_84F_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zlPuiMbBlx4g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other Comprehensive Loss</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss for the period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zZjeBrFXT8Y7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income Taxes</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounting standard on accounting for uncertainty in income taxes addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under that guidance, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a <span id="xdx_907_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20230101__20231231_zyF1dwZeHPfl" title="Income taxes likelihood">greater than 50% likelihood</span> of being realized upon ultimate settlement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> greater than 50% likelihood <p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zoUnD3SfnDb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Earnings (Loss) per Share</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company calculates earnings per share in accordance with Financial Accounting Standards Board (“FASB”) ASC 260, Earnings Per Share, which requires a dual presentation of basic and diluted earnings per share. Basic earnings per share (“EPS”) is computed by dividing earnings (losses) attributable to common shareholders by the weighted average number of common shares outstanding for the periods. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. The Company had a loss for the years ended December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_845_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zLvyaWiGB9Lb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity Based Payments</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for equity-based payment accruals under authoritative guidance as set forth in the Topics of the ASC. The guidance requires all equity-based payments to employees and non-employees, including grants of employee and non-employee stock options and warrants, to be recognized in the consolidated financial statements based at their fair values. The Company applies the provisions of ASC 718, “Compensation - Stock Compensation,” using a modified prospective application, and the Black-Scholes model to value stock options. Under this application, the Company records compensation expense for all awards granted. Compensation costs will be recognized over the period that an employee provides service in exchange for the award. During the year ended December 31, 2023 and the year ended December 31, 2022, the Company granted no options under the 2020 Stock Incentive Plan and 2022 Stock Option Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_ecustom--ConcentrationsOfCreditRiskPolicyTextBlock_zYaYXgRKzJ4g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General Concentrations of Risk</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk are accounts receivable and other receivables arising from its normal business activities. The Company has a diversified customer base. The Company controls credit risk related to accounts receivable through credit approvals, credit limits, and monitoring procedures. The Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable related credit risk exposure beyond such allowance is limited.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company purchases merchandise from 6 suppliers, and the Company’s 3 largest suppliers accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--ThreeLargestSuppliersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z5f18Gq2TXhb" title="Concentration risk, percentage">95</span>% of total purchases in fiscal 2022. A significant portion of the Company’s inventory is manufactured abroad in Asia. Foreign imports subject the Company to the risks of changes in, or the imposition of new, import tariffs, duties or quotas, new restrictions on imports, loss of “most favored nation” status with the United States for a particular foreign country, antidumping or countervailing duty orders, retaliatory actions in response to illegal trade practices, work stoppages, delays in shipment, freight expense increases, product cost increases due to foreign currency fluctuations or revaluations, public health issues that could lead to temporary closures of facilities or shipping ports, such as the recent outbreak of COVID-19, and other economic uncertainties. If a disruption of trade were to occur from the countries in which the suppliers of the Company’s vendors are located, the Company may be unable to obtain sufficient quantities of products to satisfy its requirements, or the cost of obtaining products may increase.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A substantial amount of the Company’s inventory is manufactured abroad. From time to time, shipping ports experience capacity constraints (such as delays associated with COVID-19), labor strikes, work stoppages or other disruptions that may delay the delivery of imported products. A contract dispute may lead to protracted delays in the movement of the Company’s products, which could further delay the delivery of products to the Company’s stores and impact net sales and profitability. In addition, other conditions outside of the Company’s control, such as adverse weather conditions or acts of terrorism or war, such as the current conflict in Ukraine, could significantly disrupt operations at shipping ports or otherwise impact transportation of the imported merchandise we sell, either through supply chain disruptions, or rising freight and fuel costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.95 <p id="xdx_848_eus-gaap--LesseeLeasesPolicyTextBlock_zpNFB4bWtSMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating Lease</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 842, Leases, the Company determines whether an arrangement contains a lease at inception. A lease is a contract that provides the right to control an identified asset for a period of time in exchange for consideration. For identified leases, the Company determines whether it should be classified as an operating or finance lease. Operating leases are recorded in the balance sheet as: right-of-use asset (“ROU asset”) and operating lease liability. ROU asset represents the Company’s right to use an underlying asset for the lease term and lease liability represents the Company’s obligation to make lease payments arising from the lease. ROU assets and operating lease liabilities are recognized at the commencement date of the lease and measured based on the present value of lease payments over the lease term. The ROU asset also includes deferred rent liabilities. The Company’s lease arrangement generally do not provide an implicit interest rate. As a result, in such situations the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option in the measurement of its ROU asset and liability. Lease expense for the operating lease is recognized on a straight-line basis over the lease term. The Company has a ease agreement with lease and non-lease components, which are accounted for as a single lease component and are month-to-month during the year ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zU64dY74xhEb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent Accounting Pronouncements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, FASB issued Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which amends existing guidance related to the accounting for income taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending existing guidance. This ASU is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company evaluated the effects of adoption of this guidance on the financial statements and did not have any material impact on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued an accounting standards update which changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. This update replaces the existing incurred loss impairment model with an expected loss model (referred to as the Current Expected Credit Loss model, or “CECL”). The standard update, and its related amendments, will become effective for the fiscal year beginning on January 1, 2023. The Company evaluated the effects of adoption of this guidance on the financial statements and did not have any material impact on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA and the SEC did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_80C_eus-gaap--FairValueDisclosuresTextBlock_zUc5L0QZ8tab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 – <span id="xdx_828_z9ldfT5omlt2">FAIR VALUE MEASUREMENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilizes ASC 820-10, Fair Value Measurement and Disclosure, for valuing financial assets and liabilities measured on a recurring basis. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable inputs such as quoted prices in active markets;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. There were no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. There have been no transfers between levels.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_807_ecustom--DeconsolidationDisclosureTextBlock_zeOavSWx0xzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE 4 – <span id="xdx_82A_zPHts8rNGJA6">DECONSOLIDATION (Sale of Vybe Labs, Inc.)</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On June 1, 2023, the Company entered into an Agreement for Purchase and Sale of Stock (the “Vybe Sale Agreement”) with Emblaze One, Inc., a Nevada corporation, (“Emblaze”) wherein the Company sold all <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230601__20230601__us-gaap--TypeOfArrangementAxis__custom--VybeSaleAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EmblazeOneIncMember_zSmrzFElxCu9" title="Number of shares sold">5,000</span> of its shares of common stock of its wholly owned subsidiary, Vybe Labs, Inc., a Delaware corporation (“Vybe”). Emblaze is a company <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20230601__us-gaap--TypeOfArrangementAxis__custom--VybeSaleAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EmblazeOneIncMember_zUvNQM0LfN4k" title="Ownership percentage">100</span>% owned by the Company’s Chief Executive Officer, Chairman of the Board of Directors, and majority shareholder, Jaspreet Mathur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_ecustom--ScheduleOfDeconsolidationTableTextBlock_zZLvZQTo56h5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The transaction is recorded as follows at the date of this transaction:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> </span><span id="xdx_8BE_z1zS2eIohBpb" style="display: none">SCHEDULE OF DECONSOLIDATION</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_490_20230601_zPyn29IUCnu8" style="font-weight: bold; font-style: italic; text-align: center">June 1,</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2023</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Total assets and liabilities deconsolidated for Vybe:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Assets_iI_zIzJiyWBQCQl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; width: 82%; text-align: left">Total assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,156,733</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Liabilities_iNI_di_zsC9faw5F6Ma" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Total liabilities</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,356,750</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--NetAssetsLiabilities_iTI_zwPfFAboh4v3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Net assets (liabilities)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(241,365</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--GainOnDeconsolidationOfSubsidiary_iI_zxxNrtZRhZsk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Net amount of deconsolidation – Recorded as a Gain on Deconsolidation of Subsidiary</td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">241,365</td><td style="font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zwb3v0O7Kar9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 5000 1 <p id="xdx_89E_ecustom--ScheduleOfDeconsolidationTableTextBlock_zZLvZQTo56h5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The transaction is recorded as follows at the date of this transaction:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> </span><span id="xdx_8BE_z1zS2eIohBpb" style="display: none">SCHEDULE OF DECONSOLIDATION</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_490_20230601_zPyn29IUCnu8" style="font-weight: bold; font-style: italic; text-align: center">June 1,</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2023</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Total assets and liabilities deconsolidated for Vybe:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Assets_iI_zIzJiyWBQCQl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; width: 82%; text-align: left">Total assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,156,733</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Liabilities_iNI_di_zsC9faw5F6Ma" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Total liabilities</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,356,750</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--NetAssetsLiabilities_iTI_zwPfFAboh4v3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Net assets (liabilities)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(241,365</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--GainOnDeconsolidationOfSubsidiary_iI_zxxNrtZRhZsk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Net amount of deconsolidation – Recorded as a Gain on Deconsolidation of Subsidiary</td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">241,365</td><td style="font-weight: bold; text-align: left"> </td></tr> </table> 1156733 1356750 -241365 241365 <p id="xdx_80B_ecustom--LossOnSettlementOfDebtTextBlock_zXCbJsNzARta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE 5 – <span id="xdx_829_zeqA4d0JZa38">LOSS ON SETTLEMENT OF DEBT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On June 1, 2023, the Company agreed to a settlement of a debt in the amount of $<span id="xdx_90E_eus-gaap--ExtinguishmentOfDebtAmount_c20230601__20230601__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmblazeOneIncMember_zSUWiWQvzGEa" title="Settlement of debt amount">1,167,011</span> and interest payable of $<span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230601__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmblazeOneIncMember_z69Qk0j8MzY" title="Interest payable">47,188</span> owed by the Company to Emblaze, a related party, under two Loan Authorization and Agreements dated April 1, 2022 and December 31, 2022, in the principal amounts of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20220401__us-gaap--TypeOfArrangementAxis__custom--TwoLoanAuthorizationAndAgreementsMember_zj1fvKq9K0Mi" title="Principal amounts">237,610</span> and $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoLoanAuthorizationAndAgreementsMember_zduP72T6xxFk" title="Principal amount">929,401</span>, respectively, and interest payable of $<span id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220401__us-gaap--TypeOfArrangementAxis__custom--TwoLoanAuthorizationAndAgreementsMember_zPD9CYRYI7Fb" title="Interest payable">10,012</span> and $<span id="xdx_901_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoLoanAuthorizationAndAgreementsMember_zZYPYn6ICsFd" title="Interest payable">37,176</span>, respectively, as part of the Vybe Sales Agreement with Emblaze.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_ecustom--ScheduleOfDeconsolidationLossOnSettlementOfDebtTableTextBlock_zSWa71SKXkG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The transaction is recorded as follows at the date of this transaction:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify"><span id="xdx_8BD_zvwogS1v8Xif">SCHEDULE OF DECONSOLIDATION ON LOSS ON SETTLEMENT OF DEBT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_496_20230601__20230601_zZdfD25DidLb" style="font-weight: bold; font-style: italic; text-align: center">June 1,</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Total due to and due from between Limitless X and Vybe before deconsolidation:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; width: 82%; text-align: left">Due to Emblaze One, Inc. by Limitless X</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--OtherLiabilitiesCurrent_iI_c20230601__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmblazeOneIncMember_zxFTn0wd6aQ7" style="width: 14%; text-align: right" title="Due to Emblaze One, Inc. by Limitless X">1,167,011</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Interest payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230601__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmblazeOneIncMember_zd7MaGIxQVDd" style="text-align: right" title="Interest payable">47,188</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Due from Vybe Labs, Inc. by Limitless X</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--OtherReceivablesNetCurrent_iNI_di_c20230601__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VybeLabsIncMember_zYZZZuSvakCl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Due from Vybe Labs, Inc. by Limitless X">(1,356,750</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_iT_mtNADTAzpmX_zlT4C3vh5QMb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net due to (from)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(142,551</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iT_zRPuSP7uaszj" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net amount of deconsolidation – Recorded as a Loss on Settlement of Debt</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">142,551</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zlZ85X0pxZP" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 1167011 47188 237610 929401 10012 37176 <p id="xdx_891_ecustom--ScheduleOfDeconsolidationLossOnSettlementOfDebtTableTextBlock_zSWa71SKXkG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The transaction is recorded as follows at the date of this transaction:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify"><span id="xdx_8BD_zvwogS1v8Xif">SCHEDULE OF DECONSOLIDATION ON LOSS ON SETTLEMENT OF DEBT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_496_20230601__20230601_zZdfD25DidLb" style="font-weight: bold; font-style: italic; text-align: center">June 1,</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Total due to and due from between Limitless X and Vybe before deconsolidation:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; width: 82%; text-align: left">Due to Emblaze One, Inc. by Limitless X</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--OtherLiabilitiesCurrent_iI_c20230601__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmblazeOneIncMember_zxFTn0wd6aQ7" style="width: 14%; text-align: right" title="Due to Emblaze One, Inc. by Limitless X">1,167,011</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Interest payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230601__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmblazeOneIncMember_zd7MaGIxQVDd" style="text-align: right" title="Interest payable">47,188</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Due from Vybe Labs, Inc. by Limitless X</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--OtherReceivablesNetCurrent_iNI_di_c20230601__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VybeLabsIncMember_zYZZZuSvakCl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Due from Vybe Labs, Inc. by Limitless X">(1,356,750</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_iT_mtNADTAzpmX_zlT4C3vh5QMb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net due to (from)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(142,551</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iT_zRPuSP7uaszj" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net amount of deconsolidation – Recorded as a Loss on Settlement of Debt</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">142,551</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 1167011 47188 1356750 -142551 142551 <p id="xdx_80D_ecustom--RoyaltyPayablesTextBlock_zXIqBqDLzeG6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 – <span id="xdx_824_zAYc0OL663D8">ROYALTY PAYABLES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitless Performance Inc. (“LPI”), SMILZ INC. (“Smiles”), DIVATRIM INC. (“Divatrim”), and AMAROSE INC. (“Amarose,” and collectively with LPI, Smiles, and Divatrim, the “Licensors”) are all companies at least 50% owned by a shareholder of the Company. On December 1, 2021, the Company entered into manufacturing and distributorship license agreements (each, a “License Agreement”) with each of the Licensors to distribute each of the Licensors’ respective products and for payments to such Licensor for its product designs and distribution rights. Pursuant to the License Agreements, and each of them, the Company agreed to pay to such Licensors royalty payments equal to <span id="xdx_90B_ecustom--RoyaltyPayablesPercentage_pid_dp_uPure_c20211201__20211201__us-gaap--RelatedPartyTransactionAxis__custom--LimitlessPerformanceIncMember_zbT0IS9yWrk8" title="Royalty payables percentage">4.00</span>% of gross sales, excluding returns, chargebacks, and other such allowances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the royalty payable was $<span id="xdx_90E_ecustom--RoyaltyPayable_iI_dxL_c20231231_zpUbBJoNW5u5" title="Royalty payable::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0792">0</span></span> and $<span id="xdx_904_ecustom--RoyaltyPayable_iI_c20221231_z6C0xn8lGxw5" title="Royalty payable">1,114,403</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 1, 2023, the Company terminated each of the License Agreements; however, the Company maintained its license for NZT-48 with LPI.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.0400 1114403 <p id="xdx_806_eus-gaap--LongTermDebtTextBlock_zPonxE620P99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 – <span id="xdx_82D_zXe5ZlxoAiUk">NOTE PAYABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 1, 2021, an individual loaned the predecessor company $<span id="xdx_905_eus-gaap--NotesPayableCurrent_iI_c20210301__srt--TitleOfIndividualAxis__us-gaap--IndividualMember__dei--LegalEntityAxis__custom--PrimeTimeLiveIncMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertiblePromissoryNoteMember_zKgbATx4MYg1" title="Note payable">35,000</span> in exchange for an unsecured promissory note that included interest at the rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210301__srt--TitleOfIndividualAxis__us-gaap--IndividualMember__dei--LegalEntityAxis__custom--PrimeTimeLiveIncMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertiblePromissoryNoteMember_zfjIccK9QIMd" title="Interest rate">10</span>% per annum on the unpaid principal balance with all unpaid principal and interest due on or before March 1, 2022. The maturity date was extended to <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20210228__20210301__srt--TitleOfIndividualAxis__us-gaap--IndividualMember__dei--LegalEntityAxis__custom--PrimeTimeLiveIncMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredConvertiblePromissoryNoteMember_zfJlkqf9j8Mf" title="Note payable, maturity date">December 31, 2022</span>. Interest is due and payable on the first day of each month. As of December 31, 2023, Prime Time Live, Inc. owes $<span id="xdx_906_eus-gaap--NotesPayableCurrent_iI_c20231231__dei--LegalEntityAxis__custom--PrimeTimeLiveIncMember_zGgyhmjNxqS5" title="Note payable">35,000</span> in principal and accrued interest of $<span id="xdx_907_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230101__20231231__dei--LegalEntityAxis__custom--PrimeTimeLiveIncMember_zvnCp56Bv50l" title="Accrued interest">4,595</span> as of December 31, 2023. As of December 31, 2022, Prime Time Live, Inc. owes $<span id="xdx_903_eus-gaap--NotesPayableCurrent_iI_c20221231__dei--LegalEntityAxis__custom--PrimeTimeLiveIncMember_zp4FSAcqNQk7" title="Note payable">35,000</span> in principal and accrued interest of $<span id="xdx_909_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20220101__20221231__dei--LegalEntityAxis__custom--PrimeTimeLiveIncMember_znzdvBBOdtmj" title="Accrued interest">1,095</span> as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> 35000 0.10 2022-12-31 35000 4595 35000 1095 <p id="xdx_806_eus-gaap--DebtDisclosureTextBlock_zPghwzKpPni2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 – <span id="xdx_820_z5gO61LkODX7">CONVERTIBLE NOTES PAYABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_899_eus-gaap--ScheduleOfDebtTableTextBlock_zDLOeSr3QMVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible notes payable consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zd2MlYL4Fb54" style="display: none">SCHEDULE OF CONVERTIBLE NOTE PAYABLES</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_49B_20231231_zIUuFGeUHVSf" style="font-weight: bold; font-style: italic; text-align: center">December 31,</td><td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_492_20221231_zFlKqxOpUTui" style="font-weight: bold; font-style: italic; text-align: center">December 31,</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableOneMember_zIV1DAFFP2Fi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">August 3, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableOneMember_zsa4TO18pfWh" title="Debt face amount">5,000,000</span>)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">        <span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableTwoMember_zDvIWuiPO4s2" style="vertical-align: bottom; background-color: White"> <td>August 3, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableTwoMember_zJuz5Y05ZjWd" title="Debt face amount">1,000,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0821">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember_zAsVJQobuuxj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>August 22, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember_zlMuiKI3moS3" title="Debt face amount">500,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0826">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableFourMember_zR5PbGX60bXb" style="vertical-align: bottom; background-color: White"> <td>September 22, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableFourMember_zxjP2sqq9Kr9" title="Debt face amount">250,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">250,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableFiveMember_znPncXpLOaVc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>September 25, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableFiveMember_zKtgp4N73lG6" title="Debt face amount">600,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0836">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableSixMember_zKzELl0XGcs3" style="vertical-align: bottom; background-color: White"> <td>September 25, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableSixMember_zRfiDKQovuri" title="Debt face amount">600,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableSevenMember_zT0UKkRJGTAe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>September 29, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableSevenMember_zPog1lQf9Wf6" title="Debt face amount">50,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableEightMember_ziEfvvCzjKye" style="vertical-align: bottom; background-color: White"> <td>September 29, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableEightMember_zJ0bu0YemMDe" title="Debt face amount">500,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0851">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableNineMember_z9PV5u8JpTPl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>October 10, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableNineMember_zP3WtUgdryad" title="Debt face amount">500,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0856">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableTenMember_zenPHka1ehs3" style="vertical-align: bottom; background-color: White"> <td>October 13, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableTenMember_zFvw40riDRV9" title="Debt face amount">750,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableElevenMember_zEpGuCl3paK5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>October 13, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableElevenMember_zdYUUT7PnxU8" title="Debt face amount">50,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableTwelveMember_z6Iq9RHckjRe" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">October 14, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableTwelveMember_z3LaqhqV69oj" title="Debt face amount">50,000</span>)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleNotesPayableCurrent_iI_zh5nh6oZg8tb" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total convertible note payables (current)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">9,175,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zaITzWr82Cd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From August 3, 2022 through November 28, 2022, the Company conducted a convertible note offering for a maximum offering of $<span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221128__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNoteOfferingMember__srt--RangeAxis__srt--MinimumMember_zaOKpkJa3ec4" title="Debt face amount">15,000,000</span> and a minimum of $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221128__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNoteOfferingMember__srt--RangeAxis__srt--MaximumMember_zkDXQ9SmTtth" title="Debt face amount">2,000,000</span> (the “Convertible Note Offering”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Convertible Note, the principal amount of the Note that may be outstanding from time to time shall bear interest per annum until paid in full at a rate equal to <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20231231_zg5iWaIh5W47" title="Debt bear interest rate">6</span>%, compounded annually. The principal and interest of the Note shall be due and payable to the noteholder on the one-year anniversary of the date of the Note (the “Maturity Date”) unless all principal and interest due under the Note had been converted by the Maturity Date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The conversion price shall be equal to $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvlaeBe3xk05" title="Conversion price, per share">0.25</span> per share of Common Stock. <span id="xdx_902_eus-gaap--DebtInstrumentCovenantDescription_c20230101__20231231_znpQbEyBvoMk" title="Debt instrumen, description">Any time prior to the Maturity Date, and upon the date of effectiveness of registration of the Notes on a registration statement filed with the Securities and Exchange Commission (the “SEC”), the Note shall automatically convert to shares of common stock of the Company at the Conversion Price (the “Automatic Conversion”); provided however, that in the event that Conversion Shares represent greater than 4.99% of the total Common Shares of the Company (the portion above 4.99% referred to herein as the “Excess Shares”), then the Automatic Conversion shall only apply to such portion of the Note up to 4.99% and not include the Excess Shares.</span> This Note is convertible at the option of the Noteholder, in holder’s sole discretion, in whole or in part, at any time prior to the Maturity Date or payment in full of the Note, whichever occurs first, all or any portion of principal or interest, into shares of Common Stock of the Company at the Conversion Price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company analyzed the conversion option in the notes for derivative accounting treatment under ASC Topic 815, “Derivatives and Hedging,” and determined that the instruments do not qualify for derivative accounting.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has received $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNoteOfferingMember__srt--TitleOfIndividualAxis__custom--TwelveAccreditedInvestorsMember_zqVAKHwFIFYk" title="Convertible notes payable">9,175,000</span> from 12 accredited investors pursuant to the Convertible Note Offering during 2022 and additional one accredited investor for $<span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNoteOfferingMember__srt--TitleOfIndividualAxis__custom--TwelveAccreditedInvestorsMember_zA3FZnspvsyg" title="Convertible notes payable">500,000</span> during 2023. The Company had $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20231023__20231023__us-gaap--StatementClassOfStockAxis__custom--ClassBPreferredStockMember_zI5xNmS2cZw" title="Convertible preferred stock amount">9,675,000</span> raised through the Convertible Note Offering prior to converting to Class B Preferred Stock on October 23, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 1, 2023, the Company entered into Conversion Agreements with each of the convertible noteholders to convert their respective notes into shares of Class B Preferred Stock. Pursuant to the Conversion Agreements, each noteholder agreed to receive one share of Class B Preferred Stock for each $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231001__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7MOmnHT8NJa" title="Share price">2.00</span> of principal and unpaid interest accrued through the closing date of the Conversion Agreement. As of the closing date of the Conversion Agreement, and each of them, no portion of any of the Notes had been converted into shares of the Company’s common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/> On October 23, 2023, pursuant to the Conversion Agreements, the Company planned to issue an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231023__20231023__us-gaap--StatementClassOfStockAxis__custom--ClassBPreferredStockMember_zjVrcOhkOavc" title="Number of shares issued">10,349,097</span> shares of Class B Preferred Stock before the completion of this offering and extinguish $<span id="xdx_907_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20231023__20231023__us-gaap--StatementClassOfStockAxis__custom--ClassBPreferredStockMember_zN6NrpK0G0me" title="Extinguish convertible debt">9,675,000</span> of convertible debt including accumulated interest as of October 23, 2023 in the amount of $<span id="xdx_902_eus-gaap--AccumulatedCapitalizedInterestCosts_iI_c20231023__us-gaap--StatementClassOfStockAxis__custom--ClassBPreferredStockMember_ztQldGd19aWh" title="Accumulated interest">674,097</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfDebtTableTextBlock_zDLOeSr3QMVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible notes payable consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zd2MlYL4Fb54" style="display: none">SCHEDULE OF CONVERTIBLE NOTE PAYABLES</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_49B_20231231_zIUuFGeUHVSf" style="font-weight: bold; font-style: italic; text-align: center">December 31,</td><td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_492_20221231_zFlKqxOpUTui" style="font-weight: bold; font-style: italic; text-align: center">December 31,</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableOneMember_zIV1DAFFP2Fi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">August 3, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableOneMember_zsa4TO18pfWh" title="Debt face amount">5,000,000</span>)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">        <span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableTwoMember_zDvIWuiPO4s2" style="vertical-align: bottom; background-color: White"> <td>August 3, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableTwoMember_zJuz5Y05ZjWd" title="Debt face amount">1,000,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0821">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember_zAsVJQobuuxj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>August 22, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember_zlMuiKI3moS3" title="Debt face amount">500,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0826">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableFourMember_zR5PbGX60bXb" style="vertical-align: bottom; background-color: White"> <td>September 22, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableFourMember_zxjP2sqq9Kr9" title="Debt face amount">250,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">250,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableFiveMember_znPncXpLOaVc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>September 25, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableFiveMember_zKtgp4N73lG6" title="Debt face amount">600,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0836">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableSixMember_zKzELl0XGcs3" style="vertical-align: bottom; background-color: White"> <td>September 25, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableSixMember_zRfiDKQovuri" title="Debt face amount">600,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableSevenMember_zT0UKkRJGTAe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>September 29, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableSevenMember_zPog1lQf9Wf6" title="Debt face amount">50,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableEightMember_ziEfvvCzjKye" style="vertical-align: bottom; background-color: White"> <td>September 29, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableEightMember_zJ0bu0YemMDe" title="Debt face amount">500,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0851">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableNineMember_z9PV5u8JpTPl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>October 10, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableNineMember_zP3WtUgdryad" title="Debt face amount">500,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0856">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableTenMember_zenPHka1ehs3" style="vertical-align: bottom; background-color: White"> <td>October 13, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableTenMember_zFvw40riDRV9" title="Debt face amount">750,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableElevenMember_zEpGuCl3paK5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>October 13, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableElevenMember_zdYUUT7PnxU8" title="Debt face amount">50,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableTwelveMember_z6Iq9RHckjRe" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">October 14, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEUgUEFZQUJMRVMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableTwelveMember_z3LaqhqV69oj" title="Debt face amount">50,000</span>)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleNotesPayableCurrent_iI_zh5nh6oZg8tb" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total convertible note payables (current)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">9,175,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 5000000 5000000 1000000 1000000 500000 500000 250000 250000 600000 600000 600000 600000 50000 50000 500000 500000 500000 500000 750000 75000 50000 50000 50000 50000 9175000 15000000 2000000 0.06 0.25 Any time prior to the Maturity Date, and upon the date of effectiveness of registration of the Notes on a registration statement filed with the Securities and Exchange Commission (the “SEC”), the Note shall automatically convert to shares of common stock of the Company at the Conversion Price (the “Automatic Conversion”); provided however, that in the event that Conversion Shares represent greater than 4.99% of the total Common Shares of the Company (the portion above 4.99% referred to herein as the “Excess Shares”), then the Automatic Conversion shall only apply to such portion of the Note up to 4.99% and not include the Excess Shares. 9175000 500000 9675000 2.00 10349097 9675000 674097 <p id="xdx_80B_ecustom--NotesPayableToShareholderTextBlock_zUPeqnSLPur3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 – <span id="xdx_82F_z0iim04zTjE2">NOTES PAYABLE TO SHAREHOLDER</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderMember_zbRDJxQWeHri" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable to shareholder consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_z056aT4GN7oc" style="display: none">SCHEDULE OF NOTES PAYABLE TO SHAREHOLDER</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_497_20231231_zPxCWG15vBt1" style="font-weight: bold; font-style: italic; text-align: center">December 31,</td><td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_49A_20221231_zBl3di4htNA9" style="font-weight: bold; font-style: italic; text-align: center">December 31,</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_409_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderOneMember_zqMtbvRXDE21" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">December 6, 2021 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderOneMember_zjIEVaq2ofB3" title="Debt face amount">50,000</span>)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTwoMember_zfv3y9NEmUu1" style="vertical-align: bottom; background-color: White"> <td>February 11, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTwoMember_zxJ1ztE7PKb1" title="Debt face amount">150,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderThreeMember_zTx8dVclDIDi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>May 8, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderThreeMember_zMXqythNG0uj" title="Debt face amount">550,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">550,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">550,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFourMember_zpNGPb4dbiB3" style="vertical-align: bottom; background-color: White"> <td>May 9, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFourMember_zd5xr4pgEJ9d" title="Debt face amount">1,100,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,100,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFiveMember_zfudKw1kFP0g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>May 16, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFiveMember_zTZz1mzvipG8" title="Debt face amount">450,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">450,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">450,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSixMember_z2DTuAjVfaCl" style="vertical-align: bottom; background-color: White"> <td>June 1, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSixMember_z2v8ZPw5Md09" title="Debt face amount">500,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSevenMember_zT0xbGcsRhcd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>June 30, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSevenMember_zKLKR8sVUb5f" title="Debt face amount">922,028</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">922,028</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">922,028</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderEightMember_zl6itWQ0jlVh" style="vertical-align: bottom; background-color: White"> <td>August 25, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderEightMember_zUnQNS8ZSW42" title="Debt face amount">290,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">290,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">290,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderNineMember_zcRIxJBXvIO6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>November 15, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderNineMember_zAeVoUOfBGkb" title="Debt face amount">450,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">450,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">450,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTenMember_zIcGHz7eJj2b" style="vertical-align: bottom; background-color: White"> <td>May 16, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTenMember_zDPoxMBR66V2" title="Debt face amount">150,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0953">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderElevenMember_zwIIYmB0iqyb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>May 18, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderElevenMember_zkA9iafLzoB7" title="Debt face amount">50,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0958">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTwelveMember_zOSpw2rz2Hpa" style="vertical-align: bottom; background-color: White"> <td>June 5, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTwelveMember_z6yNzHNaKr5d" title="Debt face amount">150,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0963">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderThirteenMember_zjoSyPlosZof" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>June 20, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderThirteenMember_zIw4uqmpZhW8" title="Debt face amount">50,000</span>) – Funding Commitment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0968">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFourteenMember_zqvc5nzyw1h5" style="vertical-align: bottom; background-color: White"> <td>July 13, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFourteenMember_z5U1qpKZMRjj" title="Debt face amount">50,000</span>) – Funding Commitment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFifteenMember_z1jDWrMMJR24" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>August 1, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFifteenMember_zRGNOL6UUdc7" title="Debt face amount">190,000</span>) – Funding Commitment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">190,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0978">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSixteenMember_zWdOT4rYaHP1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">August 7, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSixteenMember_zi4vX1hXGtZf" title="Debt face amount">50,000</span>) – Funding Commitment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LoansPayableCurrent_iI_zev65w8ZyLMk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total notes payable to stockholder (current)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,152,028</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,462,028</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zv7vc8C0UYok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>December 6, 2021 – $50,000</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 6, 2021, the Company entered into a Loan Authorization and Agreement for a loan of $<span id="xdx_908_eus-gaap--LongTermDebt_iI_c20211206__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderOneMember_zxOjTMoBTNEk" title="Long-term debt">50,000</span> from a shareholder, the proceeds of which were used to be used for working capital purposes. Beginning on June 1, 2022, the loan required a payment of $<span id="xdx_901_eus-gaap--PaymentsForLoans_c20220530__20220601__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderOneMember_zDMJPcnO1jT2" title="Payments for loans">4,303</span> per month, which included principal and interest with an interest rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220601__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderOneMember_zprHAK66B7O" title="Debt interest rate">6</span> % per annum. The total balance of principal and interest was due on <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20211205__20211206__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderOneMember_z4pye83cO0V8" title="Debt instrument maturity date">May 1, 2023</span>. As of December 31, 2023, the loan is due upon demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>February 11, 2022 – $150,000</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 11, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $<span id="xdx_902_eus-gaap--LongTermDebt_iI_c20220211__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTwoMember_zmKW7NA7VVM" title="Long-term debt">150,000</span> from a shareholder, the proceeds of which were to be used for working capital purposes. Beginning on June 1, 2022, the loan required a payment of $<span id="xdx_902_eus-gaap--PaymentsForLoans_c20220530__20220601__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTwoMember_zoC2khwgk80k" title="Payments for loans">12,910</span> per month, which included principal and interest with an interest rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220601__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTwoMember_zHfe8QbPXTmd" title="Debt interest rate">6</span>% per annum. The total balance of principal and interest was due on <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_c20220210__20220211__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTwoMember_zA2oIIwVFoK6" title="Debt instrument maturity date">May 1, 2023</span>. As of December 31, 2023, the loan is due upon demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>May 8, 2022 – $550,000</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 8, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $<span id="xdx_90C_eus-gaap--LongTermDebt_iI_c20220508__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderThreeMember_z6jgkKXm7wNg" title="Long-term debt">550,000</span> from a shareholder, the proceeds of which were to be used for working capital purposes. As of September 30, 2023 and December 31, 2022, the principal balance was $<span id="xdx_90C_eus-gaap--DebtCurrent_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderThreeMember_zxs3XchVYKxi" title="Debt balance">550,000</span> and $<span id="xdx_90D_eus-gaap--DebtCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderThreeMember_z7TxJ7ZiHX22" title="Debt balance">550,000</span>, respectively. Beginning on June 1, 2022, the loan required a payment of $<span id="xdx_90B_eus-gaap--PaymentsForLoans_c20220530__20220601__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderThreeMember_z1AjhxFPIqNa" title="Payments for loans">47,337</span> per month, which included principal and interest with an interest rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220601__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderThreeMember_zJfTNs6jO1tf" title="Debt interest rate">6</span>% per annum. The total balance of principal and interest was due on <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20220507__20220508__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderThreeMember_zXM5DuztVcr" title="Debt instrument maturity date">May 1, 2023</span>. As of December 31, 2023, the loan is due upon demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>May 16, 2022 – $1,100,000</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 16, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $<span id="xdx_902_eus-gaap--LongTermDebt_iI_c20220516__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFiveMember_zed2qaoTvSbb" title="Long-term debt">1,100,000</span> from a shareholder, the proceeds of which were to be used for working capital purposes. Interest began accruing at the rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220617__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFiveMember_zdcTLWXKGAkc" title="Debt interest rate">8.5</span>% per annum on June 17, 2022 and was due on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20220514__20220516__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFiveMember_z2QWLSdXSnXe" title="Debt instrument maturity date">May 16, 2023</span>. As of December 31, 2023, the loan is due upon demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>May 18, 2022 – $450,000</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 18, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $<span id="xdx_90E_eus-gaap--LongTermDebt_iI_c20220518__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSeventeenMember_zZb9anD7oen6" title="Long-term debt">450,000</span> from a shareholder, the proceeds of which were to be used for working capital purposes. Interest began accruing at the rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220619__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSeventeenMember_znDmZQ3qFAr5" title="Debt interest rate">8.5</span>% per annum on June 19, 2022 and was due on <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20220518__20220518__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSeventeenMember_zOoIRTmZ6HD9" title="Debt instrument maturity date">May 18, 2023</span>. As of December 31, 2023, the loan is due upon demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>June 1, 2022 – $500,000</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 1, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $<span id="xdx_900_eus-gaap--LongTermDebt_iI_c20220601__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSixMember_zxLC4k5j5wy3" title="Long-term debt">500,000</span> from a shareholder, the proceeds of which were to be used for working capital purposes. Beginning on August 1, 2022, the loan required a payment of $<span id="xdx_903_eus-gaap--PaymentsForLoans_c20220731__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSixMember_ztaEKW5omqyg" title="Payments for loans">43,494</span> per month, which included principal and interest with an interest rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSixMember_zjNEoWztEjv4" title="Debt interest rate">8</span>% per annum. The total balance of principal and interest was due on <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_c20220530__20220601__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSixMember_zw2BvrtY99af" title="Debt instrument maturity date">July 1, 2023</span>. As of December 31, 2023, the loan is due upon demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>September 30, 2022 – $922,028</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 30, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $<span id="xdx_903_eus-gaap--LongTermDebt_iI_c20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSevenMember_zAUKeTw0Epvd" title="Long-term debt">922,028</span> from a shareholder, the proceeds of which were to be used for working capital purposes. Beginning on August 1, 2022, the loan required a payment of $<span id="xdx_904_eus-gaap--PaymentsForLoans_c20220731__20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSevenMember_znTUHWS9ttOg" title="Payments for loans">80,206</span> per month, which included principal and interest with an interest rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSevenMember_zhTwVfp0xp32" title="Debt interest rate">8</span>% per annum. The total balance of principal and interest was due on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20220630__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSevenMember_zSVJK58OASaa" title="Debt instrument maturity date">August 1, 2023</span>. As of December 31, 2023, the loan is due upon demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>August 25, 2022 – $290,000</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 25, 2022, the Company entered into a Loan Authorization Agreement for a loan of $<span id="xdx_909_eus-gaap--LongTermDebt_iI_c20220825__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderEightMember_zJNHAyDb6kil" title="Long-term debt">290,000</span> from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220825__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderEightMember_zjkzg78Na5jc" title="Debt interest rate">10</span>% per annum and is due on demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>November 15, 2022 – $450,000</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 15, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $<span id="xdx_905_eus-gaap--LongTermDebt_iI_c20221115__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderNineMember_ziZfTsr2hFs5" title="Long-term debt">450,000</span> from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221115__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderNineMember_zv20lkNYTF6e" title="Debt interest rate">10</span>% per annum and is due on demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>May 16, 2023 – $150,000</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 16, 2023, the Company entered into a Loan Authorization and Agreement for a loan of $<span id="xdx_908_eus-gaap--LongTermDebt_iI_c20230516__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTenMember_z1b1Eg5LjTjg" title="Long-term debt">150,000</span> from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230516__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTenMember_zfVj59GaNYy2" title="Debt interest rate">10</span>% per annum and is due on demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>May 18, 2023 – $50,000</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 18, 2023, the Company entered into a Loan Authorization and Agreement for a loan of $<span id="xdx_906_eus-gaap--LongTermDebt_iI_c20230518__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderElevenMember_zFM8DDQH4kqb" title="Long-term debt">50,000</span> from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230518__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderElevenMember_ztYbbAaVUyg1" title="Debt interest rate">10</span>% per annum and is due on demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>June 5, 2023 – $150,000</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 5, 2023, the Company entered into a Loan Authorization and Agreement for a loan of $<span id="xdx_90A_eus-gaap--LongTermDebt_iI_c20230605__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTwelveMember_zlwtSlJbvFBi" title="Long-term debt">150,000</span> from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230605__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTwelveMember_zNw0hjgkiEq7" title="Debt interest rate">10</span>% per annum and is due on demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Funding Commitment Agreement</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 3, 2023, the Company entered into a Funding Commitment Agreement (the “Funding Commitment”) with its Chief Executive Officer and Chairman of the Board of Directors, Jaspreet Mathur, wherein Mr. Mathur committed to provide up to $<span id="xdx_90B_ecustom--WorkingCapital_iI_c20230603__us-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zUTVIYsrEOTd" title="Working capital">1,000,000</span> of working capital to the Company over the next six months. Mr. Mathur agreed to the Funding Commitment in exchange for a one year convertible promissory note for each drawdown amount advanced to the Company with an annual interest rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230603__us-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zLlANtNYBT83" title="Debt interest rate">10</span>% and a balloon payment of principal and interest due at maturity, unless Mr. Mathur elects to convert the outstanding principal and interest into Class B Preferred Stock of the Company at the conversion price of $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230603__us-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredClassBMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zImFmYl2kME" title="Conversion price">1.50</span> per share; provided, however, Mr. Mathur may only covert each note within the term of the Funding Commitment, in the event of the occurrence of the earlier of a public offering of securities of the Company pursuant to a registration statement filed with the SEC and declared effective pursuant to the Securities Act of 1933, upon completion of which the Company has a class of stock registered under the Securities Exchange Act of 1934 and that stock is listed on a national stock exchange, or a liquidation, merger, acquisition, sale of voting control or sale of substantially all of the assets of the Company in which the shareholders of the Company do not own a majority of the outstanding shares of the surviving corporation. For the avoidance of doubt, a national stock exchange includes Nasdaq, NYSE, and NYSE American, but excludes any over-the-counter quotation systems or trading platforms. The balance of the Funding Commitment are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_ecustom--FundingCommitmentTableTextBlock_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderMember_z5p7uoMLsxo8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zMO21J9jqg27" style="display: none">SCHEDULE OF FUNDING COMMITMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20231231_za22wc0vHt85" style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_40F_eus-gaap--DebtCurrent_iI_hus-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderThirteenMember_zkc8sJHQQv4h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; text-align: justify">June 20, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZVTkRJTkcgQ09NTUlUTUVOVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderThirteenMember_zSGUXSaPsxp" title="Funding commitment amount">50,000</span>)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DebtCurrent_iI_hus-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFourteenMember_zGLbbJAzHf3c" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">July 13, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZVTkRJTkcgQ09NTUlUTUVOVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFourteenMember_z8lVvPwTwvM8" title="Funding commitment amount">50,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DebtCurrent_iI_hus-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFifteenMember_zu6vYUGlvAed" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">August 1, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZVTkRJTkcgQ09NTUlUTUVOVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFifteenMember_z9Alil9sgBKe" title="Funding commitment amount">190,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">190,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DebtCurrent_iI_hus-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSixteenMember_z6aPW0n8ouE2" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">August 7, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZVTkRJTkcgQ09NTUlUTUVOVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSixteenMember_zD6xaGF5Kqzk" title="Funding commitment amount">50,000</span>)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DebtCurrent_iI_hus-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember_zLQ9LzAxOj3c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total Funding Commitment</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">340,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zS53zOfdIsAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the balance of notes payable to shareholder under the Funding Commitment was $<span id="xdx_90F_eus-gaap--DebtCurrent_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember_zl7KSpkGYGJb" title="Funding commitment">340,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total accrued interest related to notes payable to shareholder as of December 31, 2023 and 2022 was $<span id="xdx_902_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--NotesPayablesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderMember_zDvvnFZsWLc4" title="Accrued interest">508,524</span> and $<span id="xdx_901_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20220101__20221231__us-gaap--LongtermDebtTypeAxis__custom--NotesPayablesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderMember_z2MjgBrQM0J7" title="Accrued interest">132,938</span>, respectively. Interest expense related to notes payable to shareholder for the year ended December 31, 2023 was $<span id="xdx_90D_eus-gaap--InterestExpense_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--NotesPayablesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderMember_z8EG4GhZJu32" title="Interest expense">375,586</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderMember_zbRDJxQWeHri" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable to shareholder consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_z056aT4GN7oc" style="display: none">SCHEDULE OF NOTES PAYABLE TO SHAREHOLDER</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_497_20231231_zPxCWG15vBt1" style="font-weight: bold; font-style: italic; text-align: center">December 31,</td><td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_49A_20221231_zBl3di4htNA9" style="font-weight: bold; font-style: italic; text-align: center">December 31,</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_409_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderOneMember_zqMtbvRXDE21" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">December 6, 2021 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderOneMember_zjIEVaq2ofB3" title="Debt face amount">50,000</span>)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTwoMember_zfv3y9NEmUu1" style="vertical-align: bottom; background-color: White"> <td>February 11, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTwoMember_zxJ1ztE7PKb1" title="Debt face amount">150,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderThreeMember_zTx8dVclDIDi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>May 8, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderThreeMember_zMXqythNG0uj" title="Debt face amount">550,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">550,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">550,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFourMember_zpNGPb4dbiB3" style="vertical-align: bottom; background-color: White"> <td>May 9, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFourMember_zd5xr4pgEJ9d" title="Debt face amount">1,100,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,100,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFiveMember_zfudKw1kFP0g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>May 16, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFiveMember_zTZz1mzvipG8" title="Debt face amount">450,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">450,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">450,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSixMember_z2DTuAjVfaCl" style="vertical-align: bottom; background-color: White"> <td>June 1, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSixMember_z2v8ZPw5Md09" title="Debt face amount">500,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSevenMember_zT0xbGcsRhcd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>June 30, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSevenMember_zKLKR8sVUb5f" title="Debt face amount">922,028</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">922,028</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">922,028</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderEightMember_zl6itWQ0jlVh" style="vertical-align: bottom; background-color: White"> <td>August 25, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderEightMember_zUnQNS8ZSW42" title="Debt face amount">290,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">290,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">290,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderNineMember_zcRIxJBXvIO6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>November 15, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderNineMember_zAeVoUOfBGkb" title="Debt face amount">450,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">450,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">450,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTenMember_zIcGHz7eJj2b" style="vertical-align: bottom; background-color: White"> <td>May 16, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTenMember_zDPoxMBR66V2" title="Debt face amount">150,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0953">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderElevenMember_zwIIYmB0iqyb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>May 18, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderElevenMember_zkA9iafLzoB7" title="Debt face amount">50,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0958">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTwelveMember_zOSpw2rz2Hpa" style="vertical-align: bottom; background-color: White"> <td>June 5, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderTwelveMember_z6yNzHNaKr5d" title="Debt face amount">150,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0963">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderThirteenMember_zjoSyPlosZof" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>June 20, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderThirteenMember_zIw4uqmpZhW8" title="Debt face amount">50,000</span>) – Funding Commitment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0968">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFourteenMember_zqvc5nzyw1h5" style="vertical-align: bottom; background-color: White"> <td>July 13, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFourteenMember_z5U1qpKZMRjj" title="Debt face amount">50,000</span>) – Funding Commitment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFifteenMember_z1jDWrMMJR24" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>August 1, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFifteenMember_zRGNOL6UUdc7" title="Debt face amount">190,000</span>) – Funding Commitment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">190,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0978">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LoansPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSixteenMember_zWdOT4rYaHP1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">August 7, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gU0hBUkVIT0xERVIgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSixteenMember_zi4vX1hXGtZf" title="Debt face amount">50,000</span>) – Funding Commitment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LoansPayableCurrent_iI_zev65w8ZyLMk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total notes payable to stockholder (current)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,152,028</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,462,028</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 50000 50000 50000 150000 150000 150000 550000 550000 550000 1100000 1100000 1100000 450000 450000 450000 500000 500000 500000 922028 922028 922028 290000 290000 290000 450000 450000 450000 150000 150000 50000 50000 150000 150000 50000 50000 50000 50000 190000 190000 50000 50000 5152028 4462028 50000 4303 0.06 2023-05-01 150000 12910 0.06 2023-05-01 550000 550000 550000 47337 0.06 2023-05-01 1100000 0.085 2023-05-16 450000 0.085 2023-05-18 500000 43494 0.08 2023-07-01 922028 80206 0.08 2023-08-01 290000 0.10 450000 0.10 150000 0.10 50000 0.10 150000 0.10 1000000 0.10 1.50 <p id="xdx_89B_ecustom--FundingCommitmentTableTextBlock_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderMember_z5p7uoMLsxo8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zMO21J9jqg27" style="display: none">SCHEDULE OF FUNDING COMMITMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20231231_za22wc0vHt85" style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_40F_eus-gaap--DebtCurrent_iI_hus-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderThirteenMember_zkc8sJHQQv4h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; text-align: justify">June 20, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZVTkRJTkcgQ09NTUlUTUVOVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderThirteenMember_zSGUXSaPsxp" title="Funding commitment amount">50,000</span>)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DebtCurrent_iI_hus-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFourteenMember_zGLbbJAzHf3c" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">July 13, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZVTkRJTkcgQ09NTUlUTUVOVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFourteenMember_z8lVvPwTwvM8" title="Funding commitment amount">50,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DebtCurrent_iI_hus-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFifteenMember_zu6vYUGlvAed" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">August 1, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZVTkRJTkcgQ09NTUlUTUVOVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderFifteenMember_z9Alil9sgBKe" title="Funding commitment amount">190,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">190,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DebtCurrent_iI_hus-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSixteenMember_z6aPW0n8ouE2" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">August 7, 2023 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZVTkRJTkcgQ09NTUlUTUVOVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LoanPayableToShareholderSixteenMember_zD6xaGF5Kqzk" title="Funding commitment amount">50,000</span>)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DebtCurrent_iI_hus-gaap--TypeOfArrangementAxis__custom--FundingCommitmentMember_zLQ9LzAxOj3c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total Funding Commitment</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">340,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 50000 50000 50000 50000 190000 190000 50000 50000 340000 340000 508524 132938 375586 <p id="xdx_808_ecustom--NotesPayableToRelatedPartiesTextBlock_zDncRTdg7Au7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 – <span id="xdx_82F_z1OJmQMfCW81">NOTES PAYABLE TO RELATED PARTIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_89C_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zOV83ebS0oO" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable to related party consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zyd9SqkWBmvl" style="display: none">SCHEDULE OF NOTES PAYABLE TO RELATED PARTIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 97%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_499_20231231_zJb3R1q9FUia" style="font-weight: bold; font-style: italic; text-align: center">December 31,</td><td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_498_20221231_z9RJi0dRoOo8" style="font-weight: bold; font-style: italic; text-align: center">December 31,</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesOneMember_zVaXTmdoLJO2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">May 10, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesOneMember_zGHDsamFbPmb" title="Debt face amount">12,500</span>)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">12,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">12,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesTwoMember_zCxLAsGlVP25" style="vertical-align: bottom; background-color: White"> <td>May 10, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesTwoMember_zoQg4ARXc5Oa" title="Debt face amount">12,500</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesThreeMember_zFF3oJm5RiYg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>May 10, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesThreeMember_z66Lqzy3Na18" title="Debt face amount">20,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesFourMember_zVaUGDSBInI3" style="vertical-align: bottom; background-color: White"> <td>May 31, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesFourMember_zRYqDU6sdRp9" title="Debt face amount">5,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesFiveMember_zNnWYoVYyKph" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>May 31, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesFiveMember_zD8r5MjdgYz4" title="Debt face amount">15,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesSixMember_zuX8zIxRJsz" style="vertical-align: bottom; background-color: White"> <td>June 9, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesSixMember_zI8axvGEPcuc" title="Debt face amount">15,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesSevenMember_zNZUeNxFqgpi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">December 31, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesSevenMember_zaJ16Aihkr3d" title="Debt face amount">929,401</span>)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1134">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">929,401</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJ1JzKCPaNKe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total notes payable to related parties (current)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">80,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,247,011</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zt3RN9jbJMA2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>May 10, 2022 - $12,500</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 10, 2022, a related party of the Company loaned Prime Time Live, Inc. $<span id="xdx_902_eus-gaap--NotesPayableCurrent_iI_c20220510__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesOneMember_z1vNiOURYjDh">12,500</span> in exchange for a promissory note that includes interest at the rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220510__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesOneMember_zWmqKmyPbUj8">10</span>% per annum on the unpaid principal balance, with all unpaid principal and interest due on or before <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_c20220509__20220510__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesOneMember_zGA0ydckIAZc">May 10, 2023</span>. Interest began accruing on May 10, 2022. As of December 31, 2023, the loan is due upon demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>May 10, 2022 - $12,500</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 10, 2022, a related party of the Company loaned Prime Time Live, Inc. $<span id="xdx_902_eus-gaap--NotesPayableCurrent_iI_c20220510__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesTwoMember_zPhfqle0c1Pj" title="Total note payables to related parties (current)">12,500</span> in exchange for a promissory note that includes interest at the rate of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220510__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesTwoMember_zb3koRXCXs9f" title="Debt interest rate">10</span>% per annum on the unpaid principal balance with all unpaid principal and interest due on or before <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_c20220509__20220510__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesTwoMember_z6jIT9MrBST6" title="Debt instrument maturity date">May 10, 2023</span>. Interest began accruing on May 10, 2022. As of December 31, 2023, the loan is due upon demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>May 10, 2022 - $20,000</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 10, 2022, a related party of the Company loaned Prime Time Live, Inc. $<span id="xdx_905_eus-gaap--NotesPayableCurrent_iI_c20220510__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesThreeMember_z7XGQTsbi9qc" title="Total note payables to related parties (current)">20,000</span> in exchange for a promissory note that included interest at the rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220510__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesThreeMember_z8jZsW1BXXQc" title="Debt interest rate">10</span>% per annum on the unpaid principal balance with all unpaid principal and interest due on or before <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20220509__20220510__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesThreeMember_z8M8x6t6m615" title="Debt instrument maturity date">May 10, 2023</span>. Interest began accruing on May 10, 2022. As of December 31, 2023, the loan is due upon demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>May 31, 2022 - $5,000</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 31, 2022, a related party of the Company loaned Prime Time Live, Inc. $<span id="xdx_900_eus-gaap--NotesPayableCurrent_iI_c20220531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesFourMember_z5yyVQq5hYf6" title="Total note payables to related parties (current)">5,000</span> in exchange for a promissory note that included interest at the rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesFourMember_z4NbD6VIoZxk" title="Debt interest rate">10</span>% per annum on the unpaid principal balance with all unpaid principal and interest due on or before <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_c20220531__20220531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesFourMember_ze97A107KKt9" title="Debt instrument maturity date">May 31, 2023</span>. Interest began accruing on May 31, 2022. As of December 31, 2023, the loan is due upon demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>May 31, 2022 - $15,000</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 31, 2022, a related party of the Company loaned Prime Time Live, Inc. $<span id="xdx_902_eus-gaap--NotesPayableCurrent_iI_c20220531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesFiveMember_zcmOAfRToSP8" title="Total note payables to related parties (current)">15,000</span> in exchange for a promissory note that included interest at the rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesFiveMember_zuMvGe1Y3fmc" title="Debt interest rate">10</span>% per annum on the unpaid principal balance with all unpaid principal and interest due on or before <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_c20220531__20220531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesFiveMember_zaD0h71Hlz5j" title="Debt instrument maturity date">May 31, 2023</span>. Interest began accruing on May 31, 2022. As of December 31, 2023, the loan is due upon demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>June 9, 2022 - $15,000</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 10, 2022, a related party of the Company loaned Prime Time Live, Inc. $<span id="xdx_904_eus-gaap--NotesPayableCurrent_iI_c20220609__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesSixMember_zRd7Ew1KmGsk" title="Total note payables to related parties (current)">15,000</span> in exchange for a promissory note that included interest at the rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220609__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesSixMember_z3MWd3q0NDFf" title="Debt interest rate">10</span>% per annum on the unpaid principal balance with all unpaid principal and interest due on or before <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_c20220608__20220609__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesSixMember_zxrYBUcMZaG7" title="Debt instrument maturity date">May 10, 2023</span>. Interest began accruing on May 10, 2022. As of December 31, 2023, the loan is due upon demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>●</i></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>December 31, 2022 - $929,401</i></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 31, 2022, the Company entered into a Loan Authorization and Agreement for a loan of $<span id="xdx_907_eus-gaap--NotesPayableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesSevenMember_zYECyFAQU2dl" title="Total note payables to related parties (current)">929,401</span> from Emblaze, the proceeds of which were to be used for working capital purposes. The loan had an interest rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesSevenMember_zkuvv1b6TaG1" title="Debt interest rate">8</span>% per annum and was due on December 1, 2023. On June 1, 2023, the Company entered into an Agreement for Purchase and Sale of Stock with Emblaze wherein the Company sold all <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230601__20230601__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VybeLabsMember_zx27ZOf915V" title="Common stock shares sold">5,000</span> of its shares of common stock of Vybe Labs, as full payment and settlement of a debt in the in the principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20230601__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesSevenMember_zeIALRP7tZ1h" title="Debt face amount">929,401</span> owed by the Company to Emblaze.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total accrued interest related to notes payable to shareholder as of December 31, 2023 and 2022 was $<span id="xdx_907_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--NotesPayablesOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderOneMember_z6znp8mnsU41" title="Accrued interest">11,127</span> and $<span id="xdx_901_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20220101__20221231__us-gaap--LongtermDebtTypeAxis__custom--NotesPayablesOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderOneMember_z53sJJSSEGY5" title="Accrued interest">3,127</span>, respectively. Interest expense related to notes payable to shareholder for the year ended December 31, 2023 was $<span id="xdx_904_eus-gaap--InterestExpense_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--NotesPayablesOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderOneMember_zmUotbiTeiwa" title="Interest expense">8,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89C_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zOV83ebS0oO" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable to related party consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zyd9SqkWBmvl" style="display: none">SCHEDULE OF NOTES PAYABLE TO RELATED PARTIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 97%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_499_20231231_zJb3R1q9FUia" style="font-weight: bold; font-style: italic; text-align: center">December 31,</td><td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_498_20221231_z9RJi0dRoOo8" style="font-weight: bold; font-style: italic; text-align: center">December 31,</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesOneMember_zVaXTmdoLJO2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">May 10, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesOneMember_zGHDsamFbPmb" title="Debt face amount">12,500</span>)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">12,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">12,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesTwoMember_zCxLAsGlVP25" style="vertical-align: bottom; background-color: White"> <td>May 10, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesTwoMember_zoQg4ARXc5Oa" title="Debt face amount">12,500</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesThreeMember_zFF3oJm5RiYg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>May 10, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesThreeMember_z66Lqzy3Na18" title="Debt face amount">20,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesFourMember_zVaUGDSBInI3" style="vertical-align: bottom; background-color: White"> <td>May 31, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesFourMember_zRYqDU6sdRp9" title="Debt face amount">5,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesFiveMember_zNnWYoVYyKph" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>May 31, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesFiveMember_zD8r5MjdgYz4" title="Debt face amount">15,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesSixMember_zuX8zIxRJsz" style="vertical-align: bottom; background-color: White"> <td>June 9, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesSixMember_zI8axvGEPcuc" title="Debt face amount">15,000</span>)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesSevenMember_zNZUeNxFqgpi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">December 31, 2022 ($<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgVE8gUkVMQVRFRCBQQVJUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayablesToRelatedPartiesSevenMember_zaJ16Aihkr3d" title="Debt face amount">929,401</span>)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1134">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">929,401</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--NotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJ1JzKCPaNKe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total notes payable to related parties (current)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">80,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,247,011</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 12500 12500 12500 12500 12500 12500 20000 20000 20000 5000 5000 5000 15000 15000 15000 15000 15000 15000 929401 929401 80000 1247011 12500 0.10 2023-05-10 12500 0.10 2023-05-10 20000 0.10 2023-05-10 5000 0.10 2023-05-31 15000 0.10 2023-05-31 15000 0.10 2023-05-10 929401 0.08 5000 929401 11127 3127 8000 <p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zcATPVvmRbLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11 – <span id="xdx_820_zGbYkkGo8qA9">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the Company had <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zoFVWbkQFHu9" title="Common stock, shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_z38z12VDtjSl" title="Common stock, shares authorized">300,000,000</span></span> authorized shares of common stock par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zkVdZWzYSBWd" title="Common stock, par value"><span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zuKndFaNXf2" title="Common stock, par value">0.0001</span></span> per share and had <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20231231_zym0B2Ftc5zb" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zQWurHWWejHa" title="Common stock, shares outstanding">3,977,497</span></span> shares and <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_c20221231_zIfl8YsryV8a" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zoeyL6YhyNR1" title="Common stock, shares outstanding">3,929,834</span></span> shares issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock Issued for Services –</i></b> On May 31, 2023, the Company issued approximately <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230531__20230531_zUCAkqmSLZF1" title="Number of shares issued for services">47,000</span> shares of common stock for services provided to the Company. These shares were valued at fair value at the time of issuance and recorded stock compensation expense of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_c20230101__20231231_zXvpOXUFgkUb" title="Stock compensation expense">141,020</span>, for the year ended December 31, 2023.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock Issued for Services</i></b> – On May 10, 2022 and June 10, 2022, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220510__20220510_zq1YuwDhMX46" title="Number of shares issued for services">36,000</span> and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220610__20220610_zAzaqveMpsuf" title="Number of shares issued for services">684</span> shares of common stock, respectively, for services provided to the Company. These shares were valued at fair value at the time of issuance and recorded stock compensation expense of $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20220101__20221231_zw9AqmpdBT8h" title="Stock compensation expense">1,117,782</span> for the year ended December 31, 2022.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the Company has authorized <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredClassAMember_zCzHEgEnQHN9" title="Preferred stock, shares authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredClassAMember_zXiMUl2LkTXa" title="Preferred stock, shares authorized">30,000,000</span></span> shares of preferred stock, <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ClassAConvertiblePreferredStockMember_zQmMfTuXoGN2" title="Preferred stock, shares authorized">500,000</span> shares of which were designated as Class A Convertible Preferred Stock (“Class A Preferred Stock”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Class A Convertible Stock</i></b> – As of December 31, 2023 and 2022, there were a total of <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ClassAConvertiblePreferredStockMember_zIjnNHZc3fa6" title="Preferred stock, shares issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ClassAConvertiblePreferredStockMember_zyZiCQ6QNgL7" title="Preferred stock, shares outstanding"><span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ClassAConvertiblePreferredStockMember_zhiXB4NZF1ie" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ClassAConvertiblePreferredStockMember_zGuR2kLsOnGe" title="Preferred stock, shares outstanding">500,000</span></span></span></span> shares of Class A Preferred Stock issued and outstanding. <span id="xdx_90A_eus-gaap--PreferredStockVotingRights_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--ClassAConvertiblePreferredStockMember_zCoAL1umGZ77" title="Preferred stock, voting rights">The Class A Preferred Stock, when voting as a single class, has the votes of at least 60% of the voting power of the Company.</span> Further, the holder of the Class A Preferred Stock can convert one share of Class A Preferred Stock into two shares of the Company’s common stock, subject to adjustment. In addition, the holder of the Class A Preferred Stock is entitled to a liquidation preference of the Company senior to all other securities of the Company.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Class B Convertible Stock</i></b> – On October 23, 2023, pursuant to certain Conversion Agreements, the Company issued an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231023__20231023__us-gaap--StatementClassOfStockAxis__custom--ClassBConvertiblePreferredStockMember_zpMwXTYlVUYi" title="Shares issued">10,349,097</span> shares of Class B Preferred Stock and extinguished $<span id="xdx_90F_eus-gaap--ExtinguishmentOfDebtAmount_c20231023__20231023__us-gaap--StatementClassOfStockAxis__custom--ClassBConvertiblePreferredStockMember_zNKZI5X4RU55" title="Extinguishment convertible debt">9,675,000</span> of convertible debt including accumulated interest as of October 23, 2023 in the amount of $<span id="xdx_90D_ecustom--ConvertibleDebtIncludingAccumulatedInterest_c20231023__20231023__us-gaap--StatementClassOfStockAxis__custom--ClassBConvertiblePreferredStockMember_zdVWT2J5IENg" title="Convertible debt including accumulated interest">674,097</span>. The holders of the Class B Preferred Stock are entitled to a liquidation preference senior to common stock and junior to the Class A Preferred Stock at a liquidation price of $<span id="xdx_904_eus-gaap--PreferredStockLiquidationPreference_iI_c20231023__us-gaap--StatementClassOfStockAxis__custom--ClassBConvertiblePreferredStockMember_zPy0s1ojJEM5" title="Preferred stock liquidation price">3.00</span> per share of Class B Preferred Stock. The Class B Preferred Stock also has conversion rights, whereby each share of Class B Preferred Stock is convertible into two shares of Common Stock at the discretion of the holder, subject to beneficial ownership limitations. The holders of the Class B Preferred Stock have no voting rights, unless otherwise provided for in its Certificate of Designation or by law.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock and Recapitalization</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the LimitlessX Acquisition and LimitlessX being the acquirer, the Company retrospectively restated its common stock as if the transaction occurred at the beginning of the period. The following is the reconciliation of retrospectively restated common stock:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zAgqZnZyKqqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zrS4rHJgQMP5" style="display: none">SCHEDULE OF RECONCILIATION OF RESTATED COMMON STOCK</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_49A_20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--IssuedMember_zhC22TpDmf2" style="display: none; text-align: center"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: center"> </td><td id="xdx_499_20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--IssuableMember_zJ36J8BeNVXj" style="display: none; text-align: center"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_491_20210101__20211231_zY4Bd4lU9K25" style="display: none; text-align: center"> </td><td style="display: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issuable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40D_ecustom--CommonStock_zvAj31URzfDb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Common stock – Limitless X Inc. – as original</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,616,667</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,666,667</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--CommonStockSplit_zCgI9kaCNBYk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Common stock split (1 to 1.94) – Limitless X Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,519,366</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,566,366</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--CommonStockIssuableAdditionalStockSplit_zep4v2Znmtpa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock issuable (additional stock split) – Limitless X Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1251">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--CommonStockPriorToReverseMerger_zEGL8RtsGIaj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock (Bio Lab) – prior to reverse merger</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">360,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1256">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">360,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--TotalRetrospectivelyRestated_zx2n33mbwU2a" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Total as of December 31, 2021 – as retrospectively restated</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,496,150</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">397,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,893,150</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 300000000 300000000 0.0001 0.0001 3977497 3977497 3929834 3929834 47000 141020 36000 684 1117782 30000000 30000000 500000 500000 500000 500000 500000 The Class A Preferred Stock, when voting as a single class, has the votes of at least 60% of the voting power of the Company. 10349097 9675000 674097 3.00 <p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zAgqZnZyKqqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zrS4rHJgQMP5" style="display: none">SCHEDULE OF RECONCILIATION OF RESTATED COMMON STOCK</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_49A_20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--IssuedMember_zhC22TpDmf2" style="display: none; text-align: center"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: center"> </td><td id="xdx_499_20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--IssuableMember_zJ36J8BeNVXj" style="display: none; text-align: center"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_491_20210101__20211231_zY4Bd4lU9K25" style="display: none; text-align: center"> </td><td style="display: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issuable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40D_ecustom--CommonStock_zvAj31URzfDb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Common stock – Limitless X Inc. – as original</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,616,667</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,666,667</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--CommonStockSplit_zCgI9kaCNBYk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Common stock split (1 to 1.94) – Limitless X Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,519,366</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,566,366</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--CommonStockIssuableAdditionalStockSplit_zep4v2Znmtpa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock issuable (additional stock split) – Limitless X Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1251">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--CommonStockPriorToReverseMerger_zEGL8RtsGIaj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock (Bio Lab) – prior to reverse merger</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">360,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1256">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">360,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--TotalRetrospectivelyRestated_zx2n33mbwU2a" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Total as of December 31, 2021 – as retrospectively restated</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,496,150</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">397,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,893,150</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1616667 50000 1666667 1519366 47000 1566366 300000 300000 360117 360117 3496150 397000 3893150 <p id="xdx_802_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zRbkqVw2XMK5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12 – <span id="xdx_827_zA5iCgmWuXmk">EQUITY BASED PAYMENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had the following equity-based plan:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Incentive Plans</b></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective January 15, 2020, the Company adopted its 2020 Stock Option and Award Plan (the “2020 Stock Incentive Plan”). Under the 2020 Stock Incentive Plan, the Board of Directors may grant options or purchase rights to purchase common stock to officers, employees, and other persons who provide services to the Company or any related company. The participants to whom awards are granted, the type of awards granted, the number of shares covered for each award, and the purchase price, conditions and other terms of each award are determined by the Board of Directors, except that the term of the options shall not exceed ten years. A total of <span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200115__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zRMdkuwnzckl" title="Common stock reserved shares">2,222</span> shares of the Company’s common stock is reserved for the 2020 Stock Incentive Plan. The shares issued for the 2020 Stock Incentive Plan may be either treasury or authorized and unissued shares. During the year ended December 31, 2023 and the year ended December 31, 2022, the Company granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zjJmM8fc3XD" title="Options granted"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zTB1du10Xlmc" title="Options granted">no</span></span> options under the 2020 Stock Incentive Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective August 9, 2022, the Company adopted its 2022 Incentive and Non-statutory Stock Option Plan (the “2022 Stock Option Plan”). Under the 2022 Stock Option Plan, the Board of Directors may grant options to purchase common stock to officers, employees, and other persons who provide services to the Company. A total of <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20220809__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoStockOptionPlanMember_zAf2CjtHv6Xh" title="Common stock reserved shares">833,333</span> shares of the Company’s common stock is reserved for the 2022 Stock Option Plan. During the year ended December 31, 2023 and the year ended December 31, 2022, the Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoStockOptionPlanMember_zTjncq7aQAO8" title="Options granted"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoStockOptionPlanMember_zG1t9WainL7k" title="Options granted">no</span></span> options under the 2022 Stock Option Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective August 9, 2022, we adopted our 2022 Restricted Stock Plan (the “2022 Restricted Stock Plan”). Under the 2022 Restricted Stock Plan, the Board of Directors may grant restricted stock to officers, directors, and key employees. A total of <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20220809__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoRestrictedStockPlanMember_zcD9f56Wth6" title="Common stock reserved shares">833,333</span> shares of common stock is reserved for the 2022 Stock Option Plan. During the year ended December 31, 2023 and the year ended December 31, 2022, there have been <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoRestrictedStockPlanMember_ziNLEWaaZMcg" title="Options granted"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoRestrictedStockPlanMember_zcmqgJx9sr17" title="Options granted">no</span></span> shares of common stock granted under the 2022 Restricted Stock Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2222 0 0 833333 0 0 833333 0 0 <p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zFN9ChUfmODk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 13 – <span id="xdx_822_zZ2FMsQtTvh9">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had the following related party transactions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Royalty Payables – </b>Limitless Performance Inc. (“LPI”), SMILZ INC. (“Smiles”), DIVATRIM INC. (“Divatrim”), and AMAROSE INC. (“Amarose,” and collectively with LPI, Smiles, and Divatrim, the “Licensors”) are all companies at least 50% owned by a shareholder of the Company. On December 1, 2021, the Company entered into manufacturing and distributorship license agreements (each, a “License Agreement”) with each of the Licensors to distribute each of the Licensors’ respective products and for payments to such Licensor for its product designs and distribution rights. Pursuant to the License Agreements, and each of them, the Company agreed to pay to such Licensors royalty payments equal to <span id="xdx_90B_ecustom--RoyaltyPayablesPercentage_pid_dp_uPure_c20211201__20211201__us-gaap--RelatedPartyTransactionAxis__custom--LimitlessPerformanceIncMember_z7NuzExgXIFg" title="Royalty payables percentage">4.00</span>% of gross sales, excluding returns, chargebacks, and other such allowances. As of December 31, 2023 and 2022, the royalty payable was $<span id="xdx_90E_ecustom--RoyaltyPayable_iI_dxL_c20231231_zaAJvmktfOwi" title="Royalty payable::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1287">0</span></span> and $<span id="xdx_904_ecustom--RoyaltyPayable_iI_c20221231_z1858xZJZg2f" title="Royalty payable">1,114,403</span>, respectively. On October 1, 2023, the Company terminated each of the License Agreements; however, the Company maintained its license for NZT-48 with LPI.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes Payable to Shareholder –</b> The Company had various notes payable with its shareholder who is the Chief Executive Officer of the Company. As of December 31, 2023 and 2022, the Company had $<span id="xdx_902_eus-gaap--LoansPayableCurrent_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--NotesPayablesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderMember_zmPiiLrl0MRc" title="Notes payable outstanding">5,152,028</span> and $<span id="xdx_908_eus-gaap--LoansPayableCurrent_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--NotesPayablesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderMember_zIrs8cLusD8i" title="Notes payable outstanding">4,462,028</span> outstanding, respectively. Refer to Note 9.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes Payable to Related Parties –</b> The Company entered into various notes payable with shareholders of the Company. As of December 31, 2023 and 2022, the Company had $<span id="xdx_904_eus-gaap--NotesPayableCurrent_iI_c20231231__us-gaap--LongtermDebtTypeAxis__custom--NotesPayablesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z8FT10gmhLh2" title="Notes payable outstanding">80,000</span> outstanding. Refer to Note 10.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consulting Fees</i></b> – During the year ended December 31, 2023, the Company incurred consulting fees in the amount of $<span id="xdx_902_eus-gaap--ProfessionalFees_c20230101__20231231__srt--TitleOfIndividualAxis__srt--OfficerMember_zJHiWHxTerRg" title="Consulting fees">0</span> to an officer and an officer of one of its affiliates. During the year ended December 31, 2022, the Company incurred consulting fees in the amount of $<span id="xdx_907_eus-gaap--ProfessionalFees_c20220101__20221231__srt--TitleOfIndividualAxis__srt--OfficerMember_zuvcEI8AGZH6" title="Consulting fees">32,500</span> to an officer and an officer of one of its affiliates.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.0400 1114403 5152028 4462028 80000 0 32500 <p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zNrcHY5VvMge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14 – <span id="xdx_827_zfj8fY6sN2d8">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Commitments</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives. The Company’s variable lease payments primarily consist of maintenance and other operating expenses from their real estate leases. Variable lease payments are excluded from the ROU assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has lease agreements with lease and non-lease components. The Company has elected to account for these lease and non-lease components as a single lease component.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zw5jAOhaCAI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 842, the components of lease expense were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zLaeW3A9az5f" style="display: none">SCHEDULE OF LEASE COST</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_496_20230101__20231231_zpUnZuLpjjsj" style="font-weight: bold; font-style: italic; text-align: center">For the</td><td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_490_20220101__20221231_zpCrNXGf0Lke" style="font-weight: bold; font-style: italic; text-align: center">For the</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center">year ended</td><td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center">year ended</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; font-style: italic">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseCost_maLCzBh9_zust47gDCRic" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Operating lease expense</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1305">-</span></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">138,108</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LeaseCost_iT_mtLCzBh9_zwGwPqb42hK4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total lease expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1308">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">138,108</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zP7Qs6UcG0ol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_ecustom--ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_zCWewizPGmV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 842, other information related to leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zDvbgmazr4Aj" style="display: none">SCHEDULE OF OTHER INFORMATION RELATED TO LEASES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_491_20230101__20231231_zHur605n6NXg" style="font-weight: bold; font-style: italic; text-align: center">For the</td><td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_497_20220101__20221231_zBInX7HcICI9" style="font-weight: bold; font-style: italic; text-align: center">For the</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center">year ended</td><td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center">year ended</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; font-style: italic">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeasePayments_zLw3cm3MOmxi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Operating cash flows from operating leases</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1313">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">137,138</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_zPk8jMzN19Nh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Cash paid for amounts included in the measurement of lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1316">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">137,138</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted-average remaining lease term—operating leases</td><td> </td> <td colspan="2" style="text-align: right">Years</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 82%; text-align: left">Weighted-average discount rate—operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zmAxGCF2E7h" title="Weighted average discount rate Operating leases">3</span></td><td style="width: 1%; text-align: left">%</td></tr> </table> <p id="xdx_8A7_zp5hgykzmkHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total rent expense was $<span id="xdx_90C_eus-gaap--PaymentsForRent_c20230101__20231231_zbzyD0VJBMba" title="Rent expense">160,379</span> and $<span id="xdx_908_eus-gaap--PaymentsForRent_c20220101__20221231_zXkwN11tSII1" title="Rent expense">204,527</span> for the years ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contingencies</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="background-color: white">From time to time, the Company is involved in legal proceedings. The Company records a liability for those legal proceedings when it de<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termines it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The Company also discloses when it is reasonably possible that a material loss may be incurred, however, the amount cannot be reasonably estimated. From time to time, the Company may enter into discussions regarding settlement of these matters, and may enter into settlement agreements, if it believes settlement is in the best interest of the Company and its shareholders.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The following is a summary of our current outstanding litigation: </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Mentom Eyewear Inc. </i></b>– A legal action was filed in the Los Angeles Superior Court against Limitless X Holdings Inc., four of its officers, and an unrelated company, alleging the breach of an Implied In-Fact Agreement and other causes of action related to that alleged agreement such as conversion, fraud and unjust enrichment, Mentom Eyewear Inc. v. Limitless X Holdings Inc., et al., Case Number 23STCV24681.  We believe that there was no such agreement, and that the plaintiff has no legal standing to bring such a matter against the Company or its officers.  The case is moving into the discovery phase where we believe the true facts will lead to a dismissal; however, if the case continues, we will vigorously defend against such claims as it is our position that the allegations are not supported by the facts.  No liability has been recorded for these litigations because the Company believes that any such liability is not probable and reasonably estimable at this time.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Harpo Inc.</i></b> – A legal action was filed in the Central District of California against Limitless X Inc. and two of its officers along with Emblaze One, Inc., alleging trademark infringement and dilution, unfair competition, false advertising, and violation of the right of publicity, all based on allegations that one of our advertisements contained the unauthorized use of a celebrity’s name and intellectual property, Harpo Inc. and OW Licensing Company LLC v. Emblaze One, Inc., et al., Case Number 2:23-cv-04459 VAP (ASx).  Any exposure stemming from this action would be subject to indemnity from the advertising network responsible for the ads in question.  We have not yet filed a responsive pleading in this action as we are attempting a global settlement; however, if unable to settle we will defend the case vigorously and will attempt a contractual and equitable indemnity claim against the advertiser.  No liability has been recorded for this litigation because the Company believes that any such liability is not reasonably estimable at this time.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zw5jAOhaCAI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 842, the components of lease expense were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zLaeW3A9az5f" style="display: none">SCHEDULE OF LEASE COST</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_496_20230101__20231231_zpUnZuLpjjsj" style="font-weight: bold; font-style: italic; text-align: center">For the</td><td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_490_20220101__20221231_zpCrNXGf0Lke" style="font-weight: bold; font-style: italic; text-align: center">For the</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center">year ended</td><td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center">year ended</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; font-style: italic">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseCost_maLCzBh9_zust47gDCRic" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Operating lease expense</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1305">-</span></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">138,108</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LeaseCost_iT_mtLCzBh9_zwGwPqb42hK4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total lease expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1308">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">138,108</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 138108 138108 <p id="xdx_89F_ecustom--ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_zCWewizPGmV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 842, other information related to leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zDvbgmazr4Aj" style="display: none">SCHEDULE OF OTHER INFORMATION RELATED TO LEASES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_491_20230101__20231231_zHur605n6NXg" style="font-weight: bold; font-style: italic; text-align: center">For the</td><td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" id="xdx_497_20220101__20221231_zBInX7HcICI9" style="font-weight: bold; font-style: italic; text-align: center">For the</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center">year ended</td><td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic"> </td> <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center">year ended</td><td style="font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; font-style: italic">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeasePayments_zLw3cm3MOmxi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Operating cash flows from operating leases</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1313">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">137,138</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_zPk8jMzN19Nh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Cash paid for amounts included in the measurement of lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1316">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">137,138</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted-average remaining lease term—operating leases</td><td> </td> <td colspan="2" style="text-align: right">Years</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 82%; text-align: left">Weighted-average discount rate—operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zmAxGCF2E7h" title="Weighted average discount rate Operating leases">3</span></td><td style="width: 1%; text-align: left">%</td></tr> </table> 137138 137138 0.03 160379 204527 <p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zK02N43rxkJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 15 – <span id="xdx_829_zxKS331E9Qhk">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluated all events or transactions that occurred after December 31, 2023. During this period, the Company did not have any material recognizable subsequent events required to be disclosed.</span></p>